

CHILDREN WITH CANCER UK

England & Wales · Charity number 298405

Details

Other names	CHILDREN WITH LEUKAEMIA UK, THE FOUNDATION FOR CHILDREN WITH LEUKAEMIA, THE PAUL O'GORMAN FOUNDATION FOR CHILDREN WITH LEUKAEMIA, CHILDREN FIGHTING CANCER, CHILDREN WITH CANCER, CHILDREN WITH LEUKAEMIA, CHILDREN WITH LEUKAEMIA FOUNDATION
Status	Registered
Legal form	Charitable company
Company number	04960054
Registered	2005-01-18
Register	View on the Charity Commission register

Contact

Address	Children With Cancer Uk 21-27 Lambs Conduit Street London WC1N 3NL
Phone	02074040808
Email	info@childrenwithcancer.org.uk
Website	www.childrenwithcancer.org.uk

Activities

Objects: 1) TO PROMOTE THE RELIEF OF CHILDREN AND YOUNG PEOPLE SUFFERING FROM LEUKAEMIA OR ANY OTHER FORM OF CANCER (AND ALLIED DISORDERS) AND OF THEIR FAMILIES 2) TO RAISE PUBLIC AWARENESS AND KNOWLEDGE IN MATTERS RELATING TO LEUKAEMIA OR ANY OTHER FORM OF CANCER (AND ALLIED DISORDERS) AFFECTING CHILDREN AND YOUNG PEOPLE 3) TO PROMOTE RESEARCH INTO THE CAUSES, ALLEVIATION, PREVENTION, TREATMENT AND CURE OF LEUKAEMIA OR ANY OTHER FORM OF CANCER (AND ALLIED DISORDERS) AFFECTING CHILDREN AND YOUNG PEOPLE AND TO PUBLISH THE USEFUL RESULTS OF SUCH RESEARCH.

Activities: OUR MAIN AIMS ARE TO UNDERSTAND WHAT CAUSES CHILDREN TO DEVELOP CANCER, TO DEVELOP IMPROVED TREATMENTS AND TO PROVIDE CARE FOR AFFECTED CHILDREN AND THEIR FAMILIES. IT IS THE TRUSTEES' POLICY TO MAXIMISE THE PROPORTION OF CHARITABLE OUTPUT THAT IS ACHIEVED THROUGH GRANT MAKING TO ORGANISATIONS. IT IS

INTENDED THAT THE CHARITY WILL FOCUS ON REVENUE FUNDING FOR RESEARCH INTO CAUSES AND TREATMENT.

Classification

- **How:** Makes Grants To Individuals, Makes Grants To Organisations, Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** General Charitable Purposes, Education/training, The Advancement Of Health Or Saving Of Lives, Disability, Environment/conservation/heritage
- **Who:** Children/young People, People With Disabilities, Other Charities Or Voluntary Bodies, The General Public/mankind

Geography

- **Area of benefit:** NATIONAL AND OVERSEAS
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2024-12-31	£17,808,758	£14,098,567	£22,091,795	42
2023-12-31	£15,192,202	£12,091,962	£18,381,604	41
2022-12-31	£14,110,417	£13,850,984	£14,840,280	37
2021-12-31	£14,844,449	£9,855,149	£14,455,222	40
2020-12-31	£13,762,005	£15,342,172	£9,295,761	55

Trustees

Name	Role	Appointed
David Arthur Edmund Gibbs	Chair	2021-02-22
Dr Bruce Jonathan Morland		2022-07-05
Nicholas James Bird		2025-06-18
Phil Hall		2021-12-13
Tamara Ludlow		2025-06-26

Linked charities

- FOUNDATION FOR CHILDREN WITH LEUKAEMIA (298405-1)

CHILDREN WITH CANCER UK

England & Wales - Charity number 298405

Accounts

**Trustees' Report and Financial Statements
for the year ended 31 December 2024**



Contents

Welcome from Chair of Trustees	3
Welcome from CEO of Children with Cancer UK	4
Outcomes in 2024	5
Our Year in Research	6
Supporting Families	8
Raising Awareness	9
Fundraising Highlights	10
Thank You	13
Financial Review	14
Our Strategy	16
Human Resources	17
Going Concern	18
Investments	18
Structure, Governance and Management	22
Reference and Administration	25
Statement of Trustees' Responsibilities	27
Independent Auditor's Report to the Members of the Children with Cancer UK	28
Consolidated statement of financial activities for the year ended 31 December 2024	32
Balance sheet as at 31 December 2024	33
Consolidated cash flow statement for the year ended 31 December 2024	34
Notes to the financial statements for the year ended 31 December 2024	35

Welcome from Chair of Trustees

As we look back on 2024, I am filled with pride at the progress Children with Cancer UK has made. As ever we have remained unwavering in our mission to fund life-saving research, create awareness and support families going through a childhood cancer diagnosis.

I would like to express my heart-felt thanks to Amar Naher, who served as interim CEO since March 2024. His work on raising the profile of the charity helped us connect with new audiences thanks to projects that included our very first garden at the RHS Chelsea Flower Show and the launch of our movie, Kids Like Us, a landmark documentary which fundamentally changes the way paediatric cancer is viewed. I wish him all the best in his new endeavours.

I'd like to welcome our new CEO, Gavin Maggs, who joined us this summer from Birmingham University where he was Director of Development and Alumni Relations. I look forward to working with Gavin to usher in a new era for the charity.

Our gratitude as always to our Scientific Advisory Panel for giving their time and expertise to help in our fight against childhood cancer, particularly Ms Clare Brady who is stepping down from her role. We wish her a very happy retirement.

Research is, as always, at the heart of our work and this year saw the successful completion of the Children with Cancer UK 2024 Project Grant round, resulting in the funding of 11 new projects. We can't wait to see the ground-breaking progress these will make in the years to come and the improved understanding of childhood cancers.

Finally, I want to share my sincere thanks to our dedicated staff and loyal supporters. With your unwavering support, together we can help more children survive and thrive following a cancer diagnosis. I look forward to heading into the next phase of our work with new initiatives and strategies, helping more families together in the year to come.



David Gibbs
Chair of Trustees
Children with Cancer UK

Welcome from CEO of Children with Cancer UK

It is only right that I begin by writing how privileged I am to have taken over the role of CEO at Children with Cancer UK this year. I look forward to leading the charity into the next phase of our growth, towards a world where every child and young person survives cancer.

Children with Cancer UK is proud to continue our strategic funding of research into childhood cancer and in 2024 alone we funded research projects in collaboration with other organisations worth over £4m. This included ground-breaking projects looking into kinder, more effective treatments, such as Dr Helen Bryant and her team at Sheffield University looking into new treatments for Neuroblastoma. Professor Williams and her team at Oxford University are addressing the legacy of limited child-specific cancer treatments through fertility research for female survivors, which we supported alongside other UK-wide projects.

In 2024 we also showcased our first ever RHS Chelsea Flower Show Garden. The balcony garden 'Raines Repurposed' was designed by Thomas Clarke and helped us engage with a brand-new audience as well as win two awards.

Once again, our supporters have gone above and beyond in their fundraising for the charity, helping us raise £16 million. From 1,200 runners taking on the London Marathon to individuals such as Charlotte, whose own experience with cancer prompted her to raise funds with a Black-Tie ball. We offer our heartfelt thanks for the generosity of all our supporters; we couldn't do what we do without you.

One of the pillars of our charity remains supporting families affected by childhood cancer. This year we are proud to announce that Raines Retreat, one of the UK's very few holiday retreats designed solely for children affected by cancer and their families, will be opening soon. The new facility in North Yorkshire will allow families to escape the day-to-day stresses and worries of childhood cancer, spend quality time together and connect with other families who have experienced the pain of a cancer diagnosis. The Retreat will make a real difference to the lives of many families in the years to come.

Thank you to all our staff and supporters, whose dedication has enabled us to continue to help families and commission research that offers the hope of breakthroughs in the years to come. I look forward to working together on the next chapter for Children with Cancer UK.



Gavin Maggs
CEO of Children with Cancer UK

Outcomes in 2024

How donations have helped children and young people with cancer.

For every £1 we spend on fundraising, we raised £4 more.

For every £1 donated we spend:

- 76p on fighting childhood cancer
 - 41p on research projects,
 - 13p on supporting families,
 - 22p on raising awareness,
- 24p on raising more money.

Our Year in Research

Around 1,800 children and 2,300 young people are diagnosed with cancer each year in the United Kingdom. Whilst over 80% of patients survive, cancer recurrence is still at high rates, and it remains one of the leading diseases related causes of death for children under 15 years of age. From the time of their diagnosis, children and young people endure difficult treatments to eradicate their disease, with potentially life-altering side effects on their development. High-quality and impactful research is essential to driving forward our vision of a world where every child and young person survives cancer. Research has significantly contributed to the improvements seen in childhood cancer survival rates from 67.3% in 1990 to a predicted 85.2% recorded in 2019. Improved treatments and understanding of the disease are important on our mission.

Children with Cancer UK plays a major role in funding vital life-saving research. We are dedicated to improving survival rates across all types of childhood cancer, improving the quality of life in young cancer survivors, and finding less-toxic treatment options. As one of the UK's leading charities dedicated to childhood cancer research, we are proud of our contribution to the ongoing breakthroughs which continue to help save young lives.

2024 saw the successful completion of the Children with Cancer UK 2024 Project Grant round resulting in the funding of 11 new projects. This funding allocated to research projects in institutions across the UK aims to make improvements for childhood and young adult cancers.

Children with Cancer UK values its partnerships with others in the paediatric and young adult cancer community. And we are constantly working to build new collaborations as well as maintain our existing relationships. Our research funding includes support from other charities, government funders, cancer organisations and universities. In 2022 we co-funded a £5.5 million investment with CRUK in the Research Programme SMPaeds2 – a programme to advance precision medicine for children and young people whose cancer has returned or whose treatment has stopped working, progress will be reported at our Research Conference for 2025 in Birmingham.

Research awards

In 2024 we funded research projects in collaboration with other organisations worth £4.4 million, £3.6 million was via the grant call and funded research fellowships, while the balance was provided to other charities with similar objectives as Children with Cancer to support their specialised research priorities.

Children with Cancer UK 2024 grant call

This was a £3.5 million grant call for research into improvements in the cancer pathway for childhood and young adult cancers. We sought proposals that focus on key questions in any area of cancer research which primarily addressed the needs of children and young adults with cancer and into improved quality of ongoing life. The grant call began in 2023 and was finalised in summer 2024. Projects allocated funding included:

Dr Karen Keeshan (University of Glasgow)

Targeting leukaemia stem cells in childhood acute myeloid leukaemia (£299,732)

Dr Manav Pathania (University of Cambridge)

Investigating Resistance to Chemoradiotherapy in Paediatric-Type Diffuse High-Grade Glioma (£348,662)

Prof Suzannah Williams (University of Oxford)

Improving fertility preservation for female cancer survivors (£319,952)

Dr Timothy Ritzmann (University of Nottingham)

Biological Markers of Ependymoma in Childhood and Adolescence (BIOMECA) 2 (£350,000)

Prof Helen Bryant (University of Sheffield)

Use of CDK12/13 inhibitors to treat high-risk Neuroblastoma (£147,570)

Dr Paul Maciocia (UCL)

Development of humanised models of T cell acute lymphoblastic leukaemia for robust interrogation of immunotherapy approaches (£349,943)

Dr Maarten Hoogenkamp (University of Birmingham)

Detection of EAAT1 protein in T-ALL patient samples (£78,055)

Prof Kathy Pritchard-Jones (UCL)

International Benchmarking of Childhood Cancer Survival by Stage (BENCHISTA) Phase II (£298,773)

Prof Julie Irving (Newcastle University)

Targeting MRD in childhood acute lymphoblastic leukaemia (£337,238)

Prof Susan Burchill (University of Leeds)

Eradicating the cells responsible for progression and relapse in Ewing sarcoma using intelligent combination strategies to improve outcomes (£331,519)

Dr Zoe Walters (University of Southampton)

Harnessing the immune response in paediatric rhabdomyosarcoma (£329,067)

Scientific Advisory Panel

We are incredibly grateful to the members of our Scientific Advisory Panel (SAP) who freely give their time and expertise to help drive forward our fight against cancers affecting children and young people. Research into cancers affecting children and young people is a broad field and we aim to reflect the diversity of the field amongst the membership of panel members.

Our members in 2024 were:

- Professor Christina Halsey (University of Glasgow)
- Dr Helen Jenkinson (University of Birmingham)
- Professor Susan Burchill (University of Leeds)
- Dr Lynley Marshall (The Royal Marsden Hospital)
- Professor Matthew Murray (University of Cambridge)
- Professor Vincenzo D'Angiolella (University of Edinburgh)
- Professor Petra Hamerlik (University of Manchester)
- Ms. Clare Brady (Retired)

Supporting Families

Children with Cancer UK is committed to being there for families through treatment and beyond. Due to the staffing absence of a family events team, we were not able to deliver as many events as in previous years but have been very fortunate to be able to invite families to events supported by our generous partners. We ensured consistent contact with our families was maintained throughout this period and were still able to create special memories towards the end of the year.

Raines Retreat

We continued our development at Raines Retreat, with the refurbishment of the retreat and the completion of the building work in 2025.

A series of focus groups with our psychologist and families helped us identify the needs and wants to families during their stay at Raines Retreat. We consulted numerous groups of parents to roll out a best practise plan for their experience at the Retreat.

Children's Choir

At the Children with Cancer UK Gala in 2024, we invited 21 children currently undergoing treatment or in remission, along with their siblings, to participate in a children's choir for the third time. They performed a rendition of "You will be found" from "Dear Evan Hansen" accompanied by singer Louisa Johnson and directed by musical director Paul Herbert. This experience provided an exciting opportunity to involve our families in one of our key fundraising events, and we are committed to continuing this tradition in the years to come.

We were able to invite 6 families to join us at the Gala for a night off from their daily worries.

Beads of Courage UK

Our partnership with the Beads of Courage UK programme continued through 2024, and we helped to fund support for children and their families during some of the toughest times in their lives. Since our partnership began in 2019, we have helped support approximately 14,000 children in over 100 hospitals, acknowledging, celebrating, and recording over 10 million milestones. Our grant has also enabled training sessions for hospital staff on how to support individual patients throughout the programme both practically and emotionally. In our Real Stories focus in February, we told the story of siblings and the importance of the Beads of Courage for the whole family.

Spread a Smile Partnership

We continued our partnership with Spread a Smile to improve the well-being of seriously ill and hospitalised children and their families through entertainment and events. The team hosts an array of talented musicians, magicians, therapy dogs, and artists who visit seriously ill children, offering families a much-needed opportunity to enjoy themselves and create precious memories together. We also helped support both the Summer and Winter Parties, which hosted hundreds of children to explore a wide range of activities like silent discos, bumper cars, and face painting. In 2024 we attended their Remembrance Event with some families. The beautiful and emotional event was held especially for families that have a lost a loved child.

Spread a Smile joined us at the 2024 London Marathon with a children's corner full of entertainment for young supporters waiting to welcome their parents back from their run.

During the Westminster Mile Spread a Smile entertained all children that attended the event with their families with fun activities.

Heroes Against Cancer

We continued our Heroes Against Cancer campaign with regular requests from families for bespoke messages from their heroes. One of those was Leighton who managed to visit his favourite football team Leeds United during their training day, this was then followed by him being invited to be the team's mascot during one of their games. This particular moment was picked up by the local press and was a real highlight for Leighton.

Westminster Mile

We were very fortunate to be given our own wave at the 2024 Westminster Mile during Childhood Cancer Awareness Month. With 500 people signing up, we arrived and walked in solidarity with those affected by childhood cancer. All participants were given our orange T-Shirt, showing our support whilst walking the mile.

Christmas Hampers

During the Christmas period we collaborated with our WTW corporate partner as well as our charity partner Spread a Smile to deliver 300 bespoke hampers to families facing childhood cancer. Through these efforts, we aimed to bring some comfort and joy to those enduring challenging times during the holiday season.

Disney on Ice

On Christmas Eve, we hosted families at the O2 Arena to see the incredible Disney on Ice. Generously donated by the O2, families affected by childhood cancer were able to immerse themselves in Disney's performance from private suites, providing them with a VIP experience.

Raising Awareness

Children with Cancer UK is dedicated to increasing awareness of the causes, symptoms, treatments, and impact of childhood cancer. This commitment extends to current and potential supporters, the research community, and patient families. By raising our profile, we continue to secure essential funds for life-saving research and drive change for children and young people facing a cancer diagnosis. In 2024, we ran multiple campaigns, including Childhood Cancer Awareness Month and Christmas, and introduced exciting new events with the help of our dedicated new special events team. These key charity moments allowed us to reach millions of individuals across the UK, amplifying our mission and impact.

Making Our Voice Heard - PR

- 1,200 mentions in articles
- Reached 2.7 billion people
- Reach value of £2.2 million

Real Stories

In January we launched a new video series called Real Stories. It featured interviews with different people affected by childhood cancer. Each month, we unravelled the powerful narratives of these extraordinary individuals who have faced the unimaginable. It included bereavement stories, siblings' stories, teenager stories, fundraiser stories, in treatment stories, fatherhood stories, connecting parents' stories, full circle and research stories.

12 Groups of Cancer

12 Groups of Cancer was also launched in 2024 and consists of 12 videos, each focusing on one group of childhood cancer. The series allowed parents, children or anyone else interested to understand the key questions about childhood cancer. It gave them the tools to understand the cancer type without having to ask questions. The series was developed with our Head of Research and our Trustee, Professor Bruce Morland.

Chelsea Flower Show

In 2024 we displayed our first ever RHS Chelsea Flower Show Garden. The balcony garden 'Raines Repurposed' was designed by Thomas Clarke, whom we have been working with at our Raines Retreat in North Yorkshire. The garden helped us secure multiple broadcasting and PR opportunities, including BBC One footage, raising awareness with a brand-new audience. Our garden won two awards, the Silver Gild as well as the People Choice Award.

Childhood Cancer Awareness Month – Kids Like Us

Every September, we celebrate Childhood Cancer Awareness Month (CCAM). In 2024, we were privileged to be working with BAFTA award winning production team Echo Velvet to launch Kids Like Us. We created a ground-breaking documentary about childhood cancer, which is streaming on Sky and NowTV in over 101 countries. We are determined to keep childhood cancer on the agenda.

The film follows the extraordinary lives of eight remarkable young people from across the UK and US who have faced the unimaginable. Kids Like Us, is a landmark documentary feature which will fundamentally change the way we view paediatric cancer and the issues that surround it. The film premiered on Wednesday 11 September 2024 with a red-carpet VIP event at Cineworld, Leicester Square, sponsored by Pladis.

Ambassadors Series

We continued to work with our long-term ambassadors Dr. Mohammed Abbas Khaki, James “Jimmy” Carpenter, as well as Paula Radcliffe. In 2024 we were incredibly proud to welcome new ambassadors on board. This included Evie Pickerill, Hannah and Jake Graf, Ollie and Gareth Locke and Ali-A.

Christmas Appeal

Our 2024 Christmas Appeal looked back at the Real Stories we told in 2024 with heartfelt messages of hope for Christmas from all the participants. These messages helped those going through their cancer journey feel supported, knowing they are not alone.

Telling the story of childhood cancer

One of our most effective ways to raise awareness is by sharing the journeys of children affected by cancer. We are incredibly grateful to the 19 families who generously volunteered to share their stories in 2024. With their support we can continue to highlight the need for more funding into childhood cancer research. Welcome to the Children with Cancer UK family: Ellie, George, Madelaine, Nancy, Henry, Charlie, Jamie, Libby, Dulcie, Chester, Zayyan, Jack, Alec, Aden, Harrison, Gracie, Amelia, Issac and Jacob.

Looking Forward

Through these initiatives, we have continued to spotlight the effects of childhood cancer and the urgent need for more funding and research. Together, we are making a profound difference in the lives of children and families affected by cancer. Our work in 2024 has laid a strong foundation for future efforts, and we remain committed to our mission of providing hope, support, and life-saving research.

Fundraising Highlights

Children with Cancer UK has been diversifying our fundraising streams in order to provide supporters with various ways to contribute to the organisation’s work.

The London Marathon and Individual Giving campaigns generated significant funds in 2024, and we look forward to continuing to develop these strategies in 2025.

The Corporate Partnerships and Community teams have helped increase engagement with the charity, while the organisation’s growing brand recognition has resulted in us gaining UK wide support and Children with Cancer being selected by corporate partners as their charity of the year.

These initiatives are supported by a community of dedicated supporters across the country who fundraise for us.

Sports events

TCS London Marathon 2024

The 2024 TCS London Marathon took place on Sunday 21 April 2024. We had a team of 1,200 runners taking on the iconic course for Children with Cancer UK, and together, they raised over £2.8 million.

Great North Run 2024

We had 121 runners take part in the 2024 Great North Run. In total the team raised over £43,000.

BHF London to Brighton Cycle

Children with Cancer UK had 88 riders take part in the 2024 BHF London to Brighton Cycle, raising over £64,000.

Rat Race

The Rat Race team raised over £293,000 in 2024.

Community

Our community supporters have made a remarkable impact throughout 2024, demonstrating tremendous dedication and generosity.

Charlotte wanted to raise money for Children with Cancer UK. She felt inspired to help after she was diagnosed with Burkitt lymphoma when she was just six years old. "I received support from the charity. I know the importance of research, to try to find less painful and more effective treatments, and the emotional and financial support that my parents and brother had too." With the help of friends and family, Charlotte organised a Black-Tie Ball event, as she wanted to dress-up, have a celebration, and dance the night away. After a year of planning and overcoming challenges, Charlotte raised an incredible £20,615. We at Children with Cancer UK were so impressed by their determination and the amount raised, that Charlotte was named as one of our fundraisers of the month, you can read more about her on our website.

Tattershall Karting Centre, based in Lincolnshire, organised their second annual karting fundraiser in memory of one of their drivers Thomas, who sadly passed away from cancer in 2023 aged just 11 years old. They raised a fantastic £6,379.85, which was over £2,000 more than their previous event.

Cherubs Day Nurseries chose Children with Cancer UK as their charity partner of the year in 2024. Their initial fundraising target was £6,500, as all 10 nurseries have a target of £650 to raise. However, their incredible determination and dedication to the cause saw them raise £12,587 during the year.

The Old Red Wall Club finalised their two-year fundraising for Children with Cancer UK at the end of 2024. One of the members, Chris, went into remission in 2022, but was struck by the fact that children as young as his own daughter were undergoing the same intensive therapy as himself without any extra preparation. Throughout the past two years, the club have taken on many sporting events and have collectively raised £20,097 for the charity. We are so grateful for their brilliant support.

Our campaign Pyjamarama, which went live in 2023, has grown and reached even more groups. Children were able to wear their pyjamas to their school or their youth group for a day, in return for a donation, in solidarity with the children undergoing treatment, who spend most of their time in their favourite pyjamas. We had 142 schools and organisations signed up, raising over £20,000.

These achievements highlight the incredible impact our supporters have made, furthering our mission and bringing hope to children and families affected by cancer.

Corporate

In 2024 we had a new corporate team join the charity. The Lazard partnership, that was secured in 2023, was able to kick off their fundraising and awareness raising, with volunteers from Lazard helping the charity throughout the year at multiple charity events. WTW's efforts increased and surpassed the original goal of £200,000 reaching well over £300,000 by the end of 2024. The corporate team also secured a spontaneous £250,000 donation to the charity that is to remain anonymous.

We were thrilled to count on the generous support of MFS once again, whose sponsorship helped bring the Fundraising Gala to life. Their continued partnership has been invaluable in making this signature event a success.

The team secured a new corporate partner in Abbott Lyon, which has been instrumental in raising awareness and providing gifts for our patient families. The partnership with Ladbrokes was extended by a further year, securing their fundraising for 2025.

Building on 2024's progress, 2025 brings new opportunities to deepen corporate partnerships and drive the critical funding needed to advance our work.

Individual Giving

- Gift in Wills saw a total raised of £2.0 million and continues to be a reliable source of income for the charity. We continue to develop marketing initiatives to recruit new pledgers to the charity.
- Our prize-led programme consisting of raffle grand draws and a weekly lottery raised £1.1 million.
- The cash, stewardship and in memory appeals, featuring a mix of inspiring case studies and profiles of the research project we help to fund, raised £1.7 million from existing donors.
- Cause-led regular giving raised £2.9 million.

Retention and Stewardship

Following research to identify key insights to improve the individual giving programme we have implemented a new testing programme to validate the results of the analysis. Initial tests have seen us engage a higher proportion of our warm donors from our appeal programme.

Digital fundraising and acquisition of new donors

Digital remains to be a key marketing channel for Children with Cancer UK. In 2024 we continued with “always on” campaigns implementing a “test and learn” approach across a number of products throughout the year making changes to the adverts and audiences based on performance data. We saw particular success during Childhood Cancer Awareness Month and the Christmas season testing new ad creatives and a refreshed tone of voice.

Fundraising Compliance

Children with Cancer UK values the privacy of all those who support us in our work; we have systems in place to ensure that supporter data is collected, managed and processed in line with all necessary legislation. We are members of the Fundraising Regulator, which has responsibility for regulating fundraising, sets out the Code of Fundraising Practice and investigates and takes appropriate action on cases of public concern. Children with Cancer UK adheres to the Code of Fundraising Practice set by the Fundraising Regulator and fully complies with the Fundraising Preference Service. We comply with charity law, fundraising law and the data protection regulations. We monitor our fundraisers, volunteers and any third parties that work for us to ensure that they adhere to our high standards.

We will ask the donor how they want to hear from us about our work and appeals. If the donor wants to stop hearing from us, they can, email, phone, write or click on the link in our emails. We will always take action, so they can feel confident in contacting us at any time.

We will keep the donor’s personal information secure and will only use it to communicate with the donor; to process orders and donations; to keep the donor informed; for analysis and to improve our activities. We will NOT share the donor’s details with other charities or sell it to businesses. Some organisations help us with our fundraising but will only use the donor’s data under our instruction and only when fully compliant with how we process personal data as set out in our Privacy Policy (Reviewed February 2022).

Children with Cancer UK continues to adhere to and review policies relating to GDPR and work alongside an external consultant, Cyber and Data Protection, to ensure that we are fully compliant.

Children with Cancer UK works with some professional fundraising agencies to assist with certain elements of our fundraising, by telephone and SMS channels. We have robust contracts in place with these agencies, specifying that staff carrying out these activities should be trained and adhere to all applicable laws, regulations and codes, such as the Code of Fundraising Practice and the Data Protection Regulations. We also expect these organisations to reflect our values when talking to supporters and to voluntarily subscribe to the Fundraising Regulator.

To ensure the agencies we engage are operating to the required standards and that people should never feel harassed or pressurised to give, we carry out appropriate monitoring which includes call monitoring, site visits and call listening. We attend training sessions of their staff and give training to staff in respect of each fundraising campaign. We require all our staff and the agencies we deal with to comply with our Vulnerable People Policy, which provides guidance on how to identify a potentially vulnerable person and actions to take to considerably disengage from the fundraising process.

Children with Cancer UK require its staff and any agencies contacting our donors and members of the public on our behalf to comply with the Data Protection Law and guidelines provided by the Fundraising Regulator and Institute of Fundraising. Children with Cancer UK take all reasonable care to protect vulnerable adults in accordance with the Institute of Fundraising guidance set out in their document 'Treating Donors Fairly: Responding to the needs of People in Vulnerable Circumstances and Helping Donors make informed Decisions.' We adhere to the Fundraising Regulator Promise ensuring that our fundraising is legal, open, honest and respectful. We truly value our supporters and still stand by our Supporter Charter as a commitment to our supporters. Our Feedback and Complaints policy was reviewed in March 2023, and we will continue to review this regularly. Complaints are investigated thoroughly and corrective action taken as appropriate. During our financial year (Jan - Dec) 2024 we received 20 complaints across all teams which remains consistent with the previous year (24 complaints.). We continue to work closely with our suppliers to ensure that best practise is followed.

We continue to closely monitor all our fundraising activities and will always strive to ensure they are of the highest standard and reflect the wishes and preferences of all our generous supporters. There may be occasions when we have not met these high standards, and we will work hard to learn from our mistakes and to make sure they don't happen again. If our supporters and members of the public are unhappy with any aspect of our work, we encourage them to give feedback and take any comment or complaint seriously. We use this valuable feedback to help shape our future fundraising campaigns and improve our overall service and commitment to our supporters.

We are here to talk and listen to you - we welcome and actively encourage feedback and make it clear how people can get in touch with us.

A member of the Fundraising Regulator, the independent regulator of fundraising in the UK, Children with Cancer UK is committed to best practice in fundraising and follows the Regulators Fundraising Promise and Code of Fundraising Practice laid down by the regulator.

Special Events

The Really Big Auction

In August, we hosted our inaugural auction for a second year, raising a total of £316,767. With auction items from celebrities like Pink, Coldplay, and the popular TV weather girls' lunch, we offered supporters the chance to bid for once-in-a-lifetime prizes. This event not only raised significant funds but also drew attention to the cause of childhood cancer.

Fundraising Gala

Our annual Fundraising Gala took place on 27 November and raised an incredible £739,172. This magical night of fundraising was instrumental in advancing life-saving childhood cancer research. The event brought together supporters, celebrities, and families, all united in their commitment to making a difference.

The Ultimate Christmas Quiz

In December, we hosted our second annual Christmas Quiz. Hosted by Alex Horne it featured celebrity team captains such as Kelly Jones, Vanessa Feltz, and Matt Goss. The event was a festive and engaging way to bring together supporters for a night of fun music, Christmas cheer and festive food.

Thank You

We would like to sincerely thank all our supporters and fundraisers who helped us to raise £16 million.

Your generosity and creative efforts are helping us to build our vision of a world where every child survives cancer.

Thank you to our dedicated board of trustees.

A very special thank you to all the extraordinary families we have worked with over 2024. Your commitment to helping others facing similar situations is inspirational and only through your stories are we able to show the realities of childhood cancer. **Thank you.**

Financial Review

Incorporating the Directors' Strategic Report and Administrative Report for Companies Act Purposes

The Trustees of Children with Cancer UK present their Annual Report for the year-ended 31 December 2024 under the Charities Act 2011 and the Companies Act 2006, including the Directors' Report and the Strategic Report under the 2006 Act, together with the audited financial statements for the year.

The Consolidated Statement of Financial Activities (SOFA) set out on page 32, shows the financial results for Children with Cancer UK and its trading subsidiary: Helping Children with Cancer Limited.

This financial year has been a period of both challenge and opportunity for our charity, as we continue to advance cancer research through innovative projects and dedicated support.

Overview of Financial Performance

During 2024, the charity generated total income of £17.2 million (2023: £15.2 million), representing a 13% increase from the previous year. The key contributors to this increase were a rise in donations and legacies, which continue to form the backbone of our funding, and significant growth in other trading activities.

- Donations and legacies totalled £14.8 million (2023: £13.6 million) an increase of £1.2m year on year, reflecting the ongoing generosity of our supporters and partners. Our continued focus on donor engagement and fundraising activities has ensured stable growth in this crucial area.
- Other trading activities generated £1.1 million (2023: £883,917), an increase of 28%. This growth can be attributed to our expanded fundraising events and initiatives, which have proven successful in increasing engagement with corporate partners and the public.
- Income from investments grew substantially to £568,085 (2023: £453,300) due to improved market conditions and a proactive approach to managing our investment portfolio.

Additionally, we received other income of £641,260 (2023: £211,823), a substantive increase from the previous year, which reflects the charity's ability to secure supplementary funds through grants and miscellaneous sources.

The growth in the revenue is attributed to the valued initiatives by all staff. They have been creative in all aspects of the business, thinking outside the box, making the charity a collaborative hub, bursting with enthusiasm and a passion to succeed.

Expenditure

The charity's total expenditure for the year amounted to £14.1 million (2023: £12.1 million), reflecting a 17% increase from the previous year. This increase is attributed to a 37% increase in raising funds. Charitable activities increased expenditure by 11% due to increases in direct costs.

- Overall staff costs have reduced year on year by 34% to £1.7m, while direct costs have increased by 36% to £10.8m and support and governance by 1% to £1.6m.
- Expenditure on raising funds amounted to £3.4 million (2023: £2.4 million), representing a modest increase, driven by the need to sustain our fundraising efforts. With the increase in revenue, additional resources had to be allocated to achieve this.
- Expenditure on charitable activities was £10.7 million (2023: £9.6 million). Raising awareness and welfare saw an expansion in their costs, brought forward in investments to create awareness of the charity. The expenditure on research continued to grow to £5.8 million.

Net Movement in Funds

The charity achieved a net income of £3.7 million (2023: £3.5 million), reflecting a strong financial position by year-end. This positive movement includes the gain in investments of £627,118 (2023: a gain of £441,084), which underscores the strength of our investment strategy.

Financial Position and Reserves

At 31 December 2024, the charity's total funds stood at £22.1 million, an increase from £18.4 million in 2023. This improvement is a result of prudent financial management, effective fundraising, and strong investment performance.

- Fixed assets increased to £18.0 million (2023: £16.2 million), largely due to the acquisition and valuation of property and investment assets.
- Net current assets increased to £12.7 million (2023: £8.6 million), ensuring that the charity remains in a strong position to meet its short-term obligations.
- Creditors due within one year decreased to £6.6 million (2023: £7.8 million).

Despite an increase in long-term grant commitments (creditors due after one year), the charity remains well-positioned to meet its obligations while ensuring the continuation of its mission.

The financial results for 2024 highlight the charity's resilience and ability to adapt to changing circumstances. With a strong financial base, we are well-equipped to continue funding innovative cancer research and supporting those affected by cancer. The Trustees would like to thank all donors, supporters, and staff for their ongoing contributions, which are vital to our success.

We remain committed to ensuring financial stability and transparency, and we are confident that we will continue to make significant progress in the year ahead.

Reserves

At the end of the year, the charity held £22.1 million in total reserves (2023: £18.4 million), £21.7 million of which was classified as unrestricted reserves. There were restricted reserves at year-end of £422,830, as outlined in Note 20.

Unrestricted reserves are generated when supporters do not stipulate specific restrictions on how their donations must be spent. These funds are, therefore, available to be applied at the discretion of the Trustees to any of the charity's charitable objectives. This flexibility enables the Trustees to allocate resources efficiently and in response to the changing needs of the charity's operations and programmes.

Purpose of Reserves

The Trustees are mindful of their role as stewards of these funds and remain committed to ensuring that reserves are managed prudently. The reserves serve a dual purpose:

- **Operational Stability:** A portion of the reserves provides a financial buffer, ensuring that the charity can continue to operate and meet its obligations even in periods of reduced income. This buffer is critical for protecting the charity from unforeseen financial pressures and maintaining stability.
- **Grant Award Programmes:** The reserves also ensure the continuation of the charity's grant-making activities, enabling the Trustees to fund essential cancer research projects in the forthcoming year, irrespective of short-term fluctuations in income.

Future Considerations

The Trustees remain vigilant in monitoring both income levels and operational needs. The reserves policy will be reviewed in 2025 in light of future projects, potential risks, and the external environment. The Trustees will consider the financial challenges posed by inflationary pressures, donor behaviours, and economic uncertainty when reassessing the appropriate level of free reserves required to safeguard the charity's long-term sustainability.

The Trustees are confident that the current reserves position, alongside careful financial planning, places the charity in a strong position to meet its strategic objectives while continuing to provide valuable support to cancer research and those affected by cancer.

Our Strategy

Children with Cancer UK maintains a strategy focused on three pillars: awareness, research, wellbeing and support.

Building awareness of childhood cancer for the future

At Children with Cancer UK, we are forward-thinking in our approach to raising awareness and driving progress in the conversation about childhood cancer. Children with Cancer UK would like to become a louder advocate for our beneficiaries and research partners and drive a tangible change in treatment and care. By coming together with other charities, we can share resources, amplify our collective visions, and become a stronger voice for children with cancer. These collaborations will enable us to share learnings, accelerate change, and make a bigger impact in raising awareness. Our 'Kids Like Us' film is an example of raising awareness, sparking vital conversations and bringing the personal stories of children with cancer to the forefront, ensuring these voices are heard. The documentary has now received international recognition and can be viewed in over 101 countries. The documentary is a first of its kind in the charity sector and amplifies the creativity the team has brought forward to make awareness more impactful.

Our commitment to research

Children with Cancer UK understands the need to increase opportunities for grant applications, investment in state-of-the-art research facilities and equipment, while collaborating with other charities and organisations on research and treatment development. We fund a diverse portfolio of projects from discovering new treatments to supporting and investing in clinical trials. Our objective is to broaden our existing program across more stages of the research spectrum while expanding the research community in the field of childhood cancer.

Our research program is evolving to ensure that we make a greater impact through an even more strategic use of our funding. First, we wish to develop improved treatments so that more patients are cured with less toxic side effects. Second, we wish better to understand how cancer develops so that one day we may be able to prevent it. Our aim is to enable every child to survive cancer.

In collaboration with our Scientific Advisory Panel, we are reviewing our Research Strategy to ensure that every investment delivers the maximum benefit for children and families. We wish to invest in research that will deliver the greatest impact. A key part of this strategy is the continuation of our annual grants program, which supports pioneering research projects that will drive progress and create lasting change. By focusing our resources where they will have the greatest impact, we are confident that we can make a meaningful difference for children and young people with cancer.

Prioritising the families we support

Children with Cancer UK consults regularly with patients and families to determine their needs while trying to deliver the best support possible.

Children with Cancer UK remains dedicated to supporting families throughout their cancer journey. As part of this commitment, we are investing in the development of Raines Retreat, a new facility in North Yorkshire that will provide a welcoming and comfortable break for families. This significant investment in capital works marks the first step in ensuring the centre is fit for purpose, and we look forward to opening its doors in 2026. Alongside this, we are proud to celebrate our partnership with Spread a Smile and our continued collaboration with Beads of Courage UK, two vital programmes dedicated to enhancing the wellbeing of children during treatment.

In addition, we are taking steps to ensure that the voices of those with lived experience are more deeply embedded in our work with the help of our Patient and Public Involvement initiative. Our goal is to ensure that their insights and experiences inform our decision-making at every level. By including patient voices in everything we do, from funding cutting-edge research to improving support services, we can ensure our work remains as impactful as possible. We look forward to sharing more details soon on how families and individuals can offer their valuable input to our mission at Children with Cancer UK.

Our mission is: 'Through our pioneering research, we develop new methods for identifying and treating childhood cancers. Our aim is to improve survival as well as quality of life during and post-treatment for children, teenagers, and young adults with cancer. We help the public and scientific community understand the issues around childhood cancer better'.

Human Resources

Introduction

As the charity continues to grow and evolve in its mission to combat paediatric cancer, the focus on its people is more critical than ever. The performance and sustainability of the charity's workforce are vital in achieving our strategic goals. This report outlines key HR metrics for 2024 and highlights the priorities and initiatives for 2025 that will support employee engagement, development, and retention.

Workforce Overview

As of December 2024, the charity employed 42 staff members (2023: 41) across various roles, including fundraising, research, administration, and frontline services. The workforce is diverse, dedicated, and mission driven.

Staff Turnover

While turnover was in line with industry averages for the charity sector, the charity keeps improving its enhanced employee engagement, development, and support strategies to foster retention and job satisfaction.

HR Strategic Focus for 2025: The People Plan

The People Plan for 2025 focuses on the alignment of HR practices with the charity's long-term goals, with an emphasis on improving retention, employee wellbeing, and engagement. The following initiatives have been identified as priority areas for development and execution throughout the year:

Safeguarding

At Children with Cancer UK, safeguarding is at the heart of everything we do – not only for the children and families we serve, but also for our employees, volunteers, partners, and everyone connected to our mission. We are committed to creating a safe, respectful, and supportive environment where every individual feels protected and valued.

Key improvements include:

- Ongoing support and guidance for the newly appointed Designated Safeguarding Lead, Fiona Judge, through the new safeguarding team, made up of staff from across various departments.
- Regular training and updates for staff to stay informed and confident in safeguarding practices.

Review of Employee Contracts, Policies, and Handbook

We constantly review and update all employee contracts, policies, and the staff handbook to:

- Ensure they meet best practice standards, reflecting current employment law and sector norms.
- Address gaps identified through employee feedback and recent internal reviews.

Review of EDI Policy and Practices

Equity, Diversity, and Inclusion (EDI) remain a central focus for the charity. In 2025, we will:

- Conduct a thorough review of existing EDI policies and practices.
- Work with external consultants to identify areas for improvement, ensuring the charity remains a welcoming and inclusive workplace for all.

The charity's focus on its people is integral to its continued success and ability to deliver its mission. The activities outlined in the People Plan will drive meaningful improvements in employee satisfaction, retention, and engagement. By investing in our workforce, we are ensuring that we have the right talent, skills, and commitment in place to achieve our strategic objectives and support the ongoing fight against paediatric cancer.

The HR team will monitor the progress of these initiatives throughout the year and continue to gather feedback to ensure that we remain agile and responsive to the needs of our staff.

Going Concern

The Trustees have carefully considered the organisation's ability to continue operating as a going concern and are confident that it remains sustainable for the foreseeable future—defined as at least 12 months from the date of approving these financial statements.

In reaching this conclusion, they reviewed key financial indicators including cash flow forecasts, liquidity, reserves, and the approved budget for the year ahead. As part of this process, a range of potential risks were evaluated, such as fluctuations in income from donations and investments, inflationary pressures, and any unforeseen operational challenges.

While the broader economic environment remains uncertain, the charity has a resilient financial foundation. A strong mix of income streams, stable support from donors and partners, and responsible stewardship of resources have helped ensure year-on-year surpluses and healthy unrestricted reserves. This enables us to continue funding essential research, support services, and capital projects without interruption.

Our income strategy continues to perform well, supported by committed individual donors, corporate relationships, and grant-making organisations. Alongside this, operational discipline has allowed us to control costs effectively and plan with confidence.

Future planning incorporates regular scenario testing and sensitivity analysis, helping us stay responsive to emerging risks and adapt where necessary. With this proactive approach, we're well placed to meet upcoming challenges while remaining focused on our mission.

Taking all these factors into account, the Trustees have no material uncertainty about the organisation's ongoing viability. As such, the financial statements have been prepared on a going concern basis.

Investments

In accordance with the charity's *Memorandum of Association* and its *Investment Policy*, the Trustees are authorised to invest funds in various manners, following professional advice where appropriate. This approach ensures that investments remain well-diversified, suitable to the charity's needs, and aligned with its long-term objectives and risk tolerance.

Investment Objectives

The overarching aim of the charity's investment strategy is to support its charitable activities—particularly the funding of vital research—while maintaining financial resilience. The specific investment objectives are:

- **Generate Sustainable Returns:** To achieve a total return typically in the region of CPI +3% per annum over the long term, within a low to medium risk tolerance.
- **Enable Grant Funding:** Investments must support the charity's capacity to award research grants while seeking to achieve capital growth and inflation protection.
- **Preserve Real Capital Value:** Ensuring that invested funds retain their value in real terms, considering inflation and other economic factors.

Current Investment Portfolio

As of 31 December 2024, the charity's investment assets were allocated as follows:

- **Long-Term Investments: £12.8 million**
- **Short-Term Cash Deposits: £4.9 million**, held in low-risk, liquid accounts to meet near-term operational and grant-related cash requirements.

The portfolio remains appropriately diversified across asset classes and investment managers, in line with the charity's risk framework and liquidity needs.

Investment Strategy and Risk Management

The Trustees continue to implement a disciplined investment strategy guided by the following principles:

- **Diversification:** Investments are spread across different asset classes and managers to reduce risk and enhance potential returns. The charity currently uses Barclays Investment Managers and Rathbones Wealth & Investment to manage long-term funds, ensuring professional oversight and diversification.
- **Liquidity and Risk Alignment:** Funds earmarked for short-term obligations—particularly grant commitments—are held in instant-access, capital-secure deposits. This ensures funds remain readily available and protected from market fluctuations.
- **Ongoing Monitoring and Governance:** Investment performance is reviewed regularly against agreed benchmarks. The strategy is subject to periodic review by the Finance & Investment Committee, with oversight from the Board of Trustees, to ensure it remains fit for purpose in evolving economic conditions.

In 2024, the portfolio performed in line with expectations, delivering satisfactory returns within the defined risk parameters. Looking ahead to 2025, the charity is actively exploring opportunities to enhance returns through potential reallocation to higher-performing funds—while maintaining appropriate diversification and prudent risk controls.

Cash Management and Grant Liabilities

As part of its cash management approach, the charity maintains sufficient cash levels to cover fluctuating needs and anticipated grant liabilities. At year-end, anticipated grant liabilities stood at approximately £13.1 million (2023: £13.0 million). All short-term funds are managed conservatively, with capital preservation as the primary objective, recognising their role in fulfilling future commitments.

Forward Outlook and Strategic Alignment

The Trustees remain committed to maintaining an investment policy that balances the need for capital growth with the operational requirement for liquidity and financial prudence. The policy is reviewed regularly to reflect changes in market conditions, macroeconomic trends, and the evolving strategic priorities of the charity.

By maintaining a structured and agile investment approach, underpinned by strong governance and expert advice, the charity is well positioned to deliver on its mission—funding ground-breaking research and supporting children with cancer—while safeguarding its long-term financial sustainability.

Risk and Internal Control Governance and Oversight

The Trustees have overall responsibility for ensuring that Children with Cancer UK maintains a robust and proportionate system of internal control—covering both financial and operational activities. This framework is designed to safeguard the charity's assets, support the delivery of strategic objectives, and ensure resources are used effectively, efficiently, and in compliance with all applicable laws and regulations.

The Board is fully committed to protecting the charity from fraud, financial mismanagement, data breaches, and other risks that could compromise its mission, reputation, or operational effectiveness.

Key Areas of Internal Control Safeguarding of Assets

Comprehensive measures are in place to prevent the unauthorised use, loss, or misappropriation of assets. These include:

- Secure handling and banking of donations.
- Professional management of investments with oversight from the Trustees.
- Authorisation protocols for significant transactions.
- Periodic reconciliation and physical asset verification.

All investment portfolios are managed by FCA-regulated firms, with performance and risk reviewed regularly against agreed mandates.

Financial Accuracy and Transparency

The charity maintains a robust financial control environment to ensure the reliability of internal and external financial information. Key processes include:

- Maintenance of complete and accurate accounting records.
- Regular bank reconciliations and review of income and expenditure reports.
- Compliance with the Charities SORP and relevant UK accounting standards.

All financial reporting used for strategic decision-making undergoes rigorous review to ensure clarity, completeness, and timeliness.

Legal and Regulatory Compliance

The charity complies with all statutory and regulatory requirements relevant to its operations, including those relating to charity law, data protection, fundraising, and employment. Trustees and key staff receive regular updates and training to remain informed of legislative changes and sector expectations.

Risk Management Framework

The Trustees recognise that proactive and structured risk management is essential to the effective operation of the charity. The framework comprises:

Risk Identification and Assessment

Risks are regularly identified and assessed across all areas of activity—strategic, operational, financial, reputational, and compliance. Specific focus is given to:

- Grant and research funding risks.
- Fundraising volatility.
- External economic and regulatory changes.
- IT security and data protection.
- Safeguarding and staff conduct.

Each identified risk is assessed based on likelihood and impact and is recorded in a central risk register.

Mitigation and Monitoring

Risk mitigation strategies include the use of:

- Segregation of duties and authorisation thresholds.
- Insurance cover for key operational and liability exposures.
- Oversight by Finance, Audit and Risk Committee.
- Regular internal and external audit activity to test the effectiveness of controls.

The risk register is reviewed quarterly and updated to reflect emerging risks and actions taken.

Fraud and Safeguarding Controls

The charity operates a zero-tolerance approach to fraud and safeguarding breaches. Key measures include:

- A formal Whistleblowing Policy.
- Clear escalation procedures for concerns.
- Periodic fraud risk reviews.
- Ongoing staff training on safeguarding principles and ethical behaviour.
- Prompt investigation of any reported incidents, with appropriate action taken.

Continuous Improvement and Assurance

While no system of internal control can eliminate all risk, the charity's control environment is designed to provide reasonable assurance that key risks are being managed effectively.

The Trustees are committed to continuous improvement. Lessons learned from audits, operational reviews, and incidents are incorporated into updated procedures, with accountability built into reporting lines. Regular self-assessments and third-party reviews are used to benchmark and strengthen the overall control framework.

The Trustees are satisfied that the current internal control and risk management arrangements are appropriate for the scale and complexity of the charity. These systems provide a sound basis for maintaining public trust, protecting assets, supporting strategic delivery, and ensuring the charity continues to operate effectively in pursuit of its mission.

Principal Risks and Uncertainties

Overview

The Charity faces several principal risks and uncertainties in the current economic climate. These risks are regularly reviewed by the Trustees, and appropriate mitigation strategies are implemented to ensure the continued effectiveness and stability of our operations.

The following risks are deemed low but are reviewed frequently.

Principal Risks

Fundraising Risks:

The Charity remains heavily reliant on mainstream fundraising income to support its research activities. A significant risk is that income may decline due to economic pressures, which could impact our ability to fund research effectively and maintain stable reserves. To manage this risk, we are diversifying our income streams, investing in new fundraising channels, and continuously monitoring the impact of economic conditions on donor behaviour and contributions.

Economic Climate:

The current economic climate in the UK, including inflationary pressures, geopolitical wars and increased cost of living, poses risks to our operational and financial stability. These economic factors can affect both the availability of donor funds and the cost of delivering our programs but more importantly the value which can be earned on our investments through dividends and growth. We are actively reviewing our expenditure, renegotiating contracts where possible, and seeking efficiencies to mitigate these impacts.

Regulatory Compliance:

Ensuring compliance with relevant laws and regulations remains a critical focus. This includes adapting to any new regulatory requirements and maintaining rigorous internal controls to ensure ongoing compliance. This would include the new SORP accounting framework being reviewed at the moment.

Infrastructure & Operations:

Risks related to the adequacy and reliability of our infrastructure and operations are continuously assessed. This includes managing operational costs and ensuring that our systems and processes are resilient to economic fluctuations.

Charitable Impact:

Assessing the effectiveness and impact of our research funding is crucial. We need to ensure that our funding decisions are aligned with our strategic objectives and that funded projects deliver meaningful outcomes.

Profile & Brand:

Managing the Charity's profile and brand reputation is essential, particularly in a competitive fundraising environment. Maintaining a strong public image and effectively communicating our mission and impact are key to sustaining donor support.

Financial Risks:

Financial management risks include ensuring that our investment portfolio performs well and that we maintain sufficient reserves. We regularly review our investment strategy to balance returns with acceptable risk levels and ensure that our financial position remains robust.

Governance:

Effective governance is critical to the Charity's success. This involves ensuring that our governance structures are robust, that Trustees and management are well-supported, and that we adhere to best practices in governance and oversight.

Mitigation Strategies

Each identified risk is assessed in terms of its probability and impact, with mitigation strategies developed as necessary. These strategies include:

Diversification: Expanding fundraising activities and income sources to reduce reliance on any single source of funding.

Cost Management: Implementing stringent expenditure controls and seeking efficiencies to manage the impact of economic pressures.

Regular Review: Continuously monitoring financial performance and operational effectiveness to adapt to changing conditions.

Governance Improvements: Ensuring that governance practices are regularly reviewed and enhanced to address emerging challenges.

Policies: Update of policies and procedures to mitigate risk is ongoing with regular review and suggestions implemented.

Financial Position and Stability

Despite these risks, the Charity is in a strong financial position. The current reserves and diversified income streams provide a solid foundation for managing potential financial impacts. The Charity's robust financial management and strategic planning ensure that we can weather economic fluctuations and maintain operational stability. There is no indication of financial instability, and any potential issues can be effectively mitigated through our established risk management processes. The charity has ample resources to weather storms and can continue to trade if needs must through tough geopolitical conditions.

Trustee and Management Oversight

The trustees and senior leadership team regularly review and discuss these principal risks as part of our risk management strategy. We remain committed to addressing these risks proactively to safeguard the Charity's mission and ensure its continued success.

The trustees and senior leadership team are dedicated to managing the Charity's risks effectively in the current economic climate. By maintaining a proactive approach to risk management and adapting to changing conditions, we aim to support our mission of funding impactful cancer research and achieving our strategic objectives.

Structure, Governance and Management

The financial statements have been prepared in accordance with current statutory requirements, the Memorandum and Articles of Association, the Accounting and Reporting by Charities Statement of Recommended Practice (SORP FRS 102), and applicable accounting standards (FRS 102).

Governing Documents

These financial statements are for Children with Cancer UK and its subsidiary Helping Children with Cancer Limited.

Children with Cancer UK is a company limited by guarantee and operates under its Memorandum and Articles of Association dated 11th November 2003 as amended by special or written resolutions, dated 30th November 2004, 22nd December 2006, 12th May 2007, 28th July 2016 and 13th December 2021 and finally 20th January 2025.

On 14th May 2007 the reporting charity changed its name from CHILDREN with LEUKAEMIA UK to Children with Cancer UK. However, the charity continued to use the working name of CHILDREN with LEUKAEMIA until 11th May 2011.

The charity operates under its Trust Deed (dated 4th January 1988) and Variation of Trust Deed (dated 10th December 2003).

The Trustees have reviewed and acknowledge the principles and recommendations outlined in the Charity Governance Code. The Senior Leadership Team was assigned the responsibility of evaluating the Charity's governance practices against the Charity Governance Code and identifying key areas for improvement. Following this assessment, it was recommended that an independent Governance Review be conducted. The Trustees authorized this review and directed the Senior Leadership Team to implement all recommendations.

Significant progress has been achieved, with majority of the recommendations successfully implemented. Plans are in place to address the remaining items within the next 12 months.

Aims and Objectives

Purposes and Aims

The charity's objects as amended by written resolution of 12th May 2007, and 28th July 2016 are shown below:

- To promote the relief of children and young people suffering with leukaemia or any other form of cancer (and allied disorders) and of their families;
- To raise public awareness and knowledge in matters relating to leukaemia or any other form of cancer (and allied disorders) affecting children and young people; and
- To promote research into the causes, alleviation, prevention, treatment and cure of leukaemia or any other form of cancer (and allied disorders) affecting children and young people and to publish the useful results of such research.

Our aims are to determine the causes, find the cure and provide care for children with cancer.

We fund life-saving research into the causes, prevention and treatment of childhood cancer.

We fund innovative welfare projects to provide better care for young cancer patients and their families.

We campaign to raise awareness of childhood cancer to protect more children and to improve the lives of young cancer patients, today and for future generations.

We are a member of the Association of Medical Research Charities. We are also a member of the National Cancer Research Institute.

Further details of the projects we fund are detailed in note 23.

Public Benefit

The Trustees continue to give due regard to the public benefit provided by the charity in relation to its charitable purpose as set out by the objectives above and have given due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the activities that promote the charitable objects above will be applied to provide public benefit.

Board of Trustees

The governing body of the reporting charity is the Board of Trustees, which has a total of six members (2023: five). The Trustees of the charity also act as the Directors of the charitable company. The Board meets at least three times a year together with the Chief Executive and other senior management where appropriate.

The Finance, Audit and Risk committee is a subcommittee of the Board. The subcommittee meets at least quarterly and consists of a combination of Trustees, Staff and External Advisors and Specialised Volunteers (if required). The committee will draw to the attention of the Board any urgent issues that require authorisation, disclosure or action and escalate any urgent issues for immediate attention outside of the Board meeting schedule. The charity is in the midst of setting up other committees and expanding the board members to achieve a wholistic representation for the charity.

Trustee appointment and induction

There was one new appointment (2023: two) to the Trustee Board in 2024. Three Trustees left the board during 2024 (2023: two). The selection of Trustees is made based on vacancies arising, sympathy with the objects of the charity and the additional skills and experience that potential new Trustees are able to afford. Under the Articles of Association, Trustees are appointed by a majority vote of the members (who are all the current Trustees) by ordinary resolution.

Each new Trustee receives the Charity Commission publication 'The Essential Trustee: What you need to know', the most recent published annual report and other resources deemed necessary to complete the appointment. The Chief Executive Officer and Chair offer an induction day to all Trustees which provides full information about the operations of the charity.

Management

The Trustees exercise executive responsibility for the governance of the charity and, through the Chairman, supervise the management of the charity by the Chief Executive Officer and the executive team. The Chairman and Chief Executive Officer also task the Board with decision-making on strategic management issues as well as overseeing the research grants application process and monitoring the progress of awarded grants.

The senior management carry out the operational running of the charity and the coordinating of fundraising appeals and events.

Remuneration

The salaries of Children with Cancer UK staff are periodically benchmarked against other charities and commercial institutions to ensure that salary levels are market competitive and sufficient to attract and retain staff of the appropriate calibre. All staff posts are periodically evaluated to ensure that salary levels are reflective of industry and organisational needs, as well as individual and charity performance. The London Living Wage was used as a minimum for all new hirers. In recruitment of a new post, an assessment is made of the requirements of the role in terms of skills, experience, competency and urgency. The salary is then determined on the basis of this assessment and the current market conditions.

Salary Bands have been set based on external benchmarking, anecdotal data from head-hunters and recruiters, and charity sector salary surveys. The Salary Bands are reviewed at least every two years.

The Charity is compliant with the Hutton Fair Pay Review with the salary of the highest paid employee being no more than four times the median salary of the organisation.

Trading Subsidiary

Helping Children with Cancer Limited (company registration 2807553) is the wholly owned trading subsidiary of Children with Cancer UK. Its principal purpose is to raise funds for the charity and all taxable profits are donated under Gift Aid.

The principal activity of the Company is the licensing of the name and logo of the charity for use in corporate sponsorship, commercial agreements and royalties from contribution to clinical trials.

The trading activities generated profit for the year of £593,637 (2023: £109,048) which will be paid to Children with Cancer UK under the Gift Aid Scheme.

The trading subsidiary holds assets of £652,053 (2023: £148,893) and liabilities of £652,053 (2023: 148,793) with funds of £100 as at 31st December 2024.

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

Related parties

The Charity has a related party and conflict of interest policy in place which accompanies the Declaration of Interests submissions completed by all Trustees and senior management. A Conflicts of Interest register is in place which is updated when a conflict of interest is declared or has been identified and the register is reviewed at least annually.

Grant making policy

It is the Trustees' policy to maximise the proportion of its charitable output that is achieved through grant making.

Welfare grants

There is no open application process for welfare grants and no welfare grants are given to individuals. The Trustees determine which organisations are to be supported.

Research grants

The Trustees aim to award an increasing proportion of the charity's grants to scientific and medical research in cancers affecting children, teenagers and young adults. The charity's Code of Practice adheres to the standards set by the Association of Medical Research Charities (AMRC).

The charity advertises guidelines and invite applications for project grant rounds. Project applications are subject to formal internal and external peer review followed by scrutiny by our Scientific Advisory Panel (SAP) before the Trustees determine which projects to support. We also occasionally support research through other charity partners.

Reference and Administration

Children with Cancer UK (previously known as CHILDREN with LEUKAEMIA UK) was set up in memory of Paul O'Gorman who died on 6th February 1987 and his sister Jean, who died on 3rd November 1987. The charity was inaugurated by Diana, Princess of Wales on 12th January 1988 at Mill Hill County High School where Paul had been a pupil.

Trustees

The Trustees of Children with Cancer UK are the charity's Trustees under charity law and the directors of the charitable company:

Current Trustees

David Gibbs (Chair of Trustees)
Phil Hall
Bruce Morland
Sara Wakeling (Appointed 10th January 2025)
Nick Bird (Appointed 18th June 2025)
Tamara Ludlow (Appointed 26th June 2025)

Previous Trustees

Lindsey Cape (Resigned 29th February 2024)
Sarah Standing (Resigned 13th September 2024)
Alex Leitch (Resigned 10th October 2024)

Senior Leadership Team

Gavin Maggs (CEO)
Selina Wedderburn (Head of HR)
Ben Angus (Head of Research)
Fadil Dugolli (Head of IT)
Fiona Judge (Head of Supporter Care)
Hannah Chambers (Head of Marketing and Communications)
Ari Kotsis (Chief Finance Officer)
Alex Hayward (Head of Public Fundraising)

Registered Charity Number

298405

Registered Company Number

4960054

Principal office

21-27 Lamb's Conduit Street, London, WC1N 3NL

Auditors

PKF Littlejohn LLP, 15 Westferry Circus, London E14 4HD

Solicitors

Simons Muirhead Burton, 87-91 Newman St, London, W1A 4UQ

Bankers

National Westminster Bank PLC, 30 North Audley Street, London W1A 4UQ

Contact details

Children with Cancer UK

21-27 Lamb's Conduit Street, London, WC1N 3NL

Tel: 020 7404 0808

Email: info@childrenwithcancer.org.uk

www.childrenwithcancer.org.uk

Scientific Advisory Panel

We are indebted to the members of our Scientific Advisory Panel (SAP) who freely give their time and expertise to help drive forward our fight against cancers affecting children and young people. Research into cancers affecting children and young people is a broad field and we aim to reflect the diversity of the field amongst the membership of panel members.

Dr Christina Halsey continues to chair the Scientific Advisory Panel.

Statement of Trustees' Responsibilities

The Trustees (who are also directors of Children with Cancer UK for the purposes of company law) are responsible for preparing the Strategic Report, the Trustees' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and the group for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently.
- observe the methods and principles in the Charities SORP.
- make judgments and estimates that are reasonable and prudent.
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company and group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions, disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006 and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Insofar as each of the Trustees of the charitable company at the date of approval of this report is aware there is no relevant audit information (information needed by the charitable company's auditor in connection with preparing the audit report) of which the charitable company's auditor is unaware. Each Trustee has taken all of the steps that he/she should have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the charitable company's auditor is aware of that information.

This Annual Report of the Trustees, prepared under the Charities Act 2011 and the Companies Act 2006, was approved by the Board of Trustees on 26th September 2024 including approving in their capacity as company directors the Strategic Report contained therein, and is signed as authorised on its behalf by:



David Gibbs
Chair of Trustees
Date: 24th September 2025

Independent Auditor's Report to the Members of the Children with Cancer UK

Opinion

We have audited the financial statements of Children with Cancer UK (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2024 which comprise the Consolidated Statement of Financial Activities, the Consolidated and Parent Charitable Company Balance Sheets, the Consolidated Cash Flow Statements and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2024, and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's or parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees' annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the trustees' annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial

statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report, which includes the strategic report and the directors' report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors' report included within the trustees' report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report included within the trustees' annual report.

Under the Companies Act 2006 we are required to report in respect of the following matters if, in our opinion:

- adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

We have nothing to report in respect of these matters.

Responsibilities of trustees

As explained more fully in the statement of trustees' responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the group and parent charitable company financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the group and parent charitable company financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed auditor under the Companies Act 2006 and report in accordance with this Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that

includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

- We obtained an understanding of the group and parent charitable company and the sector in which they operate to identify laws and regulations that could reasonably be expected to have a direct effect on the financial statements. We obtained our understanding in this regard through discussions with management, sector research, application of cumulative audit knowledge and experience.
- We determined the principal laws and regulations relevant to the group and parent charitable company in this regard to be those arising from Companies Act 2006, Charities Act 2011 and employee and tax legislation.
- We designed our audit procedures to ensure the audit team considered whether there were any indications of non-compliance by the group and parent charitable company with those laws and regulations. These procedures included, but were not limited to enquiries of management, review of minutes, and review of regulatory correspondence.
- We also identified the risks of material misstatement of the financial statements due to fraud. We considered, in addition to the non-rebuttable presumption of a risk of fraud arising from management override of controls, that there was the potential for management bias in the recognition of legacy income. To address this risk we tested a sample of legacies to evaluate whether the income had been recognised appropriately under the Charities SORP, including a review of post year end correspondence to assess the completeness of legacy income.
- We also identified potential for management bias in the recognition of grant expenditure in the correct accounting period. To address this risk we tested a sample of agreements between the charitable company and its beneficiaries to evaluate whether the expenditure and the corresponding payment or creditor have been recognised appropriately.
- We also identified potential for management bias in the classification of funds between restricted and unrestricted. To address this risk we tested a sample of income and expenditure in the year to assess whether they have been classified appropriately.
- As in all of our audits, we addressed the risk of fraud arising from management override of controls by performing audit procedures which included, but were not limited to: the testing of journals; reviewing accounting estimates for evidence of bias; and evaluating the business rationale of any significant transactions that are unusual or outside the normal course of business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: <https://www.frc.org.uk/library/standards-codes-policy/audit-assurance-and-ethics/auditors-responsibilities-for-the-audit/>

. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone, other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Alastair S. Duke (Senior Statutory Auditor)
For and on behalf of PKF Littlejohn LLP
Statutory Auditor

15 Westferry Circus
Canary Wharf
London E14 4HD

25th September 2025

Consolidated statement of financial activities for the year ended 31 December 2024

(Incorporating an income and expenditure account)

	Note	Total restricted funds £	Total unrestricted funds £	Total 2024 £	Total 2023 £
Income from:					
Donations and legacies	4	732,833	14,105,220	14,838,053	13,643,162
Other trading activities	4	-	1,134,242	1,134,242	883,917
Income from investments		-	568,085	568,085	453,300
Other income		176,495	464,765	641,260	211,823
Total Income	20	909,328	16,272,312	17,181,640	15,192,202
Expenditure on:					
Raising funds	6	-	3,360,139	3,360,139	2,447,063
Charitable activities	6, 8	486,498	10,251,930	10,738,428	9,644,899
Total Expenditure	6	486,498	13,612,069	14,098,567	12,091,962
Net change in investments	14	-	627,118	627,118	441,084
Net (expenditure)/income		422,830	3,287,361	3,710,191	3,541,324
Transfers between funds		-	-	-	-
Net movement in funds		422,830	3,287,361	3,710,191	3,541,324
Reconciliation of funds:		-	-	-	-
Total funds brought forward		-	18,381,604	18,381,604	14,840,280
Total funds carried forward	20	422,830	21,668,965	22,091,795	18,381,604

The comparative figures for each fund are shown in note 3 to the financial statements.

Balance sheet as at 31 December 2024

Company Number: 4960054

	Note	2024		2023	
		Group £	Charity £	Group £	Charity £
Fixed assets					
Property	12	3,742,724	3,742,724	2,495,899	2,495,899
Intangible Assets	13	1,479,585	1,479,585	1,500,584	1,500,584
Investments	14	12,751,354	12,751,454	12,162,502	12,162,602
		17,973,663	17,973,763	16,158,985	16,159,085
Current assets					
Debtors and prepayments	15	3,172,781	3,383,447	2,765,835	2,924,038
Cash deposits		4,889,610	4,889,610	4,751,924	4,751,924
Cash at bank and in hand		11,176,934	10,955,836	8,911,885	8,762,992
		19,239,325	19,228,893	16,429,644	16,438,954
Creditors: amounts falling due within one year					
Grants	16	(4,554,027)	(4,554,027)	(6,590,941)	(6,590,941)
Other	17	(2,004,247)	(1,993,915)	(1,209,970)	(1,219,380)
Net current assets		12,681,051	12,680,951	8,628,733	8,628,633
Total assets less current liabilities		30,654,714	30,654,714	24,787,718	24,787,718
Creditors: amounts falling due after more than one year					
Grants	16	(8,562,919)	(8,562,919)	(6,406,114)	(6,406,114)
Net assets		22,091,795	22,091,795	18,381,604	18,381,604
Represented by:					
Unrestricted funds	20	21,668,965	21,668,965	18,381,604	18,381,604
Restricted funds	20	422,830	422,830	-	-


The net surplus for the financial year dealt within the financial statements of the parent charitable company was £3,710,191 (2023: net surplus £3,541,324).

The notes on pages 34 to 49 form part of the financial statements.

Approved and authorised for issue on behalf of the Trustees on 24th September 2025.



David Gibbs
Trustee



Phil Hall
Trustee

Consolidated cash flow statement for the year ended 31 December 2024

		2024		2023
		£		£
Cash flows from operating activities:				
Net cash provided by operating activities	a)	3,198,824		3,349,690
Cash flows from investing activities:				
Dividends and interest from investments		568,085		453,300
Net additions/(disposals) in the year		-		(10,005,321)
Purchase & Improvements of Fixed Assets		(1,246,825)		(895,899)
Purchase of Intangible Assets		(117,349)		(1,500,584)
Net cash provided by investing activities		(796,089)		(11,948,504)
Change in cash and cash equivalents in the reporting period		2,402,735		(8,598,814)
Cash and cash equivalents at the beginning of the reporting period	b)	13,663,809		22,262,623
Cash and cash equivalents at the end of the reporting period	b)	16,066,544		13,663,809
Notes to the Cash flow Statement				
a) Reconciliation of net (expenditure) to net cash flow from operating activities				
		2024		2023
		£		£
Net (expenditure)/income for the reporting period		3,710,191		3,541,324
Adjustments for:				
Dividends, interest and rents from investments		(568,085)		(453,300)
Investment Manager Fees		38,266		28,048
Net Change in investments		(627,118)		(441,084)
Decrease / (increase) in debtors		(406,946)		182,163
(Decrease) / increase in creditors		914,168		492,539
Amortization Charge for the year		138,348		-
Net cash provided by (used in) operating activities		3,198,824		3,349,690
b) Analysis of cash and cash equivalents				
		01-Jan-24	Cashflow	31-Dec-24
		£	£	£
Cash at bank and in hand		8,911,885	2,265,049	11,176,934
Cash held as short term investments		4,751,924	137,686	4,889,610
Cash held as long term investments		-	-	-
		13,663,809		16,066,544

Notes to the financial statements for the year ended 31 December 2024

1. Charity Information

Children with Cancer UK is limited by guarantee with no share capital (registered number 4960054), which is incorporated in England and Wales and domiciled in the UK. The address of the registered office is 21-27 Lamb's Conduit Street, London, WC1N 3NL. It is also a registered charity (registered number 298405) and as such is a non-profit making organisation. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member.

2. Accounting policies

a) Basis of preparation

The financial statements have been prepared on the historical cost basis of accounting, as modified by the revaluation of investments, and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102), the Companies Act 2006, the Charities SORP (FRS 102) and the accounting policies set out below.

The charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Children with Cancer UK is the ultimate parent company. It has two subsidiaries - Helping Children with Cancer Limited and Children with Cancer Research Limited. Children with Cancer UK owns the whole of the share capital of Helping Children with Cancer Limited, a company registered in England and Wales, number 2807553. It also holds 100% of the share capital of Children with Cancer Research Limited, a company registered in England and Wales, number 09442350 which is currently dormant.

The financial statements of the charity and its active subsidiary company are consolidated, on a line-by-line basis, to produce the Group financial statements. The consolidated entity is referred to as 'the Group'. No separate Statement of Financial Activities has been prepared for the charity as permitted by Section 408 of the Companies Act 2006. The charity has taken advantage of the exemptions in FRS 102 from the requirements to present a charity only Cash Flow Statement and certain disclosures about the charity's financial instruments.

b) Preparation of the accounts on a going concern basis

The Trustees have assessed the charity's ability to continue as a going concern and are confident that it remains financially sustainable over the foreseeable future, a period of at least 12 months from the date of approval of these financial statements.

c) Financial Instruments

The charity has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at amortised cost. Financial assets held at amortised cost comprise cash at bank and in hand, short term cash deposits together with the group's trade and other debtors excluding prepayments. Financial liabilities held at amortised cost comprise the group's short- and long-term trade and other creditors excluding deferred income and taxation payable. No discounting has been applied to these financial instruments on the basis that the periods over which amounts will be settled are such that any discounting would be immaterial.

Investments, including cash held as part of the investment portfolio are held at fair value at the Balance Sheet date, with gains and losses being recognised within the Statement of Financial Activities. Investments in subsidiary undertakings are held at cost less impairment.

d) Critical accounting judgements and key sources of estimation uncertainty

In the application of the charity's accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects the current and future periods.

The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described in the accounting policies and are summarised below:

Residuary legacies – The charity recognises residuary legacies once probate has been granted which therefore requires an estimation of the amount receivable.

e) Functional/Presentational currency

The functional currency of the charity and its subsidiary is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity/group operates. The consolidated financial statements are also presented in pounds sterling.

f) Fund accounting

Unrestricted funds comprise accumulated surpluses and deficits on general funds and are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund.

g) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Voluntary income in the form of appeals, committed giving, sports events and community fundraising income is recognised in the period of receipt. Income received in advance of an event or lottery is deferred until the criteria for income recognition are met.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

For the purposes of these financial statements, only legacy income where entitlement was established on or before May 31st has been included, after this date it is treated as a post year-end event and will be recognised in the following financial year.

Income arising from corporates and trusts is recognised in the period in which the charity has entitlement to the income.

Income from trading activities is recognised in the period in which the service has been provided or product sold.

Investment income from dividends and interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest received or receivable from the Bank.

Government grants are recognised on the performance model, when the Charitable Company has complied with any conditions attaching to the grant and the grant will be received.

h) Expenditure and basis of allocation of costs

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis and the majority is directly attributable to specific activities. Other indirect costs are apportioned to activities in accordance with staff activity and an assessment of where the resources have been applied. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Grants to third parties are included in the SOFA when approved by the Trustees when a constructive obligation exists, notwithstanding that they may be paid in future accounting periods.

Support costs include governance costs which are costs incurred to manage the charity in compliance with constitutional and statutory requirements and the direct expenditure and overhead costs relating to the appeals and fundraising functions. They also include the allocation of costs incurred to support and co-ordinate fundraising activities. These costs are allocated across the categories of charitable activities and the basis of this cost allocation has been explained in note 7 of the financial statements.

Expenditure on raising funds includes expenditure specifically incurred for fundraising purposes. This constitutes a mixture of directly attributable costs and apportionment.

i) Fixed assets

Tangible and Intangible fixed assets costing more than £10,000 are capitalised. Depreciation and amortisation are charged on fixed assets on a straight basis based on the expected useful life of the asset, once it has come into use.

The useful lives of the assets in use at year end are as follows:

Kids Like Us Documentary	-	44 months
--------------------------	---	-----------

j) Pension scheme

Eligible employees are enrolled onto a Grouped Stakeholder Pension Plan provided by Scottish Widows. During 2024, the charity made a contribution of at least 5% of salary per month to the stakeholder pension scheme for all eligible employees serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of pension costs is the contribution payable during the year.

k) Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

l) Gifts in Kind

Gifts in kind and donated goods and services are recognised in the accounts when the benefit to the charity is reasonably quantifiable and measurable. The value is the price the charity estimates it would pay should it purchase equivalent goods or services.

The estimated valuation of gifts in kind is based on the value of the contribution to the charity, or the valuation the charity would have had to pay to acquire the goods or services. A corresponding amount is recognised within expenditure in the period of receipt.

m) Private Medical Insurance

Permanent employees employed prior to 2020 were entitled to join the Group Private Medical Insurance Scheme provided by Bupa. In 2024, the charity paid a premium based on the employee's ages per month for all employees receiving benefit. The amount charged to the statement of financial activities in respect of private medical insurance is the contribution payable during the year.

3. Consolidated statement of financial activities for the year ended 31 December 2023

	Total restricted funds £	Total unrestricted funds £	Total 2023 £
Income from:			
Donations and legacies	140,959	13,502,203	13,643,162
Other trading activities	-	883,917	883,917
Income from investments	-	453,300	453,300
Other income	134,479	77,344	211,823
Total Income	275,438	14,916,764	15,192,202
Expenditure on:			
Raising funds	-	2,447,063	2,447,063
Charitable activities	275,438	9,369,461	9,644,899
Total Expenditure	275,438	11,816,524	12,091,962
Net change in investments	-	441,084	441,084
Net (expenditure)/income	-	3,541,324	3,541,324
Transfers between funds	-	-	-
Net movement in funds	-	3,541,324	3,541,324
Reconciliation of funds:			
Total funds brought forward	-	14,840,280	14,840,280
Total funds carried forward	-	18,381,604	18,381,604

4. Income

	2024 £	2023 £
Donations and legacies		
Appeals and associated donations (See below)	4,086,475	3,629,364
Committed giving	2,860,037	2,962,783
Sports events	4,020,656	3,017,894
Legacies (see contingent asset below)	1,993,300	2,444,893
Corporate and trust donations	1,269,595	951,282
Community fundraising	607,990	636,946
	14,838,053	13,643,162
Other trading activities		
Events	1,134,242	883,917
	1,134,242	883,917

Contingent asset - legacy income

As at 31 December 2024, the charity had been notified of a further 65 residuary and pecuniary legacies which have not been recognised as income in the Statement of Financial Activities as they do not meet the criteria as detailed in the accounting policies. These legacies have an estimated value of £1,496,708 (2023: £884,216) which has not been accrued.

5. Lottery income

As part of the charity's Gambling Commission Licence (Non-Remote Licence - 000-004700-N-306402-010) (Remote Licence - 000-004700-R-308531-010), during the year the charity has operated three lotteries, a weekly lottery and charity scratch card.

The following ticket sales were received for each lottery where the draw was held in 2024:

	Ticket sales £
Weekly Lottery	425,758
Christmas Raffle (draw 12 th January 2024)	278,856
Spring Raffle (draw 31 May 2024)	201,083
Summer Raffle (draw 20 th September 2024)	189,207
Total	1,094,904

The Christmas Raffle spans two accounting periods. Although the draw took place during the current accounting period, the closing date was 22 December 2023 and most ticket sales were received in the previous accounting period. All other ticket sales were received during 2024 only. All ticket sales have been included within the total income for 2024 and 2023.

In line with the requirements under Social Responsibility code provision 4.3.1 of the Licence Conditions and Codes of Practice of the Gambling Act 2005 the following section details the percentage of lottery proceeds returned to the purposes of the society (Children with Cancer UK) from the lotteries promoted in 2024.

Lottery type	Lottery Name	Percentage proceeds returned to Charity %
Managed directly by Children with Cancer UK	Weekly Lottery	54%
Managed directly by Children with Cancer UK	Children with Cancer Grand Draw	64%
Total		59%

6. Total expenditure

	Staff Costs £	Direct Costs £	Support and Governance £	2024 Total £
Expenditure on Raising funds				
Fundraising Costs	640,842	2,080,548	638,749	3,360,139
Expenditure on Charitable activities				
Research into Prevention & Causes	106,423	777,208	105,363	988,994
Research into Treatment	199,639	4,440,345	202,567	4,842,551
Welfare	245,742	1,340,793	237,930	1,824,465
Raising Awareness	463,208	2,172,971	446,239	3,082,418
	1,015,012	8,731,317	992,099	10,738,428
	1,655,854	10,811,865	1,630,848	14,098,567

	Staff Costs £	Direct Costs £	Support and Governance £	2023 Total £
Expenditure on Raising funds				
Fundraising Costs	722,127	1,260,282	464,654	2,447,063
Expenditure on Charitable activities				
Research into Prevention & Causes	324,080	233,485	219,783	777,348
Research into Treatment	317,011	4,004,065	213,063	4,534,139
Welfare	380,360	1,114,687	338,231	1,833,278
Raising Awareness	758,213	1,360,557	381,364	2,500,134
	1,779,664	6,712,794	1,152,441	9,644,899
	2,501,791	7,973,076	1,617,095	12,091,962

7. Support costs

Support costs are split as follows:

	Office Admin £	Management & Governance £	Finance, IT & HR £	Comms & Marketing £	2024 Total £
Expenditure on Raising funds					
Fundraising Costs	144,641	93,740	265,094	135,274	638,749
Expenditure on Charitable activities					
Research into Prevention & Causes	23,859	15,462	43,728	22,314	105,363
Research into Treatment	45,870	29,727	84,070	42,900	202,567
Wellness	53,878	34,917	98,746	50,389	237,930
Raising Awareness	101,048	65,487	185,199	94,505	446,239
	369,296	239,333	676,837	345,382	1,630,848

	Office Admin £	Management & Governance £	Finance, IT & HR £	Comms & Marketing £	2023 Total £
Expenditure on Raising funds					
Fundraising Costs	120,805	34,997	206,645	102,207	464,654
Expenditure on Charitable activities					
Research into Prevention & Causes	57,141	16,554	97,744	48,344	219,783
Research into Treatment	55,394	16,048	94,755	46,866	213,063
Welfare	87,937	25,475	150,421	74,398	338,231
Raising Awareness	99,864	28,651	169,175	83,674	381,364
	421,141	121,725	718,740	355,489	1,617,095

Indirect, support and governance costs are allocated on a per person basis to staff in the office. The time spent by each staff member on every activity of the charity is allocated on a month-by-month basis throughout the year. Support and staff costs are then allocated to the various charitable activities based on this staff time basis.

8. Costs of charitable activities

	Activities undertaken directly £	Grant funding of activities £	Support and governance costs £	2024 Total £	2023 Total £
Research into Prevention & Causes	645,305	238,326	105,363	988,994	777,348
Research into Treatment	826,304	3,813,680	202,567	4,842,551	4,534,139
Welfare	1,461,535	125,000	237,930	1,824,465	1,833,278
Raising Awareness	2,511,179	125,000	446,239	3,082,418	2,500,134
	5,444,323	4,302,006	992,099	10,738,428	9,644,899

9. Net Income/ expenditure for the year

	2024 Total £	2023 Total £
Net Income/ Expenditure for the year is stated after charging/(crediting):		
External Audit Fees:		
Children with Cancer UK	37,500	35,700
Helping Children with Cancer Ltd	4,410	4,200
Other services from external auditor - tax advisory		
Children with Cancer UK	2,630	950
Helping Children with Cancer Ltd	935	900

10. Staff costs

	2024 £	2023 £
Salaries and wages	1,417,399	1,526,867
National Insurance	143,458	163,632
Pension	86,019	98,357
Private Medical Insurance	8,978	5,485
	1,655,854	1,794,341

The number of employees whose remuneration fell within the following bands is set out below:

Salary Range	2024 £	2023 £
£130,000 - £140,000	-	1
£80,000 - £90,000	1	-
£70,000 - £80,000	1	1
£60,000 - £70,000	2	3

There have been nine (2023: 5) positions that have formed part of the senior leadership team during 2024. The total remuneration including pension contributions for the team amounts to £767,999 (2023: £412,645), some members of the senior leadership team were contractors, costs related to contractors included irrecoverable VAT.

During the year there were two (2023: none) redundancy, termination or settlement payments made totalling £30,000(2023: £nil).

The average weekly number of contracted employees during the year was as follows:

	2024 No.	2023 No.
Charitable Activities	2	4
Raising Funds	24	32
Support, Governance, Operations and Administration	16	5
	42	41

The Trustees received £80 reimbursement of expenses during the year (2023: £178 of travel expenses).

11. Results of Parent Charity

	2024 £	2023 £
Total income	17,191,182	15,160,662
Total expenditure	(14,108,109)	(12,060,422)
Unrealised gains / (Losses)	627,118	441,084
Net (expenditure) / Income	3,710,191	3,541,324

12. Property

The balance of £3.7m relates to a property addition in 2022 and related works in progress. No depreciation has been charged as it is an asset under construction.

	2024 £	2023 £
	'Raines Retreat' Property	'Raines Retreat' Property
	£	£
Cost at 1 st Jan	2,495,899	1,600,000
Additional works in progress	1,246,825	895,899
Depreciation	-	-
Cost at 31 st Dec	3,742,724	2,495,899

There is a further capital commitment at year end relating to the Retreat of £592,759.

13. Intangible Assets

The Intangible asset relates to production of the Kids Like Us documentary film made available on Sky in 2024, the development of a new charity website and software tools for improving fundraising.

	Kids Like Us Documentary £	New Website Development £	Software Development £	Total £
Cost at 1 st Jan	1,500,584	-	-	1,500,584
Additional works in progress	21,248	4,800	91,301	117,349
Amortization	(138,348)	-	-	(138,348)
Cost at 31 st Dec	1,383,484	4,800	91,301	1,479,585

There are further capital commitments at year end relating to the Website of £23,200 and the Software Development project of £33,215.

14. Investments

	2024 £	2023 £
Listed investments (see below)	12,751,354	12,162,502
Cash deposits held as long-term investment	-	-
	12,751,354	12,162,502
Market value of listed investments at 1 Jan	12,162,502	1,744,145
Additions to investment portfolio	-	10,005,321
Investment manager fees	(38,266)	(28,048)
Net investment gain/(loss)	627,118	441,084
Market value of listed investments at 31 Dec	12,751,354	12,162,502
Listed Investments comprise the following:		
Multi class and other investments	12,751,354	12,162,502
Total listed investments at 31 Dec	12,751,354	12,162,502

	2024 £	2023 £
Total Investments are listed in:		
United Kingdom	2,613,388	2,861,105
Overseas	10,137,966	9,301,397
	12,751,354	12,162,502

Investment in subsidiary

Children with Cancer UK holds 100% of the share capital of Helping Children with Cancer Limited which is a registered company number 02807553. The value of the share capital owned is £100. Helping Children with Cancer Limited raises funds via commercial activities.

The income and expenditure for the year ended 31 December 2024 is as follows:

	2024 £	2023 £
Income	633,656	150,000
Administrative expenses	(40,019)	(40,952)
Profit before gift aid and taxation	593,637	109,048

The balance sheet for the subsidiary as at 31 December 2024 is as follows:

	2024 £	2023 £
Assets	652,153	148,893
Liabilities	(652,053)	(148,793)
Reserves	100	100

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

15. Debtors

	2024 Group £	2024 Charity £	2023 Group £	2023 Charity £
Amounts due from subsidiary undertakings	-	639,125	-	158,203
Other debtors	723,975	722,760	670,116	670,116
Accrued income	1,167,909	738,069	1,128,318	1,128,318
Prepayments	1,022,071	1,022,071	967,401	967,401
Taxes and social security	258,826	261,422	-	-
	3,172,781	3,383,447	2,765,835	2,924,038

16. Grants to third parties

	2024 £	2023 £
Outstanding liabilities at the start of the year	12,997,055	12,583,848
Awarded during the year (note 23):		
Research into prevention and causes	238,326	40,000
Research into treatment and survival	4,116,174	4,023,640
Welfare	125,000	500,000
Raising awareness	125,000	-
Total third party grants before adjustments	4,604,500	4,563,640
Under/over spends and adjustments on previous grant awards	(302,494)	(508,483)
Total third party grants	4,302,006	4,055,157
Paid during the year	(4,182,115)	(3,641,950)
Outstanding liabilities at the end of the year	13,116,946	12,997,055
Grants falling due within one year	4,554,027	6,590,941
Grants falling due after more than one year	8,562,919	6,406,114
	13,116,946	12,997,055

17. Creditors: amounts falling due within one year

	2024 Group £	2024 Charity £	2023 Group £	2023 Charity £
Accruals and deferred income	2,004,247	1,993,915	1,206,590	1,201,490
Amounts due to subsidiary	-	-	-	16,904
Taxes and social security	-	-	3,380	986
	2,004,247	1,993,915	1,209,970	1,219,380
Grants payable	4,554,027	4,554,027	6,590,941	6,590,941
	6,558,274	6,547,942	7,800,911	7,810,321

18. Deferred income

Deferred income comprises income received in advance for entries to our weekly lottery.

	2024 Group £	2024 Charity £	2023 Group £	2023 Charity £
Balance as at 1 January	31,208	31,208	53,701	53,701
Amount released to income	(31,208)	(31,208)	(53,701)	(53,701)
Amount deferred in year	36,636	36,636	31,208	31,208
Balance as at 31 December	36,636	36,636	31,208	31,208

19. Analysis of net assets between funds

As at 31 December 2024	2024 Group Restricted funds £	2024 Group Unrestricted funds £	2024 Group Total funds £	2023 Group Unrestricted funds £
Fixed assets	-	17,973,663	17,973,663	16,158,985
Net current assets	422,830	12,258,221	12,681,051	8,628,733
Creditors falling due after more than one year	-	(8,562,919)	(8,562,919)	(6,406,114)
Net assets at the end of the year	422,830	21,668,965	22,091,795	18,381,604r

As at 31 December 2023	2023 Group Restricted funds £	2023 Group Unrestricted funds £	2023 Group Total funds £	2022 Group Unrestricted funds £
Fixed assets	-	16,158,985	16,158,985	11,600,000
Net current assets	-	8,628,733	8,628,733	7,792,542
Creditors falling due after more than one year	-	(6,406,114)	(6,406,114)	(4,552,262)
Net assets at the end of the year	-	18,381,604	18,381,604	14,840,280

20. Statement of funds

Year ended 31 December 2024	Balance at 1 January £	Total Income £	Total Expenditure £	Transfers & Investment gains/losses £	Balance at 31 December £
Restricted funds					
a) Discretionary Trust of Bertha Everitt	-	300,000	(300,000)	-	-
b) Anonymous donation	-	375,000	-	-	375,000
c) The Medical Research Council	-	176,495	(176,495)	-	-
d) Ladbrokes	-	47,830	-	-	47,830
Other Restricted	-	10,003	(10,003)	-	-
Total Restricted funds	-	909,328	(486,498)	-	422,830
Total Unrestricted funds	18,381,604	16,272,312	(13,612,069)	627,118	21,668,965
Total funds	18,381,604	17,181,640	(14,098,567)	627,118	22,091,795

Year ended 31 December 2023	Balance at 1 January £	Total Income £	Total Expenditure £	Transfers & Investment gains/losses £	Balance at 31 December £
Restricted funds					
e) Beads of Courage UK	-	139,958	(139,958)	-	-
f) The Medical Research Council	-	134,480	(134,480)	-	-
Other Restricted	-	1,000	(1,000)	-	-
Total Restricted funds	-	275,438	(275,438)	-	-
Total Unrestricted funds	14,840,280	14,916,764	(11,816,524)	441,084	18,381,604
Total funds	14,840,280	15,192,202	(12,091,962)	441,084	18,381,604

20. Statement of funds(continued)

The restricted funds comprise donations that were to be spent on specific causes and projects.

- a) Discretionary Trust of Bertha Everitt provided funding towards Raines Retreat.
- b) Anonymous donation towards Raines Retreat and the RHS Chelsea display.
- c) The Medical Research Council, government grant funding for individual projects, reinvested back into research budget.
- d) Ladbrokes, funding provided for causes in Ireland and Northern Ireland.
- e) Beads of Courage UK, which helps children in all 110 children's cancer wards in the UK visualise and articulate their cancer journey.
- f) UK Government Covid Medical Research Charity Support Fund from The Medical Research Council funding

21. Related Party Transactions

There have been no other related party transactions during the year other than those with the trading subsidiary.

A management fee of £5,000 (2023: £5,000) has been charged to the trading subsidiary for use of the charity's trademarks and a further £4,542 (2023: £4,412) for the use of charity staff (calculated on the basis of time charged to subsidiary activity by the employee). As of 31 December 2024, £639,125 (2023: £141,299) owed to the charity from the trading subsidiary.

22. Financial Instruments

The financial statements include the following in respect of items:

	2024 £	2023 £
Financial assets measured at fair value	12,751,354	12,162,502
Total interest income for financial assets held at fair value	52,133	121,992

23. Grants to third parties

Grants awarded to third parties during the year	Research into prevention and causes 2024 £	Research into treatment 2024 £	Welfare 2024 £	Raising awareness 2024 £	Total 2024 £
Solving Kids' Cancer UK		125,000		125,000	250,000
Bone Cancer Research Trust		125,000	125,000		250,000
Alice's Arc		250,000			250,000
Azaylia Foundation		250,000			250,000
International Agency for Research on Cancer		175,662			175,662
Institute of Child Health – Prof Katie Harron	116,696				116,696
Newcastle University – Prof Anthony Moorman	121,630				121,630
University of Glasgow – Dr Karen Keeshan		299,732			299,732
Newcastle University – Prof Julie Irving		337,238			337,238
University of Nottingham – Dr Timothy Ritzmann		350,000			350,000
University of Southampton – Dr Zoe Walters		329,067			329,067
University of Sheffield – Prof Helen Bryant		147,570			147,570
University of Birmingham – Dr Maarten Hoogenkamp		78,055			78,055
University of Oxford – Prof Suzannah Williams		319,952			319,952
University College London – Dr Paul Maciocia		349,943			349,943
University of Cambridge – Dr Manavendra Pathania		348,662			348,662
University College London – Prof Kathy Pritchard- Jones		298,773			298,773
University of Leeds – Prof Susan Burchill		331,520			331,520
Total grants to third parties	238,326	4,116,174	125,000	125,000	4,604,500
Grant closures and adjustments		(302,494)			(302,494)
Total grants to third parties	238,326	3,813,680	125,000	125,000	4,302,006

Note

There were 23 grant closures with a combined value of £250,054 that occurred during the year. There were 2 grant adjustments of £52,440 relating to corrections made to grants awarded in previous financial years.

23. Grants to third parties (continued)

Grants awarded to third parties during the year	Research into prevention and causes 2023 £	Research into treatment 2023 £	Welfare 2023 £	Total 2023 £
Spread A Smile			500,000	500,000
Tessa Jowell Brain Cancer Mission	40,000	40,000		80,000
UCL Great Ormond Street Institute of Child Health - Dr Srdan Rogosic		23,716		23,716
University College London - Prof Kathy Pritchard-Jones		69,423		69,423
Newcastle University - Prof Steve Clifford		962,131		962,131
University College London - Dr Jon Clayden		131,899		131,899
University of Nottingham - Dr Elizabeth Coyle		349,210		349,210
Newcastle University Centre for Cancer - Dr Debbie Hicks		343,770		343,770
Institute of Cancer Research - Prof Chris Jones		285,321		285,321
Imperial College London - Prof Cristina Lo Celso		326,789		326,789
UCL GOS ICH - Dr Marc Mansour		349,915		349,915
University of Oxford - Prof Adam Mead		350,000		350,000
University of Edinburgh - Prof Rod Mitchell		290,455		290,455
University College London - Dr Karin Straathof		231,742		231,742
UCL GOS ICH - Dr Owen Williams		269,269		269,269
Total grants to third parties awarded in the year	40,000	4,023,640	500,000	4,563,640
Grant closures and adjustments		(545,983)	37,500	(508,483)
Total grants to third parties	40,000	3,477,657	537,500	4,055,157

24. Operating Leases Payable

The group and charity had the following future minimum lease payments under operating leases for the following periods:

	2024 £	2023 £
Within one year	167,349	182,562
Between one and five years	319,484	486,832
Total	486,833	669,394

Every day 10 children and young people are diagnosed with cancer in the UK.

8 out of 10 young childhood cancer patients can be successfully treated thanks to vital, specialist research we helped fund.

Our vision is a world where every child and young person survives their cancer diagnosis.



We fund Research



We fund Welfare



We raise Awareness

Children with Cancer UK
Registered Office
21-27 Lamb's Conduit Street
London
WC1N 3NL

CHILDREN WITH CANCER UK

England & Wales - Charity number 298405

Accounts



Trustees' Report and Financial Statements for the year ended 31 December 2023





Children with Cancer UK in numbers

Research - We're committed to improving survival and finding kinder treatments for children and young people with cancer

£4m invested into vital, life-saving research
10 new research grants were awarded
1 new collaboration commenced

Supporting families - We help children with cancer and their families through the hardships of a cancer diagnosis

372 families participated in our welfare activities
£500k helping children cope with cancer treatment in collaboration with Spread a Smile

Awareness - We shine a spotlight on the impact of cancer on children and young people and their families

361 online articles
171 mentions of the charity in printed media
21 families told their childhood cancer stories



CHILDREN WITH CANCER UK

TRUSTEES' ANNUAL REPORT AND CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

Welcome from the Chair of Trustees	4
Welcome from the CEO	6
Outcomes in 2023	8
Our Year in Research	9
Supporting Families	12
Raising Awareness	14
Fundraising Highlights.....	17
Thank You.....	22
Financial Review.....	23
Our Strategy.....	27
Human Resources	29
Going Concern.....	32
Investments.....	33
Risk and Internal Controls.....	335
Structure, Governance and Management	40
Reference and Administration.....	45
Statement of Trustees' Responsibilities	47
Independent Auditor's Report to the Members of Children with Cancer UK	48
Consolidated Financial Statements.....	53
Notes to the Financial Statements	56



Welcome from the Chair of Trustees

As we reflect on 2023, I am proud to share the significant strides Children with Cancer UK has made this year. My three years as Chair of Trustees have witnessed a remarkable transformation in our charity, from the evolution of our team, to the changing approach in supporting families and advancing research.

The year was marked by substantial changes, including our comprehensive rebrand, which introduces a bold new vision for our future. This rebrand is not just a new look but a reflection of our renewed commitment to improving outcomes for children with cancer. The logo introduces two arms in an embrace – signifying the breadth of our purpose as a charity, supporting research alongside the wellbeing of children and their families, raising awareness, and fostering collaboration with various organizations. It represents a fresh chapter in our journey, allowing us to communicate our mission more effectively and engage with a broader audience.

I would like to take a moment to express our heartfelt gratitude to Jo Elvin, who stepped down as CEO at the beginning of 2024. Jo's leadership over the past two years has been invaluable, especially as she guided us through a period of transformation marked by our rebrand. Her unwavering dedication to our cause has significantly shaped the charity's direction, and her contributions have laid a strong foundation for our future work.

Our efforts to raise awareness and fund critical research have been highly successful. We've expanded our support services and focused on amplifying the voice of childhood cancer in a sector that is often underrepresented. We funded a landmark feature length documentary this year called Kids Like Us, which follows the extraordinary lives of eight remarkable young people from across the UK and US who have faced childhood cancer. We want to spark a conversation and raise awareness about the reality of childhood cancer. We hope by sharing the stories of these amazing children and young people, and their families navigating life during and after a cancer diagnosis, we are able to change the way paediatric cancer is viewed and the issues that surround it.

The addition of new team members this year has been instrumental. Our ever-growing staff brings fresh perspectives and expertise, positioning us to achieve even more remarkable things in the year ahead. Their energy and dedication are driving our mission forward, ensuring that we remain at the forefront of childhood cancer research and family support.

Looking ahead, our commitment to funding research remains unwavering. As a long-established research charity we are now also committed to focusing on the wellbeing



of families facing a childhood cancer diagnosis and how we can best support them. Our partnership with Spread a Smile has been instrumental to our cause, as well as us continuing to fund the inspiring Beads of Courage UK programme. We have also begun plans for further welfare activities for our families. The ongoing transformation within our charity is geared towards making a lasting impact and improving the quality of life for children and their families.

I want to extend my heartfelt thanks to our dedicated staff and loyal supporters. Your continued support and passion are the foundation of everything we do. Together, we are making a real difference, and I am confident that with your help, we will continue to achieve great things in the coming year.

David Gibbs
Chair of Trustees
Children with Cancer UK



Welcome from the CEO

As we look ahead, I am filled with optimism and excitement for what's to come. It has been a year of tremendous progress and change at Children with Cancer UK. Our charity has always been, and continues to be, laser-focused on three key pillars: funding cutting-edge research, raising awareness, and supporting families. These core values drive everything we do.

At Children with Cancer UK, we take pride in being one of the leading contributors to childhood cancer research in the UK, with over £4m committed to projects in 2024, following a highly successful grant call that drew a large number of high-quality applications. Through a fantastic collaboration with Newcastle University Centre for Cancer, and Dr. Debbie Hicks, we are funding human equivalent modelling pre-clinical trials to identify treatment for medulloblastoma, a cancerous brain tumour that starts in the lower back part of the brain. There is an urgent need for this type of clinical research and development.

Additionally, we are committed to supporting pioneering research led by Professor Rod Mitchell at The University of Edinburgh, which focuses on preserving fertility in boys before puberty, a critical concern for childhood cancer survivors. This landmark research has the potential to make a profound impact on the long-term quality of life for those affected by cancer treatment.

In 2024, we are excited to help grow the national agenda on paediatric cancer, working closely with our new coalition partners to make even more progress. In addition, we remain more committed than ever to supporting families going through this incredibly tough time. We understand that, especially during these difficult economic times, it's crucial to keep our mission close to the hearts of the public. As the cost-of-living crisis affects so many, we are more grateful than ever to see support growing for our charity. By reaching new demographics and growing our base of supporters, we can ensure that families facing cancer receive the help and support they need.

This year has also seen a growth in our fundraising opportunities. It has been another strong year for fundraising with the success of the London Marathon, the first Children with Cancer UK dedicated wave at the Westminster Mile, The Really Big Auction, along with the addition of new corporate partners. Looking ahead, we are excited to build on these events to further raise awareness and support for our cause.

We are also excited to announce the upcoming launch of Raines Retreat, our new holiday retreat in beautiful North Yorkshire. This space will offer families a much-needed break, giving them the opportunity to recharge in a peaceful environment specifically designed



for children with cancer. It represents our growing focus on the welfare of families, a central theme as we look ahead.

The upcoming year also marks a pivotal moment in our transformation as an organisation. While we remain deeply rooted in our founder-led origins, we are evolving into a forward-thinking charity. Our restructuring, guided by Theory of Change, is all about ensuring we are more effective in helping the families we serve, while never losing sight of the importance of research. As we evolve, research remains the heart of our mission, but we are equally focused on the well-being of children and their families.

We also continue to raise awareness through various platforms and partnerships. We are also thrilled to share that our presence at RHS Chelsea Flower Show helped us connect with new audiences and earned us the People's Choice Award – a testament to how deeply our story resonates in the hearts and minds of so many.

It is thanks to supporters like you that we are able to continue this important work. Together, we can make 2024 another year of growth, hope, and breakthrough for children with cancer and their families.

Thank you for your unwavering support.

Amar Naher

Interim CEO of Children with Cancer UK



Outcomes in 2023

How donations have helped children and young people with cancer.

For every £1 we spend on fundraising, we raised £5 more.

For every £1 donated we spend:

- 80p on fighting childhood cancer
 - 44p on research projects,
 - 15p on supporting families,
 - 21p on raising awareness,
- 20p on raising more money



Our Year in Research

Around 1,800 children and 2,400 young people are diagnosed with cancer each year in the United Kingdom. Whilst over 80% of patients survive, cancer remains one of the leading disease related causes of death for children under 15 years of age. From the time of their diagnosis, children and young people endure difficult treatments to eradicate their disease, with potentially life-altering side effects on their development. High-quality and impactful research is essential to driving forward our vision of a world where every child and young person survives cancer. Research has significantly contributed to the improvements seen in childhood cancer survival rates from 67.3% in 1990 to a predicted 85.2% recorded in 2019. Improved treatments and understanding of the disease are important in the fight against cancer.

Children with Cancer UK plays a major role in funding vital life-saving research. We are dedicated to improving survival rates across all types of childhood cancer, improving the quality of life in young cancer survivors, and finding less-toxic treatment options. As one of the UK's leading charities dedicated to childhood cancer research, we are proud of our contribution to the ongoing breakthroughs which continue to help save young lives.

2023 saw the successful completion of the Children with Cancer UK 2022 Project Grant round resulting in the funding of 10 new projects. This funding allocated to research projects in institutions across the UK aims to make improvements for childhood and young adult cancers.

Children with Cancer UK values its partnerships with others in the paediatric and young adult cancer community. Following the wind down of our historic partners at the National Cancer Research Institute (NCRI), Children with Cancer UK is working to evaluate and build new partnerships focused on supporting the efforts of the NCRI. Our research funding includes support from other charities, government funders, cancer organizations and universities. We supported several conferences including the British Neuro-oncology Society (BNOS) annual meeting. We also held our own Research Conference in Birmingham. These collaborative events during the year help to facilitate innovation and share specialist expertise.

Research awards

In 2023 we funded research programmes in collaboration with other organisations worth £4,063,640.

In 2023 we funded 10 new research programmes and one new strategic partnership.



Children with Cancer UK 2022 Grant call

This was a £2.5 million Grant call which exceeded the budget, for research into improvements of the cancer pathway for childhood and young adult cancers. We sought proposals that focus on key questions in any area of cancer research which primarily addressed the needs of children and young adults with cancer and into improved quality of ongoing life. The Grant call began in 2022 and was finalised in summer 2023. Projects allocated funding included:

Dr Marc Mansour Development of CCR9-targeting antibody therapy for paediatric T-cell acute lymphoblastic leukaemia (£349,915)

Dr Debbie Hicks Radiotherapy-induced neurocognitive deficits in medulloblastoma: Human-equivalent modelling and randomised pre-clinical trials to identify effective pharmacological interventions for clinical application (£343,770)

Prof Cristina Lo Celso Characterising and targeting the treatment resistant population in B-ALL following Inotuzumab Ozogamicin treatment (£326,789)

Dr Elizabeth Coyle Establishing tumour microenvironment models of paediatric brain tumours (£349,210)

Prof Rod Mitchell Transplantation of Cryopreserved Testicular Tissue to Restore Fertility after Childhood Cancer (£290,455)

Prof Chris Jones Combined targeting of ACVR1 and cholesterol metabolism in diffuse midline glioma (£285,321)

Prof Adam Mead Characterisation of the cross talk between RAS mutant haematopoietic stem cells and immune effector cells in Juvenile Myelomonocytic Leukaemia (£349,999)

Dr Owen Williams MYB-directed therapy for paediatric AML (£269,269)

Dr Jon Clayden A tailored image guidance approach for children undergoing surgery for brain tumours (£131,899)

Dr Karin Straathof Equipping CAR T cells with IL-12 to achieve durable tumour responses in neuroblastoma (£231,742)



Scientific Advisory Panel

We are indebted to the members of our Scientific Advisory Panel (SAP) who freely give their time and expertise to help drive forward our fight against cancers affecting children and young people. Research into cancers affecting children and young people is a broad field and we aim to reflect the diversity of the field amongst the membership of panel members. Dr Helen Jenkinson (University of Birmingham) is the Clinical lead for the Late Effects Multidisciplinary team and has a major role in the care of long-term survivors of childhood cancer, in the out-patient Oncology clinic at the Birmingham Women's and Children's Hospital.

Professor Christina Halsey continues to serve as Chair alongside Professor Susan Burchill, Dr Helen Jenkinson, Dr Yann Jamin, Dr Lynley Marshall and Professor Matthew Murray.

Tessa Jowell Brain Cancer Mission – Children's Centres of Excellence

Children with Cancer UK partnered with the Tessa Jowell Brain Cancer Mission to support their vision that children with a brain tumour will not only survive but also receive the highest quality of treatment, care and research opportunities. The Tessa Jowell Centre of Excellence for Children initiative aims to recognise paediatric neuro-oncology centres that provide excellent treatment, care and research activities for children with brain tumours and their families. The programme is the first-of-its-kind to understand and review paediatric brain cancer care across the UK and will collect valuable data and insights by doing this. With data, the Mission will work with every UK centre to continually raise the bar and ensure excellence becomes the standard for every child diagnosed with a brain tumour.



Supporting Families

Children with Cancer UK remains committed to supporting families through treatment and beyond. Despite the staffing absence of our family events team, which limited the number of events we could deliver compared to previous years, we ensured consistent contact with our families and continued to create special memories throughout the year.

Children's Choir

At the Children with Cancer UK Gala in 2023, we invited 20 children currently undergoing treatment or in remission, along with their siblings, to participate in a children's choir for the second time. They performed a rendition of "A Million Dreams" from "The Greatest Showman" accompanied by Nicola Roberts from Girls Aloud and directed by music director Addam Gerbertson. This experience provided an exciting opportunity to involve our families in one of our key fundraising events, and we are committed to continuing this tradition in the years to come.

Beads of Courage UK

Our partnership with the Beads of Courage UK programme continued through 2023, and we helped to fund support for children and their families during some of the toughest times in their lives. Since our partnership began in 2019, we have helped support approximately 14,000 children in over 100 hospitals, acknowledging, celebrating, and recording over 10 million milestones. Our grant has also enabled training sessions for hospital staff on how to support individual patients throughout the programme both practically and emotionally. Our welfare direct mailing highlighted the impact of the programme on Theo and his family. Theo's mum, Luisa, shared that the beads really helped him to "associate his treatment with something positive." Every bead tells a story of hope, support, and encouragement.

Spread a Smile Partnership

In November, we were delighted to announce an exciting new partnership with Spread a Smile to improve the well-being of seriously ill and hospitalised children and their families through entertainment and events. The team hosts an array of talented musicians, magicians, therapy dogs, and artists who visit seriously ill children, offering families a much-needed opportunity to enjoy themselves and create precious memories together. We also helped support both the Summer and Winter Parties, which hosted hundreds of children to explore a wide range of activities like silent discos, bumper cars, and face painting.

Heroes Against Cancer

Late in the year, we launched the Heroes Against Cancer campaign, granting the wishes of young cancer patients across the UK. These children received surprises from their



personal heroes, with specially recorded video messages or in-person meet-and-greets. Celebrities granting wishes included the likes of Ed Sheeran, Billie Eilish, Olly Murs, Sam Ryder, and Ant and Dec.

Battersea Dogs and Cats Home Event

In November, we invited 14 children who have experienced cancer, along with their siblings and families, to a heartwarming event at Battersea Dogs and Cats Home. Guests met many of Battersea's animal residents, had books signed by Dame Jacqueline Wilson, and decorated festive biscuits with Bake Off star Ruby Bhogal. Interacting with animals has been proven to reduce stress and provide a source of happiness and well-being for people of all ages.

Christmas Hampers

During the Christmas period we collaborated with our corporate partner WTW as well as our charity partner Spread A Smile to deliver 300 bespoke hampers to families facing childhood cancer. Through these efforts, we aimed to bring some comfort and joy to those enduring challenging times during the holiday season.

Disney on Ice

On Christmas Eve, we hosted 15 families at the O2 Arena to see the incredible Disney on Ice. Generously donated by AEG, families affected by childhood cancer were able to immerse themselves in Disney's 100 Years of Wonder performance from private suites, providing them with a VIP experience.



Raising Awareness

Children with Cancer UK is dedicated to increasing awareness of the causes, symptoms, treatments, and impact of childhood cancer. This commitment extends to current and potential supporters, the research community, and patient families. By raising our profile, we continue to secure essential funds for life-saving research and drive change for children and young people facing a cancer diagnosis. In 2023, we ran multiple campaigns, including Childhood Cancer Awareness Month and Christmas, and introduced exciting new events with the help of our dedicated new events team. These key charity moments allowed us to reach millions of individuals across the UK, amplifying our mission and impact.

Rebranding for a New Era

2023 marked the exciting launch of our rebrand, symbolizing the start of a bold new era for the charity. The fresh new look features two arms in an embrace, representing our comprehensive purpose: supporting research, the wellbeing of children and their families, raising public awareness, and fostering collaboration with various organizations. Ultimately, this new identity reflects our role in providing hope and support for the future.

Making Our Voice Heard

- 361 online articles
- 171 mentions of the charity in printed media
- 216 mentions on broadcast (Radio and TV)

Social Media Impact

- 4.6% increase in audience growth
- 80.3% uplift in posts across all channels
- 4700% increase in video views

Milestones

In March, we shared our Milestones campaign film, inspired by the real-life stories of Frankie and Rose, two childhood cancer survivors. The campaign highlighted that for families impacted by childhood cancer, milestones take on even greater significance. Each moment is a milestone, marking resilience and hope.

The Really Big Auction

In August, we hosted our inaugural auction, raising a total of £253,409. With auction items from celebrities like Rod Stewart, Sting, and the cast of Downton Abbey, we



offered supporters the chance to bid for once-in-a-lifetime prizes. This event not only raised significant funds but also drew attention to the cause of childhood cancer.

Style Against Cancer

In October, we launched the Style Against Cancer campaign, fronted by Claudia Winkleman. We enlisted hair stylists and salons nationwide to participate in fundraising through haircuts. This campaign highlighted the significance of styled hair for children undergoing cancer treatment, who often face severe side effects, including traumatic hair loss. It was a meaningful way to involve the beauty industry in our mission and to provide comfort and confidence to young patients.

Childhood Cancer Awareness Month

Every September, we observe Childhood Cancer Awareness Month (CCAM). This year, inspired by our rebranded logo with orange borders symbolizing embracing arms, we launched our Give a Hug initiative. This campaign focused on the importance of hugs for families affected by childhood cancer and how this small and simple gesture can get you through a challenging day – a temporary relief of stress. Our Give a Hug video, a finalist at the Smiley Charity Film Awards, captured the heartfelt stories of families like Jack, Summer, and Emmy's, showcasing the power of a simple gesture. Whilst our film was initially dedicated in memory of Emmy, since filming sadly Summer has also passed away. We will remember them both.

Fundraising Gala

Our annual Fundraising Gala on Saturday, November 11, raised an incredible £620,000. This magical night of fundraising was instrumental in advancing life-saving childhood cancer research. The event brought together supporters, celebrities, and families, all united in their commitment to making a difference.

The Ultimate Christmas Quiz

In December, we launched our inaugural Christmas Quiz hosted by Rob Brydon, featuring celebrity team captains such as Emma Bunton, Ricky Wilson, and Matt Goss. The event was a festive and engaging way to raise over £150,000, bringing together supporters for a night of fun music, Christmas cheer and festive food.

Christmas Appeal

Our 2023 Christmas Appeal shared Isabellah's story, highlighting the challenges her family faced spending Christmas in hospitals far from home. Diagnosed with Rhabdomyosarcoma at just three years old, Isabellah's story resonated deeply with our supporters. We also partnered with The Sun on Sunday's Xmas Cards for Kids campaign for a second year, with our designs featured in shops across the UK. This collaboration helped spread awareness and raised funds for our cause.



Telling the story of childhood cancer

One of our most effective ways to raise awareness is by sharing the journeys of children affected by cancer. We are incredibly grateful to the 21 families who generously volunteered to share their stories in 2023. With their support we can continue to highlight the need for more funding into childhood cancer research. Welcome to the Children with Cancer UK family: Reggie, Thomas, Stanley, Matilda, Amelia, Mason, Aston, Archer, Morven, Jack, Rufus, Florrie, Lucy, Isabellah, Dylan, Stanley, and Sienna. We also honour the families who have shared stories of children who have passed. We will remember them: Orla, Neive, Summer, Micky, and Christopher.

Looking Forward

Through these initiatives, we have continued to spotlight the effects of childhood cancer and the urgent need for more funding and research. Together, we are making a profound difference in the lives of children and families affected by cancer. Our work in 2023 has laid a strong foundation for future efforts, and we remain committed to our mission of providing hope, support, and life-saving research.



Fundraising Highlights

Fundraising has continued rebuilding post pandemic across all fundraising streams. We've been able to diversify our fundraising to ensure that our supporters feel they can continue to make a meaningful contribution to our vital work.

London Marathon and our Individual Giving campaigns set the tone again in 2023 in generating much needed funds and we look forward to evolving this in 2024.

It's been great to see our newly formed Corporate Partnerships team flourish in bringing in more businesses to engage with the charity. It is heartening to see the knock-on effect of our stronger brand and work being recognised by corporate partners selecting us as their charity of the year.

This is all underpinned by the community of our supporters across the country who fundraise in aid of us.

Sports events

TCS London Marathon 2023

The 2023 TCS London Marathon returned to its normal month, taking place on Sunday 23 April. We had a team of 964 runners take part in the iconic 26.2 route. We were thrilled to return to a more normal London Marathon. In 2023 our team raised over £2.1 million from the TCS London Marathon which was incredible.

Great North Run

We had 88 runners take part in the 2023 Great North Run, which was the wettest and hottest Great North Run in history! In total the team raised over £38,000.

BHF London to Brighton Cycle

We had 57 riders take part in the 2023 BHF London to Brighton Cycle. This was the first year we had places in the event and we were thrilled with its success. The team raised over £23,000, which was incredible for the first year of the event.

Rat Race

The Rat Race team raised over £144,000 in 2023.

Berlin Marathon

We had 43 runners take part in the 2023 Berlin Marathon, raising over £41,000.

Community

Our community supporters have made a remarkable impact throughout 2023, demonstrating tremendous dedication and generosity.



Josh and his classmates were set a fundraising challenge by their school. As Josh experienced childhood cancer himself, he and his friends Jasmine and Poppy, were inspired to help others going through similar journeys, stating "we wanted to help other children with cancer as the charity helped me and my family so much, so it was good that we could make a difference for them to help others." So, all three challenged themselves to climb Pendle Hill, and while a difficult trek, felt brilliant when reaching the top and raising an incredible £1,100. We at Children with Cancer UK were so impressed by their determination and the amount raised, that they were named as one of our fundraisers of the month which you can read here at: [Fundraiser of the month | Josh | Children with Cancer UK](#).

Long standing supporters, The Sammy Jo Brandon Foundation, finished their fundraising year (which runs August to August) raising an amazing total of £84,888. This includes their marathon fundraising and lots of events in their local community.

Charity Aid, a team of street collectors in the north of England organised by Peter Quinn, raised over £20,000 through organised collections at Tesco Stores through the year. Peter recruits people from the local community to volunteer and they perform for the public by singing well know songs, helping to boost donations!

We invited schools, nurseries and youth groups to join our new campaigns for children, Pyjamarama. Children were able to wear their pyjamas to their school for the day or their youth group, for a donation, in solidarity with the children undergoing treatment, who spend most of their time in their favourite pyjamas. There were 124 schools and organisations who signed up, raising over £13,000.

These achievements highlight the incredible impact our supporters have made, furthering our mission and bringing hope to children and families affected by cancer.

Corporate

The start of 2023 marked the launch of our partnership with PayPoint, which was finalised at the end of 2022. This relationship quickly became a core relationship integral to our fundraising efforts, significantly contributing to table purchases and raffle prizes at the Fundraising Gala.

The Fundraising Gala, a major highlight of the year, was also made possible by the generous sponsorship of MFS. Their support was instrumental in the success of this key event.

Beyond the gala, our corporate team achieved notable success with the Tech Tackles Cancer UK event, which stood out as a significant accomplishment.

In 2023, we also successfully secured new corporate partnerships, with WTW and Lazard signing two-year agreements beginning in April and August, respectively. These partnerships mark a significant expansion of our corporate network.



These achievements lay a strong foundation for 2024, as we continue to expand our network of corporate supporters and raise vital funds to advance our mission.

Individual Giving

- Gift in Wills saw a total raised of £2.4 million and continues to be a reliable source of income for the charity.
- Our prize-led programme consisting of raffle grand draw and a weekly lottery raised £1.2 million.
- The cash appeals to our existing donors raised £1.6 million
- Cause-led regular giving raised £2.6 million

Acquisition of committed givers

We continued face to face private site in 2023 recruiting 1,067 new Direct Debit donors. We will closely track these donors with the aim to steward them to a long tenure with the charity.

Retention, Stewardship and Legacies

Towards the end of the year, we completed research to identify key insights to improve our individual giving campaign performance. We look forward to testing and implementing changes that will see us engage more donors and raise more money.

Digital fundraising

Digital remains to be a key marketing channel for Children with Cancer UK. In 2023 we trialled an “always on” approach testing creative across a number of products throughout the year making changes to the adverts and audiences based on performance data.

Fundraising Compliance

Children with Cancer UK values the privacy of all those who support us in our work; we have systems in place to ensure that supporter data is collected, managed and processed in line with all necessary legislation. We are members of the Fundraising Regulator, which has responsibility for regulating fundraising, sets out the Code of Fundraising Practice and investigates and takes appropriate action on cases of public concern. Children with Cancer UK adheres to the Code of Fundraising Practice set by the Fundraising Regulator and also fully complies with the Fundraising Preference Service. We comply with charity law, fundraising law and the data protection regulations. We monitor our fundraisers, volunteers and any third parties that work for us to ensure that they adhere to our high standards.

We will ask the donor how they want to hear from us about our work and appeals. If the donor wants to stop hearing from us, they can, email, phone, write or click on the



link in our emails. We will always act, so they can feel confident in contacting us at any time.

We will keep the donor's personal information secure and will only use it to communicate with the donor; to process orders and donations; to keep the donor informed; for analysis and to improve our activities. We will NOT share the donor's details with other charities or sell it to businesses. Some organisations help us with our fundraising but will only use the donor's data under our instruction and only when fully compliant with how we process personal data as set out in our Privacy Policy (Reviewed February 2022).

Children with Cancer UK continues to adhere to and review policies relating to GDPR and work alongside an external consultant, Cyber and Data Protection, to ensure that we are fully compliant.

Children with Cancer UK works with some professional fundraising agencies to assist with certain elements of our fundraising, by telephone and SMS channels. We have robust contracts in place with these agencies, specifying that staff carrying out these activities should be trained and adhere to all applicable laws, regulations and codes, such as the Code of Fundraising Practice and the Data Protection Regulations. We also expect these organisations to reflect our values when talking to supporters and to voluntarily subscribe to the Fundraising Regulator.

To ensure the agencies we engage are operating to the required standards and that people should never feel harassed or pressurised to give, we carry out appropriate monitoring which includes call monitoring, site visits and call listening. We attend training sessions of their staff and give training to staff in respect of each fundraising campaign. We require all our staff and the agencies we deal with to comply with our Vulnerable People Policy, which provides guidance on how to identify a potentially vulnerable person and actions to take to considerately disengage from the fundraising process.

Children with Cancer UK require its staff and any agencies contacting our donors and members of the public on our behalf to comply with the Data Protection Law and guidelines provided by the Fundraising Regulator and Institute of Fundraising. Children with Cancer UK take all reasonable care to the protect vulnerable adults in accordance with the Institute of Fundraising guidance set out in their document '[Treating Donors Fairly: Responding to the needs of People in Vulnerable Circumstances and Helping Donors make informed Decisions.](#)'

We adhere to the [Fundraising Regulator Promise](#) ensuring that our fundraising is legal, open, honest and respectful. We truly value our supporters and still stand by our [Supporter Charter](#) as a commitment to our supporters.



Our [Feedback and Complaints policy](#) was reviewed in March 2023 and we will continue to review this regularly. Complaints are investigated thoroughly, and corrective action taken as appropriate. During our financial year (Jan – Dec) 2023 we received 24 complaints across all teams which is a significant drop on the previous year (56 complaints, source Raiser’s Edge). We continue to work closely with our suppliers to ensure that best practise is followed.

We continue to closely monitor all of our fundraising activities and will always strive to ensure they are of the highest standard and reflect the wishes and preferences of all our generous supporters. There may be occasions when we have not met these high standards, and we will work hard to learn from our mistakes and to make sure they don’t happen again. If our supporters and members of the public are unhappy with any aspect of our work, we encourage them to give feedback, and take any comment or complaint seriously. We use this valuable feedback to help shape our future fundraising campaigns and improve our overall service and commitment to our supporters.

We are here to talk and listen to you – we welcome and actively encourage feedback and make it clear how people can get in touch with us.

A member of the Fundraising Regulator, the independent regulator of fundraising in the UK, Children with Cancer UK is committed to best practice in fundraising and follows the Regulators Fundraising Promise and Code of Fundraising Practice laid down by the regulator.



Thank You

We would like to sincerely thank all our supporters and fundraisers who helped us to raise £15.2 million. Your generosity and creative efforts are helping us to build our vision of a world where every child survives cancer.

Thank you to our dedicated board of trustees:

- David Gibbs, Chair of Trustees
- Alex Leitch, Deputy Chair
- Bruce Morland
- Phil Hall
- Sarah Standing

And scientific advisor Pamela Kearns.

A heartfelt thank you to all the extraordinary families we have had the privilege of working with in 2023. Your dedication to helping others facing similar situations to yourselves is truly inspiring. It is only through your stories that we are able to show the realities of childhood cancer. **Thank you.**



Financial Review

Incorporating the Directors' Strategic Report and Administrative Report for Companies Act Purposes

The Trustees of Children with Cancer UK present their Annual Report for the year-ended 31st December 2023 under the Charities Act 2011 and the Companies Act 2006, including the Directors' Report and the Strategic Report under the 2006 Act, together with the audited financial statements for the year.

The Consolidated Statement of Financial Activities (SOFA) set out on page 53, shows the financial results for Children with Cancer UK and its trading subsidiary: Helping Children with Cancer Limited.

This financial year has been a period of both challenge and opportunity for our charity, as we continue to advance cancer research through innovative projects and dedicated support.

Overview of Financial Performance

During 2023, the charity generated total income of £15.19 million (2022: £14.11 million), representing a 7% increase from the previous year. The key contributors to this increase were a rise in donations and legacies, which continue to form the backbone of our funding, and significant growth in other trading activities.

- Donations and legacies totalled £13.64 million (2022: £13.42 million), reflecting the ongoing generosity of our supporters and partners. Our continued focus on donor engagement and fundraising activities has ensured stable growth in this crucial area.
- Other trading activities generated £883,917 (2022: £581,771), an increase of 52%. This growth can be attributed to our expanded fundraising events and initiatives, which have proven successful in increasing engagement with corporate partners and the public.
- Income from investments grew substantially to £453,300 (2022: £91,499) due to improved market conditions and a proactive approach to managing our investment portfolio.

Additionally, we received other income of £211,823 (2022: £22,000), which reflects the charity's ability to secure supplementary funds through grants and miscellaneous sources.



Expenditure

The charity's total expenditure for the year amounted to £12.09 million (2022: £13.85 million), reflecting a 12.7% reduction from the previous year. This decrease is primarily due to cost-saving measures and more efficient use of resources while ensuring the continuation of key programmes and research.

- Expenditure on raising funds amounted to £2.45 million (2022: £2.12 million), representing a modest increase, driven by the need to sustain our fundraising efforts.
- Expenditure on charitable activities was £9.64 million (2022: £11.73 million), a reduction of approximately 18%. This reflects the conclusion of several major projects during the year as well as cost efficiencies achieved in our operations.

Net Movement in Funds

The charity achieved a net income of £3.54 million (2022: £55,240), reflecting a strong financial position by year-end. This positive movement is further supported by the gain in investments of £441,084 (2022: a loss of £204,193), which underscores the strength of our investment strategy.

Financial Position and Reserves

At 31 December 2023, the charity's total funds stood at £18.38 million, an increase from £14.84 million in 2022. This improvement is a result of prudent financial management, effective fundraising, and strong investment performance.

- Fixed assets increased to £16.16 million (2022: £11.60 million), largely due to the acquisition and valuation of property and investment assets.
- Net current assets increased to £8.63 million (2022: £7.79 million), ensuring that the charity remains in a strong position to meet its short-term obligations.
- Creditors due within one year decreased to £7.80 million (2022: £9.16 million).

Despite an increase in long-term grant commitments (creditors due after one year), the charity remains well-positioned to meet its obligations while ensuring the continuation of its mission.

The financial results for 2023 highlight the charity's resilience and ability to adapt to changing circumstances. With a strong financial base, we are well-equipped to continue funding innovative cancer research and supporting those affected by cancer. The Trustees would like to thank all donors, supporters, and staff for their ongoing contributions, which are vital to our success.

We remain committed to ensuring financial stability and transparency, and we are confident that we will continue to make significant progress in the year ahead.



For every £1 donated, we spend 80p on fighting childhood cancer.

- 44p on research projects
- 15p on supporting families
- 21p on raising awareness

We reinvest 20p from every £1 raised, to raise even more money.

For every £1 we spend on fundraising, we raise £5 more.

Reserves

At the end of the year, the charity held £18,381,604 in total reserves (2022: £14,840,280), all of which were classified as unrestricted reserves. There were no restricted reserves at year-end, as all restricted donations had been spent on specific causes and projects, as outlined in Note 20.

Unrestricted reserves are generated when supporters do not stipulate specific restrictions on how their donations must be spent. These funds are, therefore, available to be applied at the discretion of the Trustees to any of the charity's charitable objectives. This flexibility enables the Trustees to allocate resources efficiently and in response to the changing needs of the charity's operations and programmes.

Purpose of Reserves

The Trustees are mindful of their role as stewards of these funds and remain committed to ensuring that reserves are managed prudently. The reserves serve a dual purpose:

- **Operational Stability:** A portion of the reserves provides a financial buffer, ensuring that the charity can continue to operate and meet its obligations even in periods of reduced income. This buffer is critical for protecting the charity from unforeseen financial pressures and maintaining stability.
- **Grant Award Programmes:** The reserves also ensure the continuation of the charity's grant-making activities, enabling the Trustees to fund essential cancer research projects in the forthcoming year, irrespective of short-term fluctuations in income.

Future Considerations

The Trustees remain vigilant in monitoring both income levels and operational needs. The reserves policy will be reviewed in 2024 in light of future projects, potential risks, and the external environment. The Trustees will take into account the financial challenges posed by inflationary pressures, donor behaviours, and economic uncertainty



when reassessing the appropriate level of free reserves required to safeguard the charity's long-term sustainability.

The Trustees are confident that the current reserves position, alongside careful financial planning, places the charity in a strong position to meet its strategic objectives while continuing to provide valuable support to cancer research and those affected by cancer.



Our Strategy

Building awareness of childhood cancer for the future

At Children with Cancer UK, we are forward-thinking in our approach to raising awareness and driving progress in the conversation about childhood cancer. By coming together with other charities, we can share resources, amplify our collective visions, and become a stronger voice for children with cancer. This collaboration enables us to share learnings, accelerate change, and make a bigger impact in raising awareness. Our 'Kids Like Us' film is an example of raising awareness, sparking vital conversations and bringing the personal stories of children with cancer to the forefront, ensuring these voices are heard.

We have committed to funding crucial projects, and through a new three-year partnership, we are excited to be able to report on the progress made. Our collaboration with charities such as The Azaylia Foundation and Alice's Arc has created a powerful coalition to further raise awareness. A key example of this is The Azaylia Foundation's funding of PhDs to attract the brightest minds to this field, ensuring we continue to raise awareness and drive progress in childhood cancer research.

Our commitment to research

Our research programme is evolving to ensure that we make a greater impact through a more strategic use of our funding. We are committed to focusing not only on treatment but also on prevention and policy, adopting a more holistic approach to childhood cancer. This shift will allow us to progress our principal aims as a charity. First, we wish to develop improved treatments so that more patients are cured with less toxic side effects. Second, we wish to better understand how cancer develops so that one day we may be able to prevent it.

In collaboration with our Scientific Advisory Panel, we are reviewing our Research Strategy to ensure that every investment delivers the maximum benefit for children and families. We wish to invest in research that will deliver the greatest impact. A key part of this strategy is the continuation of our annual grants programme, which supports pioneering research projects that will drive progress and create lasting change. By focusing our resources where they will have the greatest impact, we are confident that we can make a meaningful difference for children and young people with cancer.

Prioritising the families we support

Children with Cancer UK remains dedicated to supporting families throughout their cancer journey. As part of this commitment, we are investing in the development of Raines Retreat, a new facility in North Yorkshire that will provide a welcoming and comfortable break for families. This significant investment in capital works marks the first step in ensuring the centre is fit for purpose, and we look forward to opening its



doors in 2025. Alongside this, we are proud to celebrate the first year of our partnership with Spread a Smile and our continued collaboration with Beads of Courage UK, two vital programmes dedicated to enhancing the wellbeing of children during treatment. We will continue to seek new partnerships that allow us to extend our reach and support for families.

In addition, we are taking steps to ensure that the voices of those with lived experience are more deeply embedded in our work with the help of our Patient and Public Involvement. While we have always sought views and conversations with families, we are now embracing a more strategic approach to engaging with those who have undergone treatment. Our goal is to ensure that their insights and experiences inform our decision-making at every level. By including patient voices in everything we do, from funding cutting-edge research to improving support services, we can ensure our work remains as impactful as possible. We look forward to sharing more details soon on how families and individuals can offer their valuable input to our mission at Children with Cancer UK.



Human Resources

Introduction

As the charity continues to grow and evolve in its mission to combat paediatric cancer, the focus on its people is more critical than ever. The performance and sustainability of the charity's workforce are vital in achieving our strategic goals. This report outlines key HR metrics for 2023 and highlights the priorities and initiatives for 2024 that will support employee engagement, development, and retention.

Workforce Overview

As of December 2023, the charity employed 41 staff members (2022: 37) across various roles, including fundraising, research, administration, and frontline services. The workforce is diverse, dedicated, and mission-driven.

Staff Turnover

While turnover was in line with industry averages for the charity sector, the charity keeps improving its enhanced employee engagement, development, and support strategies to foster retention and job satisfaction.

HR Strategic Focus for 2024: The People Plan

The People Plan for 2024 focuses on the alignment of HR practices with the charity's long-term goals, with an emphasis on improving retention, employee wellbeing, and engagement. The following initiatives have been identified as priority areas for development and execution throughout the year:

Implementation of a New HR System

A new HR system has been implemented in 2024 to improve the collection, management, and analysis of employee data. The system will:

- Provide better insight into employee performance and satisfaction metrics.
- Allow for more targeted HR interventions based on data trends.
- Streamline HR operations, enabling efficiency in payroll, leave management, and performance reviews.

Review of Employee Contracts, Policies, and Handbook

We constantly review and update all employee contracts, policies, and the staff handbook to:

- Ensure they meet best practice standards, reflecting current employment law and sector norms.
- Address gaps identified through employee feedback and recent internal audits.



Enhanced Wellbeing Support

In response to feedback from staff surveys and focus groups, the charity will enhance its wellbeing offerings by:

- Providing mental health first-aider training to key staff across all departments.
- Offering regular supervision sessions and support groups, particularly for frontline employees who may face high levels of emotional stress in their work.

Review of EDI Policy and Practices

Equity, Diversity, and Inclusion (EDI) remain a central focus for the charity. In 2024, we will:

- Conduct a thorough review of existing EDI policies and practices.
- Work with external consultants to identify areas for improvement, ensuring the charity remains a welcoming and inclusive workplace for all.

Competency Framework and Training Needs Analysis

A new competency framework will be introduced, enabling a more structured approach to staff development. Key activities include:

- A comprehensive skills assessment to identify gaps across teams.
- Development of tailored learning paths for employees, with an emphasis on continuous professional development.
- Adoption of an e-learning platform to support flexible, on-demand learning for staff at all levels.

Upskilling Line Managers

We recognize that managers play a crucial role in staff retention and satisfaction. Therefore, in 2024, there will be a focus on:

- Training line managers in key people management skills, including performance management, employee relations, and HR processes.
- Ensuring managers are equipped to handle mental health concerns and promote a supportive team culture.

Enhanced Communication and Engagement Practices

To foster a more engaged and informed workforce, the charity will:

- Increase the frequency and quality of internal communications, ensuring transparency around organizational decisions.
- Create more opportunities for staff to provide feedback through surveys, focus groups, and informal channels.



- Launch regular employee engagement events to celebrate achievements and foster team cohesion.
- Run an annual engagement review to evaluate the success of people initiatives and keep the HR plan relevant

Compensation and Benefit Benchmarking

To remain competitive in the charity sector, we will conduct a comprehensive review of our compensation and benefits packages, including:

- Benchmarking salaries against other organizations in the cancer research and broader non-profit sectors.
- Committing to an annual salary review process with transparency around reward packages to ensure employees feel valued and fairly compensated.

The charity's focus on its people is integral to its continued success and ability to deliver its mission. The activities outlined in the People Plan will drive meaningful improvements in employee satisfaction, retention, and engagement. By investing in our workforce, we are ensuring that we have the right talent, skills, and commitment in place to achieve our strategic objectives and support the ongoing fight against paediatric cancer.

The HR team will monitor the progress of these initiatives throughout the year and continue to gather feedback to ensure that we remain agile and responsive to the needs of our staff.



Going Concern

The Trustees have assessed the charity's ability to continue as a going concern and are confident that it remains financially sustainable over the foreseeable future, a period of at least 12 months from the date of approval of these financial statements.

In making this assessment, the Trustees have reviewed the charity's financial position, including cash flow, liquidity, and reserves levels, alongside the budget for the forthcoming year. The impact of potential financial risks, including changes in donor income, investment income, and unforeseen operational challenges, has been carefully evaluated. Despite the challenging external environment, including economic fluctuations and uncertainty, the charity's diversified income streams, strong donor support, and prudent financial management have provided the necessary resilience.

The charity has consistently demonstrated its ability to manage costs effectively and maintain a robust level of reserves to ensure the continuity of vital cancer research programmes and related activities. In addition, fundraising efforts remain stable, with significant backing from individual donors, corporate partners, and grant-making bodies.

The Trustees acknowledge that there may be ongoing challenges as a result of fluctuating economic conditions, but they are confident that the charity's forward financial planning and the adaptability of its fundraising model will mitigate any adverse effects. The charity is well-positioned to respond to these challenges due to its strong financial foundation, dedicated supporter base, and ongoing partnerships within the cancer research community.

Taking into consideration all of the above factors, the Trustees have a reasonable expectation that the charity will continue in operational existence for the foreseeable future. Accordingly, the financial statements have been prepared on the going concern basis.



Investments

In accordance with the Memorandum of Association and Investment Policy, the charity is authorized to deposit or invest funds in various manners, provided that it obtains advice from financial experts as deemed necessary by the Trustees. This policy ensures that investments are suitable and well-diversified, aligning with the charity's objectives and risk tolerance.

Investment Objectives

The charity's primary investment objectives are:

- To Generate Optimal Returns: Investments should aim to produce the best possible financial return for an acceptable level of risk.
- To Support Research Grants: Investments must support the charity's capacity to award research grants while seeking to achieve capital growth and inflation protection.
- To Preserve Capital: Ensuring that invested funds retain their value in real terms, considering inflation and other economic factors.

Current Investment Portfolio

As of 31 December 2023, the charity's investments are allocated as follows:

- Long-term Investments: Totalling £12.2 million
 - £1.8 million in an investment portfolio managed by Barclays Investment Managers
 - £10.4 million in an investment portfolio managed by Investec Wealth & Investment

The charity also holds £4.7 million in short-term cash deposits to meet immediate liquidity needs and operational requirements.

Investment Strategy

The charity's investment strategy involves:

- Diversification: Investments are spread across different asset classes and managers to reduce risk and enhance potential returns. The charity currently uses Barclays Investment Managers and Investec Wealth & Investment to manage long-term funds, ensuring professional oversight and diversification.
- Risk Management: The Trustees ensure that all investments align with the charity's risk tolerance. Cash funds, which are designated for imminent grant payments, are kept in low-risk, instant access deposits to preserve capital and ensure liquidity.



- **Review and Performance Monitoring:** The investment policy is reviewed regularly to assess its effectiveness and adapt to changing market conditions. For 2023, the Trustees believe that the performance of investments met the policy's objectives, providing satisfactory returns within an acceptable risk profile. The charity is exploring opportunities to identify higher-performing funds for 2024 while maintaining a balanced approach to risk.

Cash Management

The charity maintains sufficient cash levels to cover fluctuating needs and anticipated grant liabilities. As of 31 December 2023, grant liabilities amount to approximately £13 million (2022: £12.6 million). The Trustees are committed to ensuring that cash funds are not exposed to undue risk, given that these funds are allocated to future grant commitments.

Future Considerations

The Trustees will continue to monitor the investment portfolio and review the policy to align with evolving financial conditions and strategic goals. This includes evaluating performance, assessing potential new investment opportunities, and adjusting strategies as necessary to meet both short-term and long-term objectives.

The charity's investment policy aims to balance the need for capital growth with the requirement for liquidity and risk management. By maintaining a diversified portfolio and adhering to a structured investment approach, the Trustees are confident in the charity's ability to support its mission and financial sustainability.



Risk and Internal Control

Responsibility and Overview

The Trustees have overall responsibility for ensuring that the Charity maintains an appropriate system of internal controls, both financial and operational. This system is designed to safeguard the Charity's assets and ensure the effective and efficient management of resources. The Trustees are committed to protecting the Charity from fraud, mismanagement, and other irregularities, and to ensuring compliance with relevant laws and regulations.

Key Areas of Internal Control

The Trustees have established internal control procedures to address the following key areas:

Safeguarding Assets:

Measures are in place to protect the Charity's assets against unauthorized use or disposition. This includes secure management of cash and investments, stringent protocols for the handling and recording of donations, and regular audits of physical assets.

Investments are monitored and managed by professional advisors, and all major transactions are reviewed and authorized by the Trustees.

Reliability of Financial Information:

The Charity maintains robust accounting records to ensure that financial information is accurate and reliable. This includes regular reconciliations and external audits, and adherence to accounting standards.

Financial information used internally for decision-making and externally for reporting is subject to rigorous review processes to ensure accuracy and completeness.

Compliance with Laws and Regulations:

The Charity complies with all relevant laws and regulations, including those governing charities, financial reporting, and fundraising activities.

Regular updates and training are provided to Trustees and staff to ensure ongoing compliance with regulatory changes and best practices.

Risk Management and Internal Control Systems

The Trustees acknowledge their responsibility for the Charity's risk management and internal control systems. Key elements of the system include:



Risk Assessment:

Regular risk assessments are conducted to identify and evaluate potential risks to the Charity's operations and objectives. This includes assessing risks related to financial management, fundraising activities, and compliance with legal requirements.

The Charity has implemented procedures to manage and mitigate identified risks, including contingency planning and insurance coverage.

Internal Controls:

Internal controls are designed to manage risks and ensure the effective operation of the Charity. These controls include segregation of duties, authorisation procedures, and regular review of financial transactions and reports.

The effectiveness of internal controls is reviewed periodically by the Trustees and through external audits. Any weaknesses identified are addressed promptly.

Fraud Prevention and Detection:

The Charity has policies and procedures in place to prevent and detect fraud. This includes a whistleblowing policy, regular monitoring of financial transactions, and a robust process for reporting and investigating any suspected fraudulent activity.

System Limitations and Continuous Improvement

The Trustees recognise that while the internal control system is designed to manage risks and achieve the Charity's objectives, it cannot eliminate all risks or provide absolute assurance against material misstatement or loss. The system is intended to provide reasonable assurance of effective and efficient operations.

The Trustees are committed to continuous improvement and regularly review the internal control system to ensure its effectiveness. Feedback from audits, risk assessments, and operational reviews are used to refine and enhance the control environment.

The Trustees are confident that the internal control and risk management systems in place provide a solid framework for managing the Charity's risks and ensuring the safeguarding of its assets. The Charity remains committed to maintaining high standards of financial management and compliance to support its mission of advancing cancer research and supporting those affected by cancer.



Principal Risks and Uncertainties

Overview

The Charity faces several principal risks and uncertainties in the current economic climate. These risks are regularly reviewed by the Trustees, and appropriate mitigation strategies are implemented to ensure the continued effectiveness and stability of our operations.

Principal Risks

Fundraising Risks:

The Charity remains heavily reliant on mainstream fundraising income to support its research activities. A significant risk is that income may decline due to economic pressures, which could impact our ability to fund research effectively and maintain stable reserves. To manage this risk, we are diversifying our income streams, investing in new fundraising channels, and continuously monitoring the impact of economic conditions on donor behaviour and contributions.

Economic Climate:

The current economic climate in the UK, including inflationary pressures and increased cost of living, poses risks to our operational and financial stability. These economic factors can affect both the availability of donor funds and the cost of delivering our programs. We are actively reviewing our expenditure, renegotiating contracts where possible, and seeking efficiencies to mitigate these impacts.

Regulatory Compliance:

Ensuring compliance with relevant laws and regulations remains a critical focus. This includes adapting to any new regulatory requirements and maintaining rigorous internal controls to ensure ongoing compliance.

Infrastructure & Operations:

Risks related to the adequacy and reliability of our infrastructure and operations are continuously assessed. This includes managing operational costs and ensuring that our systems and processes are resilient to economic fluctuations.



Charitable Impact:

Assessing the effectiveness and impact of our research funding is crucial. We need to ensure that our funding decisions are aligned with our strategic objectives and that funded projects deliver meaningful outcomes.

Profile & Brand:

Managing the Charity's profile and brand reputation is essential, particularly in a competitive fundraising environment. Maintaining a strong public image and effectively communicating our mission and impact are key to sustaining donor support.

Financial Risks:

Financial management risks include ensuring that our investment portfolio performs well and that we maintain sufficient reserves. We regularly review our investment strategy to balance returns with acceptable risk levels and ensure that our financial position remains robust.

Governance:

Effective governance is critical to the Charity's success. This involves ensuring that our governance structures are robust, that Trustees and management are well-supported, and that we adhere to best practices in governance and oversight.

Mitigation Strategies

Each identified risk is assessed in terms of its probability and impact, with mitigation strategies developed as necessary. These strategies include:

Diversification: Expanding fundraising activities and income sources to reduce reliance on any single source of funding.

Cost Management: Implementing stringent expenditure controls and seeking efficiencies to manage the impact of economic pressures.

Regular Review: Continuously monitoring financial performance and operational effectiveness to adapt to changing conditions.

Governance Improvements: Ensuring that governance practices are regularly reviewed and enhanced to address emerging challenges.



Financial Position and Stability

Despite these risks, the Charity is in a strong financial position. The current reserves and diversified income streams provide a solid foundation for managing potential financial impacts. The Charity's robust financial management and strategic planning ensure that we can weather economic fluctuations and maintain operational stability. There is no indication of financial instability, and any potential issues can be effectively mitigated through our established risk management processes.

Trustee and Management Oversight

The Trustees and Senior Management regularly review and discuss these principal risks as part of our risk management strategy. We remain committed to addressing these risks proactively to safeguard the Charity's mission and ensure its continued success.

The Trustees and Senior Management are dedicated to managing the Charity's risks effectively in the current economic climate. By maintaining a proactive approach to risk management and adapting to changing conditions, we aim to support our mission of funding impactful cancer research and achieving our strategic objectives.



Structure, Governance and Management

The financial statements have been prepared in accordance with current statutory requirements, the Memorandum and Articles of Association, the Accounting and Reporting by Charities Statement of Recommended Practice (SORP FRS 102), and applicable accounting standards (FRS 102).

The Trustees have reviewed and acknowledge the principles and recommendations outlined in the Charity Governance Code. The Senior Leadership Team was assigned the responsibility of evaluating the Charity's governance practices against the Charity Governance Code and identifying key areas for improvement. Following this assessment, it was recommended that an independent Governance Review be conducted. The Trustees authorized this review and directed the Senior Leadership Team to implement all recommendations.

Significant progress has been achieved, with majority of the recommendations successfully implemented. Plans are in place to address the remaining items within the next 12 months.

Governing Documents

These financial statements are for Children with Cancer UK and its subsidiary Helping Children with Cancer Limited.

Children with Cancer UK is a company limited by guarantee and operates under its Memorandum and Articles of Association dated 11th November 2003 as amended by special or written resolutions, dated 30th November 2004, 22nd December 2006, 12th May 2007, 28th July 2016 and 13th December 2021.

On 14th May 2007 the reporting charity changed its name from CHILDREN with LEUKAEMIA UK to Children with Cancer UK. However, the charity continued to use the working name of CHILDREN with LEUKAEMIA until 11th May 2011.

The charity operates under its Trust Deed (dated 4th January 1988) and Variation of Trust Deed (dated 10th December 2003).



Aims and Objectives

Purposes and Aims

The charity's objects as amended by written resolution of 12th May 2007, and 28th July 2016 are shown below:

- To promote the relief of children and young people suffering with leukaemia or any other form of cancer (and allied disorders) and of their families;
- To raise public awareness and knowledge in matters relating to leukaemia or any other form of cancer (and allied disorders) affecting children and young people; and
- To promote research into the causes, alleviation, prevention, treatment and cure of leukaemia or any other form of cancer (and allied disorders) affecting children and young people and to publish the useful results of such research.

Our aims are to determine the causes, find the cure and provide care for children with cancer.

We fund life-saving research into the causes, prevention and treatment of childhood cancer.

We fund innovative welfare projects to provide better care for young cancer patients and their families.

We campaign to raise awareness of childhood cancer to protect more children and to improve the lives of young cancer patients, today and for future generations.

We are a member of the Association of Medical Research Charities. We are also a member of the National Cancer Research Institute.

Further details of the projects we fund are detailed in note 23.

Public Benefit

The Trustees continue to give due regard to the public benefit provided by the charity in relation to its charitable purpose as set out by the objectives above and have given due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the activities that promote the charitable objects above will be applied to provide public benefit.

Board of Trustees

The governing body of the reporting charity is the Board of Trustees, which has a total of five members (2022: five). The Trustees of the charity also act as the Directors of the



charitable company. The Board meets at least three times a year together with the Chief Executive and other senior management where appropriate.

The Finance and Operations Committee is a subcommittee of the Board. The subcommittee meets at least bi-monthly and consists of a combination of Trustees, Staff, External Advisors and Specialised Volunteers (if required). The committee will draw to the attention of the Board any urgent issues that require authorisation, disclosure or action and escalate any urgent issues for immediate attention outside of the Board meeting schedule.

Trustee appointment and induction

There were two new appointments (2022: two) to the Trustee Board in 2023. Two Trustees left the board during 2023 (2022: five). The selection of Trustees is made based on vacancies arising, sympathy with the objects of the charity and the additional skills and experience that potential new Trustees are able to afford. Under the Articles of Association, Trustees are appointed by a majority vote of the members (who are all the current Trustees) by ordinary resolution.

Each new Trustee receives the Charity Commission publication ‘The Essential Trustee: What you need to know’ as well as the most recent published annual report. The Chief Executive Officer offers an induction day to all Trustees which provides full information about the operations of the charity.

Management

The Trustees exercise executive responsibility for the governance of the charity and, through the Chairman, supervise the management of the charity by the Chief Executive Officer and the executive team. The Chairman and Chief Executive Officer also task the Board with decision-making on strategic management issues as well as overseeing the research grants application process and monitoring the progress of awarded grants.

The senior management carry out the operational running of the charity and the coordinating of fundraising appeals and events.

Remuneration

The salaries of Children with Cancer UK staff are periodically benchmarked against other charities to ensure that salary levels are market competitive and sufficient to attract and retain staff of the appropriate calibre. All staff posts are periodically evaluated to ensure that salary levels are reflective of industry and organisational needs, as well as individual and charity performance. In recruitment of a new post, an assessment is made of the requirements of the role in terms of skills, experience, competency and urgency. The salary is then determined on the basis of this assessment and the current market conditions.



Salary Bands have been set based on external benchmarking, anecdotal data from head-hunters and recruiters, and charity sector salary surveys. The Salary Bands are reviewed at least every two years.

The Charity is compliant with the Hutton Fair Pay Review with the salary of the highest paid employee being no more than four times the median salary of the organisation.

Trading Subsidiary

Helping Children with Cancer Limited (company registration 2807553) is the wholly owned trading subsidiary of Children with Cancer UK. Its principal purpose is to raise funds for the charity and all taxable profits are donated under Gift Aid.

The principal activity of the Company is the licensing of the name and logo of the charity for use in corporate sponsorship, commercial agreements and royalties from contribution to clinical trials.

The trading activities generated profit for the year of £109,048 (2022: £158,217) which will be paid to Children with Cancer UK under the Gift Aid Scheme. It is anticipated that the trading activity within the subsidiary will continue at a similar level during the current year.

The trading subsidiary holds assets of £148,893 (2022: £167,764) and liabilities of £148,793 (2022: 167,664) with funds of £100 as at 31st December 2023.

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

Related parties

The Charity has a related party and conflict of interest policy in place which accompanies the Declaration of Interests submissions completed by all Trustees and senior management. A Conflicts of Interest register is in place which is updated when a conflict of interest is declared or has been identified and the register is reviewed at least annually.

Grant making policy

It is the Trustees' policy to maximise the proportion of its charitable output that is achieved through grant making.

Welfare grants

There is no open application process for welfare grants and no welfare grants are given to individuals. The Trustees determine which organisations are to be supported. In 2023, a total of £500,000 (2022: £3,040,000) was awarded to welfare projects.



Research grants

The Trustees aim to award an increasing proportion of the charity's grants to scientific and medical research in cancers affecting children, teenagers and young adults. The charity's Code of Practice adheres to the standards set by the Association of Medical Research Charities (AMRC).

The charity advertises guidelines and invite applications for project grant rounds. Project applications are subject to formal internal and external peer review followed by scrutiny by our Scientific Advisory Panel (SAP) before the Trustees determine which projects to support. We also occasionally support research through other AMRC members.

In 2023, a total of £4,063,640 (2022: £3,931,033) was awarded to research projects and collaborations.



Reference and Administration

Children with Cancer UK (previously known as CHILDREN with LEUKAEMIA UK) was set up in memory of Paul O’Gorman who died on 6th February 1987 and his sister Jean, who died on 3rd November 1987. The charity was inaugurated by Diana, Princess of Wales on 12th January 1988 at Mill Hill County High School where Paul had been a pupil.

Trustees

The Trustees of Children with Cancer UK are the charity’s Trustees under charity law and the directors of the charitable company:

Current Trustees

David Gibbs (Chair of Trustees)
Alex Leitch (Deputy Chair)
Phil Hall
Bruce Morland
Sarah Standing (Appointed 31st October 2023)

Previous Trustees

Georgie Wolfenden (Resigned 16th May 2023)
Caroline Randerson (Resigned 30th August 2023)
Lindsey Cape (Appointed 31st October 2023 – Resigned 29th February 2024)

Executive Team

Amar Naher (Interim Chief Executive Officer)
Anna Brooks (Interim Head of People and Culture)
Sultana Choudry (Interim Head of Research)
Fadil Dugolli (Head of IT)
Fiona Judge (Head of Supporter Care)
Hannah Chambers (Head of Marketing and Communications)
Ari Kotsis (Interim Head of Finance)
Alex Hayward (Head of Public Fundraising)

Previous members of the Executive Team during the year were:

Gary Murphy (Chief Operating Officer)
Jo Elvin (Chief Executive Officer)
Ria Griffin (Head of People and Culture)
Christiana Ogunbote (Head of Research)

**Registered Charity Number**

298405

Registered Company Number

4960054

Principal office

21-27 Lamb's Conduit Street, London,
WC1N 3NL

Auditors

PKF Littlejohn LLP, 15 Westferry Circus,
London E14 4HD

Solicitors

Bates Wells, 10 Queen Street Place,
London, EC4R 1BE

Bankers

National Westminster Bank PLC, 30
North Audley Street, London W1A 4UQ

Contact details

Children with Cancer UK

21-27 Lamb's Conduit Street, London, WC1N 3NL

Tel: 020 7404 0808

Email: info@childrenwithcancer.org.uk

www.childrenwithcancer.org.uk

Scientific Advisory Panel

We are indebted to the members of our Scientific Advisory Panel (SAP) who freely give their time and expertise to help drive forward our fight against cancers affecting children and young people. Research into cancers affecting children and young people is a broad field and we aim to reflect the diversity of the field amongst the membership of panel members.

The interim chair of the Panel for 2022/23 was Professor Roderick Skinner. In September 2023 a new Chair, Dr Christina Halsey was confirmed in post for a three-year term.



Statement of Trustees' Responsibilities

The Trustees (who are also directors of Children with Cancer UK for the purposes of company law) are responsible for preparing the Strategic Report, the Trustees' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and the group for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company and group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions, disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006 and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Insofar as each of the Trustees of the charitable company at the date of approval of this report is aware there is no relevant audit information (information needed by the charitable company's auditor in connection with preparing the audit report) of which the charitable company's auditor is unaware. Each Trustee has taken all of the steps that he/she should have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the charitable company's auditor is aware of that information.

This Annual Report of the Trustees, prepared under the Charities Act 2011 and the Companies Act 2006, was approved by the Board of Trustees on 26th September 2024 including approving in their capacity as company directors the Strategic Report contained therein, and is signed as authorised on its behalf by:

David Gibbs
Chair of Trustees
Date: 26th September 2024



Independent Auditor's Report to the Members of Children with Cancer UK

Opinion

We have audited the financial statements of Children with Cancer UK (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2023 which comprise the Consolidated Statement of Financial Activities, the Consolidated and Parent Charitable Company Balance Sheets, the Consolidated Cash Flow Statements and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2023, and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report.

We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.



Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's or parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the trustees' annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the trustees' annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report, which includes the strategic report and the directors' report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors' report included within the trustees' report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report included within the trustees' annual report.

Under the Companies Act 2006 we are required to report in respect of the following matters if, in our opinion:



- adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

We have nothing to report in respect of these matters.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the group and parent charitable company financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the group and parent charitable company financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed auditor under the Companies Act 2006 and report in accordance with this Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.



Extent to which the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

We considered the nature of the industry and its control environment, and reviewed the documentation of their policies and procedures relating to fraud and compliance with laws and regulations. We also enquired of management about their own identification and assessment of the risks of irregularities.

We obtained an understanding of the legal and regulatory frameworks that the charitable company operates in, and identified the key laws and regulations that:

- had a direct effect on the determination of material amounts and disclosures in the financial statements. These included UK Charities Act and UK Companies Act; and
- do not have a direct effect on the financial statements but compliance with which may be fundamental to the charitable company's ability to operate or to avoid a material penalty.

We discussed among the audit engagement team the opportunities and incentives that may exist within the organisation for fraud and how and where fraud might occur in the financial statements.

As a result of performing the above, we identified the greatest potential for fraud or non-compliance with laws and regulations in the following areas, and our specific procedures performed to address them are described below:

- recognition of legacy income in the correct accounting period and correctly classified. To address this risk we tested a sample of legacies to evaluate whether the income and the corresponding cash receipt or receivable have been recognised appropriately, and to assess the classification of the income as either restricted or unrestricted; and
- recognition of grant expenditure in the correct accounting period. To address this risk we tested a sample of agreements between the charitable company and its beneficiaries to evaluate whether the expenditure and the corresponding payment or creditor have been recognised appropriately; and
- classification of funds between restricted and unrestricted. To address this risk we have tested a sample of income and expenditure in the year to assess whether they have been classified appropriately.

In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override. In addressing the risk of fraud through management override of controls, we tested the appropriateness of



journal entries and other adjustments; assessed whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluated the business rationale of any significant transactions that are unusual or outside the normal course of business.

In addition to the above, our procedures to respond to the risks identified included the following:

- reviewing financial statement disclosures by testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- enquiring of management concerning actual and potential litigation and claims, and instances of non-compliance with laws and regulations; and
- reading minutes of meetings of those charged with governance and reviewing correspondence with Charity Commission.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at:

www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone, other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Alastair S. Duke (Senior Statutory Auditor)

For and on behalf of PKF Littlejohn LLP

Statutory Auditor

30th September 2024

15 Westferry Circus

Canary Wharf

London E14 4HD



Consolidated statement of financial activities for the year ended 31 December 2023 (Incorporating an income and expenditure account)

	Note	Total restricted funds £	Total unrestricted funds £	Total 2023 £	Total 2022 £
Income from:					
Donations and legacies	4	140,959	13,502,203	13,643,162	13,415,147
Other trading activities	4	-	883,917	883,917	581,771
Income from investments		-	453,300	453,300	91,499
Other income		134,479	77,344	211,823	22,000
Total Income	20	275,438	14,916,764	15,192,202	14,110,417
Expenditure on:					
Raising funds	6	-	2,447,063	2,447,063	2,119,479
Charitable activities	6, 8	275,438	9,369,461	9,644,899	11,731,505
Total Expenditure	6	275,438	11,816,524	12,091,962	13,850,984
Net change in investments	14	-	441,084	441,084	(204,193)
Net Income		-	3,541,324	3,541,324	55,240
Transfers between funds	20	-	-	-	-
Net movement in funds		-	3,541,324	3,541,324	55,240
Reconciliation of funds:					
Total funds brought forward		-	14,840,280	14,840,280	14,785,040
Total funds carried forward	20	-	18,381,604	18,381,604	14,840,280

The comparative figures for each fund are shown in note 3 to the financial statements. The notes on pages 56 to 74 form part of these financial statements.



Balance sheet as at 31 December 2023

Company Number: 4960054

	Note	2023		2022	
		Group £	Charity £	Group £	Charity £
Fixed assets					
Property	12	2,495,899	2,495,899	1,600,000	1,600,000
Intangible Assets	13	1,500,584	1,500,584		
Investments	14	12,162,502	12,162,602	10,000,000	10,000,100
		16,158,985	16,159,085	11,600,000	11,600,100
Current assets					
Debtors and prepayments	15	2,765,835	2,924,038	2,947,998	2,936,304
Cash deposits		4,751,924	4,751,924	4,650,280	4,650,280
Cash at bank and in hand		8,911,885	8,762,992	9,356,488	9,202,979
		16,429,644	16,438,954	16,954,766	16,789,563
Creditors: amounts falling due within one year					
Grants	16	(6,590,941)	(6,590,941)	(8,031,586)	(8,031,586)
Other	17,18	(1,209,970)	(1,219,380)	(1,130,638)	(965,535)
Net current assets		8,628,733	8,628,633	7,792,542	7,792,442
Total assets less current liabilities		24,787,718	24,787,718	19,392,542	19,392,542
Creditors: amounts falling due after more than one year					
Grants	16	(6,406,114)	(6,406,114)	(4,552,262)	(4,552,262)
Net assets		18,381,604	18,381,604	14,840,280	14,840,280
Represented by:					
Unrestricted funds	19,20	18,381,604	18,381,604	14,840,280	14,840,280

The net surplus for the financial year dealt within the financial statements of the parent charitable company was £3,541,324 (2022: net surplus £55,240).

The notes on pages 56 to 74 form part of the financial statements.

Approved and authorised for issue on behalf of the Trustees on 26th September 2024.

David Gibbs
Trustee

Alex Leitch
Trustee



Consolidated cash flow statement for the year ended 31 December 2023

		2023		2022
		£		£
Cash flows from operating activities:				
Net cash provided by operating activities	a)	3,349,690		3,760,133
Cash flows from investing activities:				
Dividends and interest from investments		453,300		91,636
Net additions in the year		(10,005,321)		(5,513)
Purchase & Improvements of Fixed Assets		(895,899)		(1,600,000)
Purchase of Intangible Assets		(1,500,584)		-
Net cash provided by investing activities		(11,948,504)		(1,513,877)
Change in cash and cash equivalents in the reporting period		(8,598,814)		2,246,256
Cash and cash equivalents at the beginning of the reporting period	b)	22,262,623		20,016,367
Cash and cash equivalents at the end of the reporting period	b)	13,663,809		22,262,623
Notes to the Cash flow Statement				
a) Reconciliation of net (expenditure) to net cash flow from operating activities		2023		2022
		£		£
Net income for the reporting period		3,541,324		55,250
Adjustments for:				
Dividends and interest from investments		(453,300)		(91,636)
Investment Manager Fees		28,048		5,513
Net Change in investments		(441,084)		204,321
Decrease / (increase) in debtors		182,163		(281,794)
(Decrease) / increase in creditors		492,539		3,868,479
Net cash provided by (used in) operating activities		3,349,690		3,760,133
b) Analysis of cash and cash equivalents				
		01-Jan-23	Cashflow	31-Dec-23
		£	£	£
Cash at bank and in hand		9,356,488	(444,603)	8,911,885
Cash held as short term investments		4,650,280	101,644	4,751,924
Cash held as long term investments		8,255,855	(8,255,855)	-
		22,262,623	(8,598,814)	13,663,809

The notes on pages 56 to 74 form part of the financial statements.



Notes to the financial statements for the year ended 31 December 2023

1. Charity information

Children with Cancer UK is limited by guarantee with no share capital (registered number 4960054), which is incorporated in England and Wales and domiciled in the UK. The address of the registered office is 21-27 Lamb's Conduit Street, London, WC1N 3NL. It is also a registered charity (registered number 298405) and as such is a non-profit making organisation.

2. Accounting policies

a) Basis of preparation

The financial statements have been prepared on the historical cost basis of accounting, as modified by the revaluation of investments, and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102), the Companies Act 2006, the Charities SORP (FRS 102) and the accounting policies set out below.

The charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Children with Cancer UK is the ultimate parent company. It has two subsidiaries - Helping Children with Cancer Limited and Children with Cancer Research Limited. Children with Cancer UK owns the whole of the share capital of Helping Children with Cancer Limited, a company registered in England and Wales, number 2807553. It also holds 100% of the share capital of Children with Cancer Research Limited, a company registered in England and Wales, number 09442350 which is currently dormant.

The financial statements of the charity and its active subsidiary company are consolidated, on a line-by-line basis, to produce the Group financial statements. The consolidated entity is referred to as 'the Group'. No separate Statement of Financial Activities has been prepared for the charity as permitted by Section 408 of the Companies Act 2006. The charity has taken advantage of the exemptions in FRS 102 from the requirements to present a charity only Cash Flow Statement and certain disclosures about the charity's financial instruments.

b) Preparation of the accounts on a going concern basis

The Trustees have assessed the charity's ability to continue as a going concern and are confident that it remains financially sustainable over the foreseeable future, a period of at least 12 months from the date of approval of these financial statements.



c) Financial Instruments

The charity has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at amortised cost. Financial assets held at amortised cost comprise cash at bank and in hand, short term cash deposits together with the group's trade and other debtors excluding prepayments. Financial liabilities held at amortised cost comprise the group's short- and long-term trade and other creditors excluding deferred income and taxation payable. No discounting has been applied to these financial instruments on the basis that the periods over which amounts will be settled are such that any discounting would be immaterial.

Investments, including cash held as part of the investment portfolio are held at fair value at the Balance Sheet date, with gains and losses being recognised within the Statement of Financial Activities. Investments in subsidiary undertakings are held at cost less impairment.

d) Critical accounting judgements and key sources of estimation uncertainty

In the application of the charity's accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects the current and future periods.

The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described in the accounting policies and are summarised below:

The charity recognises residuary legacies once probate has been granted which therefore requires an estimation of the amount receivable.

e) Functional/Presentational currency

The functional currency of the charity and its subsidiary is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity/group operates. The consolidated financial statements are also presented in pounds sterling.

f) Fund accounting

Unrestricted funds comprise accumulated surpluses and deficits on general funds and are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and have not been designated for other purposes.



Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund.

g) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Voluntary income in the form of appeals, committed giving, sports events and community fundraising income is recognised in the period of receipt. Income received in advance of an event or lottery is deferred until the criteria for income recognition are met.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Income arising from corporates and trusts is recognised in the period in which the charity has entitlement to the income.

Income from trading activities is recognised in the period in which the service has been provided or product sold.

Investment income from dividends and interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest received or receivable from the Bank.

Government grants are recognised on the performance model, when the Charitable Company has complied with any conditions attaching to the grant and the grant will be received. The grant in connection to the job retention scheme has been recognised in the period to which the underlying furloughed staff costs relate to.

h) Expenditure and basis of allocation of costs

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis and the majority is directly attributable to specific activities. Other indirect costs are apportioned to activities in accordance with



staff activity and an assessment of where the resources have been applied. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Grants to third parties are included in the SOFA when approved by the Trustees when a constructive obligation exists, notwithstanding that they may be paid in future accounting periods.

Support costs include governance costs which are costs incurred to manage the charity in compliance with constitutional and statutory requirements and the direct expenditure and overhead costs relating to the appeals and fundraising functions. They also include the allocation of costs incurred to support and coordinate fundraising activities. These costs are allocated across the categories of charitable activities and the basis of this cost allocation has been explained in note 7 of the financial statements.

Expenditure on raising funds includes expenditure specifically incurred for fundraising purposes. This constitutes a mixture of directly attributable costs and apportionment.

i) Tangible fixed assets

Tangible fixed assets costing more than £10,000 are capitalised and included at cost including any incidental costs of acquisition, or, where donated, are included at valuation at the date that ownership is acquired.

j) Intangible fixed assets

The charity recognizes intangible assets at cost. They are subsequently carried at cost less accumulated amortization. Amortization is calculated using the straight-line method over the estimated useful lives of the assets. Impairment of intangible assets is assessed annually. If the carrying amount of an intangible asset exceeds its recoverable amount, an impairment loss is recognized.

k) Pension scheme

Permanent employees are entitled to join the Grouped Stakeholder Pension Plan provided by Scottish Widows. During 2023, the charity made a contribution of no less than 5% of salary per month to any personal or stakeholder pension scheme selected by all employees serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of pension costs is the contribution payable during the year.



l) Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

m) Gifts in Kind

Gifts in kind and donated goods and services are recognised in the accounts when the benefit to the charity is reasonably quantifiable and measurable. The value is the price the charity estimates it would pay should it purchase equivalent goods or services.

The estimated valuation of gifts in kind is based on the value of the contribution to the charity, or the valuation the charity would have had to pay to acquire the goods or services. A corresponding amount is recognised within expenditure in the period of receipt.

n) Private Medical Insurance

From 2017 to 2022, permanent employees were entitled to join a Group Private Medical Insurance Scheme provided by Bupa. In 2023, the charity paid a premium based on the employee's ages per month for all employees who had elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of private medical insurance is the contribution payable during the year.



3. Consolidated statement of financial activities for the year ended 31 December 2022

	Total restricted funds£	Total unrestricted funds£	Total 2022 £
Income from:			
Donations and legacies	254,872	13,160,275	13,415,147
Other trading activities	-	581,771	581,771
Income from investments	-	91,499	91,499
Other income	-	22,000	22,000
Total Income	254,872	13,855,545	14,110,417
Expenditure on:			
Raising funds	-	2,119,479	2,119,479
Charitable activities	201,162	11,530,343	11,731,505
Total Expenditure	201,162	13,649,822	13,850,984
Net change in investments	-	(204,193)	(204,193)
Net (expenditure)/income	53,710	1,530	55,240
Transfers between funds	(53,710)	53,710	-
Net movement in funds	-	55,240	55,240
Reconciliation of funds:			
Total funds brought forward	-	14,785,040	14,785,040
Total funds carried forward	-	14,840,280	14,840,280

4. Income

	2023 £	2022 £
Donations and legacies		
Appeals and associated donations	3,629,364	3,286,890
Committed giving	2,962,783	3,018,538
Sports events	3,017,894	2,926,349
Legacies (see contingent asset below)	2,444,893	2,380,956
Corporate and trust donations	951,282	1,178,349
Community fundraising	636,946	624,065
	13,643,162	13,415,147
Other trading activities		
Events	883,917	581,771
	883,917	581,771



Contingent asset - legacy income

As at 31 December 2023, the charity had been notified of a further 40 residuary and pecuniary legacies which have not been recognised as income in the Statement of Financial Activities as they do not meet the criteria as detailed in the accounting policies. These legacies have an estimated value of £884,216 (2022:£1,967,279) which has not been accrued.

5. Lottery income

As part of the charity's Gambling Commission Licence (Non-Remote Licence - 000-004700-N-306402-010) (Remote Licence - 000-004700-R-308531-010), during the year the charity has operated three raffles and a weekly lottery.

The following ticket sales were received for each lottery where the draw was held in 2023:

	Ticket sales £
Weekly Lottery	470,633
Christmas Raffle (draw 13 th January 2023)	277,424
Spring Raffle (draw 9 th June 2023)	250,627
Summer Raffle (draw 8 th September 2023)	236,670
Total	1,235,354

The Christmas Raffle spans two accounting periods. Although the draw took place during the current accounting period, the closing date was 23rd December 2022 and most ticket sales were received in the previous accounting period. All other ticket sales were received during 2023 only. All ticket sales have been included within the total income for 2023 and 2022.

In line with the requirements under Social Responsibility code provision 4.3.1 of the Licence Conditions and Codes of Practice of the Gambling Act 2005 the following section details the percentage of lottery proceeds returned to the purposes of the society (Children with Cancer UK) from the lotteries promoted in 2023.

Lottery type	Lottery Name	Percentage proceeds returned to Charity %
Managed directly by Children with Cancer UK	Weekly Lottery	57%
Managed directly by Children with Cancer UK	Children with Cancer Grand Draw	64%
Total		61%



6. Total expenditure

	Staff Costs £	Direct Costs £	Support and Governance £	2023 Total £	2022 Total £
Expenditure on Raising funds					
Fundraising Costs	722,127	1,260,282	464,654	2,447,063	2,119,479
Expenditure on Charitable activities					
Research into Prevention & Causes	324,080	233,485	219,783	777,348	731,260
Research into Treatment	317,011	4,004,065	213,063	4,534,139	4,628,203
Welfare	380,360	1,114,687	338,231	1,833,278	4,259,386
Raising Awareness	758,213	1,360,557	381,364	2,500,134	2,112,656
	1,779,664	6,712,794	1,152,441	9,644,899	11,731,505
	2,501,791	7,973,076	1,617,095	12,091,962	13,850,984

	Staff Costs £	Direct Costs £	Support and Governance £	2022 Total £
Expenditure on Raising funds				
Fundraising Costs	470,552	1,243,818	405,109	2,119,479
Expenditure on Charitable activities				
Research into Prevention & Causes	219,217	337,012	175,031	731,260
Research into Treatment	213,293	4,244,270	170,640	4,628,203
Welfare	277,704	3,748,064	233,618	4,259,386
Raising Awareness	441,663	1,345,519	325,474	2,112,656
	-----	-----	-----	-----
	1,151,877	9,674,865	904,763	11,731,505
	1,622,429	10,918,683	1,309,872	13,850,984



7. Support costs

Support costs are split as follows:

	Office Admin £	Management £	Finance, IT & HR £	Comms & Marketing £	Governance £	2023 Total £
Expenditure on Raising funds						
Fundraising Costs	120,805	15,034	206,645	102,207	19,963	464,654
Expenditure on Charitable activities						
Research into Prevention & Causes	57,141	7,111	97,744	48,344	9,443	219,783
Research into Treatment	55,394	6,894	94,755	46,866	9,154	213,063
Wellness	87,937	10,943	150,421	74,398	14,532	338,231
Raising Awareness	99,864	12,308	169,175	83,674	16,343	381,364
	300,336	37,256	512,095	253,282	49,472	1,152,441
	421,141	52,290	718,740	355,489	69,435	1,617,095

	Office Admin £	Management £	Finance, IT & HR £	Comms & Marketing £	Governance £	2022 Total £
Expenditure on Raising funds						
Fundraising Costs	83,886	35,678	217,031	54,193	14,321	405,109
Expenditure on Charitable activities						
Research into Prevention & Causes	36,244	15,415	93,770	23,414	6,187	175,031
Research into Treatment	35,334	15,028	91,418	22,827	6,063	170,640
Welfare	48,375	20,575	125,158	31,252	8,258	233,618
Raising Awareness	67,396	28,665	174,368	43,540	11,505	325,474
	187,349	79,683	484,714	121,033	31,983	904,762
	271,235	115,361	701,745	175,226	46,304	1,309,871

Indirect, support and governance costs are allocated on a per person basis to staff in the office. The time spent by each staff member on every activity of the charity is allocated on a month-by-month basis throughout the year. Support and staff costs are then allocated to the various charitable activities based on this staff time basis.



8. Costs of charitable activities

	Activities undertaken directly £	Grant funding of activities £	Support and governance costs £	2023 Total £	2022 Total £
Research into Prevention & Causes	517,565	40,000	219,783	777,348	1,231,260
Research into Treatment	843,419	3,477,657	213,063	4,534,139	4,128,203
Welfare	957,546	537,500	338,232	1,833,278	4,259,386
Raising Awareness	2,118,771	-	381,363	2,500,134	2,112,656
	4,437,301	4,055,157	1,152,441	9,644,899	11,731,505

9. Auditor Costs

	2023 £	2022 £
External Audit Fees:		
Children with Cancer UK	35,700	34,000
Helping Children with Cancer Ltd	4,200	4,000
Other services from external auditor – tax advisory		
Children with Cancer UK	950	-
Helping Children with Cancer Ltd	900	-

10. Staff costs

	2023 £	2022 £
Salaries and wages	1,526,867	1,362,728
National Insurance	163,632	150,028
Pension	98,357	103,563
Private Medical Insurance	5,485	6,109
	1,794,341	1,622,428

The number of employees whose remuneration fell within the following bands is set out below:

Salary Range	2023 £	2022 £
£100,000 - £110,000	1	-
£90,000 - £100,000	-	-
£70,000 - £80,000	1	1
£60,000 - £70,000	3	5



There have been 5 (2022: 8) positions that have formed part of the executive team during 2023. The total remuneration including pension contributions for these employees amounts to £412,645 (2022: £620,296).

During the year there were no (2022: one) redundancy, termination or settlement payments made totalling £nil (2022: £12,317).

The average weekly number of contracted employees during the year was as follows:

	2023	2022
	No.	No.
Charitable Activities	4	4
Raising Funds	32	25
Support, Governance, Operations and Administration	5	8
	41	37

The Trustees received no remuneration and reimbursement of £178 of travel expenses to one trustee during the year (2022 Nil).

11. Results of the parent charity

	2023	2022
	£	£
Total income	15,160,662	14,106,417
Total expenditure	(12,060,422)	(13,846,984)
Unrealised gains / (Losses)	441,084	(204,193)
Net (expenditure) / Income	3,541,324	55,240

12. Property

The balance of £2.5m relates to a property addition in 2022 and related works in progress. No depreciation has been charged as it is an asset under construction.

	'Raines Retreat' Property
	£
Cost at 1 st Jan 2023	1,600,000
Additional works in progress	895,899
Depreciation	-
Cost at 31 st Dec 2023	2,495,899

13. Intangible Assets

The Intangible asset relates to production of the Kids Like Us film completed in 2024, no amortisation has been charged in 2023. There is a capital commitment of £166,732 to complete the production work in 2024.



14. Investments

	2023 £	2022 £
Listed investments (see below)	12,162,502	1,744,145
Cash deposits held as long-term investment	-	8,255,855
	12,162,502	10,000,000
Market value of listed investments at 1 Jan	1,744,145	1,948,338
Additions to investment portfolio	10,005,321	5,513
Investment manager fees	(28,048)	(5,513)
Net Investment gain/(loss)	441,084	(204,193)
Market value of listed investments at 31 Dec	12,162,502	1,744,145
Listed Investments comprise the following:		
Multi class and other investments	12,162,502	1,744,145
Total listed investments at 31 Dec	12,162,502	1,744,145

	2023 £	2022 £
Total Investments are listed in:		
United Kingdom	2,861,105	456,966
Overseas	9,301,397	1,287,179
	12,162,502	1,744,145

Investment in subsidiary

Children with Cancer UK holds 100% of the share capital of Helping Children with Cancer Limited which is a registered company number 04960054. The value of the share capital owned is £100. Helping Children with Cancer Limited raises funds via commercial activities and sponsorship.

The income and expenditure for the year ended 31 December 2023 is as follows:

	2023 £	2022 £
Income	150,000	171,380
Administrative expenses	(40,952)	(13,163)
Profit before gift aid and taxation	109,048	158,217

The balance sheet for the subsidiary as at 31 December 2023 is as follows:

	2023 £	2022 £
Assets	148,893	167,764
Liabilities	(148,793)	(167,664)
Reserves	100	100

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.



15. Debtors

	2023 Group £	2023 Charity £	2022 Group £	2022 Charity £
Amounts due from subsidiary undertakings	-	158,203	-	-
Other debtors	670,116	670,116	780,880	780,880
Accrued income	1,128,318	1,128,318	1,256,736	1,242,482
Prepayments	967,401	967,401	910,382	910,382
	2,765,835	2,924,038	2,947,998	2,936,304

16. Grants to third parties

	2023 £	2022 £
Outstanding liabilities at the start of the year	12,583,848	9,146,065
Awarded during the year (note 23):		
Research into prevention and causes	40,000	-
Research into treatment and survival	4,023,640	3,931,033
Welfare	500,000	3,040,000
Raising awareness	-	-
Total third party grants before adjustments	4,563,640	6,971,033
Under/over spends and adjustments on previous grant awards	(508,483)	39,295
Total third party grants	4,055,157	7,010,328
Paid during the year	(3,641,950)	(3,572,544)
Outstanding liabilities at the end of the year	12,997,055	12,583,848
Grants falling due within one year	6,590,941	8,031,586
Grants falling due after more than one year	6,406,114	4,552,262
	12,997,055	12,583,848

17. Creditors: amounts falling due within one year

	2023 Group £	2023 Charity £	2022 Group £	2022 Charity £
Accruals and deferred income	1,206,590	1,201,490	1,087,681	922,578
Amount due to subsidiary	-	16,904	-	-
Taxes and social security	3,380	986	42,957	42,957
	-----	-----	-----	-----
	1,209,970	1,219,380	1,130,638	965,535
Grants payable	6,590,941	6,590,941	8,031,586	8,031,586
	7,800,911	7,810,321	9,162,224	8,997,121



18. Deferred income

Deferred income comprises income received in advance for entries to our weekly lottery.

	2023 Group £	2023 Charity £	2022 Group £	2022 Charity £
Balance as at 1 January 2023	53,701	53,701	56,285	56,285
Amount released to income	(53,701)	(53,701)	(56,285)	(56,285)
Amount deferred in year	31,208	31,208	53,701	53,701
Balance as at 31 December 2023	31,208	31,208	53,701	53,701

19. Analysis of net assets between funds

As at 31 December 2023	2023 Group Restricted funds £	2023 Group Unrestricted funds £	2023 Group Total funds £	2022 Group Unrestricted funds £
Fixed assets	-	16,158,985	16,158,985	11,600,000
Net current assets	-	8,628,733	8,628,733	7,792,542
Creditors falling due after more than one year	-	(6,406,114)	(6,406,114)	(4,552,262)
Net assets at the end of the year	-	18,381,604	18,381,604	14,840,280

As at 31 December 2022	2022 Group Restricted funds £	2022 Group Unrestricted funds £	2022 Group Total funds £	2021 Group Unrestricted funds £
Fixed assets	-	11,600,000	11,600,000	10,293,735
Net current assets	-	7,792,542	7,792,542	9,672,199
Creditors falling due after more than one year	-	(4,552,262)	(4,552,262)	(5,180,894)
Net assets at the end of the year	-	14,840,280	14,840,280	14,785,040

20. Statement of funds

Year ended 31 December 2023	Balance at 1 January £	Total Income £	Total Expenditure £	Transfers & Investment gains/losses £	Balance at 31 December £
Restricted funds					
a) Beads of Courage UK	-	139,958	(139,958)	-	-
b) Ugie Investments	-	1,000	(1,000)	-	-
c) Yann Jamin, Institute for Cancer Research.	-	49,523	(49,523)	-	-



d) Macarena Oporto Espuelas, UCL GOS Institute of Child Health.	-	32,354	(32,354)	-	-
e) Manuela Cerbone, UCL GOS Institute of Child Health.	-	23,410	(23,410)	-	-
f) Defne Saatchi, University of Oxford.	-	14,102	(14,102)	-	-
g) Zoe Walters, University of Southampton.	-	10,591	(10,591)	-	-
h) David Clynes, University of Oxford.	-	4,500	(4,500)	-	-
Total Restricted funds	-	275,438	(275,438)	-	-
Total Unrestricted funds	14,840,280	14,916,764	(11,816,524)	441,084	18,381,604
Total funds	14,840,280	15,192,202	(12,091,962)	441,084	18,381,604

Year ended 31 December 2022	Balance at 1 January £	Total Income £	Total Expenditure £	Transfers & Investment gains/losses £	Balance at 31 December £
Restricted funds					
i) Dr Christina Halsey University of Glasgow	-	500	-	(500)	-
j) Dr Ian Hampson University of Manchester	-	100	-	(100)	-
k) Professor Sibylle Mitnacht UCL Cancer Institute	-	1,000	-	(1,000)	-
l) Sam Behjati Wellcome Sanger Institute	-	1,596	-	(1,596)	-
m) Anthony Chalmers University of Glasgow	-	500	-	(500)	-
n) Marc Mansour UCL Cancer Institute	-	20	-	(20)	-
o) Professor Chris Jones Institute of Cancer Research,	-	246	-	(246)	-
p) Professor Steve Clifford INSTINCT-MB	-	49,749	-	(49,749)	-
q) Wellness Retreat Project	-	22,052	(22,052)	-	-
a) Beads of Courage UK	-	179,110	(179,110)	-	-
Total Restricted funds	-	254,872	(201,162)	(53,710)	-
Total Unrestricted funds	14,785,040	13,855,545	(13,649,822)	(150,483)	14,840,280
Total funds	14,785,040	14,110,417	(13,850,984)	(204,193)	14,840,280

The restricted funds comprise donations that were to be spent on specific causes and projects. All restricted income was either discharged during the year or transferred from restricted back to unrestricted funds. This has occurred when restricted funds were received towards grants that were previously paid out of unrestricted reserves.

Description of restricted fund projects:

- a) Beads of Courage UK, which helps children in all 110 children's cancer wards in the UK visualise and articulate their cancer journey.



- b) Ugie Investments, funding for Scottish causes.
- c) Yann Jamin, Institute for Cancer Research, UK Government Covid Medical Research Charity Support Fund from The Medical Research Council funding.
- d) Macarena Oporto Espuelas, UCL GOS Institute of Child Health, UK Government Covid Medical Research Charity Support Fund from The Medical Research Council funding.
- e) Manuela Cerbone, UCL GOS Institute of Child Health, UK Government Covid Medical Research Charity Support Fund from The Medical Research Council funding..
- f) Defne Saatchi, University of Oxford, UK Government Covid Medical Research Charity Support Fund from The Medical Research Council funding.
- g) Zoe Walters, University of Southampton, UK Government Covid Medical Research Charity Support Fund from The Medical Research Council funding.
- h) David Clynes, University of Oxford, UK Government Covid Medical Research Charity Support Fund from The Medical Research Council funding.
- i) Dr Christina Halsey, University of Glasgow. Discovery of biomarkers and new therapeutic targets for chemotherapy associated neurotoxicity.
- j) Dr Ian Hampson, University of Manchester. Identification of infections which may play a role in the aetiology of childhood acute lymphoblastic leukaemia (ALL).
- k) Professor Sibylle Mitnacht, UCL Cancer Institute. Exploring retinoblastoma protein loss as an actionable target in paediatric bone and soft tissue sarcoma.
- l) Sam Behjati, Wellcome Sanger Institute. Developmental states of localised and metastatic osteosarcoma cells – a knowledge bank for novel biomarkers and therapeutic approaches.
- m) Anthony Chalmers, University of Glasgow. Increasing the susceptibility of neuroblastoma cells to radiotherapy by targeting glycolysis and lipogenesis.
- n) Marc Mansour - UCL Cancer Institute - CCR9 as a novel immunotherapy target in T-cell acute lymphoblastic leukaemia (T-ALL).
- o) Professor Chris Jones, Institute of Cancer Research, The role of histone H4K20 methylation in paediatric glioblastoma and DIPG.
- p) Professor Steve Clifford – INSTINCT-MB. Strategic implementation of novel combination therapeutics for high-risk medulloblastoma
- q) Wellness Retreat Project - Raines Retreat in North Yorkshire, which will offer families a much-needed break in a peaceful environment specifically designed for children with cancer.

21. Related Party Transactions

There have been no other related party transactions during the year other than those with the trading subsidiary.



A management fee of £5,000 (2022: £5,000) has been charged to the trading subsidiary for use of the charity's trademarks and a further £4,412 (2022: £4,163) for the use of charity staff (calculated on the basis of time charged to subsidiary activity by the employee). As at 31st December 2023, £141,299 (2022: £163,704) was owed to the charity from the trading subsidiary.

22. Financial Instruments

The financial statements include the following in respect of items:

	2023 £	2022 £
Financial assets measured at fair value	12,162,502	1,744,145
Total interest income for financial assets held at fair value	(121,992)	(35,736)

23. Grants to third parties

Grants awarded to third parties during the year	Research into prevention and causes 2023 £	Research into treatment 2023 £	Welfare 2023 £	Total 2023 £
Spread A Smile – Improving wellbeing of seriously ill and hospitalized children and their family members through entertainment and events.			500,000	500,000
Tessa Jowell Brain Cancer Mission - Paediatric Centres of Excellence	40,000	40,000		80,000
UCL Great Ormond Street Institute of Child Health – Dr Srdan Rogosic - Safety enhanced CAR T cell therapy for paediatric AML – Costed Extension		23,716		23,716
University College London – Prof Kathy Pritchard-Jones – International benchmarking of childhood cancer survival by stage – Costed Extension		69,423		69,423
Newcastle University - Prof Steve Clifford – INSTINCT-MB: Strategic implementation of novel combination therapeutics for high-risk medulloblastoma – As a condition of the original a formal review was conducted at 18 months after the anniversary of the start date. The initial grant was co-funded with Blue Skye Thinking and Little Hero who provided financial support to the grant.		962,131		962,131
University College London – Dr Jon Clayden - A tailored image guidance approach for children undergoing surgery for brain tumours		131,899		131,899



University of Nottingham – Dr Elizabeth Coyle - Establishing tumour microenvironment models of paediatric brain tumours		349,210		349,210
Newcastle University Centre for Cancer – Dr Debbie Hicks - Radiotherapy-induced neurocognitive deficits in medulloblastoma: Human-equivalent modelling and randomised pre-clinical trials to identify effective pharmacological interventions for clinical application		343,770		343,770
Institute of Cancer Research – Prof Chris Jones - Combined targeting of ACVR1 and cholesterol metabolism in diffuse midline glioma		285,321		285,321
Imperial College London – Prof Cristina Lo Celso - Characterising and targeting the treatment resistant population in B-ALL following Inotuzumab Ozogamicin treatment		326,789		326,789
UCL GOS ICH – Dr Marc Mansour - Development of CCR9-targeting antibody therapy for paediatric T-cell acute lymphoblastic leukaemia		349,915		349,915
University of Oxford – Prof Adam Mead - Characterisation of the cross talk between RAS mutant haematopoietic stem cells and immune effector cells in Juvenile Myelomonocytic Leukaemia		350,000		350,000
University of Edinburgh – Prof Rod Mitchell - Transplantation of Cryopreserved Testicular Tissue to Restore Fertility after Childhood Cancer		290,455		290,455
University College London – Dr Karin Straathof - Equipping CAR T-cells with IL-12 to achieve durable tumour responses in neuroblastoma		231,742		231,742
UCL GOS ICH - Dr Owen Williams - MYB-directed therapy for paediatric AML		269,269		269,269
Total grants to third parties awarded in the year	40,000	4,023,640	500,000	4,563,640
Grant closures and adjustments		(545,983)	37,500	(508,483)
Total grants to third parties	40,000	3,477,657	537,500	4,055,157

Note

There were 5 grant closures with a net value of less than £100 that occurred during the year. There were a further 24 grant closures with a combined value of £665,830 that occurred during the year. There were 8 grant adjustments of £157,347 relating to corrections made to grants awarded in previous financial years.



Grants awarded to third parties during the year	Research into prevention and causes 2022 £	Research into treatment 2022 £	Welfare 2022 £	Total 2022 £
Beads of Courage – To fund the implementation of an official sibling programme run the way it was intended, using the sibling beads as the foundation stone.			3,040,000	3,040,000
Cancer Research UK to support the funding of the stratified medicine paediatrics 2 programme.		2,755,372		2,755,372
Bone Cancer Research Trust - to collaborate and fund a new Research Programme Grant for children, teens and young adults (aged 24 years and younger) suffering from Ewing Sarcoma.		1,000,000		1,000,000
Two IARC Postdoctoral Fellowships (€200,000).		175,660		175,660
Total grants to third parties	-	3,931,032	3,040,000	6,971,032



Every day 10 children and young people are diagnosed with cancer in the UK.

8 out of 10 young childhood cancer patients can be successfully treated thanks to vital, specialist research we helped fund.

Our aims are to determine the causes, find cures and provide care for children with cancer. We are united by a common goal – to save and improve young lives.



We fund Research



We fund Welfare



We raise Awareness

Children with Cancer UK
Registered Office
21-27 Lamb's Conduit Street
London
WC1N 3NL

CHILDREN WITH CANCER UK

England & Wales - Charity number 298405

Accounts



Children with Cancer UK

Trustees' Report and Financial Statements
for the year ended 31 December 2022





Children with Cancer UK in numbers

Research - We're committed to improving survival and finding kinder treatments for children and young people with cancer

£4m invested into vital, life-saving research

2 new research grants were awarded

2 new collaborations commenced

Supporting families – We help children with cancer and their families through the hardships of a cancer diagnosis

186 families attended participated in our welfare activities

£3m helping children cope with cancer treatment through receiving beads from Beads of Courage UK, our partner charity

Awareness – We shine a spotlight on the impact of cancer on children and young people and their families

Millions of people reached through our campaigns

267 online articles

110 mentions of the charity in printed media

15 families told their childhood cancer stories



CHILDREN WITH CANCER UK

**TRUSTEES' ANNUAL REPORT
AND CONSOLIDATED FINANCIAL STATEMENTS**

FOR THE YEAR ENDED 31 DECEMBER 2022

	Page
MESSAGE FROM THE CHAIR AND CEO	4
OUTCOMES IN 2022	6
RESEARCH OUTCOMES IN 2022	7
SUPPORTING FAMILIES IN 2022	9
AWARENESS ACTIVITIES IN 2022	10
FUNDRAISING HIGHLIGHTS AND COMPLIANCE	12
THANK YOU	15
FINANCIAL REVIEW	17
STRATEGIC PLANS	19
GOING CONCERN, RISKS & GOVERNANCE	20
REFERENCE AND ADMINISTRATION	28
STATEMENT OF TRUSTEES' RESPONSIBILITIES	30
INDEPENDENT AUDITORS' REPORT	31
CONSOLIDATED FINANCIAL STATEMENTS	36
NOTES TO THE FINANCIAL STATEMENTS	39



Welcome from Chair of Trustees

2022 was another year of change for Children with Cancer UK as we continue to evolve and leave COVID-19 in the past. Building on the inspirational 35-year legacy of our Founder and Chairman, Eddie O’Gorman, we’re more determined than ever to improve outcomes for children and young people with a cancer diagnosis.

With Jo Elvin leading as CEO, we are driving forwards with new initiatives and a refreshed strategy. This includes internal changes such as our Digital Transformation Project which is implementing up to date systems for data and financial processes, moving office spaces to allow for growth and our re-brand which introduces a bold new look. Our vision is the same, but it’s a new chapter.

This year, we also saw the renewal of our board of trustees in coordination with Jo’s appointment. I’m delighted to introduce Professor Bruce Morland who recently retired as a Professor of Paediatric Oncology at Birmingham Women’s and Children’s Hospital. He has extensive experience in the development of novel new therapies for childhood cancer and we look forward to his influence on our strategic direction for research. Similarly, I’m honoured to introduce Pamela Kearns as our new Scientific Advisor. Pamela is Professor of Clinical Paediatric Oncology at the University of Birmingham and an Honorary Consultant Paediatric Oncologist at Birmingham Women and Children’s Hospital. Her expertise will be an asset to our team as we continue to fund essential and groundbreaking research.

Looking forwards, Children with Cancer UK will be focusing on the wellbeing of families facing a childhood cancer diagnosis and how we can best support this. We continue to fund the inspiring Beads of Courage UK programme and have also begun plans for a new wellness centre that will act as a haven for young families.

Finally, I would like to sincerely thank our staff who are the heart of our organisation and the supporters who have been on this journey with us and continue to help the charity support families facing the unimaginable.

David Gibbs
Chair of Trustees
Children with Cancer UK



Welcome from CEO of Children with Cancer UK

It's been a year of seismic transition at Children with Cancer UK. In the last 35 years, this charity has raised £300million to give to the fight against childhood cancers. It's my aim to amplify our message and reach even more audiences than ever before.

Children With Cancer UK is proud to be one of the biggest funders of research into childhood cancer in this country and in the past year we have invested £4 million into new projects. Through a brilliant collaboration with Bone Cancer Research Trust, we committed to funding a Ewing Sarcoma Research programme as no new treatments have been developed for this type of bone cancer in over 30 years, a shocking amount of time.

We also provided financial support for the Postdoctoral Fellowship Programme by the International Agency for Research on Cancer (IARC) as the training of early-career scientists is crucial for the future of childhood cancer research worldwide.

Over the next 12 months, I'm delighted to announce that the charity will be making a major investment in a new world-leading research facility, the Birmingham Cancer Research Institute (BCRI), in collaboration with Birmingham University. This is the charity's first ever investment in a capital project and it is one that we have full confidence in being able to accelerate the breakthroughs needed in childhood cancer research.

Our new logo features two 'arms' on either side of our name, symbolic of the embrace in which we want to hold all children and their families facing cancer. Long time supporters will already be aware of our ongoing support of the oncology arm of the Beads of Courage UK programme. This exceptional organisation rewards children with a special bead to represent every treatment they face on their journey and I've seen firsthand the profound impact these beads have on the emotional wellbeing of a child. It's why we're also delighted to be partnering with Spread a Smile. Our support of this wonderful charity means that more children, across the UK, will have the chance to experience happiness alongside the hardship of the hospital ward, as entertainers and therapy animals literally spread smiles wherever they go.

In another first for the charity, we are currently developing a holiday retreat in picturesque Yorkshire for the latter half of 2024. The retreat will give deserving families some much needed holiday time in an environment equipped for the specific needs of children with cancer.



Together with our new branding, we are working to spread our message to new audiences in innovative new ways. We have some big, at times daunting goals we've set ourselves at Children with Cancer UK. But it's also incredibly exciting to think that after 35 years, there is still so much potential for this charity to grow its impact on children and young people.

I very much appreciate your continuing support in these efforts.

Jo Elvin
CEO of Children with Cancer UK

OUTCOMES IN 2022

How donations have helped children and young people with cancer.

We are pleased to announce that in 2022 we raised £13.8 million to fund specialist childhood cancer research and support families.

For every £1 we spend on fundraising, we raised £5 more

For every £1 donated we spend

- 85p on fighting childhood cancer
 - 39p on research projects,
 - 31p on supporting families,
 - 15p on raising awareness,
- 15p on raising more money



OUR YEAR IN RESEARCH

Around 1,800 children and 2,400 young people are diagnosed with cancer each year in the United Kingdom. Whilst over 80% of patients survive, cancer remains one of the leading disease related causes of death for children under 15 years of age. From the time of their diagnosis, children and young people endure difficult treatments to eradicate their disease, with potentially life-altering side effects on their development. High-quality and impactful research is essential to driving forward our vision of a world where every child and young person survives cancer. Research has significantly contributed to the improvements seen in childhood cancer survival rates from 67.3% in 1990 to a predicted 85.2% recorded in 2019. Improved treatments and understanding of the disease are important in the fight against cancer.

Children with Cancer UK plays a major role in funding vital life-saving research. We are dedicated to improving survival rates across all types of childhood cancer, improving the quality of life in young cancer survivors, and finding less-toxic treatment options. As one of the UK's leading charities dedicated to childhood cancer research, we are proud of our contribution to the ongoing breakthroughs which continue to help save young lives.

The COVID-19 pandemic continued to have a significant impact on research in the UK and result in delays for many existing research projects due to continued redeployment, impacts to the workforce and capacities to deliver research within the laboratory environment. Despite these limitations, we funded 2 new research projects as part of a Postdoctoral fellowship programme in collaboration with the International Agency for Research on Cancer (IARC) in 2022 worth €200,000. The training of early-career scientists plays an important role in strengthening the capacity of nations in the fight against cancer. These projects are focusing on cancers in children, teenagers, and young adults.

Combined with existing active research grants, this means that we are now funding a total of 46 projects, worth over £14 million across the UK and abroad. Our funding is helping more children survive cancer and look forward to longer and healthier lives after their treatment has ended.

Children with Cancer UK values its partnerships with others in the paediatric and young adult cancer community including the National Cancer Research Institute (NCRI) and the Association of Medical Research Charities (AMRC). Our research funding includes support from other charities, government funders, cancer organizations and universities. We supported several conferences including the British Neuro-oncology Society (BNOS) annual meeting and the Bone Cancer Research Trust 3rd International Ewing Sarcoma Research Symposium. These collaborative events during the year help to facilitate innovation and share specialist expertise.



New research awards

In 2022 we funded new research programs in collaboration with other organisations worth £3,971,033.

Bone Cancer Research Trust – Ewing Sarcoma Research Programme

Ewing sarcoma represents approximately 15% of all primary bone cancers and approximately 0.02% of all cancers diagnosed in the UK each year, with a peak of incidence between 10-20 years old. Through a chronic lack of research and funding, no new treatments have been developed in over 30 years. Overall, 5-year survival has remained static for decades at 50-60% however, for patients with metastatic disease, this can be as low as 20-35%.

By combining forces, the Bone Cancer Research Trust and Children with Cancer UK hope to bring about a greater interest in Ewing sarcoma research that will accelerate the development of new and kinder treatment options that are so desperately needed for children and young people.

International Agency for Research on Cancer (IARC) – Postdoctoral Fellowship Programme

The training of early-career scientists plays an important role in strengthening the capacity of countries in the fight against cancer. Financial support from donors such as Children with Cancer UK is vital to increase the number of postdoctoral scientists who can benefit from the IARC Fellowship Programme, and ultimately to boost the impact on research capacity in countries worldwide. These funded projects to the value of €200,000 will have a focus on cancers affecting children and young people.

Cancer Research UK - Stratified Medicine Paediatrics 2 programme

In November 2022, we committed £2.7 million to Cancer Research UK to support the Stratified Medicine Paediatrics 2 programme in 2023. This programme aims to develop and study novel tests (investigations) that will build upon the success of StratMedPaediatrics, the UK's first National Molecular Tumour profiling platform for relapsed childhood cancer. We look forward to seeing the results of this collaboration

Scientific Advisory Panel

We are indebted to the members of our Scientific Advisory Panel (SAP) who freely give their time and expertise to help drive forward our fight against cancers affecting children and young people. Research into cancers affecting children and young people is a broad field and we aim to reflect the diversity of the field amongst the membership of panel members.

The interim chair of the Panel for 2022 was Professor Roderick Skinner. In 2023 a new Chair was confirmed.



SUPPORTING FAMILIES IN 2022

Children with Cancer UK is committed to being there for families through treatment and beyond. Due to the staffing absence of a special events team, we were not able to deliver as many events as in previous years. We ensured consistent contact with our families was maintained throughout this period and were still able to create special memories towards the end of the year.

Back to School Craft Kits

In September 2022, we sent 96 families a craft kit that included decorating a pencil case, making a pencil topper and creating a book bag keyring. The kits were mailed to their homes alongside a virtual instruction video which allowed the families the freedom to make the school accessories in their own time.

Hollie loved receiving her craft kit and her mum, Hayley told us:

“Hollie was very excited to receive her back-to-school craft kit. She couldn't wait to design her own pencil case. She was so excited to show her best friend at school what she had made, and everyone loved it. Thanks so much again. You're always there for us.”

Children's Choir

At the Children with Cancer UK Ball in 2022, we invited 10 children to participate in a children's choir for the first time. They performed a rendition of 'Fix you' by Coldplay and were accompanied by adult performers. This experience was an exciting opportunity to involve our families in one of our key fundraising events and we hope to continue this tradition in years to come.

Warner Brothers Harry Potter Studio Tour

In December 2022, over 80 children affected by childhood cancer and their families joined us at the Warner Brothers Harry Potter Studio Tour. Guests were escorted through the cinematic experience by characters from the Harry Potter films and into the studio tour where they were able to explore the sets, props and costumes featured in the Harry Potter film series.

One of the young guests in attendance was Sebastian Penney, aged 8, who was diagnosed with cancer of the bowel when he was 18 months old and has been in remission for the past 5 years. His mother, Natasha, said:

“The event was magical – Sebastian had an amazing time just wandering around and having fun. The highlight of his day was seeing friends he made at the Children with Cancer UK ball and giving them a big hug, I think they will be friends for life now. It normalises his treatment and it's lovely they get to do this and be together at Children with Cancer UK events.”



Beads of Courage UK

Our partnership with the Beads of Courage UK programme continued through 2022 and we helped to fund support for children and their families through some of the toughest times in their lives. Since our partnership began in 2019, we have helped support approximately 14,000 children in over 100 hospitals acknowledge, celebrate and record 10 plus million milestones. Our grant has also enabled training sessions to hospital staff on how to support individual patients throughout the programme both practically and emotionally. Every bead tells a story of hope, support and encouragement.

RAISING AWARENESS

Children with Cancer UK is dedicated to increasing awareness of the causes, symptoms, treatments and impact of childhood cancer. This commitment to spotlighting the effects of childhood cancer extends to current and potential supporters, the research community and patient families.

It is only through our raised profile that we can continue to secure funds for life-saving research and effect change for children and young people with a cancer diagnosis.

In 2022, we ran multiple campaigns including Childhood Cancer Awareness Month and Christmas. Through these key charity moments, we have reached millions of individuals across the UK.

Making our voice heard

- 267 online articles
- 110 mentions of the charity in printed media
- 285 mentions on broadcast (radio and tv)

Social media

- 20% increase in net audience growth
- 55.9% uplift in posts across all channels
- 27.7% increase in video views



Childhood Cancer Awareness Month

Childhood Cancer Awareness Month (CCAM) is a national awareness campaign that occurs every September. This year, we continued the theme of 'When I grow up...' and created two videos with childhood cancer patients Eve and Josh.

Eve's inspirational video with Dame Arlene Phillips, our ambassador, was submitted at the Smiley Charity Film Awards in March 2023 and came third in its category.

With special thanks to Josh, Eve and their families for sharing their experiences so generously and thank you to Duna Films for helping us to create a special message for other children that celebrates their eternal optimism and zest for life despite the challenges they face.

Christmas

Our 2022 Christmas Appeal shared Florie's story and the difficulties her family faced over the previous two Christmases. Florie was diagnosed with a Wilms tumour, a type of kidney cancer when she was just two years old.

We partnered with 'The Sun on Sunday's Xmas Cards for Kids' campaign and had our designs featured in 790 Tesco UK stores. We received £20,000 as a donation from these sales and were included in their online articles.

Telling the story of childhood cancer

Sharing childhood cancer journeys is one of our most effective ways in raising awareness. We are incredibly grateful to all of the families who so generously volunteered to share their story. With their support we can continue to highlight the need for more funding into childhood cancer research.

Thank you to the 12 families who shared their child's story in 2022 and welcome to the Children with Cancer UK family: Lenny, Lois, Alfie H, Florie, Jacob, Jesse, Dax, Theo, Jacob W, Liberty, Harry HP and Enguerrand.

Thank you also to the three adults who reflected on their own childhood cancer journeys and welcome to the Children with Cancer UK family: Leah, Luciano and Ellen.



FUNDRAISING HIGHLIGHTS

Some of our fundraising achievements in 2022, that are helping create a world where every child survives cancer, include:

- We saw 186 participants take on a Rat Race event, raising over £140,000
- 160 supporters took up a non-running challenge event in the UK or overseas and raised over £112,000
- We launched our first Facebook Challenge, Jog 50km in September, to mark Childhood Cancer Awareness Month 2022. It was the first time that we used Facebook fundraising in this way.
- The Peek Family raised over £7000 for Children with Cancer UK in memory of their son, Dax, who sadly died in 2020 when he was just two years old. They held a charity night, raffle and auction.
- Two of our longstanding collection tin fundraisers, Leonora Lane and Kam Kaur, raised over £5000 between them in 2022.
- Phil Stamp, in the wake of his terminal bowel cancer diagnosis, organised fundraising activities with the help of Audley End Miniature Railway and raised over £12,000 for Children with Cancer UK.

London Marathon Events 2022

The 2022 TCS London Marathon took place on Sunday 2nd October. We had a team of 1103 runners take part in the iconic 26.2 route. We were thrilled to be able to get back to a more normal London Marathon and re-establish our four cheer points around the route, with a team of volunteers at the finish line to welcome and congratulate our team.

In 2022 our team raised over £2.5million from the TCS London Marathon which was incredible and higher than expected. 2022 saw the introduction of TCS sponsoring the London Marathon.

The Great North Run

The 2022 Great North Run saw the usual route return following the change made the previous year due to the pandemic. Our team of 173 runners took to the street of South Shields and Newcastle upon Tyne, completing the 13.1 mile course. Our team raised over £56,000 in 2022.

RideLondon 2022

We saw the return of RideLondon, which has changed the route and now goes through Essex. We had 112 cyclists take part and collectively they raised over £76,000.



Corporates

We are incredibly proud to have Ladbrokes as a charity partner. We have been working together since 2019 and are delighted to report that Ladbrokes have raised over £550,000 and extended our partnership for a further 2 years.

This fantastic achievement is without a doubt a testament to the dedicated fundraising shown by Ladbrokes staff and their customers. We are very proud to have the Ladbrokes team as one of our charitable corporate partners.

In April 2022 Pentex raised over £28,000 for Children with Cancer UK. Since then, we have entered into a 2 year partnership. Pentex have pledged to raise £70,000 to help us continue funding high quality research which would otherwise go unfunded.

We would also thank our Corporate Supporters such as MFS Market Financial Solutions, Sony, Pavers and a special thank you to UK Clothing Caravan who have been supporting us for almost 4 years.

Individual Giving

- Our social media ads reached over 1.8 million people, with 575 people donating or setting up a regular gift. Year 1 income for regular gifts is £18,235.
- Across our gaming products (Grand Draw and Lottery), we've raised just over £1.4 million with over £812,500 from our Grand Draws.
- 2022 was our most successful year ever for gifts in Wills. Including accruals, the total amount raised will exceed £3 million.
- £3 million brought in from cause regular givers.
- Over £1.6 million raised from cash appeals to our existing supporters.

Acquisition of committed givers

We restarted face to face private site fundraising in 2022 following its suspension during the pandemic. Results so far are extremely positive, with Cost Per Acquisition, Return On Investment and Average Gift all very encouraging.

Retention, Stewardship, and legacies

We sent existing supporters the final edition of our supporter newsletter, 'The Chime', before it was renamed 'Every Step' once we adopted the new brand. The newsletter has two purposes: to keep supporters engaged with the charity and to ask for further donations. The newsletter raised just over £198,000 against a target of £183,000.

Digital campaigns

Digital continues to be an important marketing channel for us. In 2022 we used SMS and email to steward existing supporters and we used paid social media to recruit new supporters.



FUNDRAISING COMPLIANCE

Children with Cancer UK values the privacy of all those who support us in our work; we have systems in place to ensure that supporter data is collected, managed and processed in line with all necessary legislation. We are members of the Fundraising Regulator, which has responsibility for regulating fundraising, sets out the Code of Fundraising Practice and investigates and takes appropriate action on cases of public concern. Children with Cancer UK adheres to the Code of Fundraising Practice set by the Fundraising Regulator and also fully complies with the Fundraising Preference Service. We comply with charity law, fundraising law and the data protection regulations. We monitor our fundraisers, volunteers and any third parties that work for us to ensure that they adhere to our high standards.

We will ask the donor how they want to hear from us about our work and appeals. If the donor wants to stop hearing from us they can, email, phone, write or click on the link in our emails. We will always take action, so they can feel confident in contacting us at any time.

We will keep the donor's personal information secure and will only use it to communicate with the donor; to process orders and donations; to keep the donor informed; for analysis and to improve our activities. We will NOT share the donor's details with other charities or sell it to businesses. Some organisations help us with our fundraising, but will only use the donor's data under our instruction and only when fully compliant with how we process personal data as set out in our Privacy Policy (Reviewed February 2022).

Children with Cancer UK continues to adhere to and review policies relating to GDPR and work alongside an external consultant, Protecture, to ensure that we are fully compliant.

Children with Cancer UK works with some professional fundraising agencies to assist with certain elements of our fundraising, by telephone and SMS channels. We have robust contracts in place with these agencies, specifying that staff carrying out these activities should be trained and adhere to all applicable laws, regulations and codes, such as the Code of Fundraising Practice and the Data Protection Regulations. We also expect these organisations to reflect our values when talking to supporters and to voluntarily subscribe to the Fundraising Regulator.

To ensure the agencies we engage are operating to the required standards and that people should never feel harassed or pressurised to give, we carry out appropriate monitoring which includes: call monitoring, site visits and call listening. We attend training sessions of their staff and give training to staff in respect of each fundraising campaign. We require all our staff and the agencies we deal with to comply with our Vulnerable People Policy, which provides guidance on how to identify a potentially vulnerable person and actions to take to considerably disengage from the fundraising process.

Children with Cancer UK require its staff and any agencies contacting our donors and members of the public on our behalf to comply with the Data Protection Law and guidelines provided by the Fundraising Regulator and Institute of Fundraising. Children with Cancer UK take all reasonable care to the protect vulnerable adults in accordance with the Institute of Fundraising guidance set out in their document '[Treating Donors Fairly: Responding to the needs of People in Vulnerable Circumstances and Helping Donors make informed Decisions.](#)'



We adhere to the [Fundraising Regulator Promise](#) ensuring that our fundraising is legal, open, honest and respectful. We truly value our supporters, which is why, in 2018, we published our [Supporter Charter](#) as a commitment to our supporters.

Our [Feedback and Complaints policy](#) was reviewed in March 2023 and we will continue to review this regularly. Complaints are investigated thoroughly and corrective action taken as appropriate. During our financial year (Jan – Dec) 2022 we received 56 complaints (source Raiser’s Edge) across all teams which is a significant drop on the previous year (125 complaints, source Raiser’s Edge). This reflects a drop in activity such as the TV adverts which, whilst they generated a large amount of phone donations, also attracted a number of complaints. We have also continued to collaborate with our clothing collection partners to ensure a smooth service.

We continue to closely monitor all of our fundraising activities and will always strive to ensure they are of the highest standard and reflect the wishes and preferences of all our generous supporters. There may be occasions when we have not met these high standards and we will work hard to learn from our mistakes and to make sure they don’t happen again. If our supporters and members of the public are unhappy with any aspect of our work we encourage them to give feedback, and take any comment or complaint seriously. We use this valuable feedback to help shape our future fundraising campaigns and improve our overall service and commitment to our supporters.

We are here to talk and listen to you – we welcome and actively encourage feedback and make it clear how people can get in touch with us.

A member of the Fundraising Regulator, the independent regulator of fundraising in the UK, Children with Cancer UK is committed to best practice in fundraising and follows the Regulators Fundraising Promise and Code of Fundraising Practice laid down by the regulator.

THANK YOU

We would like to sincerely thank all our supporters and fundraisers who helped us to raise £13.8 million. Your generosity and creative efforts are helping us to build our vision of a world where every child survives cancer.

Thank you to our dedicated board of trustees:

- David Gibbs, Chair of Trustees
- Alex Leitch, Deputy Chair
- Phil Hall
- Bruce Morland
- Pamela Kearns, Scientific advisor

A very special thank you to all of the extraordinary families we have worked with over 2022. Your commitment to helping others facing similar situations to yourselves is inspirational and only through your stories are we able to show the realities of childhood cancer. **Thank you.**



FINANCIAL REVIEW

Incorporating the Directors' Strategic Report and Administrative Report for Companies Act Purposes





The Trustees of Children with Cancer UK present their Annual Report for the year-ended 31st December 2022 under the Charities Act 2011 and the Companies Act 2006, including the Directors' Report and the Strategic Report under the 2006 Act, together with the audited financial statements for the year.

Financial review

The Consolidated Statement of Financial Activities (SOFA) set out on page 36, shows the financial results for Children with Cancer UK and its trading subsidiary: Helping Children with Cancer Limited.

Our total income has decreased this year from £15.2 million to £14.1 million. As the longer term impact of the COVID-19 pandemic on our fundraising operations becomes clearer, the maintaining of our income at £14 million can be attributed to mitigation strategies that have been put in place. This included streamlining some of our activities and ensuring they achieved both their strategic and financial objectives.

The London Marathon being an important fundraising event for us with a large presence of runners raising a significant amount of sponsorship income. With the return of this live event in 2022 it was hoped for higher growth. However with fewer opportunities for fundraising and a significant number of runners deferring their places from the previously cancelled London Marathons led to lower than expected growth. The expected recovery from our Community fundraisers struggled in 2022 and plans for 2023 will address the 30% drop.

Our focus on Corporate and philanthropy saw an increase of 25% during 2022. We will continue to develop this area in 2023 with plans to build a sustained pipeline for future years starting to become realised.

Our Legacy income remaining consistent at £2 million helped mitigate the areas that struggled to show growth during 2022. The legacy income for 2022 is the second highest in the charity's history, with 2021 at £2.3 million being the highest.

Our individual giving income streams which include appeals programme, raffles and acquisition campaigns achieved income of £3.3 million this year, which is a significant reduction from £5m in 2021. This was due to our decision to remove less strategically impactful appeals (Sprig Raffle) as part of our mitigation efforts to recover from COVID-19. This also reflects the tough fundraising environment in this area.

Our continued investment in online and mainstream media has, in addition to broadening the awareness of our cause, helped us maintain our regular giving income at just over £3m which is consistent with prior years. A strategy for growth in this area is planned for 2023.

With the immediate impact of COVID-19, the effect on our income streams and risk profile, with our cost base and savings coming through, our expenditure was just under £10 million in 2021. With the return investment in all our activities, including charitable cost, our expenditure



increased to £14 million. Although this is a significant increase, this was still below pre COVID-19 levels.

As detailed in previous reports, the COVID-19 pandemic had a significant impact on research in the UK and resulted in delays for many existing research projects. This meant we were only able to invest £2 million in 2021. However with the return of projects in 2022, we were able to fund just under £7 million in third party grants. We aim to continue this investment in 2023 to ensure we continue to support this vital area.

We ended the year with a surplus of £55,240 maintaining our total reserves of £14.8 million. The reserves will be used to fund the current year's charitable spend.

For every £1 donated, we spend 85p on fighting childhood cancer.

- 39p on research projects
- 31p on welfare projects
- 15p on raising awareness

We reinvest 15p from every £1 raised, to raise even more money.

For every £1 we spend on fundraising, we raise £5 more.

Reserves

At the end of the year, the charity held £14,840,280 (2021: £14,455,222) in total reserves. All funds were held in unrestricted reserves. The restricted funds raised comprise of donations that were to be spent on specific causes and projects as detailed in Note 19.

Unrestricted reserves are generated when the supporter does not stipulate how the income may be spent. They are therefore available to be applied at the discretion of Trustees to any of the charity's charitable purposes.

The Trustees are aware of their role as custodians of these funds and plan to disburse the funds in a structured and cautious manner to meet the long term objectives of the charity

The Trustees consider the reserves to have a dual role; to provide a buffer to allow operating expenditure to be carefully minimised should the need arise, as well as facilitate the following year's grant award programme. The remainder, is set aside for fluctuations in income that could impact the charity's ability to carry out its services.

Therefore, £8 million has been set aside from total reserves to fund the current year's charitable spend. This leaves approximately £6 million as a reserve for operational expenditure.

This £6m buffer is consistent with previous financial years and will enable the charity to operate without any income for approximately 5 months. This is below the free reserves target of 6 months but deemed to be acceptable by Trustees in the current climate.



The Trustees intend to review the policy again in 2023 when future projects and current identified risks becomes clearer.

OUR STRATEGY

Building for the future

Children with Cancer UK, and the wider charity sector, continues to recover from the pandemic and the economic impact this has created. The cost-of-living crisis has created a period of uncertainty, but we remain steadfastly dedicated to our mission of funding research and supporting families through a childhood cancer diagnosis.

To secure our future, Children with Cancer UK invested in several new initiatives that allow the organisation to grow and emerge stronger from this period. Our Digital Transformation Project developed our internal systems and revised our approach to daily tasks to ensure efficiency and best practice. One such development was the implementation of Salesforce, an updated CRM system, which has provided fundraisers with increased autonomy. We also announced a full re-brand of the charity that builds on our 35-year legacy by looking towards the future with a refreshed look and feel. In this process, we asked representatives of our loyal supporter base to offer their insight into the brand development to ensure we included all voices in our decision making. Our aim is to continue to expand our audiences and seek new opportunities which our bold new brand will help appeal to.

Our commitment to research

Children with Cancer UK is currently in year two of a five-year research strategy. Our research programme is designed to progress our principal aims. First, we wish to develop improved treatments so that more patients are cured with less toxic side effects. Second, we wish to better understand how cancer develops so that one day we may be able to prevent it. 2022 was a year of planning, and we prepared to increase our investments significantly for 2023-2026. To begin this period of growth, we were delighted to restart our annual grant call with a commitment of £2.5 million. We were overwhelmed with the number and quality of applications received and look forward to awarding the successful applicants during 2023.



Prioritising the families we support

Children with Cancer UK has supported children, teenagers and young adults with cancer since its inauguration. Historically, this support has been in the form of providing grants to charities, hospitals and other organisations who can directly reach the families in treatment and beyond. This collaborative approach will continue with our investment in wellbeing programmes such as Beads of Courage UK and a new partnership with Spread a Smile, a charity dedicated to improving the experience for children in hospital. We ensure that we are working with leading providers so that families facing a childhood cancer diagnosis are continually supported throughout their journey.

To build on our own direct support for families, Children with Cancer UK invested in a respite centre in North Yorkshire. The property will be developed in line with the needs of the children and families facing childhood cancer and will provide a residential break for them. The centre will act as a haven for families at every step of the journey including point of diagnosis, treatment and bereavement.

Children with Cancer UK also recognises the financial hardships that the cost-of-living crisis can bring on families and the pressures of staying away from home during treatment. This is why we have decided to provide one off financial grants for families whose child has received a cancer diagnosis. The grants, called 'hugs' due to their embracive nature, will be a direct provision of support that we hope offers a small comfort and brings us one step closer towards our mission. The grants will be issued via a network of clinical staff within the Primary Treatment Centers across the UK.

Going Concern

The Financial Statements are approved during a period where the impact of COVID-19 is still being felt, but also a period of new uncertainties including the current cost of living crisis. The Charity is constantly assessing the short and long term impact on its fundraising activities in the current climate.

Along with the Finance and Operations Committee, the Trustees have reviewed the proposed budgets and cash flow to December 2024 and have scrutinised the reserve position, including cash held in the bank and investments. During this review the Trustees priority was to ensure the Charity is able to endure any decline in income or unexpected increase in costs.

The Reserves policy is reviewed regularly and it is vital to ensure the charity holds sufficient reserves to fund not only its ongoing grant award programme, as well as to ensure the charity can cover its operational commitments. Any risks identified are considered during each review. The Trustees have also drawn upon the experience and lessons learned during the COVID-19



pandemic, where expenditure was only being committed if it can be covered either through our fundraising activities or the reserves.

The Finance and Operations Committee monitor the financial position of the charity on a monthly basis. As well as monitoring the current financial position of the charity, the committee also review the ongoing budget, reporting any variances and ensuring the cash flow and investments are in line with projections. The committee reports to the Trustees and highlight anything that needs their attention at the subsequent Trustee meeting.

Each budget that was presented had considered various scenarios, including a drop in income and/or unexpected increased in expenditure. The most likely scenario was presented to the Trustees. These scenarios are closely monitored and constantly reviewed so any scenario can be updated and incorporated in to any reforecast which is performed at least quarterly. This approach enables the charity to respond promptly and effectively to any change of environments.

In their assessment of going concern the Trustees have considered not only the impact on the charity as a result of COVID-19, but also any new identified risks, including the increase in energy prices and the cost of living crisis. This is an area that will be closely observed, but the current impact to our fundraising is low.

With the return of in person fundraising with events like the London Marathon and the Ball, the Trustees are confident that our fundraising activities can return and be developed. At the time of writing indications are that it is possible to have a return to pre COVID levels by the end of 2023. The Trustees will continue to monitor the situation and are aware that if any situation develops that threaten this view then this opinion may change.

The Trustees are confident that there are currently significant cash balances should additional liquidity be required to meet the liabilities as they fall due and Children with Cancer UK have appropriate reserves and could adapt to future funding changes. Appropriate consideration of risks as part of its normal risk management processes and mitigating actions both already taken and available to be taken.

The Trustees believe that although there is uncertainty identified the charity remains in a strong position to use its cash deposits to take advantage of any opportunities and they are at a sufficient level to ensure the Charity will continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of the financial statements. Accordingly the Trustees consider it appropriate for the going concern basis to be adopted for these accounts.

Investments

The Memorandum of Association allows the charity to deposit or invest funds in any manner but to invest only after obtaining such advice from a financial expert as the Trustees consider necessary and having regard to the suitability of investments and the need for diversification.



The charity recognises that it must have enough resources to carry out its present and future activities effectively. Therefore, the Trustees have agreed to hold sufficient cash levels, invested mainly in instant access deposits, to meet fluctuating needs.

The charity investment policy is reviewed regularly and states that the longer term funds must produce the best financial return for an acceptable risk. The fund must balance the need to support research grants with the objective for capital growth and inflation protection. The Trustees feel the 2022 performance of the investments met the objectives of the policy and recognise the opportunity to identify higher performing funds for 2023 whilst still within an acceptable risk.

The charity currently holds £10 million of investments held for the longer term. This comprises £1.7M in an investment portfolio managed by Barclays Investment Managers and £8.3m in cash deposits. The charity also holds £4.7m in short term cash deposits.

The Trustees are keen to ensure that the cash funds are not exposed to any risk since this cash value has already been promised to grant holders. As at 31st December 2022, our grant liabilities are close to £12.6m (2021: £9.1m).

Risk and internal control

The Trustees have overall responsibility for ensuring that the Charity has an appropriate system of controls, financial and otherwise. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reassurance that:

- its assets are safeguarded against unauthorised use or disposition;
- proper records are maintained and financial information used within the Charity or for publication is reliable; and
- the Charity complies with relevant laws and regulations.

As part of the Charity's risk management process the Trustees acknowledge their responsibility for the Charity's system of internal control and reviewing its effectiveness. It is also recognised by the Trustees that such a system is designed to manage rather than eliminate the risk of failure to achieve the Charity's objectives and can only provide reasonable, not absolute, reassurance against material misstatement or loss.

Principal risks and uncertainties

At the start of 2020 the COVID-19 Pandemic was not an identified risk. Plans were immediately put in place and a full review of all the strategic risks that had previously been identified during the year in review was undertaken to incorporate this new risk. There was a high level of Trustee engagement throughout this period. Along with the review of the strategic risks that had a



particular focus on COVID-19, a separate COVID-19 risk log was developed. This was regularly updated during 2022 to respond to the changing environment.

As with many organisations in the sector COVID-19 has had an impact on multiple areas of the organisation. Whilst we are beginning to identify the long term impact of the pandemic, several plans have been implemented to mitigate this risk in the short term with longer term plans being developed. These short term strategies continue and include regular management meetings, continuous review of up to date income figures, engagement with all suppliers to review costs, strict expenditure controls with direct Trustee involvement, evaluation and renegotiation of contracts where appropriate, redeployment of resources where necessary and identification, exploitation and investment of any new fundraising opportunities like digital fundraising.

The Charity continues to be heavily reliant on mainstream fundraising income to fund charitable activity, the major risk being faced is that income falls to a level that compromises the Charity's ability to meaningfully fund future charitable activity – whilst at the same time maintaining reserves at a stable level. This risk continues to be managed by the Charity by diversifying its income streams and investing in new fundraising channels whilst ensuring the impact of the cost of living crisis is continually monitored. The Charity is continuing the process of implementing 'strategic imperatives' that will guide its future vision and strategy. The seven strategic risks that have been identified are listed below.

- Fundraising
- Regulatory compliance
- Infrastructure & Operations
- Charitable Impact
- Profile & Brand
- Financial
- Governance

These risks have been reviewed with a renewed focus on the recovery from COVID-19 and new uncertainties including the current cost of living increases. They are assessed in terms of probability and impact with a mitigation strategy put in place if required. This forms part of the charity's annual risk management strategy.

The principal risk for the trading subsidiary is its reliance on short term and ad hoc commercial arrangements to generate income. We are investing in improving our trading income streams to manage this risk.

The strategic risks have been reviewed by the Trustees. Some of the issues discussed include, continued Governance improvements, energy and other cost of living increases, post COVID long term strategy and organisational structure. These discussion points intersect with all the strategic risks and will continue to be reviewed regularly by both the Trustees and Senior Management.

Structure, governance and management

The financial statements comply with current statutory requirements, the Memorandum and Articles of Association, Statement of Recommended Practice (SORP FRS 102) and current accounting standards (FRS 102).



The Trustees have considered and acknowledge the principles and recommendations set out in the Charity Governance Code. The Senior Leadership Team were tasked of reviewing the Charity's governance against the Charity Governance Code and identifying key areas for development. It was recommended to the Trustees that an independent Governance Review was initiated. The Trustees instigated this review and tasked the Senior Leadership Team to implement all recommendations. Significant progress has been made with over 90% of the recommendations completed and plans in place for the remaining items to be addressed within the next 12 months.

Governing documents

These financial statements are for Children with Cancer UK and its subsidiary Helping Children with Cancer Limited.

Children with Cancer UK is a company limited by guarantee and operates under its Memorandum and Articles of Association dated 11th November 2003 as amended by special or written resolutions, dated 30th November 2004, 22nd December 2006, 12th May 2007, 28th July 2016 and 13th December 2021.

On 14th May 2007 the reporting charity changed its name from CHILDREN with LEUKAEMIA UK to Children with Cancer UK. However, the charity continued to use the working name of CHILDREN with LEUKAEMIA until 11th May 2011.

The charity operates under its Trust Deed (dated 4th January 1988) and Variation of Trust Deed (dated 10th December 2003).

Aims and Objectives

Purposes and Aims

The charity's objects as amended by written resolution of 12th May 2007, and 28th July 2016 are shown below:

- i) To promote the relief of children and young people suffering with leukaemia or any other form of cancer (and allied disorders) and of their families;
- ii) To raise public awareness and knowledge in matters relating to leukaemia or any other form of cancer (and allied disorders) affecting children and young people; and
- iii) To promote research into the causes, alleviation, prevention, treatment and cure of leukaemia or any other form of cancer (and allied disorders) affecting children and young people and to publish the useful results of such research.

Our aims are to determine the causes, find the cure and provide care for children with cancer.

We fund life-saving research into the causes, prevention and treatment of childhood cancer.



We fund innovative welfare projects to provide better care for young cancer patients and their families.

We campaign to raise awareness of childhood cancer to protect more children and to improve the lives of young cancer patients, today and for future generations.

We are a member of the Association of Medical Research Charities. We are also a member of the National Cancer Research Institute.

Further details of the projects we fund are detailed in note 22.

Public Benefit

The Trustees continue to give due regard to the public benefit provided by the charity in relation to its charitable purpose as set out by the objectives above and have given due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the activities that promote the charitable objects above will be applied to provide public benefit.

Board of Trustees

The governing body of the reporting charity is the Board of Trustees, which has a total of five members (2021: five). The Trustees of the charity also act as the Directors of the charitable company. The Board meets at least three times a year together with the Chief Executive and other senior management where appropriate.

The Finance and Operations Committee and Marketing and Communications Committee are subcommittees of the Board. The subcommittees meet at least bi-monthly and consist of a combination of Trustees, Staff, External Advisors and Specialised Volunteers (if required). The committees will draw to the attention of the Board any urgent issues that require authorisation, disclosure or action and escalate any urgent issues for immediate attention outside of the Board meeting schedule.

Trustee appointment and induction

There were two new appointments (2021: three) to the Trustee Board in 2022. Five Trustees left the board during 2022. These were planned resignations including two trustees from our founding family and in line with our succession plan. The selection of Trustees is made based on vacancies arising, sympathy with the objects of the charity and the additional skills and experience that potential new Trustees are able to afford. Under the Articles of Association, Trustees are appointed by a majority vote of the members (who are all the current Trustees) by ordinary resolution.



Each new Trustee receives the Charity Commission publication 'The Essential Trustee: What you need to know' as well as the most recent published annual report. The Chief Executive Officer offers an induction day to all Trustees which provides full information about the operations of the charity.

Management

The Trustees exercise executive responsibility for the governance of the charity and, through the Chairman, supervise the management of the charity by the Chief Executive Officer and the senior management team. The Chairman and Chief Executive Officer also task the Board with decision-making on strategic management issues as well as overseeing the research grants application process and monitoring the progress of awarded grants.

The senior management carry out the operational running of the charity and the coordinating of fundraising appeals and events.

Remuneration

The salaries of Children with Cancer UK staff are periodically benchmarked against other charities to ensure that salary levels are market competitive and sufficient to attract and retain staff of the appropriate calibre. All staff posts are periodically evaluated to ensure that salary levels are reflective of industry and organisational needs, as well as individual and charity performance. In recruitment of a new post, an assessment is made of the requirements of the role in terms of skills, experience, competency and urgency. The salary is then determined on the basis of this assessment and the current market conditions.

Salary Bands have been set based on external benchmarking, anecdotal data from head-hunters and recruiters, and charity sector salary surveys. The Salary Bands are reviewed at least every two years.

The Charity is compliant with the Hutton Fair Pay Review with the salary of the highest paid employee being no more than four times the median salary of the organisation.

Trading Subsidiary

Helping Children with Cancer Limited (company registration 2807553) is the wholly owned trading subsidiary of Children with Cancer UK. Its principal purpose is to raise funds for the charity and all profits are donated under Gift Aid.

The principal activity of the Company is the licensing of the name and logo of the charity for use in corporate sponsorship, commercial agreements and royalties from contribution to clinical trials.

The trading activities generated profit for the year of £158,217 (2021: £60,072) which will be paid to Children with Cancer UK under the Gift Aid Scheme. It is anticipated that the trading activity within the subsidiary will continue at a similar level during the current year.



The trading subsidiary holds assets of £167,764 (2021: £23,740) and liabilities of £167,664 (2021: £23,640) with funds of £100 as at 31st December 2022.

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

Related parties

The Charity has a related party and conflict of interest policy in place which accompanies the declaration of interests submissions completed by all Trustees and senior management. An internal conflict of interest register is in place which is updated when a conflict of interest has been identified and is reviewed at least annually.

Grant making policy

It is the Trustees' policy to maximise the proportion of its charitable output that is achieved through grant making.

Welfare grants

There is no open application process for welfare grants and no welfare grants are given to individuals. The Trustees determine which organisations are to be supported. In 2022, a total of £3,040,000 (2021: £1,297,488) was awarded to welfare projects.

Research grants

The Trustees aim to award an increasing proportion of the charity's grants to scientific and medical research in cancers affecting children, teenagers and young adults. The charity's Code of Practice adheres to the standards set by the Association of Medical Research Charities (AMRC).

The charity advertises guidelines and invite applications for project grant rounds. Project applications are subject to formal internal and external peer review followed by scrutiny by our scientific advisory panel (SAP) before the Trustees determine which projects to support. We also occasionally support research through other AMRC members.

In 2022, a total of £3,971,033 was awarded to research projects and collaborations.



REFERENCE AND ADMINISTRATION

Children with Cancer UK (previously known as CHILDREN with LEUKAEMIA UK) was set up in memory of Paul O’Gorman who died on 6th February 1987 and his sister Jean, who died on 3rd November 1987. The charity was inaugurated by Diana, Princess of Wales on 12th January 1988 at Mill Hill County High School where Paul had been a pupil.

Trustees

The Trustees of Children with Cancer UK are the charity’s Trustees under charity law and the directors of the charitable company:

Current Trustees

David Gibbs (Chair of Trustees)
Alex Leitch (Deputy Chair)
Phil Hall
Bruce Morland (Appointed 5th July 2022)

Previous Trustees

Ann Amaya-Torres (Resigned 12th March 2022)
Eddie O’Gorman OBE (Founder and previous Chair of Trustees) (resigned 12th January 2022)
Sandra Mileham (resigned 12th January 2022)
Linda Robson (resigned 12th January 2022)
Nick Goulden (resigned 18th March 2022)
Virna Midgley (Resigned 3rd August 2022)
Georgie Wolfinden (Appointed 14th November 2022) (Resigned 16th May 2023)
Caroline Randerson (Resigned 30th August 2023)

Chief Executive Officer

Jo Elvin (Appointed 19th April 2022)
David Gibbs (Honorary) (Appointed 1st January 2022) (Resigned 19th April 2022)

Executive Team

Gary Murphy (Chief Operating Officer)
Ria Griffin (Head of People and Culture)
Christiana Ogunbote (Head of Research)
Fadil Dugolli (Head of IT)



Previous members of the Senior Management during the year were

Hannah Chambers (Head of Marketing and Communications)
Emily Roff (Head of Events, Community and Sports) (Maternity Leave)
Kerry Russell (Head of Events, Community and Sports) (Maternity Cover)
Camelia Vasilcan (Head of Database)
Fiona Judge (Head of Supporter Care)

Registered Charity Number

298405

Registered Company Number

4960054

Principal office

21 27 Lamb's Conduit Street, London, WC1N 3NL

Solicitors

Bates Wells, 10 Queen Street Place, London, EC4R 1BE

Auditors

PKF Littlejohn LLP, 15 Westferry Circus, London E14 4HD

Bankers

National Westminster Bank plc, 30 North Audley Street, London W1A 4UQ

Contact details

Children with Cancer UK
21 27 Lamb's Conduit Street, London, WC1N 3NL
Tel: 020 7404 0808
Email: info@childrenwithcancer.org.uk
www.childrenwithcancer.org.uk

Scientific Advisory Panel

We are indebted to the members of our Scientific Advisory Panel (SAP) who freely give their time and expertise to help drive forward our fight against cancers affecting children and young people. Research into cancers affecting children and young people is a broad field and we aim to reflect the diversity of the field amongst the membership of panel members.

The interim chair of the Panel for 2022 was Professor Roderick Skinner. In 2023 a new Chair was confirmed.



STATEMENT OF TRUSTEES' RESPONSIBILITIES

The Trustees (who are also directors of Children with Cancer UK for the purposes of company law) are responsible for preparing the Strategic Report, the Trustees' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and the group for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company and group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions, disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006 and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Insofar as each of the Trustees of the charitable company at the date of approval of this report is aware there is no relevant audit information (information needed by the charitable company's auditor in connection with preparing the audit report) of which the charitable company's auditor is unaware. Each Trustee has taken all of the steps that he/she should have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the charitable company's auditor is aware of that information.

This Annual Report of the Trustees, prepared under the Charities Act 2011 and the Companies Act 2006, was approved by the Board of Trustees on 25th September 2023 including approving in their capacity as company directors the Strategic Report contained therein, and is signed as authorised on its behalf by:

David Gibbs
Chair of Trustees
Date: 29th September 2023



INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CHILDREN WITH CANCER UK

Opinion

We have audited the financial statements of Children with Cancer UK (the 'parent charitable company') and its subsidiary (the 'group') for the year ended 31 December 2022 which comprise the Consolidated Statement of Financial Activities, the Consolidated and Parent Charitable Company Balance Sheets, the Consolidated Cash Flow Statements and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the group's and the parent charitable company's affairs as at 31 December 2022, and of the group's incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report.

We are independent of the group and parent charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's or parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.



Other information

The other information comprises the information included in the trustees' annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the trustees' annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report, which includes the strategic report and the directors' report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors' report included within the trustees' report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report included within the trustees' annual report.

Under the Companies Act 2006 we are required to report in respect of the following matters if, in our opinion:

- adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company's financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

We have nothing to report in respect of these matters.



Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the group and parent charitable company financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the group and parent charitable company financial statements, the trustees are responsible for assessing the group and parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed auditor under the Companies Act 2006 and report in accordance with this Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Extent to which the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

We considered the nature of the industry and its control environment, and reviewed the documentation of their policies and procedures relating to fraud and compliance with laws and regulations. We also enquired of management about their own identification and assessment of the risks of irregularities.

We obtained an understanding of the legal and regulatory frameworks that the charitable company operates in, and identified the key laws and regulations that:

- had a direct effect on the determination of material amounts and disclosures in the financial statements. These included UK Charities Act and UK Companies Act; and
- do not have a direct effect on the financial statements but compliance with which may be fundamental to the charitable company's ability to operate or to avoid a material penalty.



We discussed among the audit engagement team the opportunities and incentives that may exist within the organisation for fraud and how and where fraud might occur in the financial statements.

As a result of performing the above, we identified the greatest potential for fraud or non-compliance with laws and regulations in the following areas, and our specific procedures performed to address them are described below:

- recognition of legacy income in the correct accounting period and correctly classified. To address this risk we tested a sample of legacies to evaluate whether the income and the corresponding cash receipt or receivable have been recognised appropriately, and to assess the classification of the income as either restricted or unrestricted; and
- recognition of grant expenditure in the correct accounting period. To address this risk we tested a sample of agreements between the charitable company and its beneficiaries to evaluate whether the expenditure and the corresponding payment or creditor have been recognised appropriately; and
- classification of funds between restricted and unrestricted. To address this risk we have tested a sample of income and expenditure in the year to assess whether they have been classified appropriately.

In common with all audits under ISAs (UK), we are also required to perform specific procedures to respond to the risk of management override. In addressing the risk of fraud through management override of controls, we tested the appropriateness of journal entries and other adjustments; assessed whether the judgements made in making accounting estimates are indicative of a potential bias; and evaluated the business rationale of any significant transactions that are unusual or outside the normal course of business.

In addition to the above, our procedures to respond to the risks identified included the following:

- reviewing financial statement disclosures by testing to supporting documentation to assess compliance with provisions of relevant laws and regulations described as having a direct effect on the financial statements;
- performing analytical procedures to identify any unusual or unexpected relationships that may indicate risks of material misstatement due to fraud;
- enquiring of management concerning actual and potential litigation and claims, and instances of non-compliance with laws and regulations; and
- reading minutes of meetings of those charged with governance and reviewing correspondence with Charity Commission.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.



A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone, other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Alastair S. Duke (Senior Statutory Auditor)
For and on behalf of PKF Littlejohn LLP
Statutory Auditor
29th September 2022

15 Westferry Circus
Canary Wharf
London E14 4HD



**Consolidated statement of financial activities for the year ended 31 December 2022
(Incorporating an income and expenditure account)**

	Note	Total restricted funds	Total unrestricted funds	Total 2022	Restated Total 2021
		£	£	£	£
Income from:					
Donations and legacies	4	254,872	13,160,275	13,415,147	15,118,497
Other trading activities	4	-	581,771	581,771	6,850
Income from investments		-	91,499	91,499	48,672
Other income		-	22,000	22,000	248
Total Income	19	254,872	13,855,545	14,110,417	15,174,267
Expenditure on:					
Raising funds	6	-	2,119,479	2,119,479	1,979,652
Charitable activities	6, 8	201,162	11,530,343	11,731,505	7,875,497
Total Expenditure	6	201,162	13,649,822	13,850,984	9,855,149
Net change in investments	13	-	(204,193)	(204,193)	170,161
Net (expenditure)/income		53,710	1,530	55,240	5,489,279
Transfers between funds	19	(53,710)	53,710	-	-
Net movement in funds		-	55,240	55,240	5,489,279
Reconciliation of funds:					
Total funds brought forward		-	14,785,040	14,785,040	9,295,761
Total funds carried forward	19	-	14,840,280	14,840,280	14,785,040

The comparative figures for each fund are shown in note 3 to the financial statements.



Balance sheet as at 31 December 2022

Company Number: 4960054

	Note	2022		Restated 2021	
		Group	Charity	Group	Charity
		£	£	£	£
Fixed assets					
Property	12	1,600,000	1,600,000		
Investments	13	10,000,000	10,000,100	10,293,735	10,293,835
		11,600,000	11,600,100	10,293,735	10,293,835
Current assets					
Debtors and prepayments	15	2,947,998	2,936,304	2,666,204	2,672,417
Cash deposits		4,650,280	4,650,280	4,596,702	4,596,702
Cash at bank and in hand		9,356,488	9,202,979	7,074,406	7,064,133
		16,954,767	16,789,563	14,337,312	14,333,252
Creditors: amounts falling due within one year					
Grants	16,17	(8,031,586)	(8,031,586)	(3,965,171)	(3,965,171)
Other	17	(1,130,638)	(965,535)	(699,942)	(695,982)
Net current assets	18	7,792,542	7,792,442	9,672,199	9,672,099
Total assets less current liabilities		19,392,542	19,392,542	19,965,934	19,965,934
Creditors: amounts falling due after more than one year					
Grants	15	(4,552,262)	(4,552,262)	(5,180,894)	(5,180,894)
Net assets		14,840,280	14,840,280	14,785,040	14,785,040
Represented by:					
Unrestricted funds	18,19	14,840,280	14,840,280	14,785,040	14,785,040

The net surplus for the financial year dealt within the financial statements of the parent charitable company was 55,240 (2021: net surplus £5,159,461).

The notes on pages 39 to 55 form part of the financial statements.

Approved and authorised for issue on behalf of the Trustees on 29th September 2023.

David Gibbs
Trustee

Alex Leitch
Trustee



Consolidated cash flow statement for the year ended 31 December 2022

		2022		2021
		£		£
Cash flows from operating activities:				
Net cash provided by operating activities	a)	3,728,049		5,090,738
Cash flows from investing activities:				
Dividends and interest from investments		(91,636)		(48,809)
Net additions/(disposals) in the year		(5,513)		(5,534)
Net cash provided by investing activities		(86,122)		(54,343)
Change in cash and cash equivalents in the reporting period		2,246,256		5,036,395
Cash and cash equivalents at the beginning of the reporting period	b)	20,016,367		14,979,972
Cash and cash equivalents at the end of the reporting period	b)	22,262,623		20,016,367
Notes to the Cash flow Statement				
a) Reconciliation of net (expenditure) to net cash flow from operating activities				
		2022		2021
		£		£
Net (expenditure)/income for the reporting period		55,250		5,159,461
Adjustments for:				
Dividends, interest and rents from investments		91,636		48,809
Investment Manager Fees		(5,513)		5,534
Net Change in investments		-		(170,161)
Decrease / (increase) in debtors		(281,804)		773,859
(Decrease) / increase in creditors		3,868,481		(726,764)
Net cash provided by (used in) operating activities		3,728,049		5,090,738
b) Analysis of cash and cash equivalents				
		1 January	Cashflow	31 December
		2022		2022
		£	£	£
Cash at bank and in hand		7,074,406	2,282,083	9,356,488
Cash held as short term investments		4,596,702	53,578	4,650,280
Cash held as long term investments		8,345,261	(89,405)	8,255,855
		20,016,369	2,246,256	22,262,623



Notes to the financial statements for the year ended 31 December 2022

1. Charity information

Children with Cancer UK is limited by guarantee with no share capital (registered number 4960054), which is incorporated in England and Wales and domiciled in the UK. The address of the registered office is 21 27 Lamb's Conduit Street, London, WC1N 3NL. It is also a registered charity (registered number 298405) and as such is a non-profit making organisation.

2. Accounting policies

(a) Basis of preparation

The financial statements have been prepared on the historical cost basis of accounting, as modified by the revaluation of investments, and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102), the Companies Act 2006, the Charities SORP (FRS 102) and the accounting policies set out below.

The charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Children with Cancer UK is the ultimate parent company. It has two subsidiaries - Helping Children with Cancer Limited and Children with Cancer Research Limited. Children with Cancer UK owns the whole of the share capital of Helping Children with Cancer Limited, a company registered in England and Wales, number 2807553. It also holds 100% of the share capital of Children with Cancer Research Limited, a company registered in England and Wales, number 09442350 which is currently dormant.

The financial statements of the charity and its active subsidiary company are consolidated, on a line-by-line basis, to produce the Group financial statements. The consolidated entity is referred to as 'the Group'. No separate Statement of Financial Activities has been prepared for the charity as permitted by Section 408 of the Companies Act 2006. The charity has taken advantage of the exemptions in FRS 102 from the requirements to present a charity only Cash Flow Statement and certain disclosures about the charity's financial instruments.

(b) Preparation of the accounts on a going concern basis

In their assessment of going concern the Trustees have considered the impact on the charity as a result of identified risks and the COVID19 virus. With the return of in person events during the current year this continued to have an impact on certain activities including running events and community based fundraising. The Ball had been cancelled for two years and returned in November 2022 exceeding the income for 2019. These events had previously made up approximately 40% of the charity's income prior to COVID-19.



With the return of in person fundraising with events like the London Marathon and the Ball, the Trustees are confident that our fundraising activities can return and in the case of the Ball exceed pre COVID-19 levels in 2023. At the time of writing indications are that it is possible to have a return to pre COVID-19 by the end of 2023. The Trustees will continue to monitor the situation and are aware that if any situation develops that threaten this view then this opinion may change.

There are currently significant cash balances should additional liquidity be required through any period of uncertainty to meet the liabilities as they fall due and Children with Cancer UK have appropriate reserves and could adapt to future funding changes by adapting costs.

Accordingly, the Trustees believe the Charity's financial resources are sufficient to ensure the Charity will continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of the financial statements and have therefore prepared the financial statements on the going concern basis.

(c) Financial Instruments

The charity has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at amortised cost. Financial assets held at amortised cost comprise cash at bank and in hand, short term cash deposits together with the group's trade and other debtors excluding prepayments. Financial liabilities held at amortised cost comprise the group's short- and long-term trade and other creditors excluding deferred income and taxation payable. No discounting has been applied to these financial instruments on the basis that the periods over which amounts will be settled are such that any discounting would be immaterial.

Investments, including cash held as part of the investment portfolio are held at fair value at the Balance Sheet date, with gains and losses being recognised within the Statement of Financial Activities. Investments in subsidiary undertakings are held at cost less impairment.

(d) Critical accounting judgements and key sources of estimation uncertainty

In the application of the charity's accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects the current and future periods.



The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described in the accounting policies and are summarised below:

Residuary legacies – The charity recognises residuary legacies once probate has been granted which therefore requires an estimation of the amount receivable.

(e) Functional/Presentational currency

The functional currency of the charity and its subsidiary is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity/group operates. The consolidated financial statements are also presented in pounds sterling.

(f) Fund accounting

Unrestricted funds comprise accumulated surpluses and deficits on general funds and are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund.

(g) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Voluntary income in the form of appeals, committed giving, sports events and community fundraising income is recognised in the period of receipt. Income received in advance of an event or lottery is deferred until the criteria for income recognition are met.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.



Income arising from corporates and trusts is recognised in the period in which the charity has entitlement to the income.

Income from trading activities is recognised in the period in which the service has been provided or product sold.

Investment income from dividends and interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest received or receivable from the Bank.

Government grants are recognised on the performance model, when the Charitable Company has complied with any conditions attaching to the grant and the grant will be received. The grant in connection to the job retention scheme has been recognised in the period to which the underlying furloughed staff costs relate to.

(h) Expenditure and basis of allocation of costs

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis and the majority is directly attributable to specific activities. Other indirect costs are apportioned to activities in accordance with staff activity and an assessment of where the resources have been applied. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Grants to third parties are included in the SOFA when approved by the Trustees when a constructive obligation exists, notwithstanding that they may be paid in future accounting periods.

Support costs include governance costs which are costs incurred to manage the charity in compliance with constitutional and statutory requirements and the direct expenditure and overhead costs relating to the appeals and fundraising functions. They also include the allocation of costs incurred to support and co-ordinate fundraising activities. These costs are allocated across the categories of charitable activities and the basis of this cost allocation has been explained in note 7 of the financial statements.

Expenditure on raising funds includes expenditure specifically incurred for fundraising purposes. This constitutes a mixture of directly attributable costs and apportionment.

(i) Tangible fixed assets

Tangible fixed assets costing more than £10,000 are capitalised and included at cost including any incidental costs of acquisition, or, where donated, are included at valuation at the date that ownership is acquired.



(j) Pension scheme

Permanent employees are entitled to join the Grouped Stakeholder Pension Plan provided by Scottish Widows. During 2022, the charity made a contribution of at least 5% of salary per month to any personal or stakeholder pension scheme selected by all employees serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of pension costs is the contribution payable during the year.

(k) Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

(l) Gifts in Kind

Gifts in kind and donated goods and services are recognised in the accounts when the benefit to the charity is reasonably quantifiable and measurable. The value is the price the charity estimates it would pay should it purchase equivalent goods or services.

The estimated valuation of gifts in kind is based on the value of the contribution to the charity, or the valuation the charity would have had to pay to acquire the goods or services. A corresponding amount is recognised within expenditure in the period of receipt.

(m) Private Medical Insurance

Since October 2017, permanent employees are entitled to join the Group Private Medical Insurance Scheme provided by Bupa. In 2022, the charity paid a premium based on the employee's ages per month to all employees after serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of private medical insurance is the contribution payable during the year.



3. Consolidated statement of financial activities for the year ended 31 December 2021

	Total restated restricted funds £	Total restated unrestricted funds £	Restated Total 2021 £
Income from:			
Donations and legacies	443,952	14,674,545	15,118,497
Other trading activities	-	6,850	6,850
Income from investments	-	48,672	48,672
Other income	-	248	248
Total Income	443,952	14,730,315	15,174,267
Expenditure on:			
Raising funds	207,687	1,771,965	1,979,652
Charitable activities	-	7,875,497	7,875,497
Total Expenditure	207,687	9,647,462	9,855,149
Net change in investments	-	170,161	170,161
Net (expenditure)/income	236,265	5,253,014	5,489,279
Transfers between funds	(236,265)	236,265	-
Net movement in funds	-	5,489,279	5,489,279
Reconciliation of funds:			
Total funds brought forward	-	9,295,761	9,295,761
Total funds carried forward	-	14,785,040	14,785,040

4. Income

	2022 £	Restated 2021 £
Donations and legacies		
Appeals and associated donations (See below)	3,286,890	4,951,894
Committed giving	3,018,538	3,114,654
Sports events	2,926,349	2,760,328
Legacies (see contingent asset below)	2,380,956	2,306,146
Corporate and trust donations	1,178,349	953,555
Community fundraising	624,065	1,031,920
	13,415,147	15,118,497
Other trading activities		
Events	581,771	6,850
	581,771	6,850

Included in Donations and legacies in 2021 is a government grant in the form of the Job Retention Scheme for £60,161. There was no grant during 2022.



Contingent asset – legacy income

As at 31 December 2022, the charity had been notified of a further 43 residuary and pecuniary legacies which have not been recognised as income in the Statement of Financial Activities as they do not meet the criteria as detailed in the accounting policies. These legacies have an estimated value of £1,967,279 which has not been accrued.

5. Lottery income

As part of the charity’s Gambling Commission License (Non Remote License - 000-004700-N-306402-010) (Remote License – 000-004700-R-308531-010), during the year the charity has operated three lotteries, a weekly lottery and charity scratch card.

The following ticket sales were received for each lottery where the draw was held in 2022:

	Ticket sales £
Weekly Lottery	547,365
Christmas Raffle (draw 14 th January 2022)	520,707
Summer Raffle (draw 16 th September 2022)	314,266
Total	1,382,266

The Christmas Raffle spans two accounting periods. Although the draw took place during the current accounting period, the closing date was 14th January 2022 and most ticket sales were received in the previous accounting period. All other ticket sales were received during 2022 only. All ticket sales have been included within the total income for 2022 and 2021.

In line with the requirements under Social responsibility code provision 4.3.1 of the License Conditions and Codes of Practice of the Gambling Act 2005 the following section details the percentage of lottery proceeds returned to the purposes of the society (Children with Cancer UK) from the lotteries promoted in 2022.

Lottery type	Lottery Name	Percentage proceeds returned to Charity %
Managed directly by Children With Cancer UK	Weekly Lottery	61%
Managed directly by Children With Cancer UK	Children with Cancer Grand Draw	66%
Total		64%



6. Total expenditure

	Staff Costs £	Direct Costs £	Support and Governance £	2022 Total £	2021 Total £
Expenditure on Raising funds					
Fundraising Costs	470,552	1,243,818	405,109	2,119,479	1,979,652
Expenditure on Charitable activities					
Research into Prevention & Causes	219,217	337,012	175,031	731,260	1,073,266
Research into Treatment	213,293	4,244,270	170,640	4,628,203	1,835,442
Welfare	277,704	3,748,064	233,618	4,259,386	2,931,817
Raising Awareness	441,663	1,345,519	325,474	2,112,656	2,034,972
	<u>1,151,877</u>	<u>9,674,865</u>	<u>904,763</u>	<u>11,731,505</u>	<u>7,875,497</u>
	<u>1,622,429</u>	<u>10,918,683</u>	<u>1,309,872</u>	<u>13,850,984</u>	<u>9,855,149</u>
	=====	=====	=====	=====	=====

	Staff Costs £	Direct Costs £	Support and Governance £	2021 Total £
Expenditure on Raising funds				
Fundraising Costs	443,087	1,274,561	262,004	1,979,652
Expenditure on Charitable activities				
Research into Prevention & Causes	230,745	743,119	99,402	1,073,266
Research into Treatment	224,819	1,513,823	96,800	1,835,442
Welfare	314,193	2,479,418	138,206	2,931,817
Raising Awareness	509,480	1,295,395	230,097	2,034,972
	<u>1,279,237</u>	<u>6,031,755</u>	<u>564,505</u>	<u>7,875,497</u>
	<u>1,722,324</u>	<u>7,306,316</u>	<u>826,509</u>	<u>9,855,149</u>
	=====	=====	=====	=====



7. Support costs

Support costs are split as follows:

	Office Administration £	Operational Management £	Finance / IT / HR £	Communications and Marketing £	Governance £	2022 Total £
Expenditure on Raising funds						
Fundraising Costs	83,886	35,678	217,031	54,193	14,321	405,109
Expenditure on Charitable activities						
Research into Prevention & Causes	36,244	15,415	93,770	23,414	6,187	175,031
Research into Treatment	35,334	15,028	91,418	22,827	6,063	170,640
Wellness	48,375	20,575	125,158	31,252	8,258	233,618
Raising Awareness	67,396	28,665	174,368	43,540	11,505	325,474
	187,349	79,683	484,714	121,033	31,983	904,762
	271,235	115,361	701,745	175,226	46,304	1,309,871
	=====	=====	=====	=====	=====	=====

	Office Administration £	Operational Management £	Finance / IT / HR £	Communications and Marketing £	Governance £	2021 Total £
Expenditure on Raising funds						
Fundraising Costs	39,718	58,629	110,385	39,847	13,425	262,004
Expenditure on Charitable activities						
Research into Prevention & Causes	17,461	9,992	48,529	17,518	5,902	99,402
Research into Treatment	17,004	9,731	47,259	17,059	5,747	96,800
Welfare	24,278	13,893	67,472	24,357	8,206	138,206
Raising Awareness	40,419	23,130	112,335	40,551	13,662	230,097
	99,162	56,746	275,595	99,485	33,517	564,505
	138,880	115,375	385,980	139,332	46,942	826,509
	=====	=====	=====	=====	=====	=====

Indirect, support and governance costs are allocated on a per person basis to staff in the office. The time spent by each staff member on every activity of the charity is allocated on a month by month basis throughout the year. Support and staff costs are then allocated to the various charitable activities based on this staff time basis.



8. Costs of charitable activities

	Activities undertaken directly £	Grant funding of activities £	Support and governance costs £	2022 Total £	2021 Total £
Research into Prevention & Causes	556,229	500,000	175,031	1,231,260	1,073,266
Research into Treatment	526,530	3,431,033	170,640	4,128,203	1,835,442
Welfare	985,768	3,040,000	233,618	4,259,386	2,931,817
Raising Awareness	1,787,183	-	325,473	2,112,656	2,034,972
	3,855,710	6,971,033	904,762	11,731,505	7,875,497
	=====	=====	=====	=====	=====

9. Auditor Costs

	Statutory Audit Fee £	2022 Total £
Children with Cancer UK	34,000	34,000
Helping Children with Cancer Ltd	4,000	4,000
	38,000	38,000
	=====	=====

	Statutory Audit Fee £	Other Financial Services £	2021 Total £
Children with Cancer UK	32,300	13,000	45,300
Helping Children with Cancer Ltd	3,600	-	3,600
	35,900	13,000	48,900
	=====	=====	=====

10. Staff costs

	2022 £	2021 £
Salaries and wages	1,362,728	1,410,872
National Insurance	150,028	151,437
Pension	103,563	140,623
Private Medical Insurance	6,109	19,392
	1,622,428	1,722,324
	=====	=====

During 2022, the following employees were paid in the following salary ranges.

Salary Range	2022 £	2021 £
£130,000 - £140,000	0	0
£90,000 - £100,000	0	1
£70,000 - £80,000	1	0
£60,000 - £70,000	5	1



There have been 8 (2021: 8) positions that have formed part of the senior leadership team during 2022. The total remuneration including pension contributions for these employees amounts to £620,296 (2021: £501,460).

During the year there was one (2021: six) redundancy, termination or settlement payments made totalling £12,317 (2021: £25,852).

The average weekly number of contracted employees during the year was as follows:

	2022	2021
	No.	No.
Charitable Activities	4	5
Raising Funds	25	27
Support, Governance, Operations and Administration	8	8
	<u>37</u>	<u>40</u>
	=====	=====

The Trustees received no remuneration or reimbursement of expenses during the year (2021 Nil).

11. Results of the parent charity

	2022	2021
	£	£
Total income	14,106,417	14,840,817
Total expenditure	(13,846,984)	(9,851,516)
Unrealised gains / (Losses)	(204,193)	170,161
	<u>55,240</u>	<u>5,159,462</u>
	=====	=====

12. Fixed assets

The balance of £1.6m relates to a property addition in the year. No depreciation has been charged as it is an asset under construction.

13. Investments

	2022	2021
	£	£
Listed investments (see below)	1,744,145	1,948,338
Cash deposits held as long-term investment	8,255,855	8,345,397
	<u>10,000,000</u>	<u>10,293,735</u>
	=====	=====
Market value of listed investments at 1 Jan	1,948,338	1,778,177
Additions to investment portfolio	5,513	5,534
Investment manager fees	(5,513)	(5,534)
Net Investment gain/(loss)	(204,193)	170,161
	<u>1,744,145</u>	<u>1,948,338</u>
	=====	=====
Listed Investments comprise the following:		
Multi class and other investments	1,744,145	1,948,338
Total listed investments at 31 Dec	1,744,145	1,948,338
	=====	=====



Total Investments are listed in:		
United Kingdom	456,966	510,465
Overseas	1,287,179	1,437,873
	-----	-----
	1,744,145	1,948,338
	=====	=====

Investment in subsidiary

Children with Cancer UK holds 100% of the share capital of Helping Children with Cancer Limited which is a registered company number 04960054. The value of the share capital owned is £100. Helping Children with Cancer Limited raises funds via commercial activities and sponsorship.

The income and expenditure for the year ended 31 December 2022 is as follows:

	2022 £	2021 £
Income	171,380	72,225
Administrative expenses	(13,163)	(12,153)
	-----	-----
Profit before gift aid and taxation	158,217	60,072
	=====	=====

The balance sheet for the subsidiary as at 31 December 2022 is as follows:

	2022 £	2021 £
Assets	167,764	23,740
Liabilities	(167,664)	(23,640)
	-----	-----
Reserves	100	100
	=====	=====

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

14. Debtors

	2022 Group £	2022 Charity £	Restated 2021 Group £	Restated 2021 Charity £
Amounts due from subsidiary undertakings	-	-	-	19,680
Other debtors	780,880	780,880	855,412	855,412
Accrued income	1,256,736	1,242,482	683,382	669,915
Prepayments	910,382	910,382	1,127,410	1,127,410
	-----	-----	-----	-----
	2,947,998	2,936,304	2,666,204	2,672,417
	=====	=====	=====	=====



15. Grants to third parties

	2022 £	2021 £
Outstanding liabilities at the start of the year	9,146,065	9,902,369
Awarded during the year (note 22):		
Research into prevention and causes	-	-
Research into treatment and survival	3,931,033	812,027
Welfare	3,040,000	1,297,488
Raising awareness	-	1,376
	-----	-----
Total third party grants before adjustments	6,971,033	2,110,891
Under/over spends and adjustments on previous grant awards	39,295	131,425
	-----	-----
Total third party grants	7,010,328	2,242,316
Paid during the year	(3,572,544)	(2,998,620)
	-----	-----
Outstanding liabilities at the end of the year	12,583,848	9,146,065
	=====	=====
Grants falling due within one year	8,031,586	3,965,171
Grants falling due after more than one year	4,552,262	5,180,894
	-----	-----
	12,583,848	9,146,065
	=====	=====

16. Creditors: amounts falling due within one year

	2022 Group £	2022 Charity £	2021 Group £	2021 Charity £
Accruals and deferred income	1,087,681	922,578	640,172	636,212
Taxes and social security	42,957	42,957	59,770	59,770
	-----	-----	-----	-----
	1,130,638	965,535	699,942	695,982
Grants payable	8,031,586	8,031,586	3,965,171	3,965,171
	-----	-----	-----	-----
	9,162,224	8,997,121	4,665,113	4,661,153
	=====	=====	=====	=====

17. Deferred income

Deferred income comprises income received in advance for entries to our weekly lottery.

	2022 Group £	2022 Charity £	2021 Group £	2021 Charity £
Balance as at 1 January 2022	56,285	56,285	52,053	52,053
Amount released to income	(56,285)	(56,285)	(52,053)	(52,053)
Amount deferred in year	53,701	53,701	56,285	56,285
	-----	-----	-----	-----
Balance as at 31 December 2022	53,701	53,701	56,285	56,285
	=====	=====	=====	=====



18. Analysis of net assets between funds

As at 31 December 2022	2022 Group Restricted funds £	2022 Group Unrestricted funds £	2022 Group Total funds £	2021 Group Unrestricted funds £
Fixed assets	-	11,600,000	11,600,000	10,293,735
Net current assets	-	7,792,542	7,792,542	9,672,199
Creditors falling due after more than one year	-	(4,552,262)	(4,552,262)	(5,180,894)
Net assets at the end of the year	-	14,840,280	14,840,280	14,785,040

As at 31 December 2021	2021 Group Restated Restricted funds £	2021 Group Restated Unrestricted funds £	2021 Group Restated Total funds £	2020 Group Total funds £
Fixed assets	-	10,293,735	10,293,735	10,133,555
Net current assets	-	9,672,199	9,672,199	7,082,177
Creditors falling due after more than one year	-	(5,180,894)	(5,180,894)	(7,920,071)
Net assets at the end of the year	-	14,785,040	14,785,040	9,295,661

19. Statement of funds

Year ended 31 December 2022	At the start of the year £	Total Income £	Total Expenditure £	Transfers & Investment gains/losses £	At the end of the year £
Restricted funds					
Dr Christina Halsey, University of Glasgow. Discovery of biomarkers and new therapeutic targets for chemotherapy associated neurotoxicity	-	500	-	(500)	-
Dr Ian Hampson, University of Manchester. Identification of infections which may play a role in the aetiology of childhood acute lymphoblastic leukaemia (ALL)	-	100	-	(100)	-
Professor Sibylle Mittnacht, UCL Cancer Institute- Exploring retinoblastoma protein loss as an actionable target in paediatric bone and soft tissue sarcoma	-	1,000	-	(1,000)	-
Sam Behjati - Wellcome Sanger Institute - Developmental states of localised and metastatic osteosarcoma cells – a knowledge bank for novel biomarkers and therapeutic approaches	-	1,596	-	(1,596)	-
Anthony Chalmers - University of Glasgow - Increasing the susceptibility of neuroblastoma cells to radiotherapy by targeting glycolysis and lipogenesis	-	500	-	(500)	-
Marc Mansour - UCL Cancer Institute - CCR9 as a novel immunotherapy target in T-cell acute lymphoblastic leukaemia (T-ALL)	-	20	-	(20)	-
Professor Chris Jones, Institute of Cancer Research, The role of histone H4K20 methylation in paediatric glioblastoma and DIPG	-	246	-	(246)	-
Professor Steve Clifford – INSTINCT-MB	-	49,749	-	(49,749)	-
Wellness Retreat Project	-	22,052	(22,052)	-	-
Beads of Courage UK, which helps children in all 110 children's cancer wards in the UK visualise and articulate their cancer journey	-	179,110	(179,110)	-	-
Total Restricted funds	-	254,872	(201,162)	(53,710)	-



Unrestricted funds	14,785,040	13,855,545	(13,649,822)	(150,483)	14,840,280
Total Unrestricted funds	14,785,040	13,855,545	(13,649,822)	(150,483)	14,840,280
Total funds	14,785,040	14,110,417	(13,850,984)	(204,193)	14,840,280
	=====	=====	=====	=====	=====

Note

The restricted funds comprise donations that were to be spent on specific causes and projects. All restricted income was either discharged during the year or transferred from restricted back to unrestricted funds. This has occurred when restricted funds were received towards grants that were previously paid out of unrestricted reserves.

Year ended 31 December 2021	At the start of the year £	Total Income £	Total Expenditure £	Transfers & Investment gains/losses £	At the end of the year £
Restricted funds					
Dr Christina Halsey, University of Glasgow. Discovery of biomarkers and new therapeutic targets for chemotherapy associated neurotoxicity	-	500	-	(500)	-
Clinical PHD Studentship: Markers of Hypothalamic Dysfunction in Children with Hypothalamo-Pituitary-Axis Tumours (HPAT) or Pituitary Maldevelopment	-	64	-	(64)	-
Anthony Chalmers - University of Glasgow - Increasing the susceptibility of neuroblastoma cells to radiotherapy by targeting glycolysis and lipogenesis	-	500	-	(500)	-
Macarena Oporto Espuelas - UCL Great Ormond Street Institute of Child Health - Identification of novel surface antigen targets for CAR T cell strategies in paediatric Acute Myeloid Leukaemia stem cells.	-	3,651	-	(3,651)	-
Professor Steve Clifford – INSTINCT-MB	-	231,550	-	(231,550)	-
Beads of Courage UK, which helps children in all 110 children's cancer wards in the UK visualise and articulate their cancer journey	-	207,687	(207,687)	-	-
Total Restricted funds	-	443,952	(207,68)	(236,265)	-
Unrestricted funds	9,295,761	14,730,315	(9,647,461)	406,425	14,785,040
Total Unrestricted funds	9,295,761	14,730,315	(9,647,461)	406,425	14,785,040
Total funds	9,295,761	15,174,267	(9,855,149)	170,160	14,785,040
	=====	=====	=====	=====	=====

20. Related Party Transactions

There have been no other related party transactions during the year other than those with the trading subsidiary.

A management fee of £5,000 (2021: £5,000) has been charged to the trading subsidiary for use of the charity's trademarks and a further £4,163 (2021: £3,520) for the use of charity staff (calculated on the basis of time charged to subsidiary activity by the employee). As at 31st December 2022, £163,704 (2021: £19,680) owed to the charity from the trading subsidiary.



21. Financial Instruments

The financial statements include the following in respect of items:

	2022 £	2021 £
Financial assets measured at fair value	1,744,145	1,948,338
Total interest income for financial assets held at fair value	(35,736)	(48,672)

22. Grants to third parties

Grants awarded to third parties during the year	Research into prevention and causes 2022 £	Research into treatment 2022 £	Welfare 2022 £	Total 2022 £
Beads of Courage – To fund the implementation of an official sibling programme run the way it was intended, using the sibling beads as the foundation stone			3,040,000	3,040,000
Cancer Research UK to support the funding of the stratified medicine paediatrics 2 programme		2,755,372		2,755,372
Bone Cancer Research Trust - to collaborate and fund a new Research Programme Grant for children, teens and young adults (aged 24 years and younger) suffering from Ewing Sarcoma		1,000,000		1,000,000
Two IARC Postdoctoral Fellowships (€200,000)		175,660		175,660
Total grants to third parties	-	3,931,033	3,040,000	6,971,033



Grants awarded to third parties during the year 2021	Research into prevention and causes 2021 £	Research into treatment 2021 £	Raising Awareness 2021 £	Welfare 2021 £	Total 2021 £
Birmingham Women's and Children's Hospital Charity - The purchase of a high-throughput sequencing machine (NovaSeq 6000)				1,072,488	1,072,488
INSTINCT-MB: Strategic implementation of novel combination therapeutics for high-risk medulloblastoma		712,027			712,027
Beads of Courage - 2021				225,000	225,000
Bioinformatics support for primary bone cancer plus other childhood cancer studies		100,000			100,000
British Neuro-Oncology Society Annual Meeting 2021			1,200		1,200
International Family Nursing Association Meeting 2021			176		176
Total grants to third parties awarded in the year	-	812,027	1,376	1,297,488	2,110,891
Grant closures and adjustments	(4,428)	1,294	10,559	124,000	131,425
Total grants to third parties	(4,428)	813,321	11,935	1,421,488	2,242,316

23. Prior year adjustment

The prior year's accounts have been restated for the omission of legacies.

	2021 £	2021 £
Funds as previously reported at 31 st December 2021	14,455,222	
Legacies previously omitted	329,818	
Funds restated at 31st December 2021	14,785,040	
	=====	
	Group	Charity
Debtors as previously reported at 31 st December 2021	2,336,386	2,342,599
Legacies previously omitted	329,818	329,818
Debtors restated at 31st December 2021	2,666,204	2,672,417
	=====	=====



Every day 10 children and young people are diagnosed with cancer in the UK.

8 out of 10 young childhood cancer patients can be successfully treated thanks to vital, specialist research we helped fund.

Our aims are to determine the causes, find cures and provide care for children with cancer. We are united by a common goal – to save and improve young lives.



We fund Research



We fund Welfare



We raise Awareness

Children with Cancer UK
Registered Office
21-27 Lamb's Conduit Street
London
WC1N 3NL

CHILDREN WITH CANCER UK

England & Wales - Charity number 298405

Accounts

Children with Cancer UK

Trustees' Report and Financial Statements
for the year ended 31 December 2021

Children with Cancer UK

Helping children and young
people with cancer to ring the bell



Registered Charity Number: 298405
Inaugurated by Diana, Princess of Wales
Company limited by guarantee, Number: 4960054

Children with Cancer UK in numbers

Research - We're committed to improving survival and finding kinder treatments for children and young people with cancer

£800k invested into vital, life-saving research

2 new research grants were awarded

£1m donated to Birmingham Women's and Children's Hospital Charity, in partnership with KwikFit, to provide a high-throughput sequencing machine to support their expansion of cancer and rare disease genetic testing

Supporting families – We help children with cancer and their families through the hardships of a cancer diagnosis

227 families attended our virtual parties

£200K helping children cope with cancer treatment through receiving beads from Beads of Courage UK, our partner charity

Awareness – We shine a spotlight on the impact of cancer on children and young people and their families

Millions of people reached through our campaigns

600 online articles

130 mentions of the charity in printed media

8 families told their childhood cancer stories

CHILDREN WITH CANCER UK

TRUSTEES' ANNUAL REPORT AND CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2021

MESSAGE FROM THE CHAIR AND CEO OF CHILDREN WITH CANCER UK	04 – 05
OUTCOMES IN 2021	06
RESEARCH OUTCOMES IN 2021	07 – 10
SUPPORTING FAMILIES IN 2021	11 – 12
AWARENESS ACTIVITIES IN 2021	13
FUNDRAISING HIGHLIGHTS AND COMPLIANCE	14 – 17
THANK YOU	18
FINANCIAL REVIEW	19 – 30
STRATEGIC PLANS	22 – 23
GOING CONCERN, RISKS & GOVERNANCE	23 – 30
REFERENCE AND ADMINISTRATION	31 – 32
STATEMENT OF TRUSTEES' RESPONSIBILITIES	33
INDEPENDENT AUDITORS' REPORT	34 – 37
CONSOLIDATED FINANCIAL STATEMENTS	38 – 40
NOTES TO THE FINANCIAL STATEMENTS	41 – 58

MESSAGE FROM THE CHAIR OF CHILDREN WITH CANCER UK

Welcome to our Annual Report and Accounts for 2021.

Welcome from Chair of Trustees

Firstly, I would like to thank Eddie and Cliff O’Gorman. Eddie has stepped down as Chairman - having set up the charity with his wife Marion in 1988. They built the charity as a promise to their son Paul, who died from leukaemia, that they would raise funds for children with cancer. This wonderful legacy, built from a family tragedy, is one that continues to support families going through similar experiences today. Thank you to Cliff also for all he has done alongside Eddie, since the charity was created over 30 years ago, their hard work and dedication has established it as the leading children's charity dedicated to fighting childhood cancer.

We are entering a new chapter of our journey and, with that, I am delighted to welcome Jo Elvin, our new CEO who will be a fantastic asset to the charity bringing a wealth of experience, drive and determination. We are looking forward to her working closely with our various teams to ensure that we continue to build on the fantastic work the O’Gorman family started.

Despite the inevitable challenges COVID-19 created I am proud of the resilience the charity has demonstrated. Our ability to embrace a more digital approach enabled the charity to weather the storm but also ensures we are well placed for further growth in the future. That along with our solid foundations also ensured we were able to honour existing funding commitments despite the unprecedented times we faced.

I’d like to take this opportunity to extend my gratitude to all the volunteers, supporters, collaborators, associations, researchers, corporates and the brilliant team at Children with Cancer UK for continuing to work hard to raise money, awareness and offer support to help the charity continue its research funding and support families affected by childhood cancer.

I would also like to thank my fellow trustees for their time, experience and dedication, working together with me to ensure the charity goes from strength to strength.

We are proud of our strong track record of working with other cancer charities demonstrating the clear impact joint funding can have on survival rates and improvements in treatment. We have made great progress collaborating with organisations including Teenage Cancer Trust and Young Lives Vs Cancer. We are also delighted to continue to work alongside Cancer Research UK on the Cancer Research UK-Children with Cancer UK Innovation Awards, now into its second year of funding. Another collaboration we are looking forward to in 2022 / 2023 is with the Bone Cancer Research Trust. We are funding a £1 million research programme that will look into a rare cancer that has not had survival improvements for four decades.

These are just a few of the areas in which we are making great strides as we continue to look to deliver our vision of a world where every child survives cancer.

We could not do what we do without the continued loyalty and unwavering support of every donor, thank you for every single penny. It is making a difference now and will do for years to come.

David Gibbs
Chair of Trustees
Children with Cancer UK

Welcome from CEO of Children with Cancer UK

It is a privilege to step into my new role as the CEO of Children with Cancer UK. The O’Gorman family have built an organisation that has been saving young lives for decades. They leave a huge legacy and one I am committed to protecting and ensuring continues for decades to come. The charity has been doing outstanding work for over thirty years leading the way in childhood cancer research and supporting children, young people and their families when they are at their most vulnerable. Our vision remains a world where every child survives cancer and together with my team we will continue to strive towards that, delivering our mission to ensure we improve the lives of those suffering with childhood cancer now and in the future.

Unfortunately, I know there are very few people who are not touched in some way by the devastating effects of cancer. I have the greatest admiration and respect for every person it comes into contact with, whether they have been diagnosed themselves or are working to find a cure. Knowing only too well how important pastoral care is to support families I am keen that we continue to help with emotional support as well as the logistics around dealing with the traumatic experience of finding out that your child has cancer.

The continued success of the charity, which has continued despite the adverse effects experienced due to the pandemic, is due to the passion of all those involved including donors, fundraisers, volunteers and dedicated team members. The charity’s successful track record of alliances with several partner organisations and fellow charities is also something I am keen we continue to grow. I believe these collaborations, bringing together vital specialist knowledge and skills will play a vital role in delivering further life-changing results through research.

It’s only thanks to our supporters that we can continue our vital work. Thank you so very much for your continued support.

Jo Elvin
CEO of Children with Cancer UK

OUTCOMES IN 2021

How donations have helped children and young people with cancer.

We are pleased to announce that in 2021 we raised £14.8m to fund specialist childhood cancer research and support families.

For every £1 we spend on fundraising, we raised £6 more

For every £1 donated we spend

- 80p on fighting childhood cancer
 - 30p on research projects,
 - 29p on supporting families,
 - 21p on raising awareness,
- 20p on raising more money

We receive no government funding and rely exclusively on the generosity of our supporters

OUR YEAR IN RESEARCH

Around 1,800 children and 2,400 young people are diagnosed with cancer each year in the United Kingdom. Whilst over 80% of patients survive, cancer remains the leading disease related cause of death for children under 15 years of age. From the time of their diagnosis, children and young people endure difficult treatments to eradicate their disease, with potentially life-altering side effects on their development. High-quality and impactful research is essential to driving forward our vision of a world where every child survives cancer. Research has significantly contributed to the improvements seen in childhood cancer survival rates from 67.3% in 1990 to a predicted 85.5% in 2018. Improved treatments and understanding of the disease are important in the fight against cancer. Only around 2% of cancer research funding in the UK is spent on research that is fully dedicated to childhood and young adult cancer.

Children with Cancer UK plays a major role in funding vital life-saving research. We are dedicated to improving survival rates across all types of childhood cancer, improving the quality of life in young cancer survivors and finding less-toxic treatment options. As the UK's leading charity dedicated to childhood cancer research, we are proud of our contribution to the ongoing breakthroughs which continue to help save thousands of young lives.

The COVID-19 pandemic continued to have a significant impact on research in the UK and result in delays for many existing research projects. As a result of the COVID-19 pandemic we were limited in our efforts to fund new research projects. Despite these limitations, we funded 2 new research projects in 2021, worth over £800k. These projects aim to develop effective treatment strategies and improve the long-term health outcomes for children, teenagers and young adults diagnosed with cancer.

Combined with existing active research grants, this means that we are now funding a total of 52 projects, worth over £16 million across the UK and abroad. Our funding is helping more children survive cancer and look forward to longer and healthier lives after their treatment has ended.

In 2021 we provided over £1 million as an infrastructure grant to Birmingham Women's and Children's Hospital Charity, in partnership with KwikFit, to provide a high-throughput sequencing machine (NovaSeq 6000) to support the expansion of cancer and rare disease genetic testing at the West Midlands Regional Genetic Laboratory.

Children with Cancer UK values its partnerships with others in the paediatric and young adult cancer community including the National Cancer Research Institute (NCRI) and the Association of Medical Research Charities (AMRC). Our research funding including other charities, government funders, cancer organizations and universities. We supported several conferences including the British Neuro-oncology Society (BNOS) annual meeting and the International Nursing Association Conference. These collaborative events during the year help to facilitate innovation and share specialist expertise.

In development with members of the Scientific Advisory Panel (SAP) and consultation with partners and stakeholders, 2021 saw the refresh of the research strategy which outlines our overarching research aims for the next five years.

Research Strategy

The refreshed Children with Cancer UK research strategy outlines our aims and objectives for the next five years, provides insights into what we hope to achieve and how funding can be used to help more children and young people survive cancer. The strategy was developed with insights from the Cancer Research Database (CaRD), engagement with research partners, reviews of the research landscape and guidance from the SAP.

Our research program is designed to progress our principal aims. First, we wish to develop improved treatments so that more patients are cured with less toxic side effects. Second, we wish to better understand how cancer develops so that one day we may be able to prevent it.

Children with Cancer UK's research objectives include the development of more effective treatments including immunotherapies and tailored treatments which target cancer-specific molecular changes targeted with reduced toxicity. The identification of improved diagnostic and prognostic biomarkers to allow accurate diagnosis and disease monitoring. The early identification and mitigation of treatment related toxicity. The further understanding of cellular and molecular oncogenesis and the promotion and dissemination of research findings to achieve maximum research impact.

As a charity we are committed to working in partnership with patients and the public, we recognize the valuable insight this involvement can provide. We also understand the need to invest in early-career researchers. In future, we hope to support the next generation of clinician scientists and research leaders, champion their long-term career progression through our fellowship and clinical studentship programs and prepare them to make substantial contributions to improving outcomes for children with cancer.

New research awards

In 2021 we funded 2 new research projects worth over £800k.

INSTINCT-MB: Strategic implementation of novel combination therapeutics for high-risk medulloblastoma, Professor Steve Clifford, Newcastle University

One of the major specific challenges in childhood cancer is Group 3 medulloblastoma driven by the over-abundance of a gene called MYC (MYC-MBGroup3). This tumour group occurs almost exclusively in young children and is essentially incurable, contributing significantly to overall childhood cancer death rates. New targeted treatments are urgently needed to improve the outlook for children with high-risk medulloblastoma. The INSTINCT-MB project co-funded by Blue Skye Thinking and Little Hero will seek to develop new treatments for MYC-MBGroup3, using new drugs and promising new immunotherapies known as Chimeric Antigen Receptor T-cells (CAR-T) therapies.

Brain tumours are the most common tumours that develop in children. Medulloblastoma is the most common malignant brain tumour affecting children. Over the last 50 years, advances in standard treatments such as surgery, radiotherapy and chemotherapy have led to long-term survival rates of approximately 70%. However, survival rates have plateaued, and current therapies are associated with significant long-term side effects in surviving patients. New therapies are urgently required to improve the outlook for children with high-risk medulloblastoma.

Professor Steve Clifford and his team have developed a series of experimental models which recapitulate the disease in children as closely as possible. Using these models, they will develop a deep understanding of the biological vulnerabilities of these tumours. Based on these findings, they will further develop and deliver new MYC-targeting drug and CAR-T treatments, test regimens for administration, and generate the essential evidence required to directly translate this work into clinical studies in children with medulloblastoma. Knowledge gained from pre-clinical trials will track how tumours respond to treatment, identifying potential mechanisms of treatment resistance.

The team anticipate the treatment approaches developed by this project will help to reduce the incidence of disease relapse and the late-effects associated with current standard of care treatments for children with relapsed medulloblastoma and treatment-resistant MYC-driven medulloblastomas.

Bioinformatics support for primary bone cancer plus other childhood cancer studies, Dr Darrell Greene, University of East Anglia.

Osteosarcoma (OS) is a devastating primary bone cancer mainly occurring in children, teenagers and young adults. There are around 52,000 new cases per year worldwide. Five-year survival, i.e. patients still alive 5 years after their initial diagnosis (but they may still have OS), is extremely poor at 40%. A major clinical complication in primary bone cancer is rapid spread of disease to the lungs. Metastasis causes more than 90% of patient death. The central theme of this project is to extensively understand metastatic OS at the molecular/cellular level in order to detect targets or opportunities for therapy.

Scientists will download data from several experiments and then use sophisticated methods to understand the “real life” events that underpin the data. This is extremely important to understand how cancer works –so that we can detect and fix abnormalities in cancer cells whilst not affecting healthy cells.

Expansion of cancer and rare disease genetic testing

Genomic testing for patients diagnosed with cancer is incredibly important and over the last decade, large scale sequencing projects have identified pertinent DNA changes, which have enabled scientists to develop new and improved cancer drugs and treatments to specifically target these variations. Sequencing all possible DNA changes in a single test gives scientists the best possible chance of detecting the genetic changes driving a child’s cancer; and knowing the genetic makeup of a child or young person’s cancer, or tumour, allows clinicians to offer a more tailored treatment.

The West Midlands Regional Genetic Laboratory (WMRGL), based at Birmingham Women’s and Children’s NHS Foundation Trust, uses the most up-to-date technologies and equipment to provide cancer and rare disease genetic services for patients across the West Midlands, Oxfordshire and Wessex (WMOW). With more than 200 scientific, technical and support staff, it is the largest genetics laboratory in the UK providing services for up to 20% of the UK population.

Our infrastructure grant worth over £1 million purchased the NovaSeq 6000, a state-of-the-art piece of DNA sequencing equipment. This grant has enabled the rapid expansion of cancer genetic testing and will enhance our ability to identify diagnostic and prognostic biomarkers for childhood and young people’s cancers, thereby enabling the development of more-effective and less-toxic treatments for children and young people with cancer.

Initial forecasts provided by NHS England and NHS Trusts across the West Midlands, Oxfordshire and parts of Southern England suggest that approximately 560 children and young people per year could benefit from large cancer panel genetic testing following the installation of the NovaSeq.

SUPPORTING FAMILIES IN 2021

At Children with Cancer UK we continue to prioritise keeping families together and providing much needed support to children, young people and their families during challenging times. Despite difficulties meeting together we hosted virtual events for our families throughout the year, giving them happier memories and a welcome respite from the daily worries cancer brings.

Building Strength and Courage through beading

2021 which saw the continuation of our partnership with Beads of Courage UK. Our funding helps to support children and their families through some of the toughest times in their lives through positive coping strategies by helping children to visualize and articulate their experiences through a process called beading. Ongoing research has found that the program helps alleviate treatment induced stress and anxiety, benefitting a child's mental health and wellbeing.

Amazing days out for families affected by childhood cancer

Ongoing COVID-19 restrictions resulted in us having to cancel all our amazing days out for the second year running. Instead we built on the success of the virtual parties we hosted in 2020 and created more family friendly virtual activities. We are delighted that 227 families were able to join us at these events.

Here follows a snapshot of our much-loved events that allow families to enjoy quality time together and a break from the daily stresses of a childhood cancer diagnosis.

Mother's Day Baking Party

On Sunday 14th of March we held a very special Baking Party for Mother's Day for 67 families. Each family received a baking kit in the post to create chocolate shortbread biscuits, and joined together to receive a live cooking tutorial. We then finished with a mini treasure hunt and true and false game.

Spring Craft Party

We had a morning of creating Spring themed crafts in April, and were joined by 76 children affected by childhood cancer, and their families. Our virtual party was hosted by Lexy at Made by Me Craft Parties, and the participants were kept entertained by crafting their very own bunny dream catchers, flower bookmarks and bunny ornaments.

Erin took part in the crafting with her big sister Milla. Her mum, Alexis, told us:

Thank you so much for another fabulous craft party! The girls love the oh-so-cute decorations – it's definitely starting to feel like Spring. These events have really kept us going as we found our feet post-treatment, and given the girls something to look forward to. Erin missed out on so much due to her treatment and COVID-19 meant we couldn't start giving her the usual childhood experiences when treatment finished. We really appreciate the effort Children with Cancer UK put into finding online ways of generating moments of joy and normality.

Super Science Slime Party

In May we held a virtual Science party with Einstein's Entertainers for children affected by cancer and their families.

60 families signed up to join the online party where they played party games and got involved in fun scientific experiments. A few of the experiments included slime making and helicopter making. All of the children received a mini home lab kit in the post which had everything they needed to take part in the experiments and get involved in the fun.

Halloween fun

During October Half Term around 177 families joined in with our Halloween activities, which were sent out in the post as a fun creative way to bring families together. The activities consisted of a Craft box, put together by Lexy at Made By Me Craft Parties. It included a Frankenstein monster lantern with googly eyes that glow in the dark. We also worked with Kiddy Cook who sent out a Cookie monster baking mix, which allowed the children to create their own unique cookie monsters with candy eyes, and blue icing.

Charlotte, Mum of Isla told us:

I would just like to say thank you so much for the Cookie Monster package. With a rubbish rainy day today, we thought it was a perfect day to make the Cookie Monster biscuits. My 1 year old daughter Isla got diagnosed with infant acute lymphoblastic leukaemia 16 weeks ago when she was 10 months. Her 6-year-old brother Cody was so chuffed to make these for her and it was a great way of involving him. He tried so hard. Thank you so much we had great fun.

RAISING AWARENESS OF CHILDHOOD CANCER DURING THE COVID-19 PANDEMIC

Our aim is to make society aware of the impact that cancer can have on young lives. By bringing the reality of being diagnosed and treated for cancer to the attention of the general public, we will make a change. It is only through continuing to invest in life-saving research that we will effect a change in incidence and survival rates for children and young people. We raise awareness during our campaigns to stand together against childhood cancer and bring hope to young patients and their families.

To raise awareness of cancer occurring in children and young people we ran multiple campaigns, including World Cancer Day, Brain Tumour Awareness Month and Childhood Cancer Awareness Month. Through our campaigns we have reached millions of individuals across the UK and internationally.

Making our voice heard

- Over 600 online articles
- Running TV and radio campaigns throughout the year
- Over 130 mentions in printed media
- Grown our social media audience

Childhood Cancer Awareness Month

One of the key moments in our year is Childhood Cancer Awareness Month which takes place in September. Symbolised by the colour gold and a gold ribbon, we come together with a number of other cancer charities internationally to help raise the profile of childhood cancer. For Children with Cancer UK this means that gold is splashed across all of our communications and we sold a gold ribbon to our supporters. We reached thousands of people on social media and engaged with hundreds of thousands of our existing supporters during this campaign.

With special thanks to Bella-Rose, Sophia, Harry, Suki, Darren, Christopher and Maisie who all shared their stories during our campaign in 2021. You are all so inspiring and we thank you for sharing your experience so generously with us, our supporters and the general public.

Telling the story of childhood cancer

We are so grateful to all the families affected by a childhood cancer diagnosis who choose to share their story. It's such an important element of how we are able to raise awareness of the realities of being diagnosed and treated for childhood cancer. It also helps us to demonstrate the issues that need addressing and are so generously funded through our supporters.

Thank you to the 8 new families who told their story in 2021 and welcome to the Children with Cancer UK family: Alfie, Finley, Bridenni, Lauren, Chloe, Christopher, Frankie S and Harry E

FUNDRAISING HIGHLIGHTS

Our greatest fundraising achievements in 2021, that have helped more children with cancer ring the end of treatment bell, include:

- We saw 331 participants take on a Rat Race event, raising over £140,000
- 174 supporters took up a non-running challenge in the UK or overseas and raised over £104,000
- We launched our very first Virtual Gold Ribbon Run in September during Childhood Cancer Awareness Month, where people could choose to run, walk or jog 25km, 50km or 100km within the month.
- Steve Lodge organised 80 people to climb Mount Snowdon and raised over £25,000 (Steve also took on the London Marathon for us!)
- Sophy Gurl raised over £11,000 for Children with Cancer UK in March when she did a sponsored head shave to support her niece, Grace, who is currently having cancer treatment

London Marathon Events 2021

The 2021 Virgin Money London Marathon took place on Sunday 3rd October and was our first major event back following the pandemic.

As restrictions continued to change throughout the year, we saw the team numbers increase and decrease leading up to the day of the event but on race day we had a team of just under 900 runners take to the streets and complete 26.2 miles through London, along with almost 36,000 other runners. It was a hugely successful day and we were delighted to be able to be out cheering our team on as they went on to cross the iconic finish line on the Mall.

In 2021 our team raised over £2million from the Virgin Money London Marathon from the in person and virtual Virgin Money London Marathon, which was incredible and higher than expected. 2021 was also the final year of Virgin Money sponsoring the London Marathon. The new sponsor for 2022 is TCS.

Children with Cancer UK Swim Serpentine

2021 was the final year of the partnership with London Marathon Events. The event had been cancelled in 2020 due to the pandemic. The launch of the event came later than expected in June 2021 so time to recruit was restricted. By event day on Saturday 18th September, we had an impressive team of 304 take to the water.

The 2021 Swim Serpentine team raised over £93,000.

The Great North Run

The 2021 Great North Run saw an adjustment to the usual route for 2021 due to the pandemic allowing for more social distancing. This didn't stop our team of over 230 runners taking to the street of Newcastle upon Tyne and completing the 13.1 mile course, getting the opportunity to cross the Tyne Bridge twice!

Our team raised an amazing £77,000 in 2021.

Individual Giving

- Our TV ads reached over 152 million people in 2021, with 59,052 people responding to our text to donate ask. A further 5,961 of these signed up to give a regular gift. The year 1 income from the one-off and regular gifts is expected to be £439k.
- Across our gaming products (Grand Draw and Lottery), we've raised just over £2.3 million with nearly £1.7 million from our Grand Draws.
- £1.6m from gifts in Wills
- Our 'Remembering' in memory tribute site raised £33k.
- £2.8 million brought in from cause regular givers from over 55,000 supporters
- Over £1million raised from cash appeals to our existing supporters.

Acquisition of committed givers

We continued to recruit committed regular givers in 2021 via our TV advertising and other digital campaigns, taking our total number of active cause regular givers at the end of the year to over 50,000. The Christmas TV advert in particular performed exceptionally, and we received nearly double the expected number of responses to the TV adverts (24k compared to forecast of 12k).

Retention, Stewardship, and legacies

Stewardship of our supporters and potential legacies remained a priority in 2021 and our bi-annual newsletter, 'The Chime', saw significant engagement and donations from a soft ask. This provides promising indications of our supporters' ongoing engagement with our work. We will be continuing to look at embedding stewardship within all of our supporter journeys, to ensure they feel valued and continue to give.

Digital campaigns

Optimising digital channels has increased income across the programme in 2021. We've continued to develop and test our microsites, including gaming microsites, 'Remembering' in memory tribute site and our main donation platform. Email marketing also remains an important income stream and messaging aligns with our cash programme to ensure income is maximised. We also continued to recruit new regular givers through digital, including paid social donation & lead gen campaigns.

FUNDRAISING COMPLIANCE

Children with Cancer UK values the privacy of all those who support us in our work; we have systems in place to ensure that supporter data is collected, managed and processed in line with all necessary legislation. We are members of the Fundraising Regulator, which has responsibility for regulating fundraising, sets out the Code of Fundraising Practice and investigates and takes appropriate action on cases of public concern. Children with Cancer UK adheres to the Code of Fundraising Practice set by the Fundraising Regulator and also fully complies with the Fundraising Preference Service. We comply with charity law, fundraising law and the data protection regulations. We monitor our fundraisers, volunteers and any third parties that work for us to ensure that they adhere to our high standards.

We will ask the donor how they want to hear from us about our work and appeals. If the donor wants to stop hearing from us they can, email, phone, write or click on the link in our emails. We will always take action, so they can feel confident in contacting us at any time.

We will keep the donor's personal information secure and will only use it to communicate with the donor; to process orders and donations; to keep the donor informed; for analysis and to improve our activities. We will NOT share the donor's details with other charities or sell it to businesses. Some organisations help us with our fundraising, but will only use the donor's data under our instruction and only when fully compliant with how we process personal data as set out in our Privacy Policy (Reviewed February 2022).

Children with Cancer UK continues to adhere to and review policies relating to GDPR and work alongside an external consultant, Protecture, to ensure that we are fully compliant.

Children with Cancer UK works with some professional fundraising agencies to assist with certain elements of our fundraising, by telephone and SMS channels. We have robust contracts in place with these agencies, specifying that staff carrying out these activities should be trained and adhere to all applicable laws, regulations and codes, such as the Code of Fundraising Practice and the Data Protection Regulations. We also expect these organisations to reflect our values when talking to supporters and to voluntarily subscribe to the Fundraising Regulator.

To ensure the agencies we engage are operating to the required standards and that people should never feel harassed or pressurised to give, we carry out appropriate monitoring which includes: call monitoring, site visits and live call listening and mystery shopping. We attend training sessions of their staff and give training to staff in respect of each fundraising campaign. We require all our staff and the agencies we deal with to comply with our Vulnerable People Policy, which provides guidance on how to identify a potentially vulnerable person and actions to take to considerately disengage from the fundraising process.

Children with Cancer UK require its staff and any agencies contacting our donors and members of the public on our behalf to comply with the Data Protection Law and guidelines provided by the Fundraising Regulator and Institute of Fundraising. Children with Cancer UK take all reasonable care to protect vulnerable adults in accordance with the Institute of Fundraising guidance set out in their document '[Treating Donors Fairly: Responding to the needs of People in Vulnerable Circumstances and Helping Donors make informed Decisions.](#)'

We adhere to the [Fundraising Regulator Promise](#) ensuring that our fundraising is legal, open, honest and respectful. We truly value our supporters, which is why, in 2018, we published our [Supporter Charter](#) as a commitment to our supporters.

Our [Feedback and Complaints policy](#) was reviewed in February 2020 and we will continue to review this regularly. Complaints are investigated thoroughly and corrective action taken as appropriate. During our financial year (Jan – Dec) 2021 we received 125 complaints (source Raiser’s Edge) across all teams which is a significant drop on the previous year (248 complaints, source Raiser’s Edge). Like last year we still have a large number of complaints regarding clothing collections, however we have worked hard with the supplier to change some elements of the collection to make it better for supporters and I believe this is reflected in the drop in complaints.

We continue to closely monitor all of our fundraising activities and will always strive to ensure they are of the highest standard and reflect the wishes and preferences of all our generous supporters. There may be occasions when we have not met these high standards and we will work hard to learn from our mistakes and to make sure they don’t happen again. If our supporters and members of the public are unhappy with any aspect of our work we encourage them to give feedback, and take any comment or complaint seriously. We use this valuable feedback to help shape our future fundraising campaigns and improve our overall service and commitment to our supporters.

We are here to talk and listen to you – we welcome and actively encourage feedback and make it clear how people can get in touch with us.

A member of the Fundraising Regulator, the independent regulator of fundraising in the UK, Children with Cancer UK is committed to best practice in fundraising and follows the Regulators Fundraising Promise and Code of Fundraising Practice laid down by the regulator.

We still have a mixture of both office and home working in **Supporter Care** due to the ongoing restrictions with COVID-19. However we are now hybrid working with the team splitting the week between home and office working. This continues to work well for us and the technology we have installed continues to work well. Looking ahead to the new **Salesforce database** we are already exploring how we can streamline our current processes.

THANK YOU

A massive thank you to all our supporters and fundraisers, who despite the pandemic, helped us raise an incredible £14.8m in such a difficult year.

To our corporate partners:

- Ladbrokes
- Kwik Fit
- Lockton
- Amazon
- Unilever – Zendium
- BGC Partners
- Paperchase
- Ling Designs
- Tesco
- UHY Hacker Young
- Give a Car
- Office Beaver
- Rye Bay Capital

To our dedicated Trustees:

- David Gibbs – Chair
- Virna Midgley
- Phil Hall
- Alex Leitch – Deputy Chair
- Caroline Randerson

All our supporters and volunteers who have helped improve the lives of children with cancer and their families – thank you.

A very special thank you goes to all the extraordinary families who have shared their experiences in 2021. Your involvement is central to our work and your help in raising awareness and vital funds to help young cancer patients is invaluable.

FINANCIAL REVIEW

Incorporating the Directors' Strategic Report and Administrative Report for Companies Act Purposes

Children with Cancer UK

Helping children and young
people with cancer to ring the bell



Registered Charity Number: 298405
Inaugurated by Diana, Princess of Wales
Company limited by guarantee, Number: 4960054

The Trustees of Children with Cancer UK present their Annual Report for the year-ended 31st December 2021 under the Charities Act 2011 and the Companies Act 2006, including the Directors' Report and the Strategic Report under the 2006 Act, together with the audited financial statements for the year.

Financial review

The Consolidated Statement of Financial Activities (SOFA) set out on page 38, shows the financial results for Children with Cancer UK and its trading subsidiary: Helping Children with Cancer Limited.

Our total income has increased this year from £13.7 million to £14.8 million. Although we continue to feel the longer term impact of the COVID-19 pandemic on our fundraising operations, the increase of over £1 million in our income can be attributed to a recovery in our sporting events. The London Marathon has historically been an important fundraising event for us with a large presence of runners raising a significant amount of sponsorship income. The return of this live event during the end of 2021 helped increase the income from our Sporting events from £1.7 million to £2.7 million. We also observed a slight recovery from our Community fundraisers with 20% growth. We plan to build on this growth area for 2022.

Our income from Corporate and philanthropy continued to struggle during 2021 with no growth from 2020 activity. These income streams continued to be impacted with organisations not being able to run face to face fundraising events and the financial disruption faced by our corporate supporters due to COVID-19. We anticipate this to be an important development area during 2022 to create a sustained pipeline for future years.

However, our continued investment in online and mainstream media has, in addition to broadening the awareness of our cause, led to sustainable growth in individual giving and regular giving. Both of these areas have seen growth during the year and provide core income streams with which we can engage with our supporters. This year the number of regular givers we have, through various channels, has reduced slightly from 55,000 to 52,000. This has been as a result of a review and analysis on the acquisition program during 2021.

Our individual giving income stream has achieved income of £5 million this year, which is a similar level as last year. This reflects the tough fundraising environment of our appeals programme, raffles and acquisition campaigns. Last year our legacy income at £2.1 million was the highest in the charity's history. This year we have maintained this level with £2 million income.

The continued impact of the pandemic, and the effect on our income streams and risk profile, has meant that we have carefully considered our cost base and completed various cost saving initiatives. We were therefore able to manage our expenditure down from £15.3 million to £9.9 million.

The COVID-19 pandemic had a significant impact on research in the UK and resulted in delays for many existing research projects. As a result of the COVID-19 pandemic we were limited in our efforts to fund new projects and as a result our total grant awards decreased from £7.4 million to just over £2 million.

We ended the year with a surplus of £5.2 million increasing our total reserves to £14.5 million. The increase in reserves will be used to fund the current years charitable spend.

For every £1 donated, we spend 80p on fighting childhood cancer.

- 30p on research projects
- 29p on welfare projects
- 21p on raising awareness

We reinvest 20p from every £1 raised, to raise even more money.

For every £1 we spend on fundraising, we raise £6 more.

Reserves

At the end of the year, the charity held £14,455,222 (2020: £9,295,761) in total reserves. All funds were held in unrestricted reserves.

The restricted funds raised comprise of donations that were to be spent on specific causes and projects as detailed in Note 19.

Unrestricted reserves are generated when the supporter does not stipulate how the income may be spent. They are therefore available to be applied at the discretion of Trustees to any of the charity's charitable purposes.

The Trustees are aware of their role as custodians of these funds and plan to disburse the funds in a structured and cautious manner to meet the long term objectives of the charity

The Trustees consider the reserves to have a dual role; to provide a buffer to allow operating expenditure to be carefully minimised should the need arise, as well as facilitate the following year's grant award programme. The remainder, is set aside for fluctuations in income that could impact the charity's ability to carry out its services.

Therefore, £7m has been set aside from total reserves to fund the current year's charitable spend of £7m, with a further £1m set aside to invest in to a digital transformation project to help secure existing and future fundraising potential. This leaves approximately £6m as a reserve for operational expenditure.

Although a £6m buffer is a slight increase from the previous financial year this will enable the charity to operate without any income for approximately 5 months. This is below the free reserves target of 6 months but deemed to be acceptable by Trustees in the current climate.

The Trustees intend to review the policy again in 2023 after the full impact of COVID-19 and current identified risks becomes clearer.

STRATEGIC PLANS 2022 AND BEYOND

The charity, set up by The O’Gorman family, has been doing outstanding work for over thirty years leading the way in childhood cancer research and supporting children, young people and their families when they are at their most vulnerable.

The pandemic has had a huge effect on fundraising for all charities, with many major events having been cancelled, but Children with Cancer UK is proud to have continued its commitment to support research projects throughout this difficult period. We have put recovery plans in action and we are delighted that we are facing increased engagement from donors including corporates and individual givers.

Our vision remains a world where every child survives cancer and the team will continue to strive towards that with the following goals:

- Deliver an increased programme of research spend to drive real change in paediatric cancer diagnosis, treatment and understanding
- Develop our understanding of gaps in funding of wellbeing and support services offered to families who have experienced childhood cancer
- Increase the number of donations to ensure that there is continued funding of vital research and wellbeing projects
- Create impactful campaigns to drive awareness in the wider community about the reality of being a child or young person with cancer and highlight the need for mental health support for them and their families
- Revitalise our communications with a rebranding strategy that reinforces our message of support for children and young people with cancer and their families
- Work with local, national, trade and consumer media to amplify the voice of the charity to highlight the incredible projects that our researchers have overseen and to offer insights into future developments
- Enlist more Ambassadors, including business, celebrity, patient and families to highlight the significance of the charity and recruit a new generation of supporters
- Continue to collaborate with like-minded charities, universities and organisations to support their work and to use our combined resources to drive life-changing projects
- Develop a fundraising initiative that becomes a major calendar event for Children with Cancer UK and its supporters
- The continued success of the charity is due to the passion and tenacity of all those involved from donors and fundraisers to volunteers and dedicated team members.

Children with Cancer UK’s funds, thanks to the generosity of our donors, will continue to bring together some of the world’s greatest scientific minds including the next wave of clinician scientists and research leaders. Our support will encourage their long-term career progression through a number of dedicated programmes, all of which will take us ever closer to the charity’s aim of living in a world where every single child and young person survives cancer.

We would like to thank all our supporters for your continued investment. It is loyal supporters that will ensure that together we are able to continue to build on this charity's wonderful legacy, delivering even greater impact, for many years to come.

Going Concern

The Financial Statements are approved during a period of recovery from COVID-19, but also a period of new uncertainties including the current cost of living crisis. The Charity is constantly assessing the short and long term impact on its fundraising activities in the current climate.

Along with the Finance and Operations Committee, The Trustees have reviewed the proposed budgets and cash flow to December 2023 and have scrutinised the reserve position, including cash held in the bank and investments. During this review the Trustees priority was to ensure the Charity is able to endure any decline in income or unexpected increase in costs.

The Reserves policy is reviewed regularly and it is vital to ensure the charity holds sufficient reserves to fund not only its ongoing grant award programme, as well as to ensure the charity can cover its operational commitments. Any risks identified are considered during each review. The Trustees have also drawn upon the experience and lessons learned during the COVID-19 pandemic, where expenditure was only being committed if it can be covered either through our fundraising activities or the reserves.

The Finance and Operations Committee monitor the financial position of the charity on a monthly basis. As well as monitoring the current financial position of the charity, the committee also review the ongoing budget, reporting any variances and ensuring the cash flow and investments are in line with projections. The committee report to the Trustees and highlight anything that needs their attention at the subsequent Trustee meeting.

Each budget that was presented had considered various scenarios, including a drop in income and/or unexpected increased in expenditure. The most likely scenario was presented to the Trustees. These scenarios are closely monitored and constantly reviewed so any scenario can be updated and incorporated in to any reforecast which is performed at least quarterly. This approach enables the charity to respond promptly and effectively to any change of environments.

In their assessment of going concern the Trustees have considered not only the impact on the charity as a result of the COVID-19, but also any new identified risks, including the increase in energy prices and the cost of living crisis. This is an area that will be closely observed, but the current impact to our fundraising is low.

With the return of in person fundraising with events like the London Marathon and the Ball, the Trustees are confident that our fundraising activities can return and in the case of the Ball exceed pre COVID-19 levels in 2023. At the time of writing indications are that it is possible to have a return to pre COVID-19 by the end of 2023. The Trustees will continue to monitor the situation and are aware that if any situation develops that threaten this view then this opinion may change.

The Trustees are confident that there are currently significant cash balances should additional liquidity be required to meet the liabilities as they fall due and Children with Cancer UK have appropriate reserves and could adapt to future funding changes. Appropriate consideration of risks as part of its normal risk management processes and mitigating actions both already taken and available to be taken.

The trustees believe that although there is uncertainty identified the charity remains in a strong position to use its cash deposits to take advantage of any opportunities and they are at a sufficient level to ensure the Charity will continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of the financial statements. Accordingly the Trustees consider it appropriate for the going concern basis to be adopted for these accounts.

Investments

The Memorandum of Association allows the charity to deposit or invest funds in any manner but to invest only after obtaining such advice from a financial expert as the Trustees consider necessary and having regard to the suitability of investments and the need for diversification.

The charity recognises that it must have enough resources to carry out its present and future activities effectively. Therefore, the Trustees have agreed to hold sufficient cash levels, invested mainly in instant access deposits, to meet fluctuating needs.

The charity investment policy is reviewed regularly and states that the longer term funds must produce the best financial return for an acceptable risk. The fund must balance the need to support research grants with the objective for capital growth and inflation protection. The Trustees feel the 2021 performance of the investments met the objectives of the policy and recognise the opportunity to identify higher performing funds for 2022 whilst still within an acceptable risk.

The charity currently holds £10.3m of investments held for the longer term. This comprises £1.9M in an investment portfolio managed by Barclays Investment Managers and £8.3m in cash deposits. The charity also holds £4.6m in short term cash deposits.

The Trustees are keen to ensure that the cash funds are not exposed to any risk since this cash value has already been promised to grant holders. As at 31st December 2021, our grant liabilities are close to £9.1m (2020: £9.9m).

Risk and internal control

The Trustees have overall responsibility for ensuring that the Charity has an appropriate system of controls, financial and otherwise. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reassurance that:

- its assets are safeguarded against unauthorised use or disposition;
- proper records are maintained and financial information used within the Charity or for publication is reliable; and
- the Charity complies with relevant laws and regulations.

As part of the Charity's risk management process the Trustees acknowledge their responsibility for the Charity's system of internal control and reviewing its effectiveness. It is also recognised by the Trustees that such a system is designed to manage rather than eliminate the risk of failure to achieve the Charity's objectives and can only provide reasonable, not absolute, reassurance against material misstatement or loss.

Principal risks and uncertainties

At the start of 2020 the COVID-19 Pandemic was not an identified risk. Plans were immediately put in place and a full review of all the strategic risks that had previously been identified during the year in review was undertaken to incorporate this new risk. There was a high level of Trustee engagement throughout this period. Along with the review of the strategic risks that had a particular focus on COVID-19, a separate COVID-19 risk log was developed. This was regularly updated during 2021 to respond to the changing environment.

As with many organisations in the sector COVID-19 has had an impact on multiple areas of the organisation. Whilst the long term impact of the pandemic is still to be seen, several plans have been implemented to mitigate this risk in the short term with longer term plans being developed. These short term strategies continue and include regular management meetings, continuous review of up to date income figures, engagement with all suppliers to review costs, strict expenditure controls with direct Trustee involvement, evaluation and renegotiation of contracts where appropriate, redeployment of resources where necessary and identification, exploitation and investment of any new fundraising opportunities like digital fundraising.

The Charity continues to be heavily reliant on mainstream fundraising income to fund charitable activity, the major risk being faced is that income falls to a level that compromises the Charity's ability to meaningfully fund future charitable activity – whilst at the same time maintaining reserves at a stable level. This risk continues to be managed by the Charity by diversifying its income streams and investing in new fundraising channels. The Charity is continuing the process of implementing 'strategic imperatives' that will guide its future vision and strategy.

The seven strategic risks that were identified prior to COVID-19 are listed below.

- Fundraising
- Regulatory compliance
- Infrastructure & Operations
- Charitable Impact
- Profile & Brand
- Financial
- Governance

These risks have been reviewed with a renewed focus on the recovery from COVID-19 and new uncertainties including the current cost of living increases. They are assessed in terms of probability and impact with a mitigation strategy put in place if required. This forms part of the charity's annual risk management strategy.

The principal risk for the trading subsidiary is its reliance on short term and ad hoc commercial arrangements to generate income. We are investing in improving our trading income streams to manage this risk.

The strategic risks have been reviewed by the Trustees. Some of the issues discussed include, continued Governance improvements, energy and other cost of living increases, Post COVID long term strategy and organisational structure. These discussion points intersect with all the strategic risks and will continue to be reviewed regularly by both the Trustees and Senior Management.

Structure, governance and management

The financial statements comply with current statutory requirements, the Memorandum and Articles of Association, Statement of Recommended Practice (SORP FRS 102) and current accounting standards (FRS 102).

The Trustees have considered and acknowledge the principles and recommendations set out in the Charity Governance Code. The Senior Leadership Team were tasked of reviewing the Charity's governance against the Charity Governance Code and identifying key areas for development. It was recommended to the Trustees that an independent Governance Review was initiated. The Trustees instigated this review and tasked the Senior Leadership Team to implement all recommendations. Significant progress has been made with over 90% of the recommendations completed and plans in place for the remaining items to be addressed within the next 12 months.

Governing documents

These financial statements are for Children with Cancer UK and its subsidiary Helping Children with Cancer Limited.

Children with Cancer UK is a company limited by guarantee and operates under its Memorandum and Articles of Association dated 11th November 2003 as amended by special or written resolutions, dated 30th November 2004, 22nd December 2006, 12th May 2007, 28th July 2016 and 13th December 2021.

On 14th May 2007 the reporting charity changed its name from CHILDREN with LEUKAEMIA UK to Children with Cancer UK. However, the charity continued to use the working name of CHILDREN with LEUKAEMIA until 11th May 2011.

The charity operates under its Trust Deed (dated 4th January 1988) and Variation of Trust Deed (dated 10th December 2003).

Aims and Objectives

Purposes and Aims

The charity's objects as amended by written resolution of 12th May 2007, and 28th July 2016 are shown below:

- i) To promote the relief of children and young people suffering with leukaemia or any other form of cancer (and allied disorders) and of their families;
- ii) To raise public awareness and knowledge in matters relating to leukaemia or any other form of cancer (and allied disorders) affecting children and young people; and
- iii) To promote research into the causes, alleviation, prevention, treatment and cure of leukaemia or any other form of cancer (and allied disorders) affecting children and young people and to publish the useful results of such research.

Our aims are to determine the causes, find the cure and provide care for children with cancer.

We fund life-saving research into the causes, prevention and treatment of childhood cancer.

We fund innovative welfare projects to provide better care for young cancer patients and their families.

We campaign to raise awareness of childhood cancer to protect more children and to improve the lives of young cancer patients, today and for future generations.

We are a member of the Association of Medical Research Charities.

We are also a member of the National Cancer Research Institute.

Further details of the projects we fund are detailed in note 22.

Public Benefit

The Trustees continue to give due regard to the public benefit provided by the charity in relation to its charitable purpose as set out by the objectives above and have given due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the activities that promote the charitable objects above will be applied to provide public benefit.

Board of Trustees

The governing body of the reporting charity is the Board of Trustees, which has a total of five members (2020: seven). The Trustees of the charity also act as the Directors of the charitable company. The Board meets at least three times a year together with the Chief Executive and other senior management where appropriate.

The Finance and Operations Committee and Marketing and Communications Committee are subcommittees of the Board. The subcommittee meet at least bi-monthly and consists of a combination of Trustees, Staff, External Advisors and Specialised Volunteers (if required). The committee will draw to the attention of the Board any urgent issues that require authorisation, disclosure or action and escalate any urgent issues for immediate attention outside of the Board meeting schedule.

Trustee appointment and induction

There were three new appointments (2020: three) to the Trustee Board in 2021 and an additional two post year end. Six Trustees left the board post year end. These were planned resignations including two trustees from our founding family and in line with our succession plan. The selection of Trustees is made based on vacancies arising, sympathy with the objects of the charity and the additional skills and experience that potential new Trustees are able to afford. Under the Articles of Association, Trustees are appointed by a majority vote of the members (who are all the current Trustees) by ordinary resolution.

Each new Trustee receives the Charity Commission publication 'The Essential Trustee: What you need to know' as well as the most recent published annual report. The Chief Executive offers an induction day to all Trustees which provides full information about the operations of the charity.

Management

The Trustees exercise executive responsibility for the governance of the charity and, through the Chairman, supervise the management of the charity by the Chief Executive and the senior management team. The Chairman and Chief Executive also task the Board with decision-making on strategic management issues as well as overseeing the research grants application process and monitoring the progress of awarded grants.

The senior management carry out the operational running of the charity and the coordinating of fundraising appeals and events.

Remuneration

The salaries of Children with Cancer UK staff are periodically benchmarked against other charities to ensure that salary levels are market competitive and sufficient to attract and retain staff of the appropriate calibre. All staff posts are periodically evaluated to ensure that salary levels are reflective of industry and organisational needs, as well as individual and charity performance. In recruitment of a new post, an assessment is made of the requirements of the role in terms of skills, experience, competency and urgency. The salary is then determined on the basis of this assessment and the current market conditions.

Salary Bands have been set based on external benchmarking, anecdotal data from head-hunters and recruiters, and charity sector salary surveys. The Salary Bands are reviewed at least every two years.

The Charity is compliant with the Hutton Fair Pay Review with the salary of the highest paid employee being no more than four times the median salary of the organisation.

Trading Subsidiary

Helping Children with Cancer Limited (company registration 2807553) is the wholly owned trading subsidiary of Children with Cancer UK. Its principal purpose is to raise funds for the charity and all profits are donated under Gift Aid.

The principal activity of the Company is the licensing of the name and logo of the charity for use in corporate sponsorship, commercial agreements and royalties from contribution to clinical trials.

The trading activities generated profit for the year of £60,072 (2020: £11,638) which will be paid to Children with Cancer UK under the Gift Aid Scheme. It is anticipated that the trading activity within the subsidiary will continue at a similar level during the current year.

The trading subsidiary holds assets of £23,740 (2020: £45,069) and liabilities of £23,640 (2020: £44,969) with funds of £100 as at 31st December 2021.

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

Related parties

The Charity has a related party and conflict of interest policy in place which accompanies the declaration of interests submissions completed by all Trustees and senior management. An internal conflict of interest register is in place which is updated when a conflict of interest has been identified and is reviewed at least annually.

Grant making policy

It is the Trustees' policy to maximise the proportion of its charitable output that is achieved through grant making.

Welfare grants

There is no open application process for welfare grants and no welfare grants are given to individuals. The Trustees determine which organisations are to be supported. In 2021, a total of £1,297,488 (2020: £1,285,296) was awarded to welfare projects.

Research grants

The Trustees aim to award an increasing proportion of the charity's grants to scientific and medical research in child and young person cancer. The charity's Code of Practice adheres to the standards set by the Association of Medical Research Charities (AMRC).

The charity advertises guidelines and invite applications for project grant rounds. Project applications are subject to formal internal and external peer review followed by scrutiny by our scientific advisor panels (SAPs) before the Trustees determine which projects to support. We also occasionally support research through other AMRC members.

In 2021, a total of £812,027 (2020: £6,167,773) was awarded to research projects. Project funding is directed in two areas of concern:

1. Research into treatment and survival
2. Research into prevention and causes

We also fund some 5-year Post-doctoral Fellowships and Clinical PhD Studentships on these topics at leading research Institutions regarding child and young adult cancer.

REFERENCE AND ADMINISTRATION

Children with Cancer UK (previously known as CHILDREN with LEUKAEMIA UK) was set up in memory of Paul O’Gorman who died on 6th February 1987 and his sister Jean, who died on 3rd November 1987. The charity was inaugurated by Diana, Princess of Wales on 12th January 1988 at Mill Hill County High School where Paul had been a pupil.

Trustees

The Trustees of Children with Cancer UK are the charity’s Trustees under charity law and the directors of the charitable company:

Current Trustees

David Gibbs (Chair of Trustees) (Appointed 22nd February 2021)
Alex Leitch (Deputy Chair) (Appointed 4th June 2021)
Caroline Randerson
Phil Hall (Appointed 13th December 2021)
Bruce Morland (Appointed 5th July 2022)
Georgie Wolfenden (Appointed 14th November 2022)

Previous Trustees

Virna Midgley (Resigned 3rd August 2022)
Ann Amaya-Torres (Resigned 12th March 2022)
Eddie O’Gorman OBE (Founder and previous Chair of Trustees) (resigned 12th January 2022)
Sandra Mileham (resigned 12th January 2022)
Linda Robson (resigned 12th January 2022)
Nick Goulden (resigned 18th March 2022)

Chief Executive Officer

Jo Elvin (Appointed 19th April 2022)
David Gibbs (Honorary) (Appointed 1st January 2022) (Resigned 19th April 2022)

Senior Management

Gary Murphy (Chief Operating Officer)
Hannah Chambers (Head of Marketing and Communications)
Emily Roff (Head of Events, Community and Sports) (Maternity Leave)
Kerry Russell (Head of Events, Community and Sports) (Maternity Cover)
Camelia Vasilcan (Head of Database)
Fiona Judge (Head of Supporter Care)
Fadil Dugolli (Head of IT)

Previous members of the Senior Management during the year were

Cliff O’Gorman
Sarah Goddard

Registered Charity Number
298405

Registered Company Number
4960054

Principal office
51 Great Ormond Street, London WC1N 3JQ

Solicitors
Bates Wells, 10 Queen Street Place, London, EC4R 1BE

Auditors
Crowe U.K. LLP, 55 Ludgate Hill, London, EC4M 7JW

Bankers
National Westminster Bank plc, 30 North Audley Street, London W1A 4UQ

Contact details
Children with Cancer UK
51 Great Ormond Street, London WC1N 3JQ
Tel: 020 7404 0808
Email: info@childrenwithcancer.org.uk
www.childrenwithcancer.org.uk

Scientific Advisory Panel

We are indebted to the members of our two Scientific Advisory Panels (SAP) who freely give their time and expertise to help drive forward our fight against childhood cancer. Research into childhood cancer is a broad field and we aim to reflect the diversity of the field amongst the membership of our Treatment and Survivorship and our Causes and Prevention Panels. Some members may sit on both panels.

The Chair of the Treatment SAP is Dr Owen Williams, PhD, Reader in Cancer Biology and Head of Cancer Section, UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust

The Chair of our Causes and Prevention SAP is Professor Geoff Pilkington, PhD CBiol FRSB FRCPATH, Professor of Cellular and Molecular Neuro-Oncology and Head of Brain Tumour Research Centre, University of Portsmouth.

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The Trustees (who are also directors of Children with Cancer UK for the purposes of company law) are responsible for preparing the Strategic Report, the Trustees' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and the group for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company and group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions, disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006 and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Insofar as each of the Trustees of the charitable company at the date of approval of this report is aware there is no relevant audit information (information needed by the charitable company's auditor in connection with preparing the audit report) of which the charitable company's auditor is unaware. Each Trustee has taken all of the steps that he/she should have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the charitable company's auditor is aware of that information.

This Annual Report of the Trustees, prepared under the Charities Act 2011 and the Companies Act 2006, was approved by the Board of Trustees on 27th January 2023 including approving in their capacity as company directors the Strategic Report contained therein, and is signed as authorised on its behalf by:



David Gibbs
Chair of Trustees

Date: 27th January 2023

Independent Auditor's Report to the Trustees of Children with Cancer UK

Opinion

We have audited the financial statements of Children with Cancer UK ('the charitable company') and its subsidiary ('the group')] for the year ended 31 December 2021 which comprise the Group Statement of Financial Activities, the Group and Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the charitable company's affairs as at 31 December 2021 and of the group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustee's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information contained within the annual report. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion based on the work undertaken in the course of our audit

- the information given in the trustees' report, which includes the directors' report and the strategic report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors' report included within the trustees' report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In light of the knowledge and understanding of the charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- the parent company has not kept adequate accounting records; or
- the parent company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 33, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Details of the extent to which the audit was considered capable of detecting irregularities, including fraud and non-compliance with laws and regulations are set out below.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Extent to which the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We identified and assessed the risks of material misstatement of the financial statements from irregularities, whether due to fraud or error, and discussed these between our audit team. We then designed and performed audit procedures responsive to those risks, including obtaining audit evidence sufficient and appropriate to provide a basis for our opinion.

We obtained an understanding of the legal and regulatory frameworks within which the charitable company and group operates, focusing on those laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements. The laws and regulations we considered in this context were:

- Companies Act 2006;
- The Charities SORP (FRS 102) 2019; and
- Taxation Legislation

We assessed the required compliance with these laws and regulations as part of our audit procedures on the related financial statement items.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which might be necessary to the charitable company's and the group's ability to operate or to avoid a material penalty. We also considered the opportunities and incentives that may exist within the charitable company and group for fraud. The laws and regulations we considered in this context for the UK operations were:

- Charity Commission regulations
- General Data Protection Regulation (GDPR)
- Employment legislation

Auditing standards limit the required audit procedures to identify non-compliance with these laws and regulations to enquiry of the Trustees and other management and inspection of regulatory and legal correspondence, if any.

We identified the greatest risk of material impact on the financial statements from irregularities, including fraud, to be within the timing of recognition of income and override of controls by management. Our audit procedures to respond to these risks included enquiries of management, and the Board of Trustees about their own identification and assessment of the risks of irregularities, sample testing on the posting of journals, reviewing regulatory correspondence with the Charity Commission, and reading minutes of meetings of those charged with governance.

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. In addition, as with any audit, there remained a higher risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Andrew Thomas
Senior Statutory Auditor
For and on behalf of
Crowe U.K. LLP
Statutory Auditor
London

Date: 30 January 2023

**Consolidated statement of financial activities for the year ended 31 December 2021
(Incorporating an income and expenditure account)**

	Note	Total restricted funds £	Total unrestricted funds £	Total 2021 £	Total 2020 £
Income from:					
Donations and legacies	4	443,952	14,344,727	14,788,679	13,583,698
Other trading activities	4	-	6,850	6,850	48,994
Income from investments		-	48,672	48,672	129,182
Other income		-	248	248	131
Total Income	19	443,952	14,400,497	14,844,449	13,762,005
Expenditure on:					
Raising funds	6	207,687	1,771,965	1,979,652	2,057,943
Charitable activities	6, 8	-	7,875,497	7,875,497	13,284,229
Total Expenditure	6	207,687	9,647,462	9,855,149	15,342,172
Net change in investments	12	-	170,161	170,161	(25,491)
Net (expenditure)/income		236,265	4,923,196	5,159,461	(1,605,658)
Transfers between funds	19	(236,265)	236,265	-	-
Net movement in funds		-	5,159,461	5,159,461	(1,605,658)
Reconciliation of funds:					
Total funds brought forward		-	9,295,761	9,295,761	10,901,419
Total funds carried forward	19	-	14,455,222	14,455,222	9,295,761

The comparative figures for each fund are shown in note 3 to the financial statements.

Balance sheet as at 31 December 2021


Company Number: 4960054

	Note	2021		2020	
		Group	Charity	Group	Charity
		£	£	£	£
Fixed assets					
Investments	12	10,293,735	10,293,835	10,133,555	10,133,655
		10,293,735	10,293,835	10,133,555	10,133,655
Current assets					
Debtors and prepayments	14	2,336,386	2,342,599	3,110,245	3,149,113
Cash deposits		4,596,702	4,596,702	4,554,746	4,554,746
Cash at bank and in hand		7,074,406	7,064,133	2,069,985	2,027,417
		14,007,494	14,003,434	9,734,976	9,731,276
Creditors: amounts falling due within one year					
Grants	15,16	(3,965,171)	(3,965,171)	(1,982,298)	(1,982,298)
Other	16	(699,942)	(695,982)	(670,401)	(666,801)
Net current assets	18	9,342,381	9,342,281	7,082,277	7,082,177
Total assets less current liabilities		19,636,116	19,636,116	17,215,832	17,215,832
Creditors: amounts falling due after more than one year					
Grants	15	(5,180,894)	(5,180,894)	(7,920,071)	(7,920,071)
Net assets		14,455,222	14,455,222	9,295,761	9,295,761
Represented by:					
Unrestricted funds		14,455,222	14,455,222	9,295,761	9,295,761
Restricted funds		-	-	-	-
	18,19	14,455,222	14,455,222	9,295,761	9,295,761

The net surplus for the financial year dealt within the financial statements of the parent charitable company was £5,159,461 (2020: net deficit £1,605,658).

The notes on pages 41 to 58 form part of the financial statements.

Approved and authorised for issue on behalf of the Trustees on 27th January 2023.



David Gibbs
Trustee



Alex Leitch
Trustee

Consolidated cash flow statement for the year ended 31 December 2021

		2021		2020
		£		£
Cash flows from operating activities:				
Net cash provided by operating activities	a)	5,090,738		(1,190,010)
Cash flows from investing activities:				
Dividends and interest from investments		(48,809)		129,182
Net additions/(disposals) in the year		(5,534)		(4,939)
Net cash provided by investing activities		(54,343)		124,243
Change in cash and cash equivalents in the reporting period		5,036,395		(1,065,767)
Cash and cash equivalents at the beginning of the reporting period	b)	14,979,972		16,045,739
Cash and cash equivalents at the end of the reporting period	b)	20,016,367		14,979,972
Notes to the Cash flow Statement				
a) Reconciliation of net (expenditure) to net cash flow from operating activities				
		2021		2020
		£		£
Net (expenditure)/income for the reporting period		5,159,461		(1,605,658)
Adjustments for:				
Dividends, interest and rents from investments		48,809		(129,321)
Investment Manager Fees		5,534		4,939
Net Change in investments		(170,161)		25,491
Decrease / (increase) in debtors		773,859		1,161,900
(Decrease) / increase in creditors		(726,764)		(647,361)
Net cash provided by (used in) operating activities		5,090,738		(1,190,010)
b) Analysis of cash and cash equivalents				
		1 January	Cashflow	31 December
		2021		2021
		£	£	£
Cash at bank and in hand		2,069,985	5,004,421	7,074,406
Cash held as short term investments		4,554,746	41,956	4,596,702
Cash held as long term investments		8,355,241	(9,980)	8,345,261
		14,979,972	5,036,397	20,016,369

Notes to the financial statements for the year ended 31 December 2021

1. Charity information

Children with Cancer UK is limited by guarantee with no share capital (registered number 4960054), which is incorporated in England and Wales and domiciled in the UK. The address of the registered office is 51 Great Ormond Street, London WC1N 3JQ. It is also a registered charity (registered number 298405) and as such is a non-profit making organisation.

2. Accounting policies

(a) Basis of preparation

The financial statements have been prepared on the historical cost basis of accounting, as modified by the revaluation of investments, and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102), the Companies Act 2006, the Charities SORP (FRS 102) and the accounting policies set out below.

The charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Children with Cancer UK is the ultimate parent company. It has two subsidiaries - Helping Children with Cancer Limited and Children with Cancer Research Limited. Children with Cancer UK owns the whole of the share capital of Helping Children with Cancer Limited, a company registered in England and Wales, number 2807553. It also holds 100% of the share capital of Children with Cancer Research Limited, a company registered in England and Wales, number 09442350 which is currently dormant.

The financial statements of the charity and its active subsidiary company are consolidated, on a line-by-line basis, to produce the Group financial statements. The consolidated entity is referred to as 'the Group'. No separate Statement of Financial Activities has been prepared for the charity as permitted by Section 408 of the Companies Act 2006. The charity has taken advantage of the exemptions in FRS 102 from the requirements to present a charity only Cash Flow Statement and certain disclosures about the charity's financial instruments.

(b) Preparation of the accounts on a going concern basis

In their assessment of going concern the Trustees have considered the impact on the charity as a result of identified risks and the COVID19 virus. Although we saw the return of in person events during the current year this continued to have an impact on certain activities including running events and community based fundraising. The Ball had been cancelled for two years and returned in November 2022 exceeding the income for 2019. These events had previously made up approximately 40% of the charity's income prior to COVID-19.

With the return of in person fundraising with events like the London Marathon and the Ball, the Trustees are confident that our fundraising activities can return and in the case of the Ball exceed pre COVID-19 levels in 2023. At the time of writing indications are that it is

possible to have a return to pre COVID-19 by the end of 2023. The Trustees will continue to monitor the situation and are aware that if any situation develops that threaten this view then this opinion may change.

There are currently significant cash balances should additional liquidity be required through any period of uncertainty to meet the liabilities as they fall due and Children with Cancer UK have appropriate reserves and could adapt to future funding changes by adapting costs.

Accordingly, the Trustees believe the Charity's financial resources are sufficient to ensure the Charity will continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of the financial statements and have therefore prepared the financial statements on the going concern basis.

(c) Financial Instruments

The charity has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at amortised cost. Financial assets held at amortised cost comprise cash at bank and in hand, short term cash deposits together with the group's trade and other debtors excluding prepayments. Financial liabilities held at amortised cost comprise the group's short- and long-term trade and other creditors excluding deferred income and taxation payable. No discounting has been applied to these financial instruments on the basis that the periods over which amounts will be settled are such that any discounting would be immaterial.

Investments, including cash held as part of the investment portfolio are held at fair value at the Balance Sheet date, with gains and losses being recognised within the Statement of Financial Activities. Investments in subsidiary undertakings are held at cost less impairment.

(d) Critical accounting judgements and key sources of estimation uncertainty

In the application of the charity's accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects the current and future periods.

The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described in the accounting policies and are summarised below:

Residuary legacies – The charity recognises residuary legacies once probate has been granted which therefore requires an estimation of the amount receivable.

(e) Functional/Presentational currency

The functional currency of the charity and its subsidiary is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity/group operates. The consolidated financial statements are also presented in pounds sterling.

(f) Fund accounting

Unrestricted funds comprise accumulated surpluses and deficits on general funds and are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund.

(g) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Voluntary income in the form of appeals, committed giving, sports events and community fundraising income is recognised in the period of receipt. Income received in advance of an event or lottery is deferred until the criteria for income recognition are met.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Income arising from corporates and trusts is recognised in the period in which the charity has entitlement to the income.

Income from trading activities is recognised in the period in which the service has been provided or product sold.

Investment income from dividends and interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest received or receivable from the Bank.

Government grants are recognised on the performance model, when the Charitable Company has complied with any conditions attaching to the grant and the grant will be

received. The grant in connection to the job retention scheme has been recognised in the period to which the underlying furloughed staff costs relate to.

(h) Expenditure and basis of allocation of costs

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis and the majority is directly attributable to specific activities. Other indirect costs are apportioned to activities in accordance with staff activity and an assessment of where the resources have been applied. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Grants to third parties are included in the SOFA when approved by the Trustees when a constructive obligation exists, notwithstanding that they may be paid in future accounting periods.

Support costs include governance costs which are costs incurred to manage the charity in compliance with constitutional and statutory requirements and the direct expenditure and overhead costs relating to the appeals and fundraising functions. They also include the allocation of costs incurred to support and co-ordinate fundraising activities. These costs are allocated across the categories of charitable activities and the basis of this cost allocation has been explained in note 7 of the financial statements.

Expenditure on raising funds includes expenditure specifically incurred for fundraising purposes. This constitutes a mixture of directly attributable costs and apportionment.

(i) Tangible fixed assets

Tangible fixed assets costing more than £10,000 are capitalised and included at cost including any incidental costs of acquisition, or, where donated, are included at valuation at the date that ownership is acquired.

(j) Pension scheme

Permanent employees are entitled to join the Grouped Stakeholder Pension Plan provided by Scottish Widows. During 2021, the charity made a contribution of 9% of salary per month to any personal or stakeholder pension scheme selected by all employees serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of pension costs is the contribution payable during the year.

(k) Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

(l) Gifts in Kind

Gifts in kind and donated goods and services are recognised in the accounts when the benefit to the charity is reasonably quantifiable and measurable. The value is the price the charity estimates it would pay should it purchase equivalent goods or services.

The estimated valuation of gifts in kind is based on the value of the contribution to the charity, or the valuation the charity would have had to pay to acquire the goods or services. A corresponding amount is recognised within expenditure in the period of receipt.

(m) Private Medical Insurance

Since October 2017, permanent employees are entitled to join the Group Private Medical Insurance Scheme provided by Bupa. In 2021, the charity paid a premium based on the employee's ages per month to all employees after serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of private medical insurance is the contribution payable during the year.

3. Consolidated statement of financial activities for the year ended 31 December 2020

	Total restricted funds £	Total unrestricted funds £	Total 2020 £
Income from:			
Donations and legacies	274,867	13,308,831	13,583,698
Other trading activities	-	48,994	48,994
Income from investments	-	129,182	129,182
Other income	-	131	131
Total Income	274,867	13,487,138	13,762,005
Expenditure on:			
Raising funds	-	2,057,943	2,057,943
Charitable activities	754,531	12,529,698	13,284,229
Total Expenditure	754,531	14,587,641	15,342,172
Net change in investments	-	(25,491)	(25,491)
Net (expenditure)/income	(479,664)	(1,125,994)	(1,605,658)
Transfers between funds	(47,680)	47,680	-
Net movement in funds	(527,344)	(1,078,313)	(1,605,658)
Reconciliation of funds:			
Total funds brought forward	527,344	10,374,075	10,901,419
Total funds carried forward	-	9,295,761	9,295,761

4. Income

	2021 £	2020 £
Donations and legacies		
Appeals and associated donations (See below)	4,951,894	4,924,928
Committed giving	3,114,654	2,632,190
Community fundraising	1,031,920	1,321,743
Corporate and trust donations	953,555	891,830
Legacies (see contingent asset below)	1,976,328	2,074,903
Sports events	2,760,328	1,738,104
	14,788,679	13,583,698
Other trading activities		
Events	6,850	48,994
	6,850	48,994

Included in Donations and legacies in 2021 is a government grant in the form of the Job Retention Scheme for £60,161 (2020 £29,750).

Contingent asset – legacy income

As at 31 December 2021, the charity had been notified of a further 33 residuary and pecuniary legacies which have not been recognised as income in the Statement of Financial Activities as they do not meet the criteria as detailed in the accounting policies. These legacies have an estimated value of £1,264,383 which has not been accrued.

5. Lottery income

As part of the charity's Gambling Commission License (Non Remote License - 000-004700-N-306402-010) (Remote License – 000-004700-R-308531-010), during the year the charity has operated three lotteries, a weekly lottery and charity scratch card.

The following ticket sales were received for each lottery where the draw was held in 2021:

	Ticket sales £
Weekly Lottery	574,957
Christmas Raffle (draw 15 th January 2021)	561,989
Spring Raffle (draw 4 th June 2021)	419,104
Summer Raffle (draw 3 rd September 2021)	383,457
Total	1,939,507

The Christmas Raffle spans two accounting periods. Although the draw took place during the current accounting period, the closing date was 24th December 2020 and all ticket sales were received in the previous accounting period. All other ticket sales were received during 2021 only. All ticket sales have been included within the total income for 2021 and 2020.

In line with the requirements under Social responsibility code provision 4.3.1 of the License Conditions and Codes of Practice of the Gambling Act 2005 the following section details the percentage of lottery proceeds returned to the purposes of the society (Children with Cancer UK) from the lotteries promoted in 2021.

Lottery type	Lottery Name	Percentage proceeds returned to Charity %
Managed directly by Children With Cancer UK	Weekly Lottery	63%
Managed directly by Children With Cancer UK	Children with Cancer Grand Draw	68%
Total		66%

6. Total expenditure

	Staff Costs £	Direct Costs £	Support and Governance £	2021 Total £	2020 Total £
Expenditure on Raising funds					
Fundraising Costs	443,087	1,274,561	262,004	1,979,652	2,057,943
Expenditure on Charitable activities					
Research into Prevention & Causes	230,745	743,119	99,402	1,073,266	2,751,566
Research into Treatment	224,819	1,513,823	96,800	1,835,442	5,276,839
Welfare	314,193	2,479,418	138,206	2,931,817	2,712,907
Raising Awareness	509,480	1,295,395	230,097	2,034,972	2,542,917
	1,279,237	6,031,755	564,505	7,875,497	13,284,229
	1,722,324	7,306,316	826,509	9,855,149	15,342,172
	=====	=====	=====	=====	=====

	Staff Costs £	Direct Costs £	Support and Governance £	2020 Total £
Expenditure on Raising funds				
Fundraising Costs	718,582	1,006,665	332,696	2,057,943
Expenditure on Charitable activities				
Research into Prevention & Causes	310,332	2,329,940	111,294	2,751,566
Research into Treatment	323,541	4,843,792	109,506	5,276,839
Welfare	394,214	2,162,572	156,121	2,712,907
Raising Awareness	803,778	1,421,488	317,651	2,542,917
	1,831,865	10,757,792	694,572	13,284,229
	2,550,447	11,764,457	1,027,268	15,342,172
	=====	=====	=====	=====

7. Support costs

Support costs are split as follows:

	Office Administration £	Operational Management £	Finance / IT / HR £	Communications and Marketing £	Governance £	2021 Total £
Expenditure on Raising funds						
Fundraising Costs	39,718	58,629	110,385	39,847	13,425	262,004
Expenditure on Charitable activities						
Research into Prevention & Causes	17,461	9,992	48,529	17,518	5,902	99,402
Research into Treatment	17,004	9,731	47,259	17,059	5,747	96,800
Welfare	24,278	13,893	67,472	24,357	8,206	138,206
Raising Awareness	40,419	23,130	112,335	40,551	13,662	230,097
	99,162	56,746	275,595	99,485	33,517	564,505
	138,880	115,375	385,980	139,332	46,942	826,509
	=====	=====	=====	=====	=====	=====

	Office Administration £	Operational Management £	Finance / IT / HR £	Communications and Marketing £	Governance £	2020 Total £
Expenditure on Raising funds						
Fundraising Costs	45,952	89,976	119,230	57,693	19,845	332,696
Expenditure on Charitable activities						
Research into Prevention & Causes	17,139	20,766	44,470	21,518	7,401	111,294
Research into Treatment	16,864	20,432	43,755	21,172	7,283	109,506
Welfare	24,042	29,130	62,382	30,185	10,383	156,122
Raising Awareness	48,918	59,267	126,923	61,416	21,125	317,649
	106,963	129,595	277,530	134,291	46,192	694,571
	152,915	219,571	396,760	191,984	66,037	1,027,267
	=====	=====	=====	=====	=====	=====

Indirect, support and governance costs are allocated on a per person basis to staff in the office. The time spent by each staff member on every activity of the charity is allocated on a month by month basis throughout the year. Support and staff costs are then allocated to the various charitable activities based on this staff time basis.

8. Costs of charitable activities

	Activities undertaken directly £	Grant funding of activities £	Support and governance costs £	2021 Total £	2020 Total £
Research into Prevention & Causes	978,291	(4,427)	99,402	1,073,266	2,751,565
Research into Treatment	925,322	813,320	96,800	1,835,442	5,276,839
Welfare	1,372,123	1,421,488	138,206	2,931,817	2,712,907
Raising Awareness	1,792,940	11,935	230,097	2,034,972	2,542,917
	5,068,676	2,242,316	564,505	7,875,497	13,284,228
	=====	=====	=====	=====	=====

9. Auditor Costs

	Statutory Audit Fee £	Other Financial Services £	2021 Total £
Children with Cancer UK	32,300	13,000	45,300
Helping Children with Cancer Ltd	3,600	-	3,600
	35,900	13,000	48,900
	=====	=====	=====

	Statutory Audit Fee £	2020 Total £
Children with Cancer UK	33,300	33,300
Helping Children with Cancer Ltd	3,600	3,600
	36,900	36,900
	=====	=====

Other Financial Services excludes £2,600 of irrecoverable VAT.

10. Staff costs

	2021 £	2020 £
Salaries and wages	1,410,872	2,136,936
National Insurance	151,437	224,044
Pension	140,623	175,283
Private Medical Insurance	19,392	14,185
	1,722,324	2,550,448
	=====	=====

During 2021, the following employees were paid in the following salary ranges.

Salary Range	2021 £	2020 £
£130,000 - £140,000	0	1
£90,000 - £100,000	1	1
£70,000 - £80,000	0	1
£60,000 - £70,000	1	3

There have been 8 (2020: 7) positions that have formed part of the senior leadership team during 2021. The total remuneration including pension contributions for these employees amounts to £501,460 (2020: £715,587).

During the year there were six (2020: six) redundancy, termination or settlement payments made totalling £25,852 (2020: £51,488)

An employee that is connected to a Trustee was paid £93,750 gross salary and £8,438 pension contributions (2020: nil gross salary and nil pension contributions). There is no interdependence between the Trustee and the connected person.

The average weekly number of contracted employees during the year was as follows:

	2021	2020
	No.	No.
Charitable Activities	5	7
Raising Funds	27	38
Support, Governance, Operations and Administration	8	10
	40	55
	=====	=====

11. Results of the parent charity

	2021 £	2020 £
Total income	14,840,817	13,783,863
Total expenditure	(9,851,516)	(15,364,030)
Unrealised gains / (Losses)	170,161	(25,491)
Net (expenditure) / Income	5,159,462	(1,605,658)
	=====	=====

12. Investments

	2021 £	2020 £
Listed investments (see below)	1,948,338	1,778,177
Cash deposits	8,345,397	8,355,241
	10,293,735	10,133,418
	=====	=====
Market value of listed investments at 1 Jan	1,778,177	1,803,668
Additions to investment portfolio	5,534	10,185
Disposals to investment portfolio	-	(5,246)
Investment manager fees	(5,534)	(4,939)
Net Investment gain/(loss)	170,161	(25,491)
	=====	=====
Market value of listed investments at 31 Dec	1,948,338	1,778,177
	=====	=====
Listed Investments comprise the following:		
Cash and short maturity bonds	-	-
Multi class and other investments	1,948,338	1,778,177
	=====	=====
Total listed investments at 31 Dec	1,948,338	1,778,177
	=====	=====

Total Investments are listed in:		
United Kingdom	510,465	227,607
Overseas	1,437,873	1,550,571
	=====	=====
	1,948,338	1,778,177
	=====	=====

Investment in subsidiary

Children with Cancer UK holds 100% of the share capital of Helping Children with Cancer Limited which is a registered company number 04960054. The value of the share capital owned is £100. Helping Children with Cancer Limited raises funds via commercial activities and sponsorship.

The income and expenditure for the year ended 31 December 2021 is as follows:

	2021 £	2020 £
Income	72,225	23,916
Administrative expenses	(12,153)	(12,278)
	-----	-----
Profit before gift aid and taxation	60,072	11,638
	=====	=====

The balance sheet for the subsidiary as at 31 December 2021 is as follows:

	2021 £	2020 £
Assets	23,740	45,069
Liabilities	(23,640)	(44,969)
	-----	-----
Reserves	100	100
	=====	=====

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

13. Trustees' emoluments

£250 was paid by Children with Cancer UK for Trustee indemnity insurance (2020 Nil).

14. Debtors

	2021 Group £	2021 Charity £	2020 Group £	2020 Charity £
Amounts due from subsidiary undertakings	-	19,680	-	41,369
Other debtors	855,412	855,412	1,290,708	1,290,708
Accrued income	353,564	340,097	330,469	327,969
Prepayments	1,127,410	1,127,410	1,489,068	1,489,068
	-----	-----	-----	-----
	2,336,386	2,342,599	3,110,245	3,149,114
	=====	=====	=====	=====

15. Grants to third parties

	2021 £	2020 £
Outstanding liabilities at the start of the year	9,902,369	10,527,498
Awarded during the year (note 22):		
Research into prevention and causes	-	1,570,272
Research into treatment and survival	812,027	4,597,501
Welfare	1,297,488	1,285,296
Raising awareness	1,376	20,750
Total third party grants before adjustments	2,110,891	7,473,819
Under/over spends and adjustments on previous grant awards	131,425	(487,058)
Total third party grants	2,242,316	6,986,761
Paid during the year	(2,998,620)	(7,611,890)
Outstanding liabilities at the end of the year	9,146,065	9,902,369
	=====	=====
Grants falling due within one year	3,965,171	1,982,298
Grants falling due after more than one year	5,180,894	7,920,071
	9,146,065	9,902,369
	=====	=====

Note

There were 11 grant closures with a net value of less than £100 that occurred during the year. There were a further 17 grant closures with a combined value of £877 that occurred during the year. There were 4 grant adjustments £154,560 relating to corrections made to grants awarded in previous financial years.

16. Creditors: amounts falling due within one year

	2021 Group £	2021 Charity £	2020 Group £	2020 Charity £
Accruals and deferred income	640,172	636,212	613,231	609,631
Taxes and social security	59,770	59,770	57,170	57,170
	699,942	695,982	670,401	666,801
Grants payable	3,965,171	3,965,171	1,982,298	1,982,298
	4,665,113	4,661,153	2,652,699	2,649,099
	=====	=====	=====	=====

17. Deferred income

Deferred income comprises income received in advance for entries to our weekly lottery.

	2021 Group £	2021 Charity £	2020 Group £	2020 Charity £
Balance as at 1 January 2021	52,053	52,053	51,599	51,599
Amount released to income	(52,053)	(52,053)	(51,599)	(51,599)
Amount deferred in year	56,285	56,285	52,053	52,053
Balance as at 31 December 2021	56,285	56,285	52,053	52,053
	=====	=====	=====	=====

18. Analysis of net assets between funds

As at 31 December 2021	2021 Group Restricted funds £	2021 Group Unrestricted funds £	2021 Group Total funds £	2020 Group Total funds £
Fixed assets	-	10,293,735	10,293,735	10,133,555
Net current assets	-	9,342,381	9,342,381	7,082,177
Creditors falling due after more than one year	-	(5,180,894)	(5,180,894)	(7,920,071)
Net assets at the end of the year	-	14,455,222	14,455,222	9,295,661
	=====	=====	=====	=====

As at 31 December 2020	2020 Group Restricted funds £	2020 Group Unrestricted funds £	2020 Group Total funds £	2019 Group Total funds £
Fixed assets	-	10,133,555	10,133,555	11,157,521
Net current assets	-	7,082,276	7,082,177	6,420,538
Creditors falling due after more than one year	-	(7,920,071)	(7,920,071)	(6,676,640)
Net assets at the end of the year	-	9,295,760	9,295,661	10,901,419
	=====	=====	=====	=====

19. Statement of funds

Year ended 31 December 2021	At the start of the year £	Total Income £	Total Expenditure £	Transfers & Investment gains/losses £	At the end of the year £
Restricted funds					
Dr Christina Halsey, University of Glasgow. Discovery of biomarkers and new therapeutic targets for chemotherapy associated neurotoxicity	-	500	-	(500)	-
Clinical PHD Studentship: Markers of Hypothalamic Dysfunction in Children with Hypothalamo-Pituitary-Axis Tumours (HPAT) or Pituitary Maldevelopment	-	64	-	(64)	-
Anthony Chalmers - University of Glasgow - Increasing the susceptibility of neuroblastoma cells to radiotherapy by targeting glycolysis and lipogenesis	-	500	-	(500)	-
Macarena Oporto Espuelas - UCL Great Ormond Street Institute of Child Health - Identification of novel surface antigen targets for CAR T cell strategies in paediatric Acute Myeloid Leukaemia stem cells.	-	3,651	-	(3,651)	-
Professor Steve Clifford – INSTINCT-MB	-	231,550	-	(231,550)	-
Beads of Courage UK, which helps children in all 110 children's cancer wards in the UK visualise and articulate their cancer journey	-	207,687	(207,687)	-	-
Total Restricted funds	-	443,952	(207,68)	(236,265)	-
Unrestricted funds	9,295,761	14,400,497	(9,647,461)	406,425	14,455,222
Total Unrestricted funds	9,295,761	14,400,497	(9,647,461)	406,425	14,455,222
Total funds	9,295,761	14,844,449	(9,855,149)	170,160	14,455,222
	=====	=====	=====	=====	=====

Note

The restricted funds comprise donations that were to be spent on specific causes and projects. All restricted income was either discharged during the year or transferred from restricted back to unrestricted funds. This has occurred when restricted funds were received towards grants that were previously paid out of unrestricted reserves.

Year ended 31 December 2020	At the start of the year £	Total Income £	Total Expenditure £	Transfers & Investment gains/losses £	At the end of the year £
Restricted funds					
BIOMarkers of Ependymomas in Children and Adolescents (BIOMECA) - Integrated Biological study within SIOPEP Ependymoma II trial organised by European Ependymoma Biology Consortium	-	120	-	(120)	
Dr Steven Pollard, University of Edinburgh. Genome editing of human neural stem cells using nuclease-assisted gene targeting: a tool to uncover the function of H3F3A mutations in paediatric glioma	-	1,000	-	(1,000)	
Dr Karin Straathof, UCL Institute of Child Health, Development of GD2-specific Bi-specific T-cell Engagers (BiTEs) for treatment of neuroblastoma	-	5,463	-	(5,463)	
Professor Louis Chesler, Institute for Cancer Research- Individualising Management of Paediatric Cancer Treatment - IMPACT	-	4,488	-	(4,488)	
Harnessing SMAD7 induced transcriptional pathways for novel anti-leukaemia therapies	-	17,350	-	(17,350)	
Dr John Bithell, University of Oxford- Preservation and analysis of pathology records and family histories of children with cancer	-	1,500	-	(1,500)	
Functions of DOT1L and H3K79 methylation in MLL-rearranged leukaemia	-	3,895	-	(3,895)	
Safety enhanced CAR T cell therapy for paediatric AML	-	13,365	-	(13,365)	
John Anderson - UCL Great Ormond Street Institute of Child Health - Pilot to develop CRISPR library screen for enhanced function of G-D-T cells in paediatric solid cancers.	-	14,500	(14,500)	-	
Defne Saatci - UCL Great Ormond Street Institute of Child Health - Investigating Late Effects of Surviving Childhood Cancer	-	5,000	(5,000)	-	
Beads of Courage UK, which helps children in all 110 children's cancer wards in the UK visualise and articulate their cancer journey	-	207,687	(207,687)	-	
CLIC Sargent	-	500	-	(500)	
Children's Leukaemia Trust. Restricted for research into and training for Leukaemia and Lymphoma in children	527,344	-	(527,344)	-	-
Total Restricted funds	527,344	274,868	(754,531)	(47,681)	-
Unrestricted funds	10,374,075	13,478,137	(14,587,641)	22,190	9,295,761
Total Unrestricted funds	10,374,075	13,478,137	(14,587,641)	22,190	9,295,761
Total funds	10,901,419	13,762,005	(15,342,172)	(25,491)	9,295,761

20. Related Party Transactions

There have been no other related party transactions during the year other than those with the trading subsidiary.

A management fee of £5,000 (2020: £5,000) has been charged to the trading subsidiary for use of the charity's trademarks and a further £3,520 (2020: £3,645) for the use of charity staff (calculated on the basis of time charged to subsidiary activity by the employee). As at 31st December 2021, £19,680 (2020: £41,369) owed to the charity from the trading subsidiary.

21. Financial Instruments

The financial statements include the following in respect of items:

	2021 £	2020 £
Financial assets measured at fair value	1,948,338	1,778,177

	2021 £	2020 £
The entity's income, expense, gains and losses in respect of financial instruments are summarised below:		
Total interest income for financial assets held at fair value	(48,672)	129,182

22. Grants to third parties

Grants awarded to third parties during the year	Research into prevention and causes 2021 £	Research into treatment 2021 £	Raising Awareness 2021 £	Welfare 2021 £	Total 2021 £
Birmingham Women's and Children's Hospital Charity - The purchase of a high-throughput sequencing machine (NovaSeq 6000)				1,072,488	1,072,488
INSTINCT-MB: Strategic implementation of novel combination therapeutics for high-risk medulloblastoma		712,027			712,027
Beads of Courage - 2021				225,000	225,000
Bioinformatics support for primary bone cancer plus other childhood cancer studies		100,000			100,000
British Neuro-Oncology Society Annual Meeting 2021			1,200		1,200
International Family Nursing Association Meeting 2021			176		176
Total grants to third parties awarded in the year	-	812,027	1,376	1,297,488	2,110,891
Grant closures and adjustments	(4,428)	1,294	10,559	124,000	131,425
Total grants to third parties	(4,428)	813,321	11,935	1,421,488	2,242,316

Note

There were 11 grant closures with a net value of less than £100 that occurred during the year. There were a further 17 grant closures with a combined value of £877 that occurred during the year. There were 4 grant adjustments of £154,560 relating to corrections made to grants awarded in previous financial years.

Grants awarded to third parties in 2020	Research into prevention and causes 2020 £	Research into treatment 2020 £	Raising Awareness 2020 £	Welfare 2020 £	Total 2020 £
Cancer Research UK–Children with Cancer UK Innovation Awards	1,295,725	1,204,275			2,500,000
Teenage Cancer Trust: Emergency Coronavirus Appeal				1,000,000	1,000,000
Mike Hawkins - University of Birmingham - Establish a comprehensive surveillance system for adverse health outcomes in British survivors of childhood, teenage and young adult cancer		349,982			349,982
Kathy Pritchard-Jones - UCL Great Ormond Street Institute of Child Health - International benchmarking of childhood cancer survival by stage		349,747			349,747
Chris Jones - Institute of Cancer Research - Evolutionary dynamics of MEK inhibitor sensitivity and resistance in diffuse midline glioma		349,393			349,393
Steve Clifford - Newcastle University - SMILE: An International network for Medulloblastoma Survivorship and Late-Effects		348,783			348,783
Sam Behjati - Wellcome Sanger Institute - Developmental states of localised and metastatic osteosarcoma cells – a knowledge bank for novel biomarkers and therapeutic approaches		349,419			349,419
Beads of Courage - 2020				285,296	285,296
Anthony Chalmers - University of Glasgow - Increasing the susceptibility of neuroblastoma cells to radiotherapy by targeting glycolysis and lipogenesis		249,774			249,774
Veronica Kinsler - UCL Great Ormond Street Institute of Child Health - Identification of new therapies for melanoma in congenital melanocytic naevi - a universally fatal paediatric tumour		249,756			249,756
Marc Mansour - UCL Cancer Institute - CCR9 as a novel immunotherapy target in T-cell acute lymphoblastic leukaemia (T-ALL)		249,325			249,325
Macarena Oporto Espuelas - UCL Great Ormond Street Institute of Child Health - Identification of novel surface antigen targets for CAR T cell strategies in paediatric Acute Myeloid Leukaemia stem cells.		220,000			220,000
Defne Saatci - UCL Great Ormond Street Institute of Child Health - Investigating Late Effects of Surviving Childhood Cancer		216,963			216,963
Julie Irving - Newcastle University - Optimising the use of repurposed drugs to improve the treatment of children with ALL		213,259			213,259
Schuz - International Agency for Research on Cancer - Dr Joachim Schüz, CLIC Data Coordinating Center - Extension	95,060				95,060
International Agency for Research on Cancers - IARC Postdoctoral Fellowship	81,933				81,933
Ian Fairlie - NA - Report: The effects of Low Level Ionising Radiation Exposure especially regarding child and young person cancer incidence	78,588				78,588
Chris Jones - Institute of Cancer Research - INSTINCT interim funding	10,000	58,380			68,380
Claire Clarkin - University of Southampton - Developing 3-dimensional multicellular models of osteosarcoma		49,984			49,984
John Anderson - UCL Great Ormond Street Institute of Child Health - Pilot to develop CRISPR library screen for enhanced function of G-D-T cells in paediatric solid cancers.		49,930			49,930
Faith Gibson - University of Surrey - Personalised survivorship care: customising support towards unmet psychosocial needs in young people with cancer (PATH study)		48,202			48,202
Steve Clifford - Newcastle University - INSTINCT interim funding		21,316			21,316
BCRT - Bone Cancer Research Trust			20,000		20,000

Grants awarded to third parties in 2020 - Continued	Research into prevention and causes 2020 £	Research into treatment 2020 £	Raising Awareness 2020 £	Welfare 2020 £	Total 2020 £
John Murphy - University of Westminster - A pilot Investigation of the ZFP36L1 protein as a candidate therapeutic target in osteosarcoma cells		14,013			14,013
International Agency for Research on Cancers - IARC Postdoctoral Fellowship	5,154				5,154
Raoul Reulen - University of Birmingham - Pilot study to investigate self-reported health behaviours in survivors of teenage and young adult cancer		5,000			5,000
M Niklison - Queen Mary University of London - Paul O'Gorman Post-doctoral Research Fellowship - Metabolic analysis of the tumour suppressor protein p73 in medulloblastoma	3,812				3,812
Becci Pearson - British Neuro-Oncology Society - BNOS Sponsorship			750		750
Total grants to third parties awarded in the year	1,570,272	4,597,501	20,750	1,285,296	7,473,819
Underspends on previous grant awards					
Tariq Enver - UCL Cancer Institute - Dissecting the causative and collaborating roles of candidate genetic mutations in the pathogenesis of childhood ALL	(293)				(293)
Dr Steven Pollard, University of Edinburgh. Genome editing of human neural stem cells using nuclease-assisted gene targeting: a tool to uncover the function of H3F3A mutations in paediatric glioma	(455)				(455)
Waseem Qasim - UCL Great Ormond Street Institute of Child Health - T cell receptor gene therapy: Novel strategies for children with cancer using engineered cord blood T cells		(788)			(788)
Professor Chris Jones, Institute of Cancer Research, The role of histone H4K20 methylation in paediatric glioblastoma and DIPG	(2,648)				(2,648)
Dr Marc Tischkowitz, University of Cambridge, Investigating microRNA processing genes in rhabdomyosarcomas and other DICER1-related childhood tumours	(2,661)				(2,661)
Professor Robert Mairs, University of Glasgow. Exploitation of the elevated metabolic activity of cancer cells for combination with targeted radiotherapy of neuroblastoma		(4,997)			(4,997)
Dr Suzanne Turner, University of Cambridge, CRISPR-based genome-wide knockout and overexpression screens to identify acquired resistance mechanisms to ALK inhibition in neuroblastoma		(6,511)			(6,511)
Dr Faith Gibson - Great Ormond Street Hospital - Evaluating HELP: an intervention for parents sharing information about leukaemia with their child.			(13,999)		(13,999)
Katherine Clesham - UCL Great Ormond Street Institute of Child Health - Targeting c-MYB in acute leukaemia through drug repositioning		(18,722)			(18,722)
Immunotherapy with CD19ζ gene-modified EBV-specific CTLs after stem cell transplantation in children with high-risk acute lymphoblastic leukaemia		(22,420)			(22,420)
Dr Elizabeth Calton, The Institute of Cancer Research, Mutational dynamics and their effect on chemoresistance and metastasis in a genetically engineered mouse model of relapsed neuroblastoma		(25,777)			(25,777)
Dr Patrick Hales, Institute of Child Health, University College London. Advanced magnetic resonance imaging techniques for in vivo assessment of tumour heterogeneity, risk factor, and treatment response in paediatric cancer		(115,379)			(115,379)
Professor Pamela Kearns. Programme grant: UK ALL 2011		(272,408)			(272,408)
Total grants to third parties	1,564,215	4,130,499	6,751	1,285,296	6,986,761

Every day 12 children and young people are diagnosed with cancer in the UK.

Of those 12, two will not survive

8 out of 10 young childhood cancer patients can be successfully treated thanks to vital, specialist research we helped fund.

Our aims are to determine the causes, find cures and provide care for children with cancer. We are united by a common goal – to save and improve young lives.



We fund Research



We fund Welfare



We raise Awareness

Children with Cancer UK
Registered Office
51 Great Ormond Street
London
WC1N 3JQ

CHILDREN WITH CANCER UK

England & Wales - Charity number 298405

Accounts

Children with Cancer UK

Trustees' Report and Financial Statements
for the year ended 31 December 2020



Children with Cancer UK in numbers

Research - We're committed to finding cures and kinder treatments for children and young people with cancer

£6M invested into vital, life-saving research

24 new research awards

2 Clinical PhD studentships funded

Supporting families – We help children with cancer and their families through the hardships of a cancer diagnosis

240 families attended our new format virtual events

£1m to Teenage Cancer Trust for the provision of frontline services during the COVID-19 pandemic

£285K towards Beads of Courage UK

Awareness – We shine a spotlight on the impact of cancer on children and young people and their families

827K people have interacted with us on social media

1.1Bn media reach

96 letters issued to parliamentarians as part of Childhood Cancer Awareness Month

16 families told their childhood cancer stories through our channels

CHILDREN WITH CANCER UK

TRUSTEES' ANNUAL REPORT AND CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2020

Olivia, pictured on the front cover, ringing the end of treatment bell

TRUSTEES' ANNUAL REPORT

MESSAGE FROM THE FOUNDER AND CHAIR OF CHILDREN WITH CANCER UK	05 – 06
OUTCOMES IN 2020	07
RESEARCH OUTCOMES IN 2020	08 – 13
SUPPORTING FAMILIES IN 2020	14 – 17
AWARENESS ACTIVITIES IN 2020	18 – 21
FUNDRAISING	22 – 28
THANK YOU	29
FINANCIAL REVIEW	31 – 32
STRATEGIC PLANS	33 – 37
GOING CONCERN, RISKS & GOVERNANCE	38 – 45
REFERENCE AND ADMINISTRATION	46 – 47
STATEMENT OF TRUSTEES' RESPONSIBILITIES	48
INDEPENDENT AUDITORS' REPORT	49 – 52
CONSOLIDATED FINANCIAL STATEMENTS	53 – 55
NOTES TO THE FINANCIAL STATEMENTS	56 – 74

MESSAGE FROM THE FOUNDER AND CHAIR OF CHILDREN WITH CANCER UK

Welcome to our Annual Report and Accounts for 2020.

An unprecedented year due to COVID

I write to you as the country is emerging from further lockdowns. 2020 was an unprecedented year where we have all had to deal in our own ways with the COVID-19 pandemic. I am sure some of our supporters may have suffered personal losses and I would like to extend my heartfelt condolences to you and your families. Family is at the heart of Children with Cancer UK as I set up this charity, having lost two of my children to cancer within nine months of each other in 1987.

Unfortunately COVID-19 has had a huge impact on all aspects of our lives and childhood cancer research has not been exempt from this. In June 2020, the Association of Medical Research Charities (AMRC) projected an average 41% decrease in their medical research spend over the next year, leaving a £310 million shortfall. Their research estimated it would take approximately 4.5 years for charity funded medical research spend to recover to normal levels. Sadly, with childhood cancer survival rates showing little in the way of improvement, this delay in breakthroughs and development of new treatments simply isn't acceptable.

As one of the leading UK funders of childhood and young adult cancers we have been very aware that a drop in our income would be hard felt in the child/young adult cancer research community. In particular, our charity focuses on funding basic and preclinical research, which is necessary to bring new treatments for these rare diseases to the point where they are ready for clinical trials. Despite a drop in income in 2020 I am delighted to tell you that we have managed to avoid cutting any existing or ongoing grants.

In 2020 we funded new research grants, as planned, worth £3.3 million through our Treatment and Survival funding call. These research projects will seek better and more effective treatments for childhood cancer. One of our aims is to reduce the long term side effects that many survivors are left with and we are dedicated to helping improve their quality of life after they have rung the end of treatment bell. We also continue to prioritise those cancers that face the poorest outcomes, with more than £1 million spent on brain tumour research and around £400,000 allocated towards osteosarcoma research in 2020.

We embarked on an important new collaboration with Cancer Research UK as we have co-funded new innovative research projects to transform our understanding of children's and young people's cancers and find new ways to prevent and treat these complex cancers. By committing £2.5 million and Cancer Research UK matching our award to create a £5 million Innovation Award programme we ensured that even during such uncertain times our commitment to fund medical research continues. Joining forces allows us to invest more in this field and to engage and unite a broader network of childhood cancer expertise.

We were also able to provide £1 million to Teenage Cancer Trust in 2020 for the provision of frontline services during the COVID-19 pandemic. Teenage Cancer Trust specialises in nursing and emotional support for vulnerable teenagers and young people to improve their experience, survival and recovery from cancer. During the COVID-19 pandemic young cancer patients have faced a tough time with even more isolation and uncertainty with many health services stretched beyond their limits. Our funding meant that Teenage Cancer Trust could continue to offer their services during this incredibly worrying time.

Unfortunately, it's not all positive news that I will share from 2020 as our fundraising has been hit very hard by COVID-19. We have been faced with a 26% drop in our income and we are realistically expecting that it will take us a number of years to return to pre-pandemic levels of fundraising. This is mainly due to the cancellation of events and opportunities for meeting with our supporters face to face such as the Virgin Money London Marathon, which has always been a highlight in our calendar. Our strategy now is to build on the areas where we can see opportunities for growth by seeking new growth and attracting new calling on our dedicated corporate, Trust and philanthropic supporters.

It's so important for us to continue striving towards a world where no child dies of cancer. Sadly, there are still too many children diagnosed with cancer each year and being subjected to incredibly harsh treatments. Together, we must provide hope through targeted and specialist cancer research.

Although we are still very much in the midst of the pandemic, I am optimistic about the coming years and the future of this charity. I'd like to say a personal thank you to all our loyal supporters who have seen us through the most difficult period in our 33 year history. It means a great deal that you share our vision and thanks to you, we are able to continue funding life-saving research and essential support services for children with cancer and their families.

Eddie O'Gorman OBE
Founder and Chair of Trustees

OUTCOMES IN 2020

How donations have helped children and young people with cancer.

We are pleased to announce that in 2020 we raised £13.7m to fund specialist childhood cancer research and support families.

For every £1 we spend on fundraising, we raised £7 more

For every £1 donated we spend

- 86p on fighting childhood cancer
 - 52p on research projects,
 - 18p on supporting families,
 - 16p on raising awareness,
- 14p on raising more money = £1

We receive no government funding and rely exclusively on the generosity of our supporters

OUR YEAR IN RESEARCH

Research is integral to driving forward our vision of a world where every child survives cancer. Only around 2% of cancer research funding in the UK is spent on research that is fully dedicated to childhood and young adult cancer. Children with Cancer UK plays a major role in funding vital life-saving research solely dedicated to childhood cancer - research that would otherwise go unfunded. We invest in specialist research to gain new insights into the genetic and environmental causes of cancer and improve the diagnosis, treatment and long-term care of children with cancer.

In 2020 we funded 24 new research grants, worth over £3.5 million into childhood, teenage and young adult cancer. These grants focus on projects that aim to discover and develop kinder and more effective treatments and improve the long-term health outcomes for children, teenager and young adults diagnosed with cancer.

Combined with existing active research grants, this means that we are now funding a total of 83 projects, worth over £21 million across the UK and abroad. Our funding is helping more children survive cancer and look forward to longer and healthier lives after their treatment has ended.

The COVID-19 pandemic had a significant impact on research within the UK in 2020 and it continues to be a challenging time for our funded researchers. Many researchers with clinical expertise had to pause their work to return to the NHS frontline where they helped hospitals overwhelmed by coronavirus cases. Meanwhile, some of our other researchers faced long laboratory closures or restricted laboratory access due to social distancing measures. Children with Cancer UK has been able to support our researchers during this time by allowing flexible working patterns and awarding extensions to those projects that were unavoidably delayed. With this support, most research projects were able to continue and make progress.

Cancer Research UK–Children with Cancer UK Innovation Awards

In 2020 Children with Cancer UK joined forces with Cancer Research UK to co-fund five new, innovative research projects to transform our understanding of children's and young people's cancers and find new ways to prevent and treat these complex cancers. Children with Cancer UK contributed £2.5m to the Awards with Cancer Research UK matching this value.

As two of the biggest independent funders of children's and young people's cancer research in the UK, working together allows us to fund more research into these cancers and accelerate our progress to improve survival.

Co-funded by Cancer Research UK and Children with Cancer UK, five teams of scientists who are leaders in their field have been awarded up to £1 million each to delve into the biology of children's and young people's cancers. At the time of writing funding for these projects comes in at £4.3 million in total, equally funded by Children with Cancer UK and Cancer Research UK.

The Cancer Research UK–Children with Cancer UK Innovation Awards will allow researchers to gain a better understanding of cancer in children, which they hope will lead to the development of better and less toxic treatments.

New research awards

In 2020 we funded 16 new research grants worth £3.3 million through our Treatment and Survival funding call. This grant call sought to fund research to address improved treatment for and survival from childhood and young person cancer and to improve the quality of ongoing life.

We continue to prioritise those cancers that face the poorest outcomes, with more than £1 million allocated towards brain tumour research and around £400,000 allocated towards osteosarcoma research in this call. We also awarded two Clinical PhD Studentships, which are designed to build capacity and bridge the gap between research and clinical practice, so new discoveries can reach and benefit patients sooner.

All applications to our research funding calls are rigorously scrutinised by our independent Scientific Advisory Panel and reinforced by expert peer review to the standards set by the Association of Medical Research Charities. This ensures that we only support the highest quality research that will have the greatest impact in terms of patient care.

In addition, Children with Cancer UK teamed with the International Agency for Research on Cancer (IARC), which is part of the World Health Organisation (WHO), to fund research projects under a Postdoctoral Fellowship scheme. These Fellowships are designed to develop and support future leaders in cancer research with an international focus.

Here is an overview of some of the projects we funded in 2020.

Evolutionary dynamics of MEK inhibitor sensitivity and resistance in diffuse midline glioma, Professor Chris Jones, Institute of Cancer Research

Diffuse Midline Gliomas (DMGs) are aggressive childhood brain tumours, which include diffuse intrinsic pontine gliomas (DIPG). There is currently no cure. A class of cancer drugs, called MEK inhibitors, have shown early promise in treating some DMGs but there is a risk that these tumours could develop resistance to these drugs.

MEK inhibitors, are currently being tested in children with low-grade gliomas, raising optimism for a therapeutic strategy that can be readily translated to DMGs. Prof. Chris Jones and his team have developed laboratory models of DMGs using cells taken from patients with these tumours and found that MEK inhibitors may act as effective treatments in some cases. However, MEK inhibitors have been found to have limitations when used to treat other types of cancer. In other tumours, MEK inhibitors can quickly stop working as the cancerous cells develop resistance by a variety of mechanisms. To date, this has not been explored in DMG. Prof. Jones and his team aim to work out the mechanisms by which DMG cells become resistant to MEK inhibitors and come up with new combinations treatments to overcome this.

The study team have unique resources of patient DMG tumour samples from their ongoing BIOMEDE clinical trial in children and young people. They will treat the cells with MEK inhibitors and find out which ones survive the drug, and how they have managed to become resistant to the drug. Prof. Jones and his team will also carry out large-scale drug-treatment experiments where they 'delete' every gene present in the tumour cells one-by-one and find out which combination of drug and gene 'knock-outs' causes the cells to die. From these 'hits' they will develop combined drug treatments to test in the laboratory models, and hopefully overcome the resistance that can develop when using MEK inhibitors alone.

Exploiting a novel immunotherapy target for the treatment of T-cell acute lymphoblastic leukaemia (T-ALL), Dr Marc Mansour, UCL Cancer Institute

T-cell acute lymphoblastic leukaemia (T-ALL) is a type of childhood leukaemia caused by the body overproducing T cells, a type of white blood cell. It is rarer but more aggressive than B-cell acute lymphoblastic leukaemia (B-ALL), does not always respond to chemotherapy and has very few treatment options when the disease relapses.

CAR T-cell therapy is an exciting new type of cancer treatment. It works by instructing healthy T cells from the body's immune system to attack cancer cells that display a particular molecule on their surface. Unfortunately, there isn't a CAR-T cell therapy for T-ALL, which is more difficult to treat this way.

Dr Marc Mansour and his team have identified a protein that appears to be present in high quantities on the surface of T-ALL cells, but not on healthy T-cells. In this project, Dr Mansour and his team will first investigate exactly how much protein is present on different types of T-ALL cells and at different stages of the disease. They will then check that this protein isn't present on any of the cells in important organs in the body, otherwise targeting it could have dangerous side effects. Once this is confirmed they will develop CAR T-cells capable of recognising and targeting the protein and test how effective they are in pre-clinical models.

This project hopes to produce the first CAR T-cells that can safely kill T-ALL cells without also harming healthy cells. If successful, Dr Mansour and his team will next work towards developing a clinical trial for this new treatment in relapsed and hard-to-treat T-ALL.

Investigating the long-term health impacts of surviving childhood cancer, Dr Defne Saatci, University of Oxford

As treatments continue to improve, more children are outliving their cancer into adulthood. Unfortunately, surviving childhood cancer can come with significant long-term health and social complications, which are still poorly understood.

Previous studies have helped to identify several long-term health complications faced by childhood cancer survivors. These studies, however, have not been able to paint a complete picture in our understanding on a range of these complications, including the impact on mental health, fertility, and school performance. This is because these studies either only looked at a small number of children or are missing important details about the patient journey and more recent cancer treatments children receive. This means there is still a significant gap in our understanding of these late effects of childhood cancer. There is a pressing need to understand why these long-term health complications arise and to develop appropriate clinical services and implement policy changes.

Dr Defne Saatci's project aims to better understand these long-term health impacts of childhood cancer by conducting a detailed UK-wide population investigation to overcome the limitations of previous studies. She will be using QResearch Database, the largest national primary care database linked to several other key national databases, including Hospital Episode Statistics and the National Cancer Registry.

By taking advantage of these linked national databases, Dr Saatci and her team aim to build a more comprehensive picture of these long-term health impacts faced by childhood cancer survivors in the UK. Her research is funded under the Children with Cancer UK's Clinical PhD Studentship scheme, which is provided to develop and support future leaders in clinical cancer research.

Cancer Research UK–Children with Cancer UK Innovation Awards – a turbo-boost for research into children’s and young people’s cancer

The five teams being funded through the Innovation Awards will be looking at:

1. Understanding why some children inherit a greater risk of developing cancer

Professor Richard Houlston at The Institute of Cancer Research, London, will lead a team to identify previously unknown inherited gene mutations that increase a child’s chances of getting cancer. This work could determine new ways to monitor children with these mutations, allowing doctors to diagnose cancer sooner and to better tailor each child’s treatment and care.

2. Understanding why chromosome duplication occurs in the cells of children with cancer, and if it can be used when designing new treatments

Professors Christine Harrison, Jonathan Higgins and Steve Clifford at Newcastle University will lead a team investigating a phenomenon where cancer cells of children and young people gain chromosomes, known as aneuploidy. This is found in many types of childhood cancers, and by understanding why this happens, they hope to find new ways to prevent and treat them.

3. Developing a new way to treat a type of acute lymphoblastic leukaemia (ALL) using the immune system

A form of ALL known as Mixed Lineage Leukaemia (MLL) gene rearranged infant ALL (MLLr-iALL) has poor survival. CAR T-cell therapy, which uses modified versions of a patient’s T cells to attack their cancer, is often used to treat leukaemia. But using this potentially life-saving treatment in very young patients is limited. This is because it’s very difficult to obtain T cells from them, as these patients have already gone through intensive chemotherapy and are often immunocompromised. Dr Anindita Roy at the University of Oxford, and Professor Anastasios Karadimitris of Imperial College London, plan to test a new way of treating the disease by adapting this therapy to use a different type of immune cell called invariant natural killer T (iNKT) cells that can be taken ‘off the shelf’. They hope this CAR-iNKT cell therapy will be a more effective way of treating these very young patients.

4. Improving outcomes for children and young people whose ALL relapses after treatment

Survival for children and young people with ALL is high, but the outlook is poor if treatment doesn't work and the cancer comes back. Professor Marc Mansour, Dr David O'Connor, Dr Jack Bartram and Professor Owen Williams of University College London and Great Ormond Street Hospital for Children are investigating the causes behind ALL coming back, which has been historically difficult because relapse is rare. By establishing a nationwide study, the team hope to develop new ways of treating relapsed patients and predicting which patients will respond to each therapy.

5. Identifying new targets to treat rhabdomyosarcoma (RMS), a skeletal muscle cancer, by investigating its foetal origins

The biology of RMS is largely unexplored, but is thought to originate from cells in the foetus that develop incorrectly. Some of these cells persist in children with RMS when usually they wouldn't. Dr Sam Behjati at the Wellcome Sanger Institute, and Dr Karin Straathof at University College London, want to understand why this happens by building a cell 'atlas' – a complete guide to the cells that form RMS. They hope that understanding how RMS develops will help bring to light new targets for treatment.

Bone Cancer Awareness Initiative - A new life-saving collaboration

To mark the start of Sarcoma Awareness Month in July 2020, Children with Cancer UK and the Bone Cancer Research Trust announced their second collaborative project – the Bone Cancer Awareness Initiative. Primary bone cancer is a devastating rare form of cancer, affecting around 560 children, teenagers and adults each year in the UK. For decades patients have reported experiences of late diagnosis and progressed disease by the time a diagnosis has been made. This dramatically reduces survival, increases the need for life-changing surgery and treatment and significantly reduces post-treatment quality of life. Medical professionals, including General Practitioners, receive no dedicated training on the signs and symptoms of the disease, despite 10-year survival rates being little over 50%.

To tackle this problem, The Bone Cancer Awareness Initiative developed free educational resources for medical professionals as part of its 100-day online and postal campaign. The initiative reached out to GP practices, medical students, radiology departments, muscular skeletal physiotherapists, and pharmacies in the UK. It provided them with free medical resources tailored for each discipline, including posters and flashcards that explained the presenting symptoms, radiological features and referral pathways for primary bone cancers and tumours. For the first time, this campaign provided them with the knowledge and tailored tools to identify a potential case of primary bone cancer and provided guidance on how to confirm or rule out a diagnosis. In total over 25,000 information packs were posted to healthcare professionals across the UK. By increasing awareness and understanding we can increase speed of diagnosis, improve outcomes and save lives.

SUPPORTING FAMILIES IN 2020

We funded £1,285,296 towards projects aimed at alleviating some of the burdens a cancer diagnosis places on children with cancer and their families. We also hosted 240 families at 10 events throughout the year, giving them happy memories and a welcome respite from the daily worries cancer brings.

Vital support for frontline services during the COVID-19 pandemic

During 2020 we were able to provide £1 million to Teenage Cancer Trust in 2020 for the provision of frontline services during the COVID-19 pandemic. Children with Cancer UK is proud to have supported Teenage Cancer Trust's crucial frontline services during this particularly challenging time.

Teenage Cancer Trust is the only UK charity specialising in nursing and emotional support for vulnerable teenagers and young people to improve their experience, survival and recovery from cancer. They work with the NHS to provide age-appropriate hospital wards and specialist care services. Teenage Cancer Trust's frontline staff support almost 79% of young people who are newly diagnosed with cancer, and many more as they continue their treatment or need support after their treatment has ended. They also support the young patients' family and friends, to help them cope and to support each other.

During the COVID-19 pandemic, these young patients have been going through the toughest times they may have faced, with even greater uncertainty and isolation than ever before, and healthcare services becoming incredibly stretched. Many patients are particularly at risk from COVID-19 and have been forced to shield, and many found that their treatments and check-ups were delayed or cancelled due to the pandemic.

Teenage Cancer Trust had to quickly adapt to keep young people and themselves safe from the Coronavirus. While COVID-19 cases rapidly increased across the country, hospitals had to alter the way they operate to facilitate the volume of patients. This has meant that some of the hospital wards have had to change the way they support young people with cancer.

Vital funding provided by Children with Cancer UK meant that Teenage Cancer Trust could continue to provide support to young people during this time. These services included providing specialist nurses, Youth Support Coordinators and facilities management. They also included the development and management of online support for patients, including an online community, advice hub and virtual events. Together, these services helped to make sure young people with cancer did not face this crisis alone and continued to receive the best treatment, care and support.

Beading helps healing

In 2020 we continued our partnership with Beads of Courage UK and committed to funding the Beads of Courage Oncology Programme for a further three years.

The programme promotes positive coping strategies by helping children to visualise and articulate their experiences through a process called beading. Different beads are given to children to represent and record each step of their treatment. The hope, support and encouragement given to children with this positive reinforcement tool, whilst going through cancer treatment enables families and children to come to terms with the many treatments and protocols on their journey. Children are able to own, record and then show and tell others the courage they faced during treatment.

In 2020, three new beads were introduced to the programme, expanding the reach and support given to children. These beads represent different types of therapeutic support children receive through their cancer journey:

- **Music therapy:** this bead is given when children attend a music therapy session. Music therapy is an important and therapeutic way to release any frustrations and stresses children may be experiencing.
- **Art therapy:** this bead is given when children attend therapy sessions with (but not exclusive to) play leaders, counsellors, or psychologists. Art is a very tactile way for a child to express the things they have going on in their lives, it is often a good way to express themselves and reach out to adults in a way they can't use words for. Very often children have fears and anxiety surrounding treatment and art therapy will help with that.
- **Pet therapy:** Not all hospitals have pet therapy animals, however during recovery or maintenance treatment many families choose to introduce a pet into the household, to help with a child's recovery, and this bead acknowledges that important event in their treatment.

Amazing days out for families affected by childhood cancer

A snapshot of our much-loved events that allow families to enjoy quality time together and a break from the daily stresses of a childhood cancer diagnosis.

COVID-19 restrictions resulted in us having to cancel all our amazing days out. Not being able to physically meet up didn't stop us from putting on amazing days in for children with cancer and their families. Instead we adapted to the changing environment and hosted the following virtual parties.

Pirate and Fairy Virtual Party

On Wednesday 27 May 2020, we held two virtual parties for children affected by cancer, hosted by Fairy Sparkles and Pirate Pete.

These parties kept children entertained with dancing, magic and games, including a scavenger hunt around the house, allowing the children to forget about lockdown, COVID-19 and cancer for a little while.

Harry Potters Birthday Virtual Party

We celebrated Harry Potter's birthday in July by putting on a virtual party for 50 children impacted by cancer. The party was hosted by Harry Potter and the children were kept entertained with dancing, magic, and they tested their wizarding knowledge in a Harry Potter quiz. The children dressed up for the occasion in their finest Hogwarts gear and submitted their photos for a costume competition.

Harry Potter stars, Bonnie Wright (Ginny Weasley), Evanna Lynch (Luna Lovegood) and Matthew Lewis (Neville Longbottom) all sent special video messages, wishing the children a magical time at Harry's birthday party.

Super Science Virtual Party

In September we hosted an interactive virtual Science Party with Einstein Entertainers. 70 families signed up to join the virtual party lasting 45 minutes, to play party games and get involved in fun scientific experiments. A few of the experiments included bubble cannon, slime making and helicopter making. All of the children received a mini home lab kit in the post which had everything they needed to take part in the experiments and get involved in the fun.

"Gwen really enjoyed the party. She has had a tough weekend after lots of seizures, so it really helped us. Gwen's been talking about how much she loves science and wants to be a scientist ever since" – Mahoney, Gwen's dad

Halloween Craft Virtual Party

In October, we sent out 80 craft kits to families to have their own crafty afternoon during the half term. They created Lanterns, Keyrings and bookmarks with a YouTube link provided by Made by Me Parties.

Christmas Virtual Welfare Activities

We wanted to bring some magic and Christmas cheer into the homes of families affected by childhood cancer. Unfortunately, our usual Christmas parties were unable to go ahead, but we still had lots of festive fun for families to get involved in.

We held a virtual Christmas Craft Party on 13th December and over 90 families received their craft kit in the post beforehand ready for the crafty fun! The children made a beaded snowflake decoration, an LED snowman decoration and they also decorated their own fabric stocking. Our Virtual Christmas Party, held on 21st December, was hosted by Captain Fantastic and saw 65 families get involved with games, dancing and some exciting challenges.

“Seb had a wonderful time at the party. He laughed so much he nearly fell off his chair. It was so interactive and simple to follow. Thank you for all your amazing events and bringing so much joy to our family during these hard times.” Natasha, Seb’s mum.

We temporarily transformed our office into a COVID secure Santa’s workshop and packed and posted 180 gift boxes for families affected by childhood cancer. These gift boxes included sweet treats, baking kits and games to play with the whole family!

Finally, Christmas wouldn’t be complete without Santa. We gave families the opportunity to sign up to receive a personalised video message from Santa, recorded all the way from the North Pole! One of the messages was for Beatrix, age 4, and Santa gave her a special well done for finishing her chemotherapy in November and ringing the end of the treatment bell.

“This is phenomenal. The girls absolutely loved it. Their faces were a picture. So incredibly special given Beatrix has her port removal operation in 4 days and we’re shielding at home in preparation. They loved the special mention with their names in. It got even the 9 year old to still ‘believe’.” Lin-Marie, Beatrix’s mum

RAISING AWARENESS OF CHILDHOOD CANCER DURING THE COVID-19 PANDEMIC

We began 2020 with clear objectives of raising awareness of childhood cancer and building our audience of supporters, but within a few months the world was changing as we entered the COVID-19 crisis. When the country went into national lockdown it was clear that our plans would have to change rapidly. Overnight we had to adapt to digital only communication between all our teams as we would be working from home for the foreseeable future.

It was estimated that our income was at risk due to the cancellation and postponement of our fundraising events. This would place significant limitations on the amount of life-saving research and support we would be able to fund. The charity had to adapt very quickly to maximise our digital donations in lieu of any face-to-face opportunities we had relied on in previous years. The varying degrees of lockdown that we encountered regionally and nationally provided us with an opportunity to engage with more people digitally as most people were spending time at home watching more television and consuming more content online.

We decided it was more important than ever to keep communicating with our target audiences and supporters via digital channels. We needed to keep our supporters up to speed with what we're doing and how we will continue to provide hope to families affected by childhood cancer. We also needed to continue reaching new audiences and building our supporter base for the future.

How our digital channels performed and adapted to COVID-19

We looked at ways of increasing our digital revenue through the website by:

- Creating a new COVID-19 appeal landing page which has had **34,511** page views
- Optimising our content on the site to help maximise donations
- Conducting multiple Conversion Rate Optimisation tests to help understand what it took a user to take a desired action
- Building and implementing an exit pop-up box which is displayed when a user attempts to navigate away from the page, with the purpose of convincing them not to leave and encouraging them to make an action. The exit pop-ups generated **£15,278.48**

We produced content about COVID-19

- We created a landing page giving advice on COVID-19 for families affected by childhood cancer. This page had **1,966 page views + a £50 donation**
- We highlighted how COVID-19 was affecting children with cancer and their families through 7 blogs with over 2.6k page views
- We produced a video of a child with cancer in isolation due to the pandemic, which had around 4.5K views across our platforms

Overall digital performance in 2020

- Social media performance:
- 826,521 people engaged with our content across Facebook, Twitter, Instagram and LinkedIn (up 32.4% on 2019)
- 130,763 people clicked on links in our posts across Facebook, Twitter, Instagram and LinkedIn (up 9.6% on 2019)
- Our total audience across Facebook, Twitter, Instagram and LinkedIn grew to 66,317 people (up 26.1% on 2019)
- 501,961 people visited our website in 2020, which is around the same level as in 2019. However, the total donation revenue increased by 46% reaching £548,433, which means that more people who visited our website, chose to give a donation.

Our website

Midway through 2020, we successfully restructured and launched our new improved website. The restructure helped make navigating through the website a lot easier for people visiting our website.

The restructure allowed us:

- To enhance the onsite user journey
- To help improve brand image with a refreshed design
- To make our key content more accessible to users
- To introduce new landing pages

We also constantly test and optimise our website to give our supporters the best possible experience. It is this work that has contributed to more donations being received through our website in 2020 than in any previous years.

Making our voice heard

- TV advert had a reach of 254 million people
- 1,412 print and online articles (1,882 in 2019)
- Publicity value of £1 million (£2.1m in 2019)
- Reach of 1.1billion (2 billion in 2019)
- 202 broadcast (TV and radio) pieces (14 TV pieces in 2019)

Raising our profile with MPs and key influencers in Westminster

In 2020 we set out to establish a political engagement programme to help to drive childhood cancer up the political agenda, highlight the need for increased research funding and promote the AMRC's ask for a life sciences charity partnership fund. In light of the COVID-19 pandemic, we needed to make decision makers aware that our research funding was under threat and this would result in delays to discoveries and improvements in treatment.

We managed a political engagement programme that helped to drive childhood cancer up the political agenda and with the aim of increasing research funding. We were calling upon Government to see the following action:

- To increase funding for childhood and young adult cancer treatments, to enable increased survival rates and more effective, kinder treatments.
- To recognise the causes of cancer in children and young adults and enact policy change so that no child has to suffer.
- To look at how charity giving and philanthropy can be further encouraged through the tax system.
- To fund a coordinated effort across the UK and internationally that brings together the greatest minds in different areas of expertise in order to improve childhood cancer survival rates and treatments.

As part of our engagement we sent letters to the following MPs who held the following position at the time of writing to them:

- Matt Hancock MP Secretary of State for Health and Social Care
- Baroness Barran Minister for Civil Society
- Members of the Health and Social Care Select Committee
- Members of the Digital Culture Media and Sport Select Committee

This led to meetings with:

- Chair of the Health Select Committee Jeremy Hunt MP
- Neale Hanvey MP who following the call co-ordinated a cross-party letter which accumulated 51 signatories
- Dr James Davies MP
- Paul Bristow MP

Neale Hanvey MP spoke at a Debate in the House of Commons on 24th November 2020 where he called on the Government to provide at least £310 million in funding in the financial year 2021 to a life sciences charity partnership fund, to secure medical research for the next three years, thus preserving research charities' vital and unique contribution to society and to the economy. He proposed that this would be matched by funding from charities to secure the continuity of their research. In his role as Chair of the Health Select Committee, Jeremy Hunt MP sent a letter to the Treasury on behalf of the charity as did Committee Member Dr James Davies MP.

We also issued a letter to 96 parliamentarians ahead of Childhood Cancer Awareness month in September to make them aware of our campaign and policy asks. This led to some engagement on social media from Members of Parliament.

Telling the story of childhood cancer

We are so grateful to all the families affected by a childhood cancer diagnosis who choose to share their story. It's such an important element of how we are able to raise awareness of the realities of being diagnosed and treated for childhood cancer. It also helps us to demonstrate the issues that need addressing and are so generously funded through our supporters.

Thank you to the 16 new families who told their story in 2020 and welcome to the Children with Cancer UK family:

Ethan, Izzy, Alice, Mia, Astrid, Ceylian, Gaspard, Lewis, Emmy, Isla-Mae, Sholto, Jessica, Tattianah, Thomas, Eve and Teddie

FUNDRAISING HIGHLIGHTS

Our greatest fundraising achievements in 2020, that have helped more children with cancer ring the end of treatment bell, include:

- £454k raised in Facebook donations
- £1.4 million raised in 2020 from the Virgin Money London Marathon with over 800 runners taking part in the 2020 Virtual Virgin Money London Marathon
- Our TV ads reached over 254 million people in 2020, with 100,965 people responding to our text to donate ask. A further 11,289 of these signed up to give a regular gift. The year 1 income from the one-off and regular gifts is expected to be £777k.
- Across our gaming products (Grand Draw and Lottery), we've raised nearly £2.5 million with over £1.9 million from our Grand Draws
- £2.1 million from gifts in Wills and our first integrated promotion of our free Wills service
- New 'Remembering' in memory tribute site launched in September and raised nearly £15k.
- £2.6 million brought in from cause regular givers from over 48k supporters
- £1.7 million raised from cash appeals to our existing supporters.
- Ladbrokes Christmas Campaign raised £38k
- £37k raised in 2020 from the Great North Run, with 20 runners taking on the Virtual Great North Run
- £10k was raised by 384 people taking on our 'Together As One' virtual run on the 26th April.
- BGC Charity day raised £70K
- Amazon donated £21K
- 63 people cycled the Virtual My Prudential RideLondon in July and raised over £40k
- 101 people took on the 2.6 challenge in April and raised over £35k
- Mini Superhero Challenge raised over £30k from 249 people taking on a challenge based around the number 12.
- £96k raised through our partnership with Rat Race Events. Including 45 people that completed the Rat Race Born to Run virtual Viking run.
- The Georgia Morris Fund raised £14.5k by hosting their annual fundraising Charity Dinner
- Tizzard Racing Limited raised £18.5k by cycling 226 miles from Lower Zeal to Land's End.
- 856 supporters raised over £680k by taking on their own DIY fundraising challenges including; non-stop DJ set for 8 hours, head shaves, virtual quizzes and walking challenges.
- During CCAM we partnered with Zendium toothpaste, a brand of Unilever, which resulted in £15k in donations from the sale online.

Corporate

COVID-19 had an extreme impact on the corporate partnerships team's ability to fundraise this year as the majority of our partnerships raise funds through employee fundraising. We were still able to leverage the two most productive fundraising months of the year for Children with Cancer UK (Childhood Cancer Awareness Month in September and Christmas in December) to engage our current and new partners in fundraising activations.

Childhood Cancer Awareness Month – Unilver - Zendium

During Childhood Cancer Awareness Month we partnered with Zendium toothpaste, a brand of Unilever, which resulted in £15,000 in donations from online sales of the toothpaste from the Zendium shop, Amazon and views of the YouTube video. The activity also created greater awareness of Children with Cancer UK with 4.5 million impressions of social media posts and increased traffic to our website.

Christmas - Ladbrokes

We received a donation of £38,841 from Ladbrokes post our Christmas fundraising campaign. The funds were generated from employee fundraising which was an amazing achievement considering all of their shops were closed and 90% of employees were on furlough. We worked with the Ladbrokes retail leadership team to launch an engagement activity over Christmas for retail employees to get involved.

Entitled The 12 Days of Christmas, employees were encouraged to get involved with daily challenges and messages of goodwill. Daily challenges included competing for the title of "Best Dressed Christmas Tree", "Best Christmas Pet" and "Best Elf on a Shelf" to name a few by sending in photos to the Retail Communications Team. To kick start the event, the senior retail operations team created a video, The 12 Days of Lockdown, using the familiar 12 Days of Christmas tune but with changed lyrics reflecting everything that had happened in 2020.

Kwik Fit

Children with Cancer UK were selected as Kwik Fit's first ever charity of the year following a vote open to more than 5,000 Kwik Fit employees across the UK. The partnership which ran throughout 2019 ended in June 2020. Thanks to Kwik Fit's hard work and dedication they raised £1.07 million. This donation will be used to purchase a NovaSeq 6000 high-throughput DNA sequencing machine for Birmingham Women's and Children's Hospitals Trust, annual maintenance costs for five years and additional IT storage capacity, and will contribute towards the necessary estate costs.

Committed givers

Economic uncertainty and the shift in time spent at home with the pandemic has seen a significant benefit of recruiting supporters through TV advertisements for us and will remain a priority area. We significantly exceeded targets for TV advertisements due to a combination of new 'locked down' audiences and lower media rates. The 1 year return on investment was the highest we've ever seen. The Christmas adverts in particular performed exceptionally, and we received over double the expected number of responses to the TV adverts (29.8k compared to forecast of 14.9k).

Playing to win and to help more children with cancer

Increase in gaming activity is often a trend in times of economic uncertainty and has been seen across the charity sector. Both our cash and raffle appeals exceeded our year on year targets, with particular growth in raffle appeal income. In 2020, we recruited over 2.6k new weekly lottery players which is nearly 3 times the number recruited in 2019. This is largely due to the success of our lottery TV advert. Before the first lockdown, we also found success in our small-scale testing of face to face lottery recruitment at supermarkets and Poundlands, we hope to build on this in 2021.

Future focus: Stewardship and legacies

COVID-19 saw our legacy event programme cancelled, but throughout the year we continued to look at opportunities to engage supporters giving gifts in their Wills. We ran our first external digital promotion of our Free Wills service that integrated with our Christmas activities. 2020 has seen our highest legacy income of over £2.1 million and this area remains a key opportunity for us to continue to develop and grow.

Stewardship of our supporters and potential legators has remained a priority and our new bi-annual newsletter, 'The Chime', has seen significant engagement. Results have benefitted from the limitations on activity in lockdown and this provides promising indications of our supporters' ongoing engagement with our work.

Digital enhancement of campaigns

2020 saw the launch of three new microsites; for our gaming products, which have significantly improved results for both our Grand Draws and weekly lottery, and our new 'Remembering' in memory tribute site, which is performing well since its launch in September having raised nearly £15k and will continue to grow with greater promotion in 2021.

Virgin Money London Marathon

2020 began well with 1274 runners registered to take part in the Virgin Money London Marathon on 26th April for Children with Cancer UK. Due to COVID-19 the 2020 Virgin Money London Marathon was postponed until October and eventually cancelled with a virtual event taking place instead.

On Sunday 4th October, we had a team of over 800 runners, across the world, including staff members of the charity, taking to their streets locally to complete 26.2 miles within 24 hours. The Virtual Virgin Money London Marathon had a total of 37,966 finishers meaning it was awarded an official Guinness World Records title for the 'Most users to run a remote marathon in 24 hours.

In 2020 we raised over £1.4m from the Virgin Money London Marathon. The runners who were due to take part in the physical 2020 Virgin Money London Marathon have been able to defer their place to the 2021, 2022 or 2023 London Marathon.

The Children with Cancer UK Ball

The Children with Cancer UK Ball is one of the highlights of our event calendar, with expected income of over £700k. 2020 would have marked the 33rd year of The Children with Cancer UK Ball. We should have welcomed over 800 guests for an evening of spectacular entertainment and fundraising at The Grosvenor House Hotel in London. Unfortunately, due to COVID-19 restrictions, the 2020 Ball was cancelled. Due to continued uncertainty, we are not due to welcome this event back until 2022.

Event cancellations

Due to COVID-19 restrictions the majority of our Sports and Special Events were unfortunately cancelled or postponed. This has had a massive impact on the charity and resulted in a 67% decrease in income from 2019 to 2020 across these fundraising streams. We have started to bring back these Sports and Special events tentatively with smaller audiences during 2021, with a plan to build up to our usual event calendar in 2022. A Golf event and Swim Serpentine being held during the summer of 2021 is encouraging evidence that these events can return in 2022.

Mini Superhero Challenge

The Mini Superhero Challenge is a Children with Cancer UK event originally aimed at schools and youth groups to take on a challenge of their choice revolving around the number 12. In light of the COVID-19 pandemic, together with knowing that even during the pandemic 12 children and young people would still continue to be diagnosed with cancer every day in the UK, the Mini Superhero Challenge was adapted to enable individual children to get involved from the comfort of their own homes. By encouraging children to take on a challenge of their choosing (such as Mini Superhero Chores for Change or the Mini Superhero Mile a Day March), the event saw 249 people taking part including Karley Ward's two children, Evie and Tommy, who fundraised in memory of their baby sister Isobelle and raised over £11k by doing the washing at home for 12 days. It is thanks to Evie and Tommy and all of the amazing children who took part that helped raise over £30k and we would like to thank everyone for their wonderful support.

The Georgia Morris Fund

The Georgia Morris Fund was set up in 2017 after Richard Morris lost his daughter Georgia to Neuroblastoma in October 2016. They have been fundraising ever since, choosing to split the funds between Children with Cancer UK and Neuroblastoma UK. They were fortunate enough to be able to host their annual fundraising Charity Dinner a week before the national lockdown was imposed and raised a fantastic £14.5k. Children with Cancer UK would like to wholeheartedly thank them for all their incredible dedication and ongoing support in Georgia's memory.

Tizzard Racing Limited

Tizzard Racing Limited kindly chose to support Children with Cancer UK and Target Ovarian Cancer by fundraising in memory of Kim Gingell, who passed away in May this year from a short battle with cancer. With the support of Freddie, Dave, Joe, Richard, Glen, Kat and Joanna, Tizzard Racing Limited completed a 226 mile cycle ride from Lower Zeals to Lands End. By following national COVID-19 rules and guidance around outdoor events, the team raised £18.5k for Children with Cancer UK. We would like to say a huge thank you to everyone who took part and to Tizzard Racing Limited for their incredible donation and support in memory of Kim.

Finnley's Warrior's

Finnley's Warrior's was set up in 2017 by Finnley's parents, Ali and Donna, after Finnley was diagnosed with a rare and aggressive form of cancer, Anaplastic Large Cell Lymphoma at 16 months old. During the COVID-19 pandemic their fundraising didn't stop and they decided to adapt and take advantage of the situation by holding a summer fundraising event which they wouldn't usually hold. They also set up a virtual event, 'Wrap Our Arms Around the World Challenge'. This saw over 250 people take part in the physical team challenge, together circumnavigating the earth by running, cycling or walking and raising £5.4k. We are so grateful to everyone who took part in this challenge and to Ali, Donna, Finnley (and new arrival Rosie), for their incredible dedication and ongoing support.

FUNDRAISING COMPLIANCE

Children with Cancer UK values the privacy of all those who support us in our work; we have systems in place to ensure that supporter data is collected, managed and processed in line with all necessary legislation. We are members of the Fundraising Regulator, which has responsibility for regulating fundraising, sets out the Code of Fundraising Practice and investigates and takes appropriate action on cases of public concern. Children with Cancer UK adheres to the Code of Fundraising Practice set by the Fundraising Regulator and also fully complies with the Fundraising Preference Service. We comply with charity law, fundraising law and the data protection regulations. We monitor our fundraisers, volunteers and any third parties that work for us to ensure that they adhere to our high standards.

We will ask the donor how they want to hear from us about our work and appeals. If the donor wants to stop hearing from us they can, email, phone, write or click on the link in our emails. We will always take action, so they can feel confident in contacting us at any time.

We will keep the donor's personal information secure and will only use it to communicate with the donor; to process orders and donations; to keep the donor informed; for analysis and to improve our activities. We will NOT share the donor's details with other charities or sell it to businesses. Some organisations help us with our fundraising, but will only use the donor's data under our instruction and only when fully compliant with how we process personal data as set out in our Privacy Policy (updated February 2020).

Children with Cancer UK continues to adhere to and review policies relating to GDPR and work alongside an external consultant, Protecture, to ensure that we are fully compliant.

Children with Cancer UK works with some professional fundraising agencies to assist with certain elements of our fundraising, by telephone and SMS channels. We have robust contracts in place with these agencies, specifying that staff carrying out these activities should be trained and adhere to all applicable laws, regulations and codes, such as the Code of Fundraising Practice and the Data Protection Regulations. We also expect these organisations to reflect our values when talking to supporters and to voluntarily subscribe to the Fundraising Regulator.

To ensure the agencies we engage are operating to the required standards and that people should never feel harassed or pressurised to give, we carry out appropriate monitoring which includes: call monitoring, site visits and live call listening and mystery shopping. We attend training sessions of their staff and give training to staff in respect of each fundraising campaign. We require all our staff and the agencies we deal with to comply with our Vulnerable People Policy, which provides guidance on how to identify a potentially vulnerable person and actions to take to considerately disengage from the fundraising process.

Children with Cancer UK require its staff and any agencies contacting our donors and members of the public on our behalf to comply with the Data Protection Law and guidelines provided by the Fundraising Regulator and Institute of Fundraising. Children with Cancer UK take all reasonable care to protect vulnerable adults in accordance with the Institute of Fundraising guidance set out in their document '[Treating Donors Fairly: Responding to the needs of People in Vulnerable Circumstances and Helping Donors make informed Decisions.](#)'

We adhere to the [Fundraising Regulator Promise](#) ensuring that our fundraising is legal, open, honest and respectful. We truly value our supporters, which is why, in 2018, we published our [Supporter Charter](#) as a commitment to our supporters.

Our [Feedback and Complaints policy](#) was reviewed in February 2020 and we will continue to review this regularly. Complaints are investigated thoroughly and corrective action taken as appropriate. During our financial year (Jan – Dec) 2020 we received 248 complaints across all teams which is an increase on the previous year (162 complaints). The majority of these complaints relate to clothing collections that take place through a third party and this is to be expected for this type of activity.

We continue to closely monitor all of our fundraising activities and will always strive to ensure they are of the highest standard and reflect the wishes and preferences of all our generous supporters. There may be occasions when we have not met these high standards and we will work hard to learn from our mistakes and to make sure they don't happen again. If our supporters and members of the public are unhappy with any aspect of our work we encourage them to give feedback, and take any comment or complaint seriously. We use this valuable feedback to help shape our future fundraising campaigns and improve our overall service and commitment to our supporters.

We are here to talk and listen to you – we welcome and actively encourage feedback and make it clear how people can get in touch with us.

A member of the Fundraising Regulator, the independent regulator of fundraising in the UK, Children with Cancer UK is committed to best practice in fundraising and follows the Regulators Fundraising Promise and Code of Fundraising Practice laid down by the regulator.

COVID-19 has had an impact on the way Supporter Care work. We have been very fortunate that a staff member lives close by and has been able to walk to the office. This has meant that we have not had to set up a redirection on post, as some charities have done, and that all money is batched on site. We have been able to use technology to help us communicate with supporters by phone through our laptops as usual. In future we feel the Supporter Care Team will be able to work from home and from the office which gives the team a better work/life balance.

THANK YOU

A massive thank you to all our supporters and fundraisers, who despite the pandemic, helped us raise an incredible £13.5m in such a difficult year.



To our corporate partners:

- Ladbrokes
- Kwik Fit
- Lockton
- Amazon
- Unilever – Zendium
- BGC Partners
- Paperchase
- Ling Designs
- Tesco
- UHY Hacker Young
- Give a Car
- Office Beaver
- Rye Bay Capital

To everyone who continued to support Children with Cancer UK's fundraising efforts:

- The Children with Cancer UK Ball Committee
- The Opera at Syon Committee
- London Marathon Events
- The 2.6 Challenge
- Richmond Runfest
- Action Challenge
- Rat Race Events
- The Great Run Series
- Mike Levitz
- Team Torri
- Finnley's Warriors
- The Sammy Jo Brandon Foundation
- Anglers Against Cancer
- Colin Tizzard Racing

To our dedicated Trustees:

- Eddie O'Gorman - Chair
- Sandra Mileham
- Linda Robson
- Virna Midgley
- Alex Leitch
- Caroline Randerson
- Ann Amaya-Torres
- Dr Nick Goulden
- David Gibbs – Deputy Chair

All our supporters and volunteers have helped improved the lives of children with cancer and their families – thank you.

A very special thank you goes to all the extraordinary families who have shared their experiences in 2020. Your involvement is central to our work and your help in raising awareness and vital funds to help young cancer patients is invaluable.

FINANCIAL REVIEW

Incorporating the Directors' Strategic Report and Administrative Report for
Companies Act Purposes



The Trustees of Children with Cancer UK present their Annual Report for the year-ended 31st December 2020 under the Charities Act 2011 and the Companies Act 2006, including the Directors' Report and the Strategic Report under the 2006 Act, together with the audited financial statements for the year.

Financial review

The Consolidated Statement of Financial Activities (SOFA) set out on page 51, shows the financial results for Children with Cancer UK and its trading subsidiary: Helping Children with Cancer Limited.

Our total income has fallen this year from £17.3 million to £13.7 million. The fall of almost £4 million is due to the impact of the COVID-19 pandemic on our fundraising operations. The London Marathon has historically been an important fundraising event for us with a large presence of runners raising a significant amount of sponsorship income. The absence of the event during 2020 and the early part of 2021 has meant that income has fallen from £3.1 million to £1.4 million. The only income realised for the 2020 London Marathon has been sponsorship received in advance and from the virtual event. We have also observed a drop in income from corporate and philanthropy by £1.2 million, community fundraising by £0.5 million and events income by £0.8 million. These income streams were impacted due to the infeasibility of being able to run face to face events and the disruption faced by our corporate supporters.

However, our continued investment in online and mainstream media has, in addition to broadening the awareness of our cause, led to sustainable growth in individual giving and regular giving. Both of these areas have seen growth during the year and provide core income streams with which we can engage with our supporters. This year the number of regular givers we have, through various channels, has grown from 42,000 to 55,000. This has been as a result of acquisition expenditure incurred in the current and previous years.

Our individual giving income stream has achieved income of £7.5 million this year, an increase of £1.5 million. This reflects the success of our appeals programme, raffles and acquisition campaigns during the year. Our legacy income has also risen during the year by £0.7 million to £2.1 million.

The uncertainty of the pandemic, and the impact on our income streams and risk profile, has meant that we have carefully considered our cost base and completed various cost saving initiatives, including restructuring of our staffing. In addition, we were able to save some costs due to the cancellation of events and the closure of the office. Due to the nature of the London Marathon, where places are bought in advance of the race, we were able to roll forward these costs to allocate against future races. We were therefore able to manage our expenditure down from £16.8 million to £15.3 million. This is despite increasing our level of grant awards from £4.2 million to £7.4 million – with £2.5 million being contributed to the co-funded Cancer Research UK-Children with Cancer UK Innovation Awards and £1 million being awarded to Teenage Cancer Trust for Emergency Coronavirus Appeal.

During these challenging circumstances, we ended the year with a deficit of £1.6 million that has decreased our total reserves to £9.3 million. We have been able to manage our costs down in response to the impact on our income streams and economic uncertainty. Despite the decrease in our reserve position, they are still at a level that gives us stability during these uncertain times.

For every £1 donated, we spend 84p on fighting childhood cancer.

- 52p on research projects
- 18p on welfare projects
- 16p on raising awareness

We reinvest 14p from every £1 raised, to raise even more money.

For every £1 we spend on fundraising, we raise £7 more.

Reserves

At the end of the year, the charity held £9,295,761 (2019: £10,901,419) in total reserves. All funds were held in unrestricted reserves with none in restricted reserves (2019: £527,344).

The restricted funds comprise of donations that were to be spent on specific causes and projects as detailed in Note 19.

Unrestricted reserves are generated when the supporter does not stipulate how the income may be spent. They are therefore available to be applied at the discretion of Trustees to any of the charity's charitable purposes.

The Trustees are aware of their role as custodians of these funds and plan to disburse the funds in a structured and cautious manner to meet the long term objectives of the charity

The Trustees consider the reserves to have a dual role; to provide a buffer to allow operating expenditure to be carefully minimised should the need arise, as well as facilitate the following year's grant award programme. The remainder, is set aside for fluctuations in income that could impact the charity's ability to carry out its services.

Therefore, £4M has been set aside from total reserves to fund the current year's grant award programme of £4M, leaving approximately £5.3M as a reserve for operational expenditure. Heading in to 2021 with reduced activity and operational expenditure planned due to COVID-19, this buffer is a reduction from the previous financial year. £5.3M will enable the charity to operate without any income for approximately 8 months. This has exceeded the target of 6 months, but due to continued COVID-19 uncertainty, this was felt by the Trustees to be a prudent approach.

As a result of the changing environment due to COVID-19 the reserves were reviewed towards the end of 2021. The Trustees aim to review the policy again in 2022 after the full impact of COVID-19 becomes clearer and to ensure that the charity can continue to meet both its short and long term obligations.

STRATEGIC PLANS 2020 AND BEYOND

In 2019, we reviewed our fundraising strategy and revisited our strategic vision and mission(s) to ensure they remained true to our charitable aims and objectives.

Our vision is: A world where every child survives cancer.

To achieve this vision, we will continue with our primary mission which is to fund scientific research to:

1. better understand the causes of childhood cancer.
2. find kinder and safer treatments and ultimately to find cures for all forms of childhood cancer.

Alongside this funding we also look to support initiatives which help promote earlier diagnosis from healthcare professionals so that childhood cancer can be caught earlier, which in turn will support better outcomes for the child.

Our secondary mission is to support children and their families during and after their cancer treatment by supporting welfare projects often provided by other specialist charities. Examples include the grant to Teenage Cancer Trust for the provision of frontline services during the COVID-19 pandemic, the Beads of Courage UK oncology programme and grant to the Little Brains Trust.

Collaboration

COVID-19 has laid bare the challenges that charities are facing on a daily basis. For progress to be made in the area of childhood and young adult cancers, charities, Governments and researchers need to come together to improve survival rates and outcomes for patients and families.

We need to work together with other cancer charities in order to resolve the difficult challenges that we are facing and seek collaborations to fulfil our mission. We were founding members of the Children and Young People with Cancer Coalition and continue to play an active part. We are keen to continue developing this collaboration of cancer charities, across the UK, to ensure that we are all working efficiently and effectively towards the same aim.

We have a strong track record of providing funding to other charities which understand the support needed by children and young people who are going through cancer treatment. We have historically funded charities that provide this support on the front line including CLIC Sargent, Ronald McDonald Charities and Teenage Cancer Trust.

Looking ahead we have embarked on an important new collaboration with Cancer Research UK as we have co-funded five new, innovative research projects to transform our understanding of children's and young people's cancers and find new ways to prevent and treat these complex cancers. Joining forces allows us to invest more in this field and to engage and unite a broader network of childhood cancer expertise.

Governance

As a long established charity, we are always keen to make improvements and ensure we are following best practice. In January 2021 the Board of Trustees instructed an external review of our Governance. Two new Trustees joined the board in 2021 and we expect there to be continued changes to the Board of Trustees over the next couple of years. The Trustees want to ensure that there are the correct processes in place around governance and oversight of the organisation to operate effectively as we enter into a period of transition.

Due to investments made in 2019 we were able to implement our new grant database, which is now helping us to administrate and manage all our financial grants better. Crucially, it will help us track the impact of our grants in future years. The investment will continue with the creation and implementation of our Scientific Strategy, which has had its launch delayed until 2022. This strategy will create a clear path to demonstrate how we will support research in the future for all our supporters and fundraisers.

We have undertaken a comprehensive review of our Welfare program. This important area of our spending has always focused on delivering the best outcome/support for families that are affected by childhood cancer. We have recently implemented new Terms and Conditions for all Welfare grant applications and grants to ensure that we are able to administer support where it is most needed that will deliver the greatest impact for young cancer patients and their families.

Consolidation

Due to the COVID-19 pandemic, 2020 was a very difficult time for the charity as it resulted in an annual reduction in income of 30%. Unfortunately, with plans for growth of the charity in early 2020 further staff were employed, but it was apparent towards the end of the year that the situation across the country and for the economy was unlikely to change in the immediate future. It was identified by the Trustees that the ongoing staff costs would be unsustainable based on our new income. In December 2020 we took the very difficult decision to undertake a consolidation of expenditure, which included utilisation of the furlough scheme and a redundancy process. We would like to thank all members of the team who were affected for their professionalism and the dedication demonstrated throughout this difficult time.

People

The priority for 2021 and onwards will be to focus on building the morale of our existing staff, ensure that all training needs are met and to create a highly motivated team. We are committed to remaining an excellent place of work that values and prioritises staff wellbeing. A number of staff initiatives including introducing a Wellness Hub, weekly virtual catch ups and wellness hours have been implemented for 2021. Additional initiatives along with an assessment of our working practices are part of our ongoing plans. COVID-19 has altered our approach to working in many ways and we will work with staff to ensure that we support them to work to the best of their ability.

Attracting new supporters

To ensure the long term financial security of the charity we intend to continue our efforts to attract new supporters. Since 2018, when we embarked upon a large rebranding project and invested into a new TV advert we have attracted a new demographic of supporter, typically younger families. We will continue our work to attract new supporters, primarily with a renewed focus on digital platforms such as Facebook, Instagram and other social media platforms alongside investment into our website. This strategy has become ever more important since the COVID-19 pandemic as we search for more ways to ensure financial stability whilst in-person fundraising will inevitably continue to take a back seat. We also recognise there are unexplored opportunities in corporate, philanthropic and trust fundraising, so we will invest resource into these areas over the coming years.

Fundraising

The ongoing impact COVID-19 has had on our income, has resulted in a 30% decrease in our income from 2019 to the 2020 financial year. We need to ensure that now, more than ever, we continue to work hard to maximise the impact of existing and new fundraising opportunities across the sector.

Individual Giving includes a range of multi-channel appeals and ways to support our vital work including playing our Grand Draw or Weekly Lottery, donating a one-off gift, signing up for a regular gift or leaving a gift in your Will. It continues to be our core area of our fundraising with over 69% of our 2020 income coming from this area. The pandemic presented a new opportunity to bring on board new 'locked down' audience through our TV adverts, as well as more time to engage and seek support from our existing supporters. Our focus on both regular giving and gaming (Grand Draw and Weekly Lottery) contributed to our 10% increase in income from 2019 to 2020. For 2021 and 2022, we will continue to look at ways to continue to grow our acquisition channels and revisit activity that was postponed with the pandemic. Our priority remains to take a supporter-centric approach and look at opportunities to build long-term relationships with our charity that could lead to gifts in Wills; another vital and growing source of income for our charity. Ensuring we offer a wide range of easy ways to support our work and taking a test-and-learn approach to our programme will remain a priority.

Sports events has always been a key area of fundraising, with the Virgin Money London Marathon raising over £3m in 2018 and 2019. Due to COVID-19, we saw the majority of our sports events cancelled or postponed in 2020. The result of this was an income decrease of 62% from sports events compared with the 2019 financial year. Looking forward we plan to get to pre pandemic income from sports events (£4.549m) by the end of the 2023 financial year. We will do this by focusing on our supporter experience, reviewing and diversifying our sports events offering, and ensuring that we remain flexible and agile to the changing sports events sector.

COVID-19 saw the cancelation of our event portfolio and a decrease in the number of community fundraising activities, which resulted in a 52% decrease of income from Community and Events fundraising in 2020 compared with the 2019 financial year. We plan to get to pre pandemic income from Community and Events (£2.641m) by the end of the 2023 financial year. To achieve this we will focus on delivering excellent supporter experience, review and develop our portfolio of events and campaigns, revive The Children with Cancer UK Ball from 2022, develop boards of highly motivated and well networked supporters, engage more patient families to support the cause, and make sure we are proactive and adapt to the changing fundraising environment.

A key growth and relatively untapped area of fundraising that we plan to explore includes corporate, philanthropy and trusts. We want to create a robust income stream for the charity with a healthy future pipeline. To do this we have actively recruited Trustees with knowledge, contacts and expertise to help lead these fundraising areas. We will aim to raise £2.5m by 2023 by actively pursuing £25k plus partnerships, multi-year partnerships, creating cultivation plans, and exploring and utilising all networks across the organisation.

We will ensure our fundraising is as cost efficient as possible ensuring we produce the net income which will allow us to fulfil our charitable objectives. Operational efficiency will also be key and we will continue to utilise systems and tools which allow us to spend much more time with our donors than on internal administration and processing.

We continue to demonstrate our ability to operate remotely with all staff fully functioning from home, allowing us to rethink our space requirements in the future with undoubted operational savings.

Marketing and Communications

The COVID-19 pandemic has taught us to be adaptable and to approach our communications strategy with flexibility. It has certainly made it harder to raise awareness on some platforms because we have been fighting for space amongst all of the COVID-19 content, for example in the media. However, this year has also presented us with new opportunities to exploit and we have managed to achieve a great deal in 2020 against all odds.

There was a very quick shift in focus toward our digital communications and fundraising programmes. Digital communications were the only way for much of 2020 to reach new audiences and connect with our existing supporters. We focused on providing quality and compelling content for our social media channels and on our website to really engage people with the issues of childhood cancer. We found that more people were watching and commenting on our videos and stories, particularly on social media. We also shifted our resource into ensuring our website was as optimised as possible for accepting donations to ensure that it was a well-functioning income stream for the charity.

As the year progressed, and the projected cut in income was being fully understood, we also needed to consolidate our expenditure. This has resulted in number of roles not being replaced within the marketing and communications team. This means that our output will reduce by around half for 2021 and how we will adapt will be reflected in our strategy moving forwards.

For 2021 the strategy remains the same that we are focusing on raising awareness of cancer in children and young people and supporting our fundraising teams to generate income for the charity. We will be doing this in a couple of key areas – through engaging with the media and through digital communications channels.

It is important to increase awareness of Children with Cancer UK by raising our profile within the media and securing coverage of our work. We will continue to develop the in-house press office function and our reputation by providing an exceptional service to the media. We will also work to respond to issue affecting children and families with cancer in the media by reacting through key spokespeople to further our brand presence.

Our focus on digital continues including undertaking some research to understand our existing audiences better and how they interact with us. We aim to put our supporters at the heart of how we communicate.

The COVID-19 pandemic has meant that there is increased need for digital to deliver fundraising and marketing goals, which means we will continue to test out different optimization tests to ensure we are gaining as many donations as possible. We continue to increase our investments into digital marketing in 2021 compared to the previous year.

Operations

Our staff have been working from home now for over a year, which has meant we have adapted our processes and systems to ensure that this can continue efficiently and effectively. We will work with staff to assess our working practices longer term. It will also include a review of our systems, which was delayed from 2020 due to the added pressures of COVID-19 on the charity. This review will specifically look at the IT systems along with the Fundraising and Finance databases to ensure they complement the fundraising and communications strategy. This review will ensure the charity maximises its fundraising potential and is able to adapt effectively to the changing operational landscape.

Going Concern

The accounts are approved during a period where there is continued uncertainty as a result of COVID-19. The Charity is constantly assessing the short and long term impact on its fundraising activities in the current climate.

The charity has presented multiple budgets for the current year which takes into account the uncertainty of plans to return to business as usual. These budgets consider various best and worst case scenarios with many outcomes. By closely monitoring the likelihood of each scenario in real time the Trustees are able respond promptly and effectively.

In their assessment of going concern the Trustees have considered the current and ongoing impact on the charity as a result of the COVID-19 virus. This continues to have a significant impact on certain activities in the current financial year including the Ball, running events and community based fundraising, which made up approximately 40% of the charity's income prior to COVID-19. With the return of certain events like the London Marathon in October 2021, the Trustees are optimistic that the return to pre COVID-19 fundraising levels will be possible. The Ball for 2021 was cancelled with an anticipated return date in 2022. At the time of writing indications are that it is possible to have a return to pre COVID-19 by the end of 2022. The success of the recent London Marathon event in October 2021 is an encouraging sign. The Trustees are aware that if the situation worsens and becomes prolonged then this view may change.

The Trustees have considered scenarios including a worsening of the current recovery with events being cancelled and virtual events being prevalent. There are currently significant cash balances should additional liquidity be required through this period of uncertainty to meet the liabilities as they fall due and Children with Cancer UK have appropriate reserves and could adapt to future funding changes by adapting costs.

The ultimate impact of COVID-19 on the charity is yet to be seen. Our cash deposits could easily be drawn down should working capital be required. Appropriate consideration of risks as part of its normal risk management processes and mitigating actions both already taken and available to be taken.

The trustees believe that although there is uncertainty regarding COVID-19 the charity remains in a strong position to use its cash deposits to take advantage of any opportunities and they are at a sufficient level to ensure the Charity will continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of the financial statements. Accordingly the Trustees consider it appropriate for the going concern basis to be adopted for these accounts.

Investments

The Memorandum of Association allows the charity to deposit or invest funds in any manner but to invest only after obtaining such advice from a financial expert as the Trustees consider necessary and having regard to the suitability of investments and the need for diversification.

The charity recognises that it must have enough resources to carry out its present and future activities effectively. Therefore, the Trustees have agreed to hold sufficient cash levels, invested mainly in instant access deposits, to meet fluctuating needs.

The charity investment policy is reviewed regularly and states that the longer term funds must produce the best financial return for an acceptable risk. The fund must balance the need to support research grants with the objective for capital growth and inflation protection. The Trustees feel the 2020 performance of the investments met the objectives of the policy and recognise the opportunity to identify higher performing funds for 2021 whilst still within an acceptable risk.

The charity currently holds £10.1M of investments held for the longer term. This comprises £1.8M in an investment portfolio managed by Barclays Investment Managers and £8.3 in cash deposits. The charity also holds £4.6M in short term cash deposits.

The Trustees are keen to ensure that the cash funds are not exposed to any risk since this cash value has already been promised to grant holders. As at 31st December 2020, our grant liabilities are close to £10.3M (2019: £10.6M).

Risk and internal control

The Trustees have overall responsibility for ensuring that the Charity has an appropriate system of controls, financial and otherwise. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities and to provide reassurance that:

- its assets are safeguarded against unauthorised use or disposition;
- proper records are maintained and financial information used within the Charity or for publication is reliable; and
- the Charity complies with relevant laws and regulations.

As part of the Charity's risk management process the Trustees acknowledge their responsibility for the Charity's system of internal control and reviewing its effectiveness. It is also recognised by the Trustees that such a system is designed to manage rather than eliminate the risk of failure to achieve the Charity's objectives and can only provide reasonable, not absolute, reassurance against material misstatement or loss.

Principal risks and uncertainties

At the start of 2020 the COVID-19 Pandemic was not an identified risk. Plans were immediately put in place and a full review of all the strategic risks that had previously been identified during the year in review was undertaken to incorporate this new risk. There was a high level of Trustee engagement throughout this period. The Chair of Trustees was in regular contact with the CEO during this time with updates to the Board. Frequent discussions of key issues amongst the Board also occurred during this time. One Trustee regularly attended the weekly update meetings attended by all staff. Each team has been assigned a Trustee that they can engage with to assist Trustee oversight.

Along with the review of the strategic risks that had a particular focus on COVID-19, a separate COVID-19 risk log was developed. This has been regularly updated to respond to the changing environment.

The pandemic has had an impact on multiple areas of the organisation. Whilst the long term impact of the pandemic is still to be seen, several plans have been implemented to mitigate this risk in the short term with longer term plans being developed. These short term strategies continue and include regular management meetings, continuous review of up to date income figures, engagement with all suppliers to review costs, evaluation and renegotiation of contracts where appropriate, redeployment of resources where necessary and identification, exploitation and investment of any new fundraising opportunities like digital fundraising.

The Charity continues to be heavily reliant on mainstream fundraising income to fund charitable activity, the major risk being faced is that income falls to a level that compromises the Charity's ability to meaningfully fund future charitable activity – whilst at the same time maintaining reserves at a stable level. This risk continues to be managed by the Charity by diversifying its income streams and investing in new fundraising channels. The Charity is continuing the process of implementing 'strategic imperatives' that will guide its future vision and strategy.

The seven strategic risks that were identified prior to COVID-19 are listed below.

- Fundraising
- Regulatory compliance
- Infrastructure & Operations
- Charitable Impact
- Profile & Brand
- Financial
- Governance

These risks have been reviewed with a new focus of COVID-19 and assessed in terms of probability and impact with a mitigation strategy put in place if required. This forms part of the charity's annual risk management strategy.

The principal risk for the trading subsidiary is its reliance on short term and ad hoc commercial arrangements to generate income. We are investing in improving our trading income streams to manage this risk.

The strategic risks have been reviewed by the Trustees. Some of the issues discussed include, Governance Review, Strategy Income position, succession planning and organisational structure. These discussion points intersect with all the strategic risks and will continue to be reviewed regularly by both the Trustees and Senior Management.

Structure, governance and management

The financial statements comply with current statutory requirements, the Memorandum and Articles of Association, Statement of Recommended Practice (SORP FRS 102) and current accounting standards (FRS 102).

The Trustees have considered and acknowledge the principles and recommendations set out in the Charity Governance Code. The Senior Leadership Team were tasked of reviewing the Charity's governance against the Charity Governance Code and identifying key areas for development. It was recommended to the Trustees that an independent Governance Review was initiated. The Trustees instigated this review and tasked the Senior Leadership Team to implement all recommendations. Significant progress has been made with nearly 50% of the recommendations completed and plans in place for the remaining items to be addressed within the next 12 months.

Governing documents

These financial statements are for Children with Cancer UK and its subsidiary Helping Children with Cancer Limited.

Children with Cancer UK is a company limited by guarantee and operates under its Memorandum and Articles of Association dated 11th November 2003 as amended by special or written resolutions, dated 30th November 2004, 22nd December 2006, 12th May 2007 and 28th July 2016. On 14th May 2007 the reporting charity changed its name from CHILDREN with LEUKAEMIA UK to Children with Cancer UK. However, the charity continued to use the working name of CHILDREN with LEUKAEMIA until 11th May 2011.

The charity operates under its Trust Deed (dated 4th January 1988) and Variation of Trust Deed (dated 10th December 2003).

Aims and Objectives

Purposes and Aims

The charity's objects as amended by written resolution of 12th May 2007, and 28th July 2016 are shown below:

- i) To promote the relief of children and young people suffering with leukaemia or any other form of cancer (and allied disorders) and of their families;
- ii) To raise public awareness and knowledge in matters relating to leukaemia or any other form of cancer (and allied disorders) affecting children and young people; and
- iii) To promote research into the causes, alleviation, prevention, treatment and cure of leukaemia or any other form of cancer (and allied disorders) affecting children and young people and to publish the useful results of such research.

Our aims are to determine the causes, find the cure and provide care for children with cancer.

We fund life-saving research into the causes, prevention and treatment of childhood cancer.

We fund innovative welfare projects to provide better care for young cancer patients and their families.

We campaign to raise awareness of childhood cancer to protect more children and to improve the lives of young cancer patients, today and for future generations.

We are a member of the Association of Medical Research Charities.

We are also a member of the National Cancer Research Institute.

Further details of the projects we fund are detailed in note 22.

Public Benefit

The Trustees continue to give due regard to the public benefit provided by the charity in relation to its charitable purpose as set out by the objectives above and have given due consideration to the relevant guidance issued by the Charity Commission. The Trustees will continue to ensure that the activities that promote the charitable objects above will be applied to provide public benefit.

Board of Trustees

The governing body of the reporting charity is the Board of Trustees, which has a total of seven members (2019: six). The Trustees of the charity also act as the Directors of the charitable company. The Board meets at least three times a year together with the Chief Executive and other senior management where appropriate.

Trustee appointment and induction

There were three new appointments (2019: two) to the Trustee Board in 2020 and an additional two post year end. One Trustee left the board on 22nd September 2020. The selection of Trustees is made based on vacancies arising, sympathy with the objects of the charity and the additional skills and experience that potential new Trustees are able to afford. Under the Articles of Association, Trustees are appointed by a majority vote of the members (who are all the current Trustees) by ordinary resolution.

Each new Trustee receives the Charity Commission publication 'The Essential Trustee: What you need to know' as well as the most recent published annual report. The Chief Executive offers an induction day to all Trustees which provides full information about the operations of the charity.

Management

The Trustees exercise executive responsibility for the governance of the charity and, through the Chairman, supervise the management of the charity by the Chief Executive and the senior management team. The Chairman and Chief Executive also task the Board with decision-making on strategic management issues as well as overseeing the research grants application process and monitoring the progress of awarded grants.

The senior management carry out the operational running of the charity and the coordinating of fundraising appeals and events.

Remuneration

The salaries of Children with Cancer UK staff are periodically benchmarked against other charities to ensure that salary levels are market competitive and sufficient to attract and retain staff of the appropriate calibre. All staff posts are periodically evaluated to ensure that salary levels are reflective of industry and organisational needs, as well as individual and charity performance. In recruitment of a new post, an assessment is made of the requirements of the role in terms of skills, experience, competency and urgency. The salary is then determined on the basis of this assessment and the current market conditions.

Salary Bands and grading of job roles was introduced in 2018. Salary Bands have been set based on external benchmarking, anecdotal data from head-hunters and recruiters, and charity sector salary surveys. The Salary Bands will be revised as required and at least once every two years.

The Charity is compliant with the Hutton Fair Pay Review with the salary of the highest paid employee being no more than four times the median salary of the organisation.

Trading Subsidiary

Helping Children with Cancer Limited (company registration 2807553) is the wholly owned trading subsidiary of Children with Cancer UK. Its principal purpose is to raise funds for the charity and all profits are donated under Gift Aid.

The principal activity of the Company is the licensing of the name and logo of the charity for use in corporate sponsorship and commercial agreements.

The trading activities generated profit for the year of £11,638 (2019: £18,625) which will be paid to Children with Cancer UK under the Gift Aid Scheme. It is anticipated that the trading activity within the subsidiary will continue at a similar level during the current year.

The trading subsidiary holds assets of £45,069 (2019: £44,706) and liabilities of £44,969 (2019: £44,606) with funds of £100 as at 31st December 2020.

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

Related parties

The Charity has a related party and conflict of interest policy in place which accompanies the declaration of interests submissions completed by all Trustees and senior management. An internal conflict of interest register is in place which is updated when a conflict of interest has been identified and is reviewed at least annually.

Grant making policy

It is the Trustees' policy to maximise the proportion of its charitable output that is achieved through grant making.

Welfare grants

There is no open application process for welfare grants and no welfare grants are given to individuals. The Trustees determine which organisations are to be supported. In 2020, a total of £1,285,296 (2019: £918,000) was awarded to welfare projects.

Research grants

The Trustees aim to award an increasing proportion of the charity's grants to scientific and medical research in child and young person cancer. The charity's Code of Practice adheres to the standards set by the Association of Medical Research Charities (AMRC).

The charity advertises guidelines and invite applications for project grant rounds. Project applications are subject to formal internal and external peer review followed by scrutiny by our scientific advisor panels (SAPs) before the Trustees determine which projects to support. We also occasionally support research through other AMRC members.

In 2020, a total of £6,167,773 (2019: £3,353,277) was awarded to research projects. This figure includes £2.5m awarded as part of the equally co-funded Cancer Research UK–Children with Cancer UK Innovation Awards. Project funding is directed in two areas of concern:

1. Research into treatment and survival
2. Research into prevention and causes

We also fund some 5-year Post-doctoral Fellowships and Clinical PhD Studentships on these topics at leading research Institutions regarding child and young adult cancer.

REFERENCE AND ADMINISTRATION

Children with Cancer UK (previously known as CHILDREN with LEUKAEMIA UK) was set up in memory of Paul O’Gorman who died on 6th February 1987 and his sister Jean, who died on 3rd November 1987. The charity was inaugurated by Diana, Princess of Wales on 12th January 1988 at Mill Hill County High School where Paul had been a pupil.

Trustees

The Trustees of Children with Cancer UK are the charity’s Trustees under charity law and the directors of the charitable company:

Eddie O’Gorman OBE (Founder and Chair of Trustees)
Sandra Mileham
Linda Robson
Virna Midgley
Caroline Randerson (Appointed 8th September 2020)
Ann Amaya-Torres (Appointed 8th September 2020)
Alasdair Philips (Left Board 22nd September 2020)
Nick Goulden (Appointed 12th December 2020)
David Gibbs (Appointed 22nd February 2021)
Alex Leitch (Appointed 12th May 2021)

Chief Executive Officer

Cliff O’Gorman (Appointed 6th October 2020)

Senior Management

Gary Murphy (Head of Finance)
Hannah Chambers (Head of Marketing and Communications)
Emily Roff (Head of Events, Community and Sports)
Camelia Vasilcan (Head of Database)
Fiona Judge (Head of Supporter Care)
Fadil Dugolli (Head of IT)

Previous members of the Senior Management during the year were

Mark Brider
Sophie Wiles
Zahra Scott-Gunnlaugsson
Caroline Lane
Samia Choudhri

Registered Charity Number
298405

Registered Company Number
4960054

Principal office
51 Great Ormond Street, London WC1N 3JQ

Solicitors
Bates Wells, 10 Queen Street Place, London, EC4R 1BEB

Auditors
Crowe U.K. LLP, 55 Ludgate Hill, London, EC4M 7JW.

Bankers
National Westminster Bank plc, 30 North Audley Street, London W1A 4UQ

Contact details
Children with Cancer UK
51 Great Ormond Street, London WC1N 3JQ
Tel: 020 7404 0808
Email: info@childrenwithcancer.org.uk
www.childrenwithcancer.org.uk

Scientific Advisory Panel

We are indebted to the members of our two Scientific Advisory Panels (SAP) who freely give their time and expertise to help drive forward our fight against childhood cancer. Research into childhood cancer is a broad field and we aim to reflect the diversity of the field amongst the membership of our Treatment and Survivorship and our Causes and Prevention Panels. Some members may sit on both panels.

The Chair of the Treatment SAP is Dr Owen Williams, PhD, Reader in Cancer Biology and Head of Cancer Section, UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital for Children NHS Trust

The Chair of our Causes and Prevention SAP is Professor Geoff Pilkington, PhD CBiol FRSB FRCPATH, Professor of Cellular and Molecular Neuro-Oncology and Head of Brain Tumour Research Centre, University of Portsmouth.

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The Trustees (who are also directors of Children with Cancer UK for the purposes of company law) are responsible for preparing the Strategic Report, the Trustees' Report and the financial statements in accordance with applicable law and regulations.


Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable company and the group for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgments and estimates that are reasonable and prudent;
- state whether applicable UK accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company and group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions, disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006 and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Insofar as each of the Trustees of the charitable company at the date of approval of this report is aware there is no relevant audit information (information needed by the charitable company's auditor in connection with preparing the audit report) of which the charitable company's auditor is unaware. Each Trustee has taken all of the steps that he/she should have taken as a Trustee in order to make himself/herself aware of any relevant audit information and to establish that the charitable company's auditor is aware of that information.

This Annual Report of the Trustees, prepared under the Charities Act 2011 and the Companies Act 2006, was approved by the Board of Trustees on 10th October 2021 including approving in their capacity as company directors the Strategic Report contained therein, and is signed as authorised on its behalf by:



Eddie O'Gorman OBE
Founder and Chair of Trustees

Date: 22nd November 2021

Independent Auditor's Report to the Trustees of Children with Cancer UK

Opinion

We have audited the financial statements of Children with Cancer UK ('the charitable company') [and its subsidiary ('the group')] for the year ended 31 December 2020 which comprise the Group Statement of Financial Activities, the Group and Company Balance Sheets, the Group Cash Flow Statement and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and the charitable company's affairs as at 31 December 2020 and of the group's income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustee's use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's or the group's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information contained within the annual report. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion based on the work undertaken in the course of our audit

- the information given in the trustees' report, which includes the directors' report and the strategic report prepared for the purposes of company law, for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and the directors' report included within the trustees' report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In light of the knowledge and understanding of the group and charitable company and their environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate and proper accounting records have not been; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 47, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Details of the extent to which the audit was considered capable of detecting irregularities, including fraud and non-compliance with laws and regulations are set out below.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Extent to which the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We identified and assessed the risks of material misstatement of the financial statements from irregularities, whether due to fraud or error, and discussed these between our audit team. We then designed and performed audit procedures responsive to those risks, including obtaining audit evidence sufficient and appropriate to provide a basis for our opinion.

We obtained an understanding of the legal and regulatory frameworks within which the charitable company and group operates, focusing on those laws and regulations that have a direct effect on the determination of material amounts and disclosures in the financial statements. The laws and regulations we considered in this context were the Companies Act 2006, taxation legislation, together with the Charities SORP (FRS 102). We assessed the required compliance with these laws and regulations as part of our audit procedures on the related financial statement items.

In addition, we considered provisions of other laws and regulations that do not have a direct effect on the financial statements but compliance with which might be fundamental to the charitable company's and the group's ability to operate or to avoid a material penalty. We also considered the opportunities and incentives that may exist within the charitable company and the group for fraud. The laws and regulations we considered in this context were Data Protection Regulation (GDPR) and employment legislation.

Auditing standards limit the required audit procedures to identify non-compliance with these laws and regulations to enquiry of the Trustees and other management and inspection of regulatory and legal correspondence, if any.

We identified the greatest risk of material impact on the financial statements from irregularities, including fraud, to be within the timing of recognition of income and the override of controls by management. Our audit procedures to respond to these risks included enquiries of management and the Board of Trustees about their own identification and assessment of the risks of irregularities, sample testing on the posting of journals, reviewing accounting estimates for biases, reviewing regulatory correspondence with the Charity Commission, and reading minutes of meetings of those charged with governance.

Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements, even though we have properly planned and performed our audit in accordance with auditing standards. For example, the further removed non-compliance with laws and regulations (irregularities) is from the events and transactions reflected in the financial statements, the less likely the inherently limited procedures required by auditing standards would identify it. In addition, as with any audit, there remained a higher risk of non-detection of irregularities, as these may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. We are not responsible for preventing non-compliance and cannot be expected to detect non-compliance with all laws and regulations.

Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Andrew Thomas
Senior Statutory Auditor
For and on behalf of
Crowe U.K. LLP
Statutory Auditor
London

Date:

**Consolidated statement of financial activities for the year ended 31 December 2020
(Incorporating an income and expenditure account)**

	Note	Total restricted funds	Total unrestricted funds	Total 2020	Total 2019
		£	£	£	£
Income from:					
Donations and legacies	4	274,867	13,308,831	13,583,698	16,378,190
Other trading activities	4	-	48,994	48,994	828,225
Income from investments		-	129,182	129,182	82,636
Other income		-	131	131	41,375
Total Income	19	274,867	13,487,138	13,762,005	17,330,426
Expenditure on:					
Raising funds	6	-	2,057,943	2,057,943	3,956,547
Charitable activities	6, 8	754,531	12,529,698	13,284,229	12,860,400
Total Expenditure	6,16	754,531	14,587,641	15,342,172	16,816,947
Net change in investments	12	-	(25,491)	(25,491)	216,320
Net (expenditure)/income		(479,664)	(1,125,994)	(1,605,658)	729,798
Transfers between funds	19	(47,681)	47,681	-	-
Net movement in funds		(527,344)	(1,078,313)	(1,605,658)	729,797
Reconciliation of funds:					
Total funds brought forward		527,344	10,374,075	10,901,419	10,171,622
Total funds carried forward	19	-	9,295,762	9,295,761	10,901,419

The comparative figures for each fund are shown in note 3 to the financial statements.

Balance sheet as at 31 December 2020


Company Number: 4960054

	Note	2020		2019	
		Group	Charity	Group	Charity
		£	£	£	£
Fixed assets					
Investments	12	10,133,555	10,133,655	11,157,521	11,157,621
		10,133,555	10,133,655	11,157,521	11,157,621
Current assets					
Debtors and prepayments	14	3,110,245	3,149,113	4,272,145	4,299,474
Cash deposits		4,554,746	4,554,746	4,445,032	4,445,032
Cash at bank and in hand		2,069,985	2,027,417	2,246,853	2,215,824
		9,734,976	9,731,276	10,964,030	10,960,330
Creditors: amounts falling due within one year					
Grants	15,16	(1,982,298)	(1,982,298)	(3,850,858)	(3,850,858)
Other	16	(670,401)	(666,801)	(692,634)	(689,034)
Net current assets	18	7,082,277	7,082,177	6,420,538	6,420,438
Total assets less current liabilities		17,215,831	17,215,831	17,578,059	17,578,059
Creditors: amounts falling due after more than one year					
Grants	15	(7,920,071)	(7,920,071)	(6,676,640)	(6,676,640)
Net assets		9,295,760	9,295,760	10,901,419	10,901,419
Represented by:					
Unrestricted funds		9,295,761	9,295,761	10,374,075	10,374,075
Restricted funds		-	-	527,344	527,344
	18,19	9,295,761	9,295,761	10,901,419	10,901,419

The net deficit for the financial year dealt within the financial statements of the parent charitable company was £1,605,658 (2019: net surplus £767,274).

The notes on pages 54 to 72 form part of the financial statements.

Approved and authorised for issue on behalf of the Trustees on 22nd November 2021.



Eddie O'Gorman OBE
Trustee



Sandra Mileham
Trustee

Consolidated cash flow statement for the year ended 31 December 2020

		2020		2019
		£		£
Cash flows from operating activities:				
Net cash provided by operating activities	a)	(1,190,010)		(1,316,750)
Cash flows from investing activities:				
Dividends and interest from investments		129,182		82,636
Net additions/(disposals) in the year		(4,939)		(1,678)
Net cash provided by investing activities		124,243		80,958
Change in cash and cash equivalents in the reporting period		(1,065,767)		(1,235,792)
Cash and cash equivalents at the beginning of the reporting period	b)	16,045,739		17,281,531
Cash and cash equivalents at the end of the reporting period	b)	14,979,972		16,045,738
Notes to the Cash flow Statement				
a) Reconciliation of net (expenditure) to net cash flow from operating activities				
		2020		2019
		£		£
Net (expenditure)/income for the reporting period		(1,605,658)		729,797
Adjustments for:				
Dividends, interest and rents from investments		(129,321)		(82,636)
Investment Manager Fees		4,939		5,141
Net Change in investments		25,491		(216,320)
Decrease / (increase) in debtors		1,161,900		(836,206)
(Decrease) / increase in creditors		(647,361)		(916,526)
Net cash provided by (used in) operating activities		(1,190,010)		(1,316,750)
b) Analysis of cash and cash equivalents				
		1 January 2020	Cashflow	31 December 2020
		£	£	£
Cash at bank and in hand		2,246,853	(176,868)	2,069,985
Cash held as short term investments		4,445,032	109,714	4,554,746
Cash held as long term investments		9,353,853	(998,612)	8,355,241
		16,045,738	(1,065,766)	14,979,972

Notes to the financial statements for the year ended 31 December 2020

1. Charity information

Children with Cancer UK is limited by guarantee with no share capital (registered number 4960054), which is incorporated in England and Wales and domiciled in the UK. The address of the registered office is 51 Great Ormond Street, London WC1N 3JQ. It is also a registered charity (registered number 298405) and as such is a non-profit making organisation.

2. Accounting policies

(a) Basis of preparation

The financial statements have been prepared on the historical cost basis of accounting, as modified by the revaluation of investments, and in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102), the Companies Act 2006, the Charities SORP (FRS 102) and the accounting policies set out below.

The charity meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy note(s).

Children with Cancer UK is the ultimate parent company. It has two subsidiaries - Helping Children with Cancer Limited and Children with Cancer Research Limited. Children with Cancer UK owns the whole of the share capital of Helping Children with Cancer Limited, a company registered in England and Wales, number 2807553. It also holds 100% of the share capital of Children with Cancer Research Limited, a company registered in England and Wales, number 09442350 which is currently dormant.

The financial statements of the charity and its active subsidiary company are consolidated, on a line-by-line basis, to produce the Group financial statements. The consolidated entity is referred to as 'the Group'. No separate Statement of Financial Activities has been prepared for the charity as permitted by Section 408 of the Companies Act 2006. The charity has taken advantage of the exemptions in FRS 102 from the requirements to present a charity only Cash Flow Statement and certain disclosures about the charity's financial instruments.

(b) Preparation of the accounts on a going concern basis

In their assessment of going concern the Trustees have considered the current and developing impact on the charity as a result of the COVID19 virus. This has had a significant impact on certain activities in the current financial year including running events, community based fundraising. The Ball for 2020 was cancelled with an anticipated return date in 2022. These events made up approximately 40% of the charity's income prior to COVID-19.

With the return of certain events like the London Marathon in October 2021, the Trustees are optimistic that the return to pre COVID-19 fundraising levels will be possible. The Trustees are aware that if the situation worsens and becomes prolonged then this may change.

The charity has presented multiple budgets for the current year which takes into account the uncertainty and consider various best and worst case scenarios with many outcomes. By closely monitoring the likelihood of each scenario in real time the Trustees are able respond promptly and effectively.

There are currently significant cash balances should additional liquidity be required through this period of uncertainty to meet the liabilities as they fall due and Children with Cancer UK have appropriate reserves and could adapt to future funding changes by adapting costs.

Accordingly, the Trustees believe the Charity's financial resources are sufficient to ensure the Charity will continue as a going concern for the foreseeable future, being at least 12 months from the date of approval of the financial statements and have therefore prepared the financial statements on the going concern basis.

(c) Financial Instruments

The charity has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at amortised cost. Financial assets held at amortised cost comprise cash at bank and in hand, short term cash deposits together with the group's trade and other debtors excluding prepayments. Financial liabilities held at amortised cost comprise the group's short- and long-term trade and other creditors excluding deferred income and taxation payable. No discounting has been applied to these financial instruments on the basis that the periods over which amounts will be settled are such that any discounting would be immaterial.

Investments, including cash held as part of the investment portfolio are held at fair value at the Balance Sheet date, with gains and losses being recognised within the Statement of Financial Activities. Investments in subsidiary undertakings are held at cost less impairment.

(d) Critical accounting judgements and key sources of estimation uncertainty

In the application of the charity's accounting policies, Trustees are required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects the current and future periods.

The key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements are described in the accounting policies and are summarised below:

Residuary legacies – The charity recognises residuary legacies once probate has been granted which therefore requires an estimation of the amount receivable.

(e) Functional/Presentational currency

The functional currency of the charity and its subsidiary is considered to be in pounds sterling because that is the currency of the primary economic environment in which the charity/group operates. The consolidated financial statements are also presented in pounds sterling.

(f) Fund accounting

Unrestricted funds comprise accumulated surpluses and deficits on general funds and are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund.

(g) Income

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the item(s) of income have been met, it is probable that the income will be received and the amount can be measured reliably.

Voluntary income in the form of appeals, committed giving, sports events and community fundraising income is recognised in the period of receipt. Income received in advance of an event or lottery is deferred until the criteria for income recognition are met.

For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Income arising from corporates and trusts is recognised in the period in which the charity has entitlement to the income.

Income from trading activities is recognised in the period in which the service has been provided or product sold.

Investment income from dividends and interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest received or receivable from the Bank.

Government grants are recognised on the performance model, when the Charitable Company has complied with any conditions attaching to the grant and the grant will be received. The grant in connection to the job retention scheme has been recognised in the period to which the underlying furloughed staff costs relate to.

(h) Expenditure and basis of allocation of costs

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis and the majority is directly attributable to specific activities. Other indirect costs are apportioned to activities in accordance with staff activity and an assessment of where the resources have been applied. Irrecoverable VAT is charged as a cost against the activity for which the expenditure was incurred.

Grants to third parties are included in the SOFA when approved by the Trustees when a constructive obligation exists, notwithstanding that they may be paid in future accounting periods.

Support costs include governance costs which are costs incurred to manage the charity in compliance with constitutional and statutory requirements and the direct expenditure and overhead costs relating to the appeals and fundraising functions. They also include the allocation of costs incurred to support and co-ordinate fundraising activities. These costs are allocated across the categories of charitable activities and the basis of this cost allocation has been explained in note 7 of the financial statements.

Expenditure on raising funds includes expenditure specifically incurred for fundraising purposes. This constitutes a mixture of directly attributable costs and apportionment.

(i) Tangible fixed assets

Tangible fixed assets costing more than £10,000 are capitalised and included at cost including any incidental costs of acquisition, or, where donated, are included at valuation at the date that ownership is acquired.

(j) Pension scheme

Permanent employees are entitled to join the Grouped Stakeholder Pension Plan provided by Scottish Widows. During 2020, the charity made a contribution of 9% of salary per month to any personal or stakeholder pension scheme selected by all employees serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of pension costs is the contribution payable during the year.

(k) Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value and subsequently measured at their fair value as at the balance sheet date using the closing quoted market price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

All gains and losses are taken to the Statement of Financial Activities as they arise. Realised gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealised gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realised and unrealised investment gains and losses are combined in the Statement of Financial Activities.

(l) Gifts in Kind

Gifts in kind and donated goods and services are recognised in the accounts when the benefit to the charity is reasonably quantifiable and measurable. The value is the price the charity estimates it would pay should it purchase equivalent goods or services.

The estimated valuation of gifts in kind is based on the value of the contribution to the charity, or the valuation the charity would have had to pay to acquire the goods or services. A corresponding amount is recognised within expenditure in the period of receipt.

(m) Private Medical Insurance

Since October 2017, permanent employees are entitled to join the Group Private Medical Insurance Scheme provided by Bupa. In 2020, the charity paid a premium based on the employee's ages per month to all employees after serving for more than three months who elected to take advantage of this benefit. The amount charged to the statement of financial activities in respect of private medical insurance is the contribution payable during the year.

3. Consolidated statement of financial activities for the year ended 31 December 2019

	Total restricted funds £	Total unrestricted funds £	Total 2019 £
Income from:			
Donations and legacies	240,594	16,137,595	16,378,190
Other trading activities	-	828,225	828,225
Income from investments	-	82,636	82,636
Other income	-	41,375	41,375
Total Income	240,594	17,089,831	17,330,426
Expenditure on:			
Raising funds	-	3,956,547	3,956,547
Charitable activities	621,947	12,238,453	12,860,400
Total Expenditure	621,947	16,195,000	16,816,947
Net change in investments	-	216,320	216,320
Net (expenditure)/income	(381,353)	1,111,151	729,798
Transfers between funds	(155,781)	155,781	-
Net movement in funds	(537,134)	1,266,931	729,797
Reconciliation of funds:			
Total funds brought forward	1,064,478	9,107,144	10,171,622
Total funds carried forward	527,344	10,374,075	10,901,419

4. Income

	2020 £	2019 £
Donations and legacies		
Appeals and associated donations	4,924,928	4,357,740
Committed giving	2,632,190	2,080,202
Community fundraising	1,321,743	1,813,260
Corporate and trust donations	891,830	2,163,789
Legacies (see contingent asset below)	2,074,903	1,396,017
Sports events	1,738,104	4,549,199
Transfer of funds (See below)	-	(7,177)
	13,583,698	16,353,030
Scratch cards (see scratch card income below)	-	25,160
	13,583,698	16,378,190
Other trading activities		
Events	48,994	828,225
	48,994	828,225

Included in Donations and legacies in 2020 is a government grant in the form of the Job Retention Scheme for £29,750. Included in 2019 is a (£7,177) adjustment for £1,064,748 of funds received in 2018 which relates to the transfer of funds from Children's Leukaemia Trust (charity number 1000341). This is the difference of expected and actual funds received. See Note 19.

Contingent asset – legacy income

As at 31 December 2020, the charity had been notified of a further 12 residuary and 16 pecuniary legacies which have not been recognised as income in the Statement of Financial Activities as they do not meet the criteria as detailed in the accounting policies. These legacies have an estimated value of £253,187 which has not been accrued.

5. Lottery income

As part of the charity's Gambling Commission License (Non Remote License - 000-004700-N-306402-010) (Remote License – 000-004700-R-308531-010), during the year the charity has operated three lotteries, a weekly lottery and charity scratch card.

The following ticket sales were received for each lottery where the draw was held in 2020:

	Ticket sales £
Weekly Lottery	530,804
Christmas Raffle (draw 17 th January 2020)	501,539
Spring Raffle (draw 5 th June 2020)	419,309
Summer Raffle (draw 18 th September 2020)	465,085
Total	1,916,737

As the Christmas raffle spans two accounting periods, £832 was received during 2020 and £500,707 during 2019. All other ticket sales were received during 2020 only. All ticket sales have been included within the total income for 2020 and 2019.

In line with the requirements under Social responsibility code provision 4.3.1 of the License Conditions and Codes of Practice of the Gambling Act 2005 the following section details the percentage of lottery proceeds returned to the purposes of the society (Children with Cancer UK) from the lotteries promoted in 2020.

Lottery type	Lottery Name	Percentage proceeds returned to Charity %
Managed directly by Children With Cancer UK	Weekly Lottery	59%
Managed directly by Children With Cancer UK	Children with Cancer Grand Draw	69%
Total		67%

6. Total expenditure

	Staff Costs £	Direct Costs £	Support and Governance £	2020 Total £	2019 Total £
Expenditure on Raising funds					
Fundraising Costs	718,582	1,006,665	332,696	2,057,943	3,956,547
Expenditure on Charitable activities					
Research into Prevention & Causes	310,332	2,329,940	111,294	2,751,565	4,105,839
Research into Treatment	323,541	4,843,792	109,506	5,276,839	1,985,897
Welfare	394,214	2,162,572	156,122	2,712,907	2,605,761
Raising Awareness	803,778	1,421,488	317,650	2,542,917	4,162,903
	1,831,865	10,757,792	694,571	13,284,229	12,860,400
	2,550,447	11,764,457	1,027,267	15,342,172	16,816,947
	=====	=====	=====	=====	=====

	Staff Costs £	Direct Costs £	Support and Governance £	2019 Total £
Expenditure on Raising funds				
Fundraising Costs	772,912	2,656,151	527,484	3,956,547
Expenditure on Charitable activities				
Research into Prevention & Causes	271,175	3,666,016	168,648	4,105,839
Research into Treatment	292,385	1,527,405	166,107	1,985,897
Welfare	346,718	2,010,255	248,788	2,605,761
Raising Awareness	841,904	2,833,049	487,950	4,162,903
	1,752,182	10,036,725	1,071,493	12,860,400
	2,525,094	12,692,876	1,598,977	16,816,947
	=====	=====	=====	=====

7. Support costs

Support costs are split as follows:

	Office Administration £	Operational Management £	Finance / IT / HR £	Communications and Marketing £	Governance £	2020 Total £
Expenditure on Raising funds						
Fundraising Costs	45,952	89,976	119,230	57,693	19,845	332,696
Expenditure on Charitable activities						
Research into Prevention & Causes	17,139	20,766	44,470	21,518	7,401	111,294
Research into Treatment	16,864	20,432	43,755	21,172	7,283	109,506
Welfare	24,042	29,130	62,382	30,185	10,383	156,122
Raising Awareness	48,917	59,268	126,924	61,416	21,125	317,650
	106,963	129,595	277,530	134,291	46,192	694,571
	152,915	219,571	396,760	191,964	66,037	1,027,267
	=====	=====	=====	=====	=====	=====

	Office Administration £	Operational Management £	Finance / IT / HR £	Communications and Marketing £	Governance £	2019 Total £
Expenditure on Raising funds						
Fundraising Costs	56,035	146,794	179,023	77,519	68,113	527,484
Expenditure on Charitable activities						
Research into Prevention & Causes	19,162	38,468	61,218	26,508	23,292	168,648
Research into Treatment	18,873	37,889	60,295	26,109	22,941	166,107
Welfare	28,267	56,748	90,307	39,105	34,360	248,787
Raising Awareness	55,440	111,300	177,123	76,697	67,390	487,950
	121,742	244,405	388,943	168,419	147,983	1,071,492
	177,777	391,199	567,966	245,938	216,096	1,598,976
	=====	=====	=====	=====	=====	=====

Indirect, support and governance costs are allocated on a per person basis to staff in the office. The time spent by each staff member on every activity of the charity is allocated on a month by month basis throughout the year. Support and staff costs are then allocated to the various charitable activities based on this staff time basis.

8. Costs of charitable activities

	Activities undertaken directly £	Grant funding of activities £	Support and governance costs £	2020 Total £	2019 Total £
Research into Prevention & Causes	1,076,057	1,564,215	111,294	2,751,565	4,105,839
Research into Treatment	1,036,834	4,130,499	109,506	5,276,839	1,985,897
Welfare	1,271,490	1,285,296	156,122	2,712,907	2,605,761
Raising Awareness	2,218,516	6,751	317,650	2,542,917	4,162,903
	—————	—————	—————	—————	—————
	5,,602,897	6,986,761	694,572	13,284,228	12,860,390
	=====	=====	=====	=====	=====

9. Auditor Costs

	Statutory Audit Fee £	2020 Total £
Children with Cancer UK	33,300	33,300
Helping Children with Cancer Ltd	3,600	3,600
	—————	—————
	36,900	36,900
	=====	=====

	Statutory Audit Fee £	Other Financial Services £	2019 Total £
Children with Cancer UK	30,700	1,428	32,128
Helping Children with Cancer Ltd	3,600	-	3,600
	—————	—————	—————
	34,300	1,428	35,728
	=====	=====	=====

Other Financial Services Includes £238 of irrecoverable VAT.

10. Staff costs

	2020 £	2019 £
Salaries and wages	2,136,936	2,104,647
National Insurance	224,044	218,778
Pension	175,283	190,084
Private Medical Insurance	14,185	11,585
	—————	—————
	2,550,448	2,525,094
	=====	=====

During 2020, the following employees were paid in the following salary ranges.

Salary Range	2020 £	2019 £
£130,000 - £140,000	1	1
£70,000 - £80,000	1	0
£60,000 - £70,000	3	1

There have been 7 (2019: 8) positions that have formed part of the senior leadership team during 2020. The total remuneration including pension contributions for these employees amounts to £720,745 (2019: £807,307).

During the year there were five settlement payments (2019: two), made totalling £51,488 (2019: £97,095).

The average weekly number of contracted employees during the year was as follows:

	2020	2019
	No.	No.
Charitable Activities	7	4
Raising Funds	38	39
Support, Governance, Operations and Administration	10	13
	=====	=====
	55	56
	=====	=====

11. Results of the parent charity

	2020	2019
	£	£
Total income	13,783,863	17,354,706
Total expenditure	(15,364,030)	(16,813,313)
Unrealised gains/ (Loses)	(25,491)	216,320
Net (expenditure)/ Income	(1,605,658)	757,713
	=====	=====

12. Investments

	2020	2019
	£	£
Listed investments (see below)	1,778,177	1,803,668
Cash deposits	8,355,241	9,353,853
	=====	=====
	10,133,418	11,157,521
	=====	=====
Market value of listed investments at 1 Jan	1,803,668	1,590,812
Additions to investment portfolio	10,185	5,389
Disposals to investment portfolio	(5,246)	(3,712)
Investment manager fees	(4,939)	(5,141)
Net Investment gain/(loss)	(25,491)	216,320
	=====	=====
Market value of listed investments at 31 Dec	1,778,177	1,803,668
	=====	=====
Listed Investments comprise the following:		
Cash and short maturity bonds	-	5,246
Multi class and other investments	1,778,177	1,798,422
	=====	=====
Total listed investments at 31 Dec	1,778,177	1,803,668
	=====	=====

Total Investments are listed in:		
United Kingdom	227,607	226,360
Overseas	1,550,571	1,577,308
	=====	=====
	1,778,177	1,803,668
	=====	=====

Investment in subsidiary

Children with Cancer UK holds 100% of the share capital of Helping Children with Cancer Limited which is a registered company number 04960054. The value of the share capital owned is £100. Helping Children with Cancer Limited raises funds via commercial activities and sponsorship.

The income and expenditure for the year ended 31 December 2020 is as follows:

	2020 £	2019 £
Income	23,916	30,742
Administrative expenses	(12,278)	(12,117)
	-----	-----
Profit before gift aid and taxation	11,638	18,625
	=====	=====

The balance sheet for the subsidiary as at 31 December 2020 is as follows:

	2020 £	2019 £
Assets	45,069	44,706
Liabilities	(44,969)	(44,606)
	-----	-----
Reserves	100	100
	=====	=====

The charity also holds 100% of the share capital of Children with Cancer Research Limited (09442350) which is currently dormant.

13. Trustees' emoluments

The Trustees received no remuneration or reimbursement of expenses during the year (2019 Nil).

14. Debtors

	2020 Group £	2020 Charity £	2019 Group £	2019 Charity £
Amounts due from subsidiary undertakings	-	41,369	-	41,006
Other debtors	1,290,708	1,290,708	1,513,009	1,516,009
Accrued income	330,469	327,969	986,757	973,080
Prepayments	1,489,068	1,489,068	1,772,379	1,772,379
	-----	-----	-----	-----
	3,110,245	3,149,114	4,272,145	4,299,474
	=====	=====	=====	=====

15. Grants to third parties

	2020 £	2019 £
Outstanding liabilities at the start of the year	10,527,498	10,880,921
Awarded during the year (note 22):		
Research into prevention and causes	1,570,272	2,718,936
Research into treatment	4,597,501	634,341
Welfare	1,285,296	918,000
Raising awareness	20,750	18,400
	<u>7,473,819</u>	<u>4,289,677</u>
Under-spends on previous grant awards	(487,058)	(250,000)
Paid during the year	(7,611,890)	(4,393,100)
Outstanding liabilities at the end of the year	9,902,369	10,527,498
	=====	=====
Grants falling due within one year	1,982,298	3,850,858
Grants falling due after more than one year	7,920,071	6,676,640
	<u>9,902,369</u>	<u>10,527,498</u>
	=====	=====

16. Creditors: amounts falling due within one year

	2020 Group £	2020 Charity £	2019 Group £	2019 Charity £
Accruals and deferred income	613,232	609,632	640,720	637,120
Taxes and social security	57,170	57,170	51,914	51,914
	<u>670,401</u>	<u>666,801</u>	<u>692,634</u>	<u>689,034</u>
Grants payable	1,982,298	1,982,298	3,850,858	3,850,858
	<u>2,652,700</u>	<u>2,649,099</u>	<u>4,543,492</u>	<u>4,539,892</u>
	=====	=====	=====	=====

17. Deferred income

Deferred income comprises income received in advance for entries to our weekly lottery.

	2020 Group £	2020 Charity £	2019 Group £	2019 Charity £
Balance as at 1 January 2020	51,599	51,599	53,020	53,020
Amount released to income	(51,599)	(51,599)	(53,020)	(53,020)
Amount deferred in year	52,053	52,053	51,599	51,599
Balance as at 31 December 2020	52,053	52,053	51,599	51,599

18. Analysis of net assets between funds

As at 31 December 2020	2020 Group Restricted funds £	2020 Group Unrestricted funds £	2020 Group Total funds £	2019 Group Total funds £
Fixed assets	-	10,133,555	10,133,555	11,157,521
Net current assets	-	7,082,276	7,082,177	6,420,538
Creditors falling due after more than one year	-	(7,920,071)	(7,920,071)	(6,676,640)
Net assets at the end of the year	-	9,295,760	9,295,661	10,901,419

As at 31 December 2019	2019 Group Restricted funds £	2019 Group Unrestricted funds £	2019 Group Total funds £	2018 Group Total funds £
Fixed assets	-	11,157,521	11,157,521	12,881,039
Net current assets	527,344	5,893,194	6,420,538	3,221,005
Creditors falling due after more than one year	-	(6,676,640)	(6,676,640)	(5,930,422)
Net assets at the end of the year	527,344	10,374,075	10,901,419	10,171,622

19. Statement of funds

Year ended 31 December 2020	At the start of the year £	Total Income £	Total Expenditure £	Transfers & Investment gains/losses £	At the end of the year £
Restricted funds					
BIOMarkers of Ependymomas in Children and Adolescents (BIOMECA) - Integrated Biological study within SIOP Ependymoma II trial organised by European Ependymoma Biology Consortium	-	120	-	(120)	
Dr Steven Pollard, University of Edinburgh. Genome editing of human neural stem cells using nuclease-assisted gene targeting: a tool to uncover the function of H3F3A mutations in paediatric glioma	-	1,000	-	(1,000)	
Dr Karin Straathof, UCL Institute of Child Health, Development of GD2-specific Bi-specific T-cell Engagers (BiTEs) for treatment of neuroblastoma	-	5,463	-	(5,463)	
Professor Louis Chesler, Institute for Cancer Research- Individualising Management of Paediatric Cancer Treatment - IMPACT	-	4,488	-	(4,488)	
Harnessing SMAD7 induced transcriptional pathways for novel anti-leukaemia therapies	-	17,350	-	(17,350)	
Dr John Bithell, University of Oxford- Preservation and analysis of pathology records and family histories of children with cancer	-	1,500	-	(1,500)	
Functions of DOT1L and H3K79 methylation in MLL-rearranged leukaemia	-	3,895	-	(3,895)	
Safety enhanced CAR T cell therapy for paediatric AML	-	13,365	-	(13,365)	
John Anderson - UCL Great Ormond Street Institute of Child Health - Pilot to develop CRISPR library screen for enhanced function of G-D-T cells in paediatric solid cancers.	-	14,500	(14,500)	-	
Defne Saatci - UCL Great Ormond Street Institute of Child Health - Investigating Late Effects of Surviving Childhood Cancer	-	5,000	(5,000)	-	
Beads of Courage UK, which helps children in all 110 children's cancer wards in the UK visualise and articulate their cancer journey	-	207,687	(207,687)	-	
CLIC Sargent	-	500	-	(500)	
Children's Leukaemia Trust. Restricted for research into and training for Leukaemia and Lymphoma in children	527,344	-	(527,344)	-	-
Total Restricted funds	527,344	274,867	(754,531)	(47,681)	-
Unrestricted funds	10,374,075	13,478,138	(14,587,641)	22,190	9,295,761
Total Unrestricted funds	10,374,075	13,478,138	(14,587,641)	22,190	9,295,761
Total funds	10,901,419	13,762,005	(15,342,172)	(25,491)	9,295,761
	=====	=====	=====	=====	=====

Note

The restricted funds comprise donations that were to be spent on specific causes and projects. Following the dissolution of Children's Leukaemia Trust (charity number 1000341) we benefited from a one off donation of £1,064,478 in 2018, which was restricted to research into and training for Leukaemia and Lymphoma in children. £529,957 of this fund was allocated in 2019 and a further £527,344 in 2020 leaving the total fund discharged.

Children's Leukaemia Trust restricted donation allocation	Research into prevention and causes £	Research into treatment £	Total £
Safety enhanced CART cell therapy for paediatric AML	-	250,000	250,000
Energy supplements protect pancreas from side effects of Asparaginase	50,000	-	50,000
Exploring the role of the tumour suppressor ATRX in Leukaemia	-	50,000	50,000
Functions of DOT1L and H3K79 methylation in MLL-rearranged leukaemia	-	26,000	26,000
CCL17 and the early diagnosis of classical Hodgkin lymphoma – a feasibility study in the primary care setting	49,780	-	49,780
Professor Pamela Keams. Programme grant UK ALL 2011	-	104,177	104,177
Optimising the use of repurposed drugs to improve the treatment of children with ALL	-	213,259	213,259
CCR9 as a novel immunotherapy target in T-cell acute lymphoblastic leukaemia (T-ALL)	-	249,325	249,325
Identification of novel surface antigen targets for CAR T cell strategies in paediatric Acute Myeloid Leukaemia stem cells.	-	64,760	64,760
Total funds	99,780	957,521	1,057,301

All other restricted income was either discharged during the year or transferred from restricted back to unrestricted funds. This has occurred when restricted funds were received towards grants that were previously paid out of unrestricted reserves.

Year ended 31 December 2019	At the start of the year £	Total Income £	Total Expenditure £	Transfers & Investment gains/losses £	At the end of the year £
Restricted funds					
Discovery of biomarkers and new therapeutic targets for chemotherapy associated neurotoxicity	-	3,000	-	(3,000)	-
BIOMarkers of Ependymomas in Children and Adolescents (BIOMECA) - Integrated Biological study within SIOP Ependymoma II trial organised by European Ependymoma Biology Consortium	-	300	-	(300)	-
Advanced magnetic resonance imaging techniques for in vivo assessment of tumour heterogeneity, risk factor, and treatment response in paediatric cancer	-	8,300	-	(8,300)	-
Evaluation of B7H3 as a novel target for immunotherapy in childhood cancer	-	2,560	-	(2,560)	-
Dr Karin Straathof, UCL Institute of Child Health, Development of GD2-specific Bi-specific T-cell Engagers (BiTEs) for treatment of neuroblastoma	-	9,500	-	(9,500)	-
Professor Christine Harrison, Northern Institute for Cancer Research, Newcastle University, Sequencing the unsequenceable: development of ground-breaking technologies to investigate the role of complex genomic sequences in childhood cancer	-	56,108	-	(56,108)	-
Helen E Bryant, University of Sheffield, Novel therapies for MYCN-amplified neuroblastoma	-	500	-	(500)	-
Dr Amin Hajitou, Imperial College London, Investigation of a harmless prokaryotic virus for intravenous targeting delivery of therapeutic nucleic acids to DIPG	-	25,000	-	(25,000)	-
Professor Louis Chesler, Institute for Cancer Research- Individualising Management of Paediatric Cancer Treatment - IMPACT	-	49,188	-	(49,188)	-
Professor Sibylle Mitnacht, UCL Cancer Institute- Exploring retinoblastoma protein loss as an actionable target in paediatric bone and soft tissue sarcoma	-	750	-	(750)	-
Dr John Bithell, University of Oxford- Preservation and analysis of pathology records and family histories of children with cancer	-	500	-	(500)	-

Year ended 31 December 2019	At the start of the year £	Total Income £	Total Expenditure £	Transfers & Investment gains/losses £	At the end of the year £
Clinical PHD Studentship: Markers of Hypothalamic Dysfunction in Children with Hypothalamo-Pituitary-Axis Tumours (HPAT) or Pituitary Maldevelopment	-	75	-	(75)	-
Osteosarcoma Symposium	-	30,000	(30,000)	-	-
Functions of DOT1L and H3K79 methylation in MLL-rearranged leukaemia	-	11,753	(11,753)	-	-
Beads of Courage UK, which helps children in all 110 children's cancer wards in the UK visualise and articulate their cancer journey	-	50,238	(50,238)	-	-
Children's Leukaemia Trust. Restricted for research into and training for Leukaemia and Lymphoma in children	1,064,478	(7,177)	(529,957)	-	527,344
Total Restricted funds	1,064,478	240,594	(621,947)	(155,781)	527,344
Unrestricted funds	9,107,144	17,089,346	(16,195,000)	372,449	10,373,939
Total Unrestricted funds	9,107,144	17,089,346	(16,195,000)	372,449	10,373,939
Total funds	10,171,622	17,329,940	(16,816,947)	216,668	10,901,283

20. Related Party Transactions

There have been no other related party transactions during the year other than those with the trading subsidiary.

A management fee of £5,000 (2019: £5,000) has been charged to the trading subsidiary for use of the charity's trademarks and a further £3,645 (2019: £3,484) for the use of charity staff (calculated on the basis of time charged to subsidiary activity by the employee). As at 31st December 2020, £41,369 (2019: £41,006) owed to the charity from the trading subsidiary.

21. Financial Instruments

The financial statements include the following in respect of items:

	2020 £	2019 £
Financial assets measured at fair value	1,778,177	1,803,668

	2020 £	2019 £
The entity's income, expense, gains and losses in respect of financial instruments are summarised below:		
Total interest income for financial assets held at fair value	129,182	82,499

22. Grants to third parties

	Research into prevention and causes 2020 £	Research into treatment 2020 £	Raising Awareness 2020 £	Welfare 2020 £	Total 2020 £
Cancer Research UK–Children with Cancer UK Innovation Awards	1,295,725	1,204,275			2,500,000
Teenage Cancer Trust: Emergency Coronavirus Appeal				1,000,000	1,000,000
Mike Hawkins - University of Birmingham - Establish a comprehensive surveillance system for adverse health outcomes in British survivors of childhood, teenage and young adult cancer		349,982			349,982
Kathy Pritchard-Jones - UCL Great Ormond Street Institute of Child Health - International benchmarking of childhood cancer survival by stage		349,747			349,747
Chris Jones - Institute of Cancer Research - Evolutionary dynamics of MEK inhibitor sensitivity and resistance in diffuse midline glioma		349,393			349,393
Steve Clifford - Newcastle University - SMILE: An International network for Medulloblastoma Survivorship and Late-Effects		348,783			348,783
Sam Behjati - Wellcome Sanger Institute - Developmental states of localised and metastatic osteosarcoma cells – a knowledge bank for novel biomarkers and therapeutic approaches		349,419			349,419
Beads of Courage - 2020				285,296	285,296
Anthony Chalmers - University of Glasgow - Increasing the susceptibility of neuroblastoma cells to radiotherapy by targeting glycolysis and lipogenesis		249,774			249,774
Veronica Kinsler - UCL Great Ormond Street Institute of Child Health - Identification of new therapies for melanoma in congenital melanocytic naevi - a universally fatal paediatric tumour		249,756			249,756
Marc Mansour - UCL Cancer Institute - CCR9 as a novel immunotherapy target in T-cell acute lymphoblastic leukaemia (T-ALL)		249,325			249,325
Macarena Oporto Espuelas - UCL Great Ormond Street Institute of Child Health - Identification of novel surface antigen targets for CAR T cell strategies in paediatric Acute Myeloid Leukaemia stem cells.		220,000			220,000
Defne Saatci - UCL Great Ormond Street Institute of Child Health - Investigating Late Effects of Surviving Childhood Cancer		216,963			216,963
Julie Irving - Newcastle University - Optimising the use of repurposed drugs to improve the treatment of children with ALL		213,259			213,259
Schuz - International Agency for Research on Cancer - Dr Joachim Schüz, CLIC Data Coordinating Center - Extension	95,060				95,060
International Agency for Research on Cancers - IARC Postdoctoral Fellowship	81,933				81,933
Ian Fairlie - NA - Report: The effects of Low Level Ionising Radiation Exposure especially regarding child and young person cancer incidence	78,588				78,588
Chris Jones - Institute of Cancer Research - INSTINCT interim funding	10,000	58,380			68,380
Claire Clarkin - University of Southampton - Developing 3-dimensional multicellular models of osteosarcoma		49,984			49,984
John Anderson - UCL Great Ormond Street Institute of Child Health - Pilot to develop CRISPR library screen for enhanced function of G-D-T cells in paediatric solid cancers.		49,930			49,930
Faith Gibson - University of Surrey - Personalised survivorship care: customising support towards unmet psychosocial needs in young people with cancer (PATH study)		48,202			48,202
Steve Clifford - Newcastle University - INSTINCT interim funding		21,316			21,316
BCRT - Bone Cancer Research Trust -			20,000		20,000

	Research into prevention and causes 2020 £	Research into treatment 2020 £	Raising Awareness 2020 £	Welfare 2020 £	Total 2020 £
John Murphy - University of Westminster - A pilot Investigation of the ZFP36L1 protein as a candidate therapeutic target in osteosarcoma cells		14,013			14,013
International Agency for Research on Cancers - IARC Postdoctoral Fellowship	5,154				5,154
Raoul Reulen - University of Birmingham - Pilot study to investigate self-reported health behaviours in survivors of teenage and young adult cancer		5,000			5,000
M Niklison - Queen Mary University of London - Paul O'Gorman Post-doctoral Research Fellowship - Metabolic analysis of the tumour suppressor protein p73 in medulloblastoma	3,812				3,812
Becci Pearson - British Neuro-Oncology Society - BNOS Sponsorship			750		750
Total grants to third parties awarded in the year	1,570,272	4,597,501	20,750	1,285,296	7,473,819
Underspends on previous grant awards					
Tariq Enver - UCL Cancer Institute - Dissecting the causative and collaborating roles of candidate genetic mutations in the pathogenesis of childhood ALL	(293)				(293)
Dr Steven Pollard, University of Edinburgh. Genome editing of human neural stem cells using nuclease-assisted gene targeting: a tool to uncover the function of H3F3A mutations in paediatric glioma	(455)				(455)
Waseem Qasim - UCL Great Ormond Street Institute of Child Health - T cell receptor gene therapy: Novel strategies for children with cancer using engineered cord blood T cells		(788)			(788)
Professor Chris Jones, Institute of Cancer Research, The role of histone H4K20 methylation in paediatric glioblastoma and DIPG	(2,648)				(2,648)
Dr Marc Tischkowitz, University of Cambridge, Investigating microRNA processing genes in rhabdomyosarcomas and other DICER1-related childhood tumours	(2,661)				(2,661)
Professor Robert Mairs, University of Glasgow. Exploitation of the elevated metabolic activity of cancer cells for combination with targeted radiotherapy of neuroblastoma		(4,997)			(4,997)
Dr Suzanne Turner, University of Cambridge, CRISPR-based genome-wide knockout and overexpression screens to identify acquired resistance mechanisms to ALK inhibition in neuroblastoma		(6,511)			(6,511)
Dr Faith Gibson - Great Ormond Street Hospital - Evaluating HELP: an intervention for parents sharing information about leukaemia with their child.			(13,999)		(13,999)
Katherine Clesham - UCL Great Ormond Street Institute of Child Health - Targeting c-MYB in acute leukaemia through drug repositioning		(18,722)			(18,722)
Immunotherapy with CD19ζ gene-modified EBV-specific CTLs after stem cell transplantation in children with high-risk acute lymphoblastic leukaemia		(22,420)			(22,420)
Dr Elizabeth Calton, The Institute of Cancer Research, Mutational dynamics and their effect on chemoresistance and metastasis in a genetically engineered mouse model of relapsed neuroblastoma		(25,777)			(25,777)
Dr Patrick Hales, Institute of Child Health, University College London. Advanced magnetic resonance imaging techniques for in vivo assessment of tumour heterogeneity, risk factor, and treatment response in paediatric cancer		(115,379)			(115,379)
Professor Pamela Keams. Programme grant UK ALL 2011		(272,408)			(272,408)
Total grants to third parties	1,564,215	4,130,499	6,751	1,285,296	6,986,761



Every day more than 12 children and young people are diagnosed with cancer in the UK.



8 out of 10 young childhood cancer patients can be successfully treated thanks to vital, specialist research we helped fund.



We need to develop safer, kinder and more effective cancer therapies for children, with fewer toxic side effects. We strive to ensure that we are doing everything we can to improve the lives of children with cancer.



We fund Research



We fund Welfare



We raise Awareness

Children with Cancer UK
Registered Office
51 Great Ormond Street
London
WC1N 3JQ